Single nucleotide polymorphisms in genes

BACKGROUND OF THE INVENTION

The genomes of all organisms undergo spontaneous mutation in the course of their continuing evolution, generating variant forms of progenitor nucleic acid sequences (Gusella, Ann. Rev. Biochem. 55, 831-854 (1986)). The variant form may confer an evolutionary advantage or disadvantage relative to a progenitor form, or may be neutral. In some instances, a variant form confers a lethal disadvantage and is not transmitted to subsequent generations of the organism. In other instances, a variant form confers an evolutionary advantage to the species and is eventually incorporated into the DNA of many or most members of the species and effectively becomes the progenitor form. In many instances, both progenitor and variant form(s) survive and co-exist in a species population. The coexistence of multiple forms of a sequence gives rise to polymorphisms.

Several different types of polymorphism have been reported. A restriction fragment length polymorphism (RFLP) is a variation in DNA sequence that alters the length of a restriction fragment (Botstein et al., Am. J. Hum. Genet. 32, 314-331 (1980)). The restriction fragment length polymorphism may create or delete a restriction site, thus changing the length of the restriction fragment. RFLPs have been widely used in human and animal genetic analyses (see WO 90/13668; W090/11369; Donis-Keller, Cell 51, 319-337 (1987); Lander et al., Genetics 121, 85-99 (1989)). When a heritable trait can be linked to a particular RFLP, the presence of the RFLP in an individual can be used to predict the likelihood that the animal will also exhibit the trait.

Other polymorphisms take the form of short tandem repeats (STRs) that include tandem di-, tri- and tetra-nucleotide repeated motifs. These tandem repeats are also referred to as variable number tandem repeat (VNTR) polymorphisms. VNTRs have been used in identity and paternity analysis (U.S. Pat. No. 5,075,217; Armour et al., FEBS Lett. 307, 113-115 (1992); Horn et al., WO 91/14003; Jeffreys, EP 370,719), and in a large number of genetic mapping studies.

Other polymorphisms take the form of single nucleotide variations between individuals of the same species. Such polymorphisms are far more frequent than RFLPs, STRs and VNTRs. Some single nucleotide polymorphisms (SNP) occur in protein-coding nucleic acid sequences (coding sequence SNP (cSNP)), in which case, one of the polymorphic forms may give rise to the expression of a defective or otherwise variant protein and, potentially, a genetic disease. Examples of genes in which polymorphisms within coding sequences give rise to genetic disease include β-globin (sickle cell anemia), apoE4 (Alzheimer's Disease), Factor V Leiden (thrombosis), and CFTR (cystic fibrosis). cSNPs can alter the codon sequence of the gene and therefore specify an alternative amino acid. Such changes are called “missense” when another amino acid is substituted, and “nonsense” when the alternative codon specifies a stop signal in protein translation. When the cSNP does not alter the amino acid specified the cSNP is called “silent”.

Other single nucleotide polymorphisms occur in noncoding regions. Some of these polymorphisms may also result in defective protein expression (e.g., as a result of defective splicing). Other single nucleotide polymorphisms have no phenotypic effects.

Single nucleotide polymorphisms can be used in the same manner as RFLPs and VNTRs, but offer several advantages. Single nucleotide polymorphisms occur with greater frequency and are spaced more uniformly throughout the genome than other forms of polymorphism. The greater frequency and uniformity of single nucleotide polymorphisms means that there is a greater probability that such a polymorphism will be found in close proximity to a genetic locus of interest than would be the case for other polymorphisms. The different forms of characterized single nucleotide polymorphisms are often easier to distinguish than other types of polymorphism (e.g., by use of assays employing allele-specific hybridization probes or primers).

Only a small percentage of the total repository of polymorphisms in humans and other organisms has been identified. The limited number of polymorphisms identified to date is due to the large amount of work required for their detection by conventional methods. For example, a conventional approach to identifying polymorphisms might be to sequence the same stretch of DNA in a population of individuals by dideoxy sequencing. In this type of approach, the amount of work increases in proportion to both the length of sequence and the number of individuals in a population and becomes impractical for large stretches of DNA or large numbers of persons.

SUMMARY OF THE INVENTION

Work described herein pertains to the identification of polymorphisms which can predispose individuals to disease, by resequencing large numbers of genes in a large number of individuals. Various genes from a number of individuals have been resequenced as described herein, and SNPs in these genes have been discovered (see the Table and FIG. 3). Some of these SNPs are cSNPs which specify a different amino acid sequence, some of the SNPs are silent cSNPs and some of these cSNPs specify a stop signal in protein translation. Some of the identified SNPs were located in non-coding regions.

The invention relates to a gene which comprises a single nucleotide polymorphism at a specific location. In a particular embodiment the invention relates to the variant allele of a gene having a single nucleotide polymorphism, which variant allele differs from a reference allele by one nucleotide at the site(s) identified in the Table and FIG. 3. Complements of these nucleic acid sequences are also included. The nucleic acid molecules can be DNA or RNA, and can be double- or single-stranded. Nucleic acid molecules can be, for example, 5-10, 5-15, 10-20, 5-25, 10-30, 10-50 or 10-100 bases long.

The invention further provides allele-specific oligonucleotides that hybridize to the reference or variant allele of a gene comprising a single nucleotide polymorphism or to the complement thereof. These oligonucleotides can be probes or primers.

The invention further provides a method of analyzing a nucleic acid from an individual. The method determines which base is present at any one of the polymorphic sites shown in the Table and/or FIG. 3. Optionally, a set of bases occupying a set of the polymorphic sites shown in the Table and/or FIG. 3 is determined. This type of analysis can be performed on a number of individuals, who are tested for the presence of a disease phenotype. The presence or absence of disease phenotype is then correlated with a base or set of bases present at the polymorphic site or sites in the individuals tested.

Thus, the invention further relates to a method of predicting the presence, absence, likelihood of the presence or absence, or severity of a particular phenotype or disorder associated with a particular genotype. The method comprises obtaining a nucleic acid sample from an individual and determining the identity of one or more bases (nucleotides) at polymorphic sites of genes described herein, wherein the presence of a particular base is correlated with a specified phenotype or disorder, thereby predicting the presence, absence, likelihood of the presence or absence, or severity of the phenotype or disorder in the individual.

The thrombospondins are a family of extracellular matrix (ECM) glycoproteins that modulate many cell behaviors including adhesion, migration, and proliferation. Thrombospondins (also known as thrombin sensitive proteins or TSPs) are large molecular weight glycoproteins composed of three identical disulfide-linked polypeptide chains. The results described herein also reveal an important association between alterations, particularly SNPs, in TSP genes, particularly TSP-1 and TSP-4, and vascular disease. In particular, SNPs in these genes which are associated with premature coronary artery disease (CAD)(or coronary heart disease) and myocardial infarction (MI) have been identified and represent a potentially vital marker of upstream biology influencing the complex process of atherosclerotic plaque generation and vulnerability.

Thus, the invention relates to the TSP gene SNPs identified as described herein, both singly and in combination, as well as to the use of these SNPs, and others in TSP genes, particularly those nearby in linkage disequilibrium with these SNPs, for diagnosis, prediction of clinical course and treatment response for vascular disease, development of new treatments for vascular disease based upon comparison of the variant and normal versions of the gene or gene product, and development of cell-culture based and animal models for research and treatment of vascular disease. The invention further relates to novel compounds and pharmaceutical compositions for use in the diagnosis and treatment of such disorders. In preferred embodiments, the vascular disease is CAD or MI.

The invention relates to isolated nucleic acid molecules comprising all or a portion of the variant allele of TSP-1 (e.g., as exemplified by SEQ ID NO: 1), and to isolated nucleic acid molecules comprising all or a portion of the variant allele of TSP-4 (e.g., as exemplified by SEQ ID NO: 3). Preferred portions are at least 10 contiguous nucleotides and comprise the polymorphic site, e.g., a portion of SEQ ID NO: 1 which is at least 10 contiguous nucleotides and comprises the “G” at position 2210, or a portion of SEQ ID NO: 3 which is at least 10 contiguous nucleotides and comprises the “C” at position 1186. The invention further relates to isolated gene products, e.g., polypeptides or proteins, which are encoded by a nucleic acid molecule comprising all or a portion of the variant allele of TSP-1 or TSP-4 (e.g., SEQ ID NO: 1 or SEQ ID NO: 3, respectively). The invention also relates to nucleic acid molecules which hybridize to and/or share identity with the variant alleles identified herein (or their complements) and which also comprise the variant nucleotide at the SNP site.

The invention further relates to isolated proteins or polypeptides comprising all or a portion of the variant amino acid sequence of TSP-1 (e.g., as exemplified by SEQ ID NO: 2), and to isolated proteins or polypeptides comprising all or a portion of the variant amino acid sequence of TSP-4 (e.g., as exemplified by SEQ ID NO: 4). Preferred polypeptides are at least 10 contiguous amino acids and comprise the polymorphic amino acid, e.g., a portion of SEQ ID NO: 2 which is at least 10 contiguous amino acids and comprises the serine at residue 700, or a portion of SEQ ID NO: 4 which is at least 10 contiguous amino acids and comprises the proline at residue 387. The invention further relates to isolated nucleic acid molecules encoding such proteins and polypeptides, as well as to antibodies which bind, e.g., specifically, to such proteins and polypeptides.

The invention further relates to a method of diagnosing or aiding in the diagnosis of a disorder associated with the presence of one or more of (a) a G at nucleotide position 2210 of SEQ ID NO: 1; or (b) a C at nucleotide position 1186 of SEQ ID NO: 3 in an individual. The method comprises obtaining a nucleic acid sample from the individual and determining the nucleotide present at one or more of the indicated nucleotide positions, wherein presence of one or more of (a) a G at nucleotide position 2210 of SEQ ID NO: 1; or (b) a C at nucleotide position 1186 of SEQ ID NO: 3 is indicative of increased likelihood of said disorder in the individual as compared with an appropriate control, e.g., an individual having the reference nucleotide at one or more of said positions. In a particular embodiment the disorder is a vascular disease selected from the group consisting of atherosclerosis, coronary heart or artery disease, MI, stroke, peripheral vascular diseases, venous thromboembolism and pulmonary embolism. In a preferred embodiment, the vascular disease is selected from the group consisting of CAD and MI.

The invention further relates to a method of diagnosing or aiding in the diagnosis of a disorder associated with one or more of (a) a G at nucleotide position 2210 of SEQ ID NO: 1; or (b) a C at nucleotide position 1186 of SEQ ID NO: 3 in an individual. The method comprises obtaining a nucleic acid sample from the individual and determining the nucleotide present at one or more of the indicated nucleotide positions, wherein presence of one or more of (a) an A at nucleotide position 2210 of SEQ ID NO: 1; or (b) a G at nucleotide position 1186 of SEQ ID NO: 3 is indicative of decreased likelihood of said disorder in the individual as compared with an appropriate control, e.g., an individual having the variant nucleotide at said position. In a particular embodiment the disorder is a vascular disease selected from the group consisting of atherosclerosis, coronary heart or artery disease, MI, stroke, peripheral vascular diseases, venous thromboembolism and pulmonary embolism. In a preferred embodiment, the vascular disease is selected from the group consisting of CAD and MI.

In one embodiment, the invention relates to a method for predicting the likelihood that an individual will have a vascular disease (or aiding in the diagnosis of a vascular disease), comprising the steps of obtaining a DNA sample from an individual to be assessed and determining the nucleotide present at one or more of nucleotide positions 2210 of SEQ ID NO: 1 or 1186 of SEQ ID NO: 3. The presence of the reference nucleotide at one or more of these positions indicates that the individual has a lower likelihood of having a vascular disease than an individual having the variant nucleotide at one or more of these positions, or a lower likelihood of having severe symptomology. In a particular embodiment, the individual is an individual at risk for development of a vascular disease.

The invention further relates to a method of diagnosing or aiding in the diagnosis of a disorder associated with the presence of one or more of (a) a serine at amino acid position 700 of SEQ ID NO: 2; or (b) a proline at amino acid position 387 of SEQ ID NO: 4 in an individual. The method comprises obtaining a biological sample containing the TSP-1 and/or TSP-4 protein or relevant portion thereof from the individual and determining the amino acid present at one or more of the indicated amino acid positions, wherein presence of one or more of (a) a serine at amino acid position 700 of SEQ ID NO: 2; or (b) a proline at amino acid position 387 of SEQ ID NO: 4 is indicative of increased likelihood of said disorder in the individual as compared with an appropriate control, e.g., an individual having the reference amino acid at one or more of said positions.

The invention further relates to a method of diagnosing or aiding in the diagnosis of a disorder associated with one or more of (a) a serine at amino acid position 700 of SEQ ID NO: 2; or (b) a proline at amino acid position 387 of SEQ ID NO: 4 in an individual. The method comprises obtaining a biological sample containing the TSP-1 and/or TSP-4 protein or relevant portion thereof from the individual and determining the amino acid present at one or more of the indicated amino acid positions, wherein presence of one or more of (a) an asparagine at amino acid position 700 of SEQ ID NO: 2; or (b) an alanine at amino acid position 387 of SEQ ID NO: 4 is indicative of decreased likelihood of said disorder in the individual as compared with an appropriate control, e.g., an individual having the variant amino acid at one or more of said positions.

In one embodiment, the invention relates to a method for predicting the likelihood that an individual will have a vascular disease (or aiding in the diagnosis of a vascular disease), comprising the steps of obtaining a biological sample comprising the TSP-1 and/or TSP-4 protein or relevant portion thereof from an individual to be assessed and determining the amino acid present at one or more of amino acid positions 700 of SEQ ID NO: 2 or 387 of SEQ ID NO: 4. The presence of the reference amino acid at one or more of these positions indicates that the individual has a lower likelihood of having a vascular disease than an individual having the variant amino acid at one or more of these positions, or a lower likelihood of having severe symptomology. In a particular embodiment, the individual is an individual at risk for development of a vascular disease.

In another embodiment, the invention relates to pharmaceutical compositions comprising a reference TSP-1 and/or TSP-4 gene or gene product, or active portion thereof, for use in the treatment of vascular diseases. The invention further relates to the use of agonists and antagonists of TSP-1 and TSP-4 activity for use in the treatment of vascular diseases. In a particular embodiment the vascular disease is selected from the group consisting of atherosclerosis, coronary heart or artery disease, MI, stroke, peripheral vascular diseases, venous thromboembolism and pulmonary embolism. In a preferred embodiment, the vascular disease is selected from the group consisting of CAD and MI.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A-1D show the reference nucleotide (SEQ ID NO: 1) and amino acid (SEQ ID NO: 2) sequences for TSP-1.

FIGS. 2A-2C show the reference nucleotide (SEQ ID NO: 3) and amino acid (SEQ ID NO: 4) sequences for TSP-4.

FIG. 3 shows a table providing detailed information about the SNPs identified herein. Column one shows the internal polymorphism identifier. Column two shows the accession number for the reference sequence in the TIGR database which can be found on the world wide web at tigr.org/tdb/hgi/searching/hgigreports.html. Column three shows the nucleotide position for the SNP site. Column four shows the gene in which the polymorphism was identified. Column five shows the polymorphic site and additional flanking sequence on each side of the polymorphism. Column six shows the type of mutation produced by the polymorphism. Columns seven and eight show the reference and alternate (variant) nucleotides, respectively, for the SNP. Columns nine and ten show the reference and alternate (variant) amino acids, respectively, encoded by the alleles of the gene.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to a gene which comprises a single nucleotide polymorphism (SNP) at a specific location. The gene which includes the SNP has at least two alleles, referred to herein as the reference allele and the variant allele. The reference allele (prototypical or wild type allele) has been designated arbitrarily and typically corresponds to the nucleotide sequence of the gene which has been deposited with GenBank or TIGR under a given Accession number. The variant allele differs from the reference allele by one nucleotide at the site(s) identified in the Table. The present invention also relates to variant alleles of the described genes and to complements of the variant alleles. The invention also relates to nucleic acid molecules which hybridize to and/or share identity with the variant alleles identified herein (or their complements) and which also comprise the variant nucleotide at the SNP site.

The invention further relates to portions of the variant alleles and portions of complements of the variant alleles which comprise (encompass) the site of the SNP and are at least 5 nucleotides in length. Portions can be, for example, 5-10, 5-15, 10-20, 5-25, 10-30, 10-50 or 10-100 bases long. For example, a portion of a variant allele which is 21 nucleotides in length includes the single nucleotide polymorphism (the nucleotide which differs from the reference allele at that site) and twenty additional nucleotides which flank the site in the variant allele. These nucleotides can be on one or both sides of the polymorphism. Polymorphisms which are the subject of this invention are defined in the Table with respect to the reference sequence deposited in GenBank or TIGR under the Accession number indicated. For example, the invention relates to a portion of a gene (e.g., AT3) having a nucleotide sequence as deposited in GenBank (e.g., U11270) comprising a single nucleotide polymorphism at a specific position (e.g., nucleotide 11918). The reference nucleotide for AT3 is shown in column 8, and the variant nucleotide is shown in column 9 of the Table. The nucleotide sequences of the invention can be double- or single-stranded.

Definitions

A nucleic acid molecule or oligonucleotide can be DNA or RNA, and single- or double-stranded. Nucleic acid molecules and oligonucleotides can be naturally occurring or synthetic, but are typically prepared by synthetic means. Preferred nucleic acid molecules and oligonucleotides of the invention include segments of DNA, or their complements, which include any one of the polymorphic sites shown in the Table. The segments can be between 5 and 250 bases, and, in specific embodiments, are between 5-10, 5-20, 10-20, 10-50, 20-50 or 10-100 bases. For example, the segment can be 21 bases. The polymorphic site can occur within any position of the segment. The segments can be from any of the allelic forms of DNA shown in the Table.

As used herein, the terms “nucleotide”, “base” and “nucleic acid” are intended to be equivalent. The terms “nucleotide sequence”, “nucleic acid sequence”, “nucleic acid molecule” and “segment” are intended to be equivalent.

Hybridization probes are oligonucleotides which bind in a base-specific manner to a complementary strand of nucleic acid. Such probes include peptide nucleic acids, as described in Nielsen et al., Science 254, 1497-1500 (1991). Probes can be any length suitable for specific hybridization to the target nucleic acid sequence. The most appropriate length of the probe may vary depending upon the hybridization method in which it is being used; for example, particular lengths may be more appropriate for use in microfabricated arrays, while other lengths may be more suitable for use in classical hybridization methods. Such optimizations are known to the skilled artisan. Suitable probes and primers can range from about 5 nucleotides to about 30 nucleotides in length. For example, probes and primers can be 5, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 25, 26, 28 or 30 nucleotides in length. The probe or primer preferably overlaps at least one polymorphic site occupied by any of the possible variant nucleotides. The nucleotide sequence can correspond to the coding sequence of the allele or to the complement of the coding sequence of the allele.

As used herein, the term “primer” refers to a single-stranded oligonucleotide which acts as a point of initiation of template-directed DNA synthesis under appropriate conditions (e.g., in the presence of four different nucleoside triphosphates and an agent for polymerization, such as DNA or RNA polymerase or reverse transcriptase) in an appropriate buffer and at a suitable temperature. The appropriate length of a primer depends on the intended use of the primer, but typically ranges from 15 to 30 nucleotides. Short primer molecules generally require cooler temperatures to form sufficiently stable hybrid complexes with the template. A primer need not reflect the exact sequence of the template, but must be sufficiently complementary to hybridize with a template. The term primer site refers to the area of the target DNA to which a primer hybridizes. The term primer pair refers to a set of primers including a 5′ (upstream) primer that hybridizes with the 5′ end of the DNA sequence to be amplified and a 3′ (downstream) primer that hybridizes with the complement of the 3′ end of the sequence to be amplified.

As used herein, linkage describes the tendency of genes, alleles, loci or genetic markers to be inherited together as a result of their location on the same chromosome. It can be measured by percent recombination between the two genes, alleles, loci or genetic markers.

As used herein, polymorphism refers to the occurrence of two or more genetically determined alternative sequences or alleles in a population. A polymorphic marker or site is the locus at which divergence occurs. Preferred markers have at least two alleles, each occurring at frequency of greater than 1%, and more preferably greater than 10% or 20% of a selected population. A polymorphic locus may be as small as one base pair. Polymorphic markers include restriction fragment length polymorphisms, variable number of tandem repeats (VNTR's), hypervariable regions, minisatellites, dinucleotide repeats, trinucleotide repeats, tetranucleotide repeats, simple sequence repeats, and insertion elements such as Alu. The first identified allelic form is arbitrarily designated as the reference form and other allelic forms are designated as alternative or variant alleles. The allelic form occurring most frequently in a selected population is sometimes referred to as the wildtype form. Diploid organisms may be homozygous or heterozygous for allelic forms. A diallelic or biallelic polymorphism has two forms. A triallelic polymorphism has three forms.

Work described herein pertains to the resequencing of large numbers of genes in a large number of individuals to identify polymorphisms which can predispose individuals to disease. For example, polymorphisms in genes which are expressed in liver may predispose individuals to disorders of the liver. By altering amino acid sequence, SNPs may alter the function of the encoded proteins. The discovery of the SNP facilitates biochemical analysis of the variants and the development of assays to characterize the variants and to screen for pharmaceutical that would interact directly with on or another form of the protein. SNPs (including silent SNPs) also enable the development of specific DNA, RNA, or protein-based diagnostics that detect the presence or absence of the polymorphism in particular conditions.

A single nucleotide polymorphism occurs at a polymorphic site occupied by a single nucleotide, which is the site of variation between allelic sequences. The site is usually preceded by and followed by highly conserved sequences of the allele (e.g., sequences that vary in less than 1/100 or 1/1000 members of the populations).

A single nucleotide polymorphism usually arises due to substitution of one nucleotide for another at the polymorphic site. A transition is the replacement of one purine by another purine or one pyrimidine by another pyrimidine. A transversion is the replacement of a purine by a pyrimidine or vice versa. Single nucleotide polymorphisms can also arise from a deletion of a nucleotide or an insertion of a nucleotide relative to a reference allele. Typically the polymorphic site is occupied by a base other than the reference base. For example, where the reference allele contains the base “T” at the polymorphic site, the altered allele can contain a “C”, “G” or “A” at the polymorphic site.

The invention also relates to nucleic acid molecules which hybridize to the variant alleles identified herein (or their complements) and which also comprise the variant nucleotide at the SNP site. Hybridizations are usually performed under stringent conditions, for example, at a salt concentration of no more than 1 M and a temperature of at least 25° C. For example, conditions of 5×SSPE (750 mM NaCl, 50 mM NaPhosphate, 5 mM EDTA, pH 7.4) and a temperature of 25-30° C., or equivalent conditions, are suitable for allele-specific probe hybridizations. Equivalent conditions can be determined by varying one or more of the parameters given as an example, as known in the art, while maintaining a similar degree of identity or similarity between the target nucleotide sequence and the primer or probe used.

The invention also relates to nucleic acid molecules which share substantial sequence identity to the variant alleles identified herein (or their complements) and which also comprise the variant nucleotide at the SNP site. Particularly preferred are nucleic acid molecules and fragments which have at least about 60%, preferably at least about 70, 80 or 85%, more preferably at least about 90%, even more preferably at least about 95%, and most preferably at least about 98% identity with nucleic acid molecules described herein. The percent identity of two nucleotide or amino acid sequences can be determined by aligning the sequences for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first sequence). The nucleotides or amino acids at corresponding positions are then compared, and the percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % identity=# of identical positions/total # of positions×100). In certain embodiments, the length of a sequence aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 60%, and even more preferably at least 70%, 80% or 90% of the length of the reference sequence. The actual comparison of the two sequences can be accomplished by well-known methods, for example, using a mathematical algorithm. A preferred, non-limiting example of such a mathematical algorithm is described in Karlin et al., Proc. Natl. Acad. Sci. USA, 90:5873-5877 (1993). Such an algorithm is incorporated into the NBLAST and XBLAST programs (version 2.0) as described in Altschul et al., Nucleic Acids Res., 25:389-3402 (1997). When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., NBLAST) can be used. See the world wide web at ncbi.nlm.nih.gov. In one embodiment, parameters for sequence comparison can be set at score=100, wordlength=12, or can be varied (e.g., W=5 or W=20).

The term “isolated” is used herein to indicate that the material in question exists in a physical milieu distinct from that in which it occurs in nature. For example, an isolated nucleic acid of the invention may be substantially isolated with respect to the complex cellular milieu in which it naturally occurs. In some instances, the isolated material will form part of a composition (for example, a crude extract containing other substances), buffer system or reagent mix. In other circumstance, the material may be purified to essential homogeneity, for example as determined by PAGE or column chromatography such as HPLC. Preferably, an isolated nucleic acid comprises at least about 50, 80 or 90 percent (on a molar basis) of all macromolecular species present.

I. Novel Polymorphisms of the Invention

Some of the novel polymorphisms of the invention are shown in the Table. Columns one and two show designations for the indicated polymorphism. Column three shows the Genbank or TIGR Accession number for the wild type (or reference) allele. Column four shows the location of the polymorphic site in the nucleic acid sequence with reference to the Genbank or TIGR sequence shown in column three. Column five shows common names for the gene in which the polymorphism is located. Column six shows the polymorphism and a portion of the 3′ and 5′ flanking sequence of the gene. Column seven shows the type of mutation; N, non-sense, S, silent, M, missense. Columns eight and nine show the reference and alternate nucleotides, respectively, at the polymorphic site. Columns ten and eleven show the reference and alternate amino acids, respectively, encoded by the reference and variant, respectively, alleles. Other novel polymorphisms of the invention are shown in FIG. 3.

II. Analysis of Polymorphisms

A. Preparation of Samples

Polymorphisms are detected in a target nucleic acid from an individual being analyzed. For assay of genomic DNA, virtually any biological sample (other than pure red blood cells) is suitable. For example, convenient tissue samples include whole blood, semen, saliva, tears, urine, fecal material, sweat, buccal, skin and hair. For assay of cDNA or mRNA, the tissue sample must be obtained from an organ in which the target nucleic acid is expressed. For example, if the target nucleic acid is a cytochrome P450, the liver is a suitable source.

Many of the methods described below require amplification of DNA from target samples. This can be accomplished by e.g., PCR. See generally PCR Technology: Principles and Applications for DNA Amplification (ed. H. A. Erlich, Freeman Press, NY, N.Y., 1992); PCR Protocols: A Guide to Methods and Applications (eds. Innis, et al., Academic Press, San Diego, Calif., 1990); Mattila et al., Nucleic Acids Res. 19, 4967 (1991); Eckert et al., PCR Methods and Applications 1, 17 (1991); PCR (eds. McPherson et al., IRL Press, Oxford); and U.S. Pat. No. 4,683,202.

Other suitable amplification methods include the ligase chain reaction (LCR) (see Wu and Wallace, Genomics 4, 560 (1989), Landegren et al., Science 241, 1077 (1988), transcription amplification (Kwoh et al., Proc. Natl. Acad. Sci. USA 86, 1173 (1989)), and self-sustained sequence replication (Guatelli et al., Proc. Nat. Acad. Sci. USA, 87, 1874 (1990)) and nucleic acid based sequence amplification (NASBA). The latter two amplification methods involve isothermal reactions based on isothermal transcription, which produce both single stranded RNA (ssRNA) and double stranded DNA (dsDNA) as the amplification products in a ratio of about 30 or 100 to 1, respectively.

B. Detection of Polymorphisms in Target DNA

There are two distinct types of analysis of target DNA for detecting polymorphisms. The first type of analysis, sometimes referred to as de novo characterization, is carried out to identify polymorphic sites not previously characterized (i.e., to identify new polymorphisms). This analysis compares target sequences in different individuals to identify points of variation, i.e., polymorphic sites. By analyzing groups of individuals representing the greatest ethnic diversity among humans and greatest breed and species variety in plants and animals, patterns characteristic of the most common alleles/haplotypes of the locus can be identified, and the frequencies of such alleles/haplotypes in the population can be determined. Additional allelic frequencies can be determined for subpopulations characterized by criteria such as geography, race, or gender. The de novo identification of polymorphisms of the invention is described in the Examples section. The second type of analysis determines which form(s) of a characterized (known) polymorphism are present in individuals under test. There are a variety of suitable procedures, which are discussed in turn.

1. Allele-Specific Probes

The design and use of allele-specific probes for analyzing polymorphisms is described by e.g., Saiki et al., Nature 324, 163-166 (1986); Dattagupta, EP 235,726, Saiki, WO 89/11548. Allele-specific probes can be designed that hybridize to a segment of target DNA from one individual but do not hybridize to the corresponding segment from another individual due to the presence of different polymorphic forms in the respective segments from the two individuals. Hybridization conditions should be sufficiently stringent that there is a significant difference in hybridization intensity between alleles, and preferably an essentially binary response, whereby a probe hybridizes to only one of the alleles. Some probes are designed to hybridize to a segment of target DNA such that the polymorphic site aligns with a central position (e.g., in a 15-mer at the 7 position; in a 16-mer, at either the 8 or 9 position) of the probe. This design of probe achieves good discrimination in hybridization between different allelic forms.

Allele-specific probes are often used in pairs, one member of a pair showing a perfect match to a reference form of a target sequence and the other member showing a perfect match to a variant form. Several pairs of probes can then be immobilized on the same support for simultaneous analysis of multiple polymorphisms within the same target sequence.

2. Tiling Arrays

The polymorphisms can also be identified by hybridization to nucleic acid arrays, some examples of which are described in WO 95/11995. One form of such arrays is described in the Examples section in connection with de novo identification of polymorphisms. The same array or a different array can be used for analysis of characterized polymorphisms. WO 95/11995 also describes subarrays that are optimized for detection of a variant form of a precharacterized polymorphism. Such a subarray contains probes designed to be complementary to a second reference sequence, which is an allelic variant of the first reference sequence. The second group of probes is designed by the same principles as described in the Examples, except that the probes exhibit complementarity to the second reference sequence. The inclusion of a second group (or further groups) can be particularly useful for analyzing short subsequences of the primary reference sequence in which multiple mutations are expected to occur within a short distance commensurate with the length of the probes (e.g., two or more mutations within 9 to 21 bases).

3. Allele-Specific Primers

An allele-specific primer hybridizes to a site on target DNA overlapping a polymorphism and only primes amplification of an allelic form to which the primer exhibits perfect complementarity. See Gibbs, Nucleic Acid Res. 17, 2427-2448 (1989). This primer is used in conjunction with a second primer which hybridizes at a distal site. Amplification proceeds from the two primers, resulting in a detectable product which indicates the particular allelic form is present. A control is usually performed with a second pair of primers, one of which shows a single base mismatch at the polymorphic site and the other of which exhibits perfect complementarity to a distal site. The single-base mismatch prevents amplification and no detectable product is formed. The method works best when the mismatch is included in the 3′-most position of the oligonucleotide aligned with the polymorphism because this position is most destabilizing to elongation from the primer (see, e.g., WO 93/22456).

4. Direct-Sequencing

The direct analysis of the sequence of polymorphisms of the present invention can be accomplished using either the dideoxy chain termination method or the Maxam-Gilbert method (see Sambrook et al., Molecular Cloning, A Laboratory Manual (2nd Ed., CSHP, New York 1989); Zyskind et al., Recombinant DNA Laboratory Manual, (Acad. Press, 1988)).

5. Denaturing Gradient Gel Electrophoresis

Amplification products generated using the polymerase chain reaction can be analyzed by the use of denaturing gradient gel electrophoresis. Different alleles can be identified based on the different sequence-dependent melting properties and electrophoretic migration of DNA in solution. Erlich, ed., PCR Technology, Principles and Applications for DNA Amplification, (W. H. Freeman and Co, New York, 1992), Chapter 7.

6. Single-Strand Conformation Polymorphism Analysis

Alleles of target sequences can be differentiated using single-strand conformation polymorphism analysis, which identifies base differences by alteration in electrophoretic migration of single stranded PCR products, as described in Orita et al., Proc. Nat. Acad. Sci. 86, 2766-2770 (1989). Amplified PCR products can be generated as described above, and heated or otherwise denatured, to form single stranded amplification products. Single-stranded nucleic acids may refold or form secondary structures which are partially dependent on the base sequence. The different electrophoretic mobilities of single-stranded amplification products can be related to base-sequence differences between alleles of target sequences.

7. Single-Base Extension

An alternative method for identifying and analyzing polymorphisms is based on single-base extension (SBE) of a fluorescently-labeled primer coupled with fluorescence resonance energy transfer (FRET) between the label of the added base and the label of the primer. Typically, the method, such as that described by Chen et al., (PNAS 94:10756-61 (1997), incorporated herein by reference) uses a locus-specific oligonucleotide primer labeled on the 5′ terminus with 5-carboxyfluorescein (FAM). This labeled primer is designed so that the 3′ end is immediately adjacent to the polymorphic site of interest. The labeled primer is hybridized to the locus, and single base extension of the labeled primer is performed with fluorescently labeled dideoxyribonucleotides (ddNTPs) in dye-terminator sequencing fashion, except that no deoxyribonucleotides are present. An increase in fluorescence of the added ddNTP in response to excitation at the wavelength of the labeled primer is used to infer the identity of the added nucleotide.

III. Methods of Use

After determining polymorphic form(s) present in an individual at one or more polymorphic sites, this information can be used in a number of methods.

A. Forensics

Determination of which polymorphic forms occupy a set of polymorphic sites in an individual identifies a set of polymorphic forms that distinguishes the individual. See generally National Research Council, The Evaluation of Forensic DNA Evidence (Eds. Pollard et al., National Academy Press, DC, 1996). The more sites that are analyzed, the lower the probability that the set of polymorphic forms in one individual is the same as that in an unrelated individual. Preferably, if multiple sites are analyzed, the sites are unlinked. Thus, polymorphisms of the invention are often used in conjunction with polymorphisms in distal genes. Preferred polymorphisms for use in forensics are biallelic because the population frequencies of two polymorphic forms can usually be determined with greater accuracy than those of multiple polymorphic forms at multi-allelic loci.

The capacity to identify a distinguishing or unique set of forensic markers in an individual is useful for forensic analysis. For example, one can determine whether a blood sample from a suspect matches a blood or other tissue sample from a crime scene by determining whether the set of polymorphic forms occupying selected polymorphic sites is the same in the suspect and the sample. If the set of polymorphic markers does not match between a suspect and a sample, it can be concluded (barring experimental error) that the suspect was not the source of the sample. If the set of markers does match, one can conclude that the DNA from the suspect is consistent with that found at the crime scene. If frequencies of the polymorphic forms at the loci tested have been determined (e.g., by analysis of a suitable population of individuals), one can perform a statistical analysis to determine the probability that a match of suspect and crime scene sample would occur by chance.

p(ID) is the probability that two random individuals have the same polymorphic or allelic form at a given polymorphic site. In biallelic loci, four genotypes are possible: AA, AB, BA, and BB. If alleles A and B occur in a haploid genome of the organism with frequencies x and y, the probability of each genotype in a diploid organism is (see WO 95/12607):

- Homozygote: p(AA)=x²
- Homozygote: p(BB)=y²=(1−x)²
- Single Heterozygote: p(AB)=p(BA)=xy=x(1−x)
- Both Heterozygotes: p(AB+BA)=2xy=2x(1−x)

The probability of identity at one locus (i.e, the probability that two individuals, picked at random from a population will have identical polymorphic forms at a given locus) is given by the equation:

p(ID)=(x²)²+(2xy)²+(y²)².

These calculations can be extended for any number of polymnorphic forms at a given locus. For example, the probability of identity p(ID) for a 3-allele system where the alleles have the frequencies in the population of x, y and z, respectively, is equal to the sum of the squares of the genotype frequencies:

p(ID)=x⁴+(2xy)²+(2yz)²+(2xz)²+z⁴+y⁴

In a locus of n alleles, the appropriate binomial expansion is used to calculate p(ID) and p(exc).

The cumulative probability of identity (cum p(ID)) for each of multiple unlinked loci is determined by multiplying the probabilities provided by each locus.

cum p(ID)=p(ID1)p(ID2)p(ID3) . . . p(IDn)

The cumulative probability of non-identity for n loci (i.e. the probability that two random individuals will be different at 1 or more loci) is given by the equation:

cump(nonID)=1−cump(ID).

If several polymorphic loci are tested, the cumulative probability of non-identity for random individuals becomes very high (e.g., one billion to one). Such probabilities can be taken into account together with other evidence in determining the guilt or innocence of the suspect.

B. Paternity Testing

The object of paternity testing is usually to determine whether a male is the father of a child. In most cases, the mother of the child is known and thus, the mother's contribution to the child's genotype can be traced. Paternity testing investigates whether the part of the child's genotype not attributable to the mother is consistent with that of the putative father. Paternity testing can be performed by analyzing sets of polymorphisms in the putative father and the child.

If the set of polymorphisms in the child attributable to the father does not match the set of polymorphisms of the putative father, it can be concluded, barring experimental error, that the putative father is not the real father. If the set of polymorphisms in the child attributable to the father does match the set of polymorphisms of the putative father, a statistical calculation can be performed to determine the probability of coincidental match.

The probability of parentage exclusion (representing the probability that a random male will have a polymorphic form at a given polymorphic site that makes him incompatible as the father) is given by the equation (see WO 95/12607):

p(exc)=xy(1−xy)

where x and y are the population frequencies of alleles A and B of a biallelic polymorphic site.

(At a triallelic site p(exc)=xy(1−xy)+yz(1−yz)+xz(1−xz)+3xyz(1−xyz))), where x, y and z and the respective population frequencies of alleles A, B and C).

The probability of non-exclusion is

p(non-exc)=1−p(exc)

The cumulative probability of non-exclusion (representing the value obtained when n loci are used) is thus:

cump(non-exc)=p(non-exc1)p(non-exc2)p(non-exc3) . . . p(non-excn)

The cumulative probability of exclusion for n loci (representing the probability that a random male will be excluded)

cump(exc)=1−cump(non-exc).

If several polymorphic loci are included in the analysis, the cumulative probability of exclusion of a random male is very high. This probability can be taken into account in assessing the liability of a putative father whose polymorphic marker set matches the child's polymorphic marker set attributable to his/her father.

C. Correlation of Polymorphisms with Phenotypic Traits

The polymorphisms of the invention may contribute to the phenotype of an organism in different ways. Some polymorphisms occur within a protein coding sequence and contribute to phenotype by affecting protein structure. The effect may be neutral, beneficial or detrimental, or both beneficial and detrimental, depending on the circumstances. For example, a heterozygous sickle cell mutationi confers resistance to malaria, but a homozygous sickle cell mutation is usually lethal. Other polymorphisms occur in noncoding regions but may exert phenotypic effects indirectly via influence on replication, transcription, and translation. A single polymorphism may affect more than one phenotypic trait. Likewise, a single phenotypic trait may be affected by polymorphisms in different genes. Further, some polymorphisms predispose an individual to a distinct mutation that is causally related to a certain phenotype.

Phenotypic traits include diseases that have known but hitherto unmapped genetic components (e.g., agammaglobulimenia, diabetes insipidus, Lesch-Nyhan syndrome, muscular dystrophy, Wiskott-Aldrich syndrome, Fabry's disease, familial hypercholesterolemia, polycystic kidney disease, hereditary spherocytosis, von Willebrand's disease, tuberous sclerosis, hereditary hemorrhagic telangiectasia, familial colonic polyposis, Ehlers-Danlos syndrome, osteogenesis imperfecta, and acute intermittent porphyria). Phenotypic traits also include symptoms of, or susceptibility to, multifactorial diseases of which a component is or may be genetic, such as autoimmune diseases, inflammation, cancer, diseases of the nervous system, and infection by pathogenic microorganisms. Some examples of autoimmune diseases include rheumatoid arthritis, multiple sclerosis, diabetes (insulin-dependent and non-independent), systemic lupus erythematosus and Graves disease. Some examples of cancers include cancers of the bladder, brain, breast, colon, esophagus, kidney, leukemia, liver, lung, oral cavity, ovary, pancreas, prostate, skin, stomach and uterus. Phenotypic traits also include characteristics such as longevity, appearance (e.g., baldness, obesity), strength, speed, endurance, fertility, and susceptibility or receptivity to particular drugs or therapeutic treatments.

The correlation of one or more polymorphisms with phenotypic traits can be facilitated by knowledge of the gene product of the wild type (reference) gene. The genes in which cSNPs of the present invention have been identified are genes which have been previously sequenced and characterized in one of their allelic forms.

Correlation is performed for a population of individuals who have been tested for the presence or absence of a phenotypic trait of interest and for polymorphic markers sets. To perform such analysis, the presence or absence of a set of polymorphisms (i.e. a polymorphic set) is determined for a set of the individuals, some of whom exhibit a particular trait, and some of which exhibit lack of the trait. The alleles of each polymorphism of the set are then reviewed to determine whether the presence or absence of a particular allele is associated with the trait of interest. Correlation can be performed by standard statistical methods such as a κ-squared test and statistically significant correlations between polymorphic form(s) and phenotypic characteristics are noted. For example, it might be found that the presence of allele A1 at polymorphism A correlates with heart disease. As a further example, it might be found that the combined presence of allele A1 at polymorphism A and allele B1 at polymorphism B correlates with increased milk production of a farm animal.

Such correlations can be exploited in several ways. In the case of a strong correlation between a set of one or more polymorphic forms and a disease for which treatment is available, detection of the polymorphic form set in a human or animal patient may justify immediate administration of treatment, or at least the institution of regular monitoring of the patient. Detection of a polymorphic form correlated with serious disease in a couple contemplating a family may also be valuable to the couple in their reproductive decisions. For example, the female partner might elect to undergo in vitro fertilization to avoid the possibility of transmitting such a polymorphism from her husband to her offspring. In the case of a weaker, but still statistically significant correlation between a polymorphic set and human disease, immediate therapeutic intervention or monitoring may not be justified. Nevertheless, the patient can be motivated to begin simple life-style changes (e.g., diet, exercise) that can be accomplished at little cost to the patient but confer potential benefits in reducing the risk of conditions to which the patient may have increased susceptibility by virtue of variant alleles. Identification of a polymorphic set in a patient correlated with enhanced receptiveness to one of several treatment regimes for a disease indicates that this treatment regime should be followed.

For animals and plants, correlations between characteristics and phenotype are useful for breeding for desired characteristics. For example, Beitz et al., U.S. Pat. No. 5,292,639 discuss use of bovine mitochondrial polymorphisms in a breeding program to improve milk production in cows. To evaluate the effect of mtDNA D-loop sequence polymorphism on milk production, each cow was assigned a value of 1 if variant or 0 if wildtype with respect to a prototypical mitochondrial DNA sequence at each of 17 locations considered. Each production trait was analyzed individually with the following animal model:

Y_ijkpn=μ+YS_i+P_j+X_k+β₁+ . . . β₁₇+PE_n+a_n+e_p

where Y_ijknpis the milk, fat, fat percentage, SNF, SNF percentage, energy concentration, or lactation energy record; μ is an overall mean; YS_iis the effect common to all cows calving in year-season; X_kis the effect common to cows in either the high or average selection line; β₁to β₁₇are the binomial regressions of production record on mtDNA D-loop sequence polymorphisms; PE_nis permanent environmental effect common to all records of cow n; a_nis effect of animal n and is composed of the additive genetic contribution of sire and dam breeding values and a Mendelian sampling effect; and e_pis a random residual. It was found that eleven of seventeen polymorphisms tested influenced at least one production trait. Bovines having the best polymorphic forms for milk production at these eleven loci are used as parents for breeding the next generation of the herd.

D. Genetic Mapping of Phenotypic Traits

The previous section concerns identifying correlations between phenotypic traits and polymorphisms that directly or indirectly contribute to those traits. The present section describes identification of a physical linkage between a genetic locus associated with a trait of interest and polymorphic markers that are not associated with the trait, but are in physical proximity with the genetic locus responsible for the trait and co-segregate with it. Such analysis is useful for mapping a genetic locus associated with a phenotypic trait to a chromosomal position, and thereby cloning gene(s) responsible for the trait. See Lander et al., Proc. Natl. Acad. Sci. (USA) 83, 7353-7357 (1986); Lander et al., Proc. Natl. Acad. Sci. (USA) 84, 2363-2367 (1987); Donis-Keller et al., Cell 51, 319-337 (1987); Lander et al., Genetics 121, 185-199 (1989)). Genes localized by linkage can be cloned by a process known as directional cloning. See Wainwright, Med. J. Australia 159, 170-174 (1993); Collins, Nature Genetics 1, 3-6 (1992).

Linkage studies are typically performed on members of a family. Available members of the family are characterized for the presence or absence of a phenotypic trait and for a set of polymorphic markers. The distribution of polymorphic markers in an informative meiosis is then analyzed to determine which polymorphic markers co-segregate with a phenotypic trait. See, e.g., Kerem et al., Science 245, 1073-1080 (1989); Monaco et al., Nature 316, 842 (1985); Yamoka et al., Neurology 40, 222-226 (1990); Rossiter et al., FASEB Journal 5, 21-27 (1991).

Linkage is analyzed by calculation of LOD (log of the odds) values. A lod value is the relative likelihood of obtaining observed segregation data for a marker and a genetic locus when the two are located at a recombination fraction θ, versus the situation in which the two are not linked, and thus segregating independently (Thompson & Thompson, Genetics in Medicine (5th ed, W. B. Saunders Company, Philadelphia, 1991); Strachan, “Mapping the human genome” in The Human Genome (BIOS Scientific Publishers Ltd, Oxford), Chapter 4). A series of likelihood ratios are calculated at various recombination fractions (θ), ranging from θ=0.0 (coincident loci) to θ=0.50 (unlinked). Thus, the likelihood at a given value of θ is: probability of data if loci linked at θ to probability of data if loci unlinked. The computed likelihoods are usually expressed as the log₁₀of this ratio (i.e., a lod score). For example, a lod score of 3 indicates 1000:1 odds against an apparent observed linkage being a coincidence. The use of logarithms allows data collected from different families to be combined by simple addition. Computer programs are available for the calculation of lod scores for differing values of θ (e.g., LIPED, MLINK (Lathrop, Proc. Nat. Acad. Sci. (USA) 81, 3443-3446 (1984)). For any particular lod score, a recombination fraction may be determined from mathematical tables. See Smith et al., Mathematical tables for research workers in human genetics (Churchill, London, 1961); Smith, Ann. Hum. Genet. 32, 127-150 (1968). The value of θ at which the lod score is the highest is considered to be the best estimate of the recombination fraction.

Positive lod score values suggest that the two loci are linked, whereas negative values suggest that linkage is less likely (at that value of θ) than the possibility that the two loci are unlinked. By convention, a combined lod score of +3 or greater (equivalent to greater than 1000:1 odds in favor of linkage) is considered definitive evidence that two loci are linked. Similarly, by convention, a negative lod score of −2 or less is taken as definitive evidence against linkage of the two loci being compared. Negative linkage data are useful in excluding a chromosome or a segment thereof from consideration. The search focuses on the remaining non-excluded chromosomal locations.

IV. Modified Polypeptides and Gene Sequences

The invention further provides variant forms of nucleic acids and corresponding proteins. The nucleic acids comprise one of the sequences described in the Table, column 5, in which the polymorphic position is occupied by one of the alternative bases for that position. Some nucleic acids encode full-length variant forms of proteins. Similarly, variant proteins have the prototypical amino acid sequences encoded by nucleic acid sequences shown in the Table, column 5, (read so as to be in-frame with the full-length coding sequence of which it is a component) except at an amino acid encoded by a codon including one of the polymorphic positions shown in the Table. That position is occupied by the amino acid coded by the corresponding codon in any of the alternative forms shown in the Table.

Variant genes can be expressed in an expression vector in which a variant gene is operably linked to a native or other promoter. Usually, the promoter is a eukaryotic promoter for expression in a mammalian cell. The transcription regulation sequences typically include a heterologous promoter and optionally an enhancer which is recognized by the host. The selection of an appropriate promoter, for example trp, lac, phage promoters, glycolytic enzyme promoters and tRNA promoters, depends on the host selected. Commercially available expression vectors can be used. Vectors can include host-recognized replication systems, amplifiable genes, selectable markers, host sequences useful for insertion into the host genome, and the like.

The means of introducing the expression construct into a host cell varies depending upon the particular construction and the target host. Suitable means include fusion, conjugation, transfection, transduction, electroporation or injection, as described in Sambrook, supra. A wide variety of host cells can be employed for expression of the variant gene, both prokaryotic and eukaryotic. Suitable host cells include bacteria such as E. coli, yeast, filamentous fuigi, insect cells, mammalian cells, typically immortalized, e.g., mouse, CHO, human and monkey cell lines and derivatives thereof. Preferred host cells are able to process the variant gene product to produce an appropriate mature polypeptide. Processing includes glycosylation, ubiquitination, disulfide bond formation, general post-translational modification, and the like. As used herein, “gene product” includes mRNA, peptide and protein products.

The protein may be isolated by conventional means of protein biochemistry and purification to obtain a substantially pure product, i.e., 80, 95 or 99% free of cell component contaminants, as described in Jacoby, Methods in Enzymology Volume 104, Academic Press, New York (1984); Scopes, Protein Purification, Principles and Practice, 2nd Edition, Springer-Verlag, New York (1987); and Deutscher (ed), Guide to Protein Purification, Methods in Enzymology, Vol. 182 (1990). If the protein is secreted, it can be isolated from the supernatant in which the host cell is grown. If not secreted, the protein can be isolated from a lysate of the host cells.

The invention further provides transgenic nonhuman animals capable of expressing an exogenous variant gene and/or having one or both alleles of an endogenous variant gene inactivated. Expression of an exogenous variant gene is usually achieved by operably linking the gene to a promoter and optionally an enhancer, and microinjecting the construct into a zygote. See Hogan et al., “Manipulating the Mouse Embryo, A Laboratory Manual,” Cold Spring Harbor Laboratory. Inactivation of endogenous variant genes can be achieved by forming a transgene in which a cloned variant gene is inactivated by insertion of a positive selection marker. See Capecchi, Science 244, 1288-1292 (1989). The transgene is then introduced into an embryonic stem cell, where it undergoes homologous recombination with an endogenous variant gene. Mice and other rodents are preferred animals. Such animals provide useful drug screening systems.

In addition to substantially full-length polypeptides expressed by variant genes, the present invention includes biologically active fragments of the polypeptides, or analogs thereof, including organic molecules which simulate the interactions of the peptides. Biologically active fragments include any portion of the full-length polypeptide which confers a biological function on the variant gene product, including ligand binding, and antibody binding. Ligand binding includes binding by nucleic acids, proteins or polypeptides, small biologically active molecules, or large cellular structures.

Polyclonal and/or monoclonal antibodies that specifically bind to variant gene products but not to corresponding prototypical gene products are also provided. Antibodies can be made by injecting mice or other animals with the variant gene product or synthetic peptide fragments thereof. Monoclonal antibodies are screened as are described, for example, in Harlow & Lane, Antibodies, A Laboratory Manual, Cold Spring Harbor Press, New York (1988); Goding, Monoclonal antibodies, Principles and Practice (2d ed.) Academic Press, New York (1986). Monoclonal antibodies are tested for specific immunoreactivity with a variant gene product and lack of immunoreactivity to the corresponding prototypical gene product. These antibodies are useful in diagnostic assays for detection of the variant form, or as an active ingredient in a pharmaceutical composition.

V. Kits

The invention further provides kits comprising at least one allele-specific oligonucleotide as described herein. Often, the kits contain one or more pairs of allele-specific oligonucleotides hybridizing to different forms of a polymorphism. In some kits, the allele-specific oligonucleotides are provided immobilized to a substrate. For example, the same substrate can comprise allele-specific oligonucleotide probes for detecting at least 10, 100 or all of the polymorphisms shown in the Table. Optional additional components of the kit include, for example, restriction enzymes, reverse-transcriptase or polymerase, the substrate nucleoside triphosphates, means used to label (for example, an avidin-enzyme conjugate and enzyme substrate and chromogen if the label is biotin), and the appropriate buffers for reverse transcription, PCR, or hybridization reactions. Usually, the kit also contains instructions for carrying out the methods.

The thrombospondins are a family of extracellular matrix (ECM) glycoproteins that modulate many cell behaviors including adhesion, migration, and proliferation. Thrombospondins (also known as thrombin sensitive proteins or TSPs) are large molecular weight glycoproteins composed of three identical disulfide-linked polypeptide chains. TSPs are stored in the alpha-granules of platelets and secreted by a variety of mesenchymal and epithelial cells (Majack et al., Cell Membrane 3:57-77 (1987)). Platelets secrete TSPs when activated in the blood by such physiological agonists such as thrombin. TSPs have lectin properties and a broad function in the regulation of fibrinolysis and as a component of the ECM, and are one of a group of ECM proteins which have adhesive properties. TSPs bind to fibronectin and fibrinogen (Lahav et al., Eur J Biochem 145:151-6 (1984)), and these proteins are known to be involved in platelet adhesion to substratum and platelet aggregation (Leung, J Clin Invest 74:1764-1772 (1986)).

Recent work has implicated TSPs in response of cells to growth factors. Submitogenic doses of PDGF induce a rapid but transitory, increase in TSP synthesis and secretion by rat aortic smooth muscle cells (Majack et al., J Biol Chem 101: 1059-70 (1985)). PDGF responsiveness to TSP synthesis in glial cells has also been shown (Asch et al., Proc Natl Acad Sci 83:2904-8 (1986)). TSP mRNA levels rise rapidly in response to PDGF (Majack et al., J. Biol Chem 262:8821-5 (1987)). TSPs act synergistically with epidermal growth factor to increase DNA synthesis in smooth muscle cells (Majack et al., Proc Natl Acad Sci 83:9050-4 (1986)), and monoclonal antibodies to TSPs inhibit smooth muscle cell proliferation (Majack et al., J Biol Chem 106:415-22 (1988)). TSPs modulate local adhesions in endothelial cells, and TSPs, particularly TSP-1 primarily derived from platelet granules, are known to be an important activator of transforming growth factor beta-1 (TGFB-1) (Crawford et al., Cell 93:1159 (1998)) and appear to be a potential link between platelet-thrombosis and development of atherosclerosis.

To determine pivotal genes associated with premature coronary artery disease, we analyzed DNA from 347 patients with MI or coronary revascularization before age 40 (men) or 45 (women) and 422 general population controls. Cases were drawn (one per family) from a retrospective collection of sibling pairs with premature CAD. Controls were ascertained through random-digit dialing. Both cases and controls were Caucasian. A complete database of phenotypic and laboratory variables for the affected patients afforded logistic regression to control for age, diabetes, body mass index, gender.

Thrombospondin (TSP) 4 and 1 emerged as important SNPs associated with premature CAD and MI. For CAD, 148 of 347 patients carried at least one copy of the TSP-4 variant compared with 142 of 422 control subjects; adjusted odds ratio 1.47, p=0.01. For premature MI, the association was even stronger: 91 of 187 cases vs. 142 of 422 controls had the variant; adjusted odds ratio 2.08, p=0.0003. The TSP-1 SNP was rare. Nonetheless, homozygosity for the variant allele gave an adjusted odds ratio of 9.5, p=0.04.

Specific reference nucleotide (SEQ ID NO: 1) and amino acid (SEQ ID NO: 2) sequences for TSP-1 are shown in FIGS. 1A-1D. Specific reference nucleotide (SEQ ID NO: 3) and amino acid (SEQ ID NO: 4) sequences for TSP-4 are shown in FIGS. 2A-2C. It is understood that the invention is not limited by these exemplified reference sequences, as variants of these sequences which differ at locations other than the SNP sites identified herein can also be utilized. The skilled artisan can readily determine the SNP sites in these other reference sequences which correspond to the SNP sites identified herein by aligning the sequence of interest with the reference sequences specifically disclosed herein, and programs for performing such alignments are commercially available. For example, the ALIGN program in the GCG software package can be used, utilizing a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4, for example.

Two SNPs have been specifically studied as described herein. The first (G334u4) is a change from A (reference nucleotide) to G (alternate or variant nucleotide) at nucleotide position 2210 of the nucleic acid sequence of TSP—I (FIGS. 1A-1D), resulting in a missense amino acid mutation from asparagine (reference) to serine (alternate) at amino acid 700. The second SNP (G355u2) is a change from G (reference) to C (alternate) at nucleotide position 1186 of the nucleic acid sequence of TSP-4 (FIGS. 2A-2C), resulting in a missense amino acid alteration from alanine (reference) to proline (alternate) at amino acid 387. With respect to the G355u2 SNP, individuals with CAD carried at least one copy of the variant “C” allele more frequently than control individuals (43% as compared with 34%). With respect to the G355u2 SNP, individuals with MI carried at least one copy of the variant “C” allele more frequently than control individuals (49% as compared with 34%). With respect to the G334u4 SNP, individuals with CAD carried two copies of the variant “G” allele more frequently than control individuals (1.7% as compared with 0.2%). With respect to the G334u4 SNP, individuals with MI carried two copies of the variant “G” allele more frequently than control individuals (2% as compared with 0.2%).

As used herein, the term “polymorphism” refers to the occurrence of two or more genetically determined alternative sequences or alleles in a population. A polymorphic marker or site is the locus at which divergence occurs. Preferred markers have at least two alleles, each occurring at frequency of greater than 1%, and more preferably greater than 10% or 20% of a selected population. A polymorphic locus may be as small as one base pair, in which case it is referred to as a single nucleotide polymorphism (SNP).

Thus, the invention relates to a method for predicting the likelihood that an individual will have a vascular disease, or for aiding in the diagnosis of a vascular disease, or predicting the likelihood of having altered symptomology associated with a vascular disease, comprising the steps of obtaining a DNA sample from an individual to be assessed and determining the nucleotide present at one or more of nucleotide positions 2210 of the TSP-1 gene or 1186 of the TSP-4 gene. In a preferred embodiment, the nucleotides present at both of these nucleotide positions are determined. In one embodiment the TSP-1 gene has the nucleotide sequence of SEQ ID NO: 1 and the TSP-4 gene has the nucleotide sequence of SEQ ID NO: 3. The presence of one or more of a G (the variant nucleotide) at position 2210 of SEQ ID NO: 1 or a C (the variant nucleotide) at position 1186 of SEQ ID NO: 1186 indicates that the individual has a greater likelihood of having a vascular disease, or a greater likelihood of having severe symptomology associated with a vascular disease, than if that individual had the reference nucleotide at one or more of these positions. Conversely, the presence of one or more of an A (the reference nucleotide) at position 2210 of SEQ ID NO: 1 or a G (the reference nucleotide) at position 1186 of SEQ ID NO: 3 indicates that the individual has a reduced likelihood of having a vascular disease or a likelihood of having reduced symptomology associated with a vascular disease than if that individual had the variant nucleotide at one or more of these positions.

In a particular embodiment, the individual is an individual at risk for development of a vascular disease. In another embodiment the individual exhibits clinical symptomology associated with a vascular disease. In one embodiment, the individual has been clinically diagnosed as having a vascular disease. Vascular diseases include, but are not limited to, atherosclerosis, coronary heart disease, myocardial infarction (MI), stroke, peripheral vascular diseases, venous thromboembolism and puhnonary embolism. In preferred embodiments, the vascular disease is CAD or MI.

The genetic material to be assessed can be obtained from any nucleated cell from the individual. For assay of genomic DNA, virtually any biological sample (other than pure red blood cells) is suitable. For example, convenient tissue samples include whole blood, semen, saliva, tears, urine, fecal material, sweat, skin and hair. For assay of cDNA or mRNA, the tissue sample must be obtained from a tissue or organ in which the target nucleic acid is expressed.

Many of the methods described herein require amplification of DNA from target samples. This can be accomplished by e.g., PCR. See generally PCR Technology: Principles and Applications for DNA Amplification (ed. H. A. Erlich, Freeman Press, NY, N.Y., 1992); PCR Protocols: A Guide to Methods and Applications (eds. Innis, et al., Academic Press, San Diego, Calif., 1990); Mattila et al., Nucleic Acids Res. 19, 4967 (1991); Eckert et al., PCR Methods and Applications 1, 17 (1991); PCR (eds. McPherson et al., IRL Press, Oxford); and U.S. Pat. No. 4,683,202.

The nucleotide which occupies the polymorphic site of interest (e.g., nucleotide position 2210 in TSP-1 and/or nucleotide position 1186 in TSP-4) can be identified by a variety of methods, such as Southern analysis of genomic DNA; direct mutation analysis by restriction enzyme digestion; Northern analysis of RNA; denaturing high pressure liquid chromatography (DHPLC); gene isolation and sequencing; hybridization of an allele-specific oligonucleotide with amplified gene products; single base extension (SBE). In a preferred embodiment, determination of the allelic form of TSP is carried out using SBE-FRET methods as described herein, or using chip-based oligonucleotide arrays as described herein.

The invention also relates to a method for predicting the likelihood that an individual will have a vascular disease, or for aiding in the diagnosis of a vascular disease, or predicting the likelihood of having altered symptomology associated with a vascular disease, comprising the steps of obtaining a biological sample comprising TSP-1 and/or TSP-4 protein or relevant portion thereof from an individual to be assessed and determining the amino acid present at one or more of amino acid positions 700 of the TSP-1 gene product (e.g., as exemplified by SEQ ID NO: 2) or 387 of the TSP-4 gene product (e.g., as exemplified by SEQ ID NO: 4). In a preferred embodiment, the amino acids present at both of these amino acid positions are determined. As used herein, the term “relevant portion” of the TSP-1 and TSP-4 proteins is intended to encompass any portion of the protein which comprises the polymorphic amino acid positions. The presence of one or more of a serine (the variant amino acid) at position 700 of SEQ ID NO: 2, or a proline (the variant amino acid) at position 387 of SEQ ID NO: 4 indicates that the individual has a greater likelihood of having a vascular disease, or a greater likelihood of having severe symptomology associated with a vascular disease, than if that individual had the reference amino acid at one or more of these positions. Conversely, the presence of one or more of an asparagine (the reference amino acid) at position 700 of SEQ ID NO: 2, or an alanine (the reference amino acid) at position 387 of SEQ ID NO: 4 indicates that the individual has a reduced likelihood of having a vascular disease or a likelihood of having reduced symptomology associated with a vascular disease, than if that individual had the varaint amino acid at one or more of these positions.

In this embodiment of the invention, the biological sample contains protein molecules from the test subject. In vitro techniques for detection of protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence. Furthermore, in vivo techniques for detection of protein include introducing into a subject a labeled anti-protein antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques. Polyclonal and/or monoclonal antibodies that specifically bind to variant gene products but not to corresponding reference gene products, and vice versa, are also provided. Antibodies can be made by injecting mice or other animals with the variant gene product or synthetic peptide fragments thereof comprising the variant portion. Monoclonal antibodies are screened as are described, for example, in Harlow & Lane, Antibodies, A Laboratory Manual, Cold Spring Harbor Press, New York (1988); Goding, Monoclonal antibodies, Principles and Practice (2d ed.) Academic Press, New York (1986). Monoclonal antibodies are tested for specific immunoreactivity with a variant gene product and lack of immunoreactivity to the corresponding prototypical gene product. These antibodies are useful in diagnostic assays for detection of the variant form, or as an active ingredient in a pharmaceutical composition.

The polymorphisms of the invention may be associated with vascular disease in different ways. The polymorphisms may exert phenotypic effects indirectly via influence on replication, transcription, and translation. Additionally, the described polymorphisms may predispose an individual to a distinct mutation that is causally related to a certain phenotype, such as susceptibility or resistance to vascular disease and related disorders. The discovery of the polymorphisms and their correlation with CAD and MI facilitates biochemical analysis of the variant and reference forms and the development of assays to characterize the variant and reference forms and to screen for pharmaceutical agents that interact directly with one or another form of the protein.

Alternatively, these particular polymorphisms may belong to a group of two or more polymorphisms in the TSP gene(s) which contributes to the presence, absence or severity of vascular disease. An assessment of other polymorphisms within the TSP gene(s) can be undertaken, and the separate and combined effects of these polymorphisms, as well as alternations in other, distinct genes, on the vascular disease phenotype can be assessed.

Correlation between a particular phenotype, e.g., the CAD or MI phenotype, and the presence or absence of a particular allele is performed for a population of individuals who have been tested for the presence or absence of the phenotype. Correlation can be performed by standard statistical methods such as a Chi-squared test and statistically significant correlations between polymorphic form(s) and phenotypic characteristics are noted. This correlation can be exploited in several ways. In the case of a strong correlation between a particular polymorphic form, e.g., the variant allele for TSP-1 and/or TSP-4, and a disease for which treatment is available, detection of the polymorphic form in an individual may justify immediate administration of treatment, or at least the institution of regular monitoring of the individual. Detection of a polymorphic form correlated with a disorder in a couple contemplating a family may also be valuable to the couple in their reproductive decisions. For example, the female partner might elect to undergo in vitro fertilization to avoid the possibility of transmitting such a polymorphism from her husband to her offspring. In the case of a weaker, but still statistically significant correlation between a polymorphic form and a particular disorder, immediate therapeutic intervention or monitoring may not be justified. Nevertheless, the individual can be motivated to begin simple life-style changes (e.g., diet modification, therapy or counseling) that can be accomplished at little cost to the individual but confer potential benefits in reducing the risk of conditions to which the individual may have increased susceptibility by virtue of the particular allele. Furthermore, identification of a polymorphic form correlated with enhanced receptiveness to one of several treatment regimes for a disorder indicates that this treatment regimen should be followed for the individual in question.

Furthermore, it may be possible to identify a physical linkage between a genetic locus associated with a trait of interest (e.g., CAD or MI) and polymorphic markers that are or are not associated with the trait, but are in physical proximity with the genetic locus responsible for the trait and co-segregate with it. Such analysis is useful for mapping a genetic locus associated with a phenotypic trait to a chromosomal position, and thereby cloning gene(s) responsible for the trait. See Lander et al., Proc. Natl. Acad. Sci. (USA) 83, 7353-7357 (1986); Lander et al., Proc. Natl. Acad. Sci. (USA) 84, 2363-2367 (1987); Donis-Keller et al., Cell 51, 319-337 (1987); Lander et al., Genetics 121, 185-199 (1989)). Genes localized by linkage can be cloned by a process known as directional cloning. See Wainwright, Med. J Australia 159, 170-174 (1993); Collins, Nature Genetics 1, 3-6 (1992). Linkage studies are discussed in more detail above.

In another embodiment, the invention relates to pharmaceutical compositions comprising a reference TSP-1 and/or TSP-4 gene or gene product for use in the treatment of vascular disease, e.g., CAD and MI. As used herein, a reference TSP gene product is intended to mean gene products which are encoded by the reference allele of the TSP gene. In addition to substantially full-length polypeptides expressed by the genes, the present invention includes biologically active fragments of the polypeptides, or analogs thereof, including organic molecules which simulate the interactions of the peptides. Biologically active fragments include any portion of the full-length polypeptide which confers a biological function on the variant gene product, including ligand binding, and antibody binding. Ligand binding includes binding by nucleic acids, proteins or polypeptides, small biologically active molecules, or large cellular structures.

For instance, the polypeptide or protein, or fragment thereof, of the present invention can be formulated with a physiologically acceptable medium to prepare a pharmaceutical composition. The particular physiological medium may include, but is not limited to, water, buffered saline, polyols (e.g., glycerol, propylene glycol, liquid polyethylene glycol) and dextrose solutions. The optimum concentration of the active ingredient(s) in the chosen medium can be determined empirically, according to procedures well known to medicinal chemists, and will depend on the ultimate pharmaceutical formulation desired. Methods of introduction of exogenous peptides at the site of treatment include, but are not limited to, intradernal, intramuscular, intraperitoneal, intravenous, subcutaneous, oral and intranasal. Other suitable methods of introduction can also include rechargeable or biodegradable devices and slow release polymeric devices. The pharmaceutical compositions of this invention can also be administered as part of a combinatorial therapy with other agents and treatment regimens.

The invention further pertains to compositions, e.g., vectors, comprising a nucleotide sequence encoding reference or variant TSP-1 and/or TSP-4 gene products. For example, reference genes can be expressed in an expression vector in which a reference gene is operably linked to a native or other promoter. Usually, the promoter is a eukaryotic promoter for expression in a mammalian cell. The transcription regulation sequences typically include a heterologous promoter and optionally an enhancer which is recognized by the host. The selection of an appropriate promoter, for example trp, lac, phage promoters, glycolytic enzyme promoters and tRNA promoters, depends on the host selected. Commercially available expression vectors can be used. Vectors can include host-recognized replication systems, amplifiable genes, selectable markers, host sequences useful for insertion into the host genome, and the like.

The means of introducing the expression construct into a host cell varies depending upon the particular construction and the target host. Suitable means include fusion, conjugation, transfection, transduction, electroporation or injection, as described in Sambrook, supra. A wide variety of host cells can be employed for expression of the variant gene, both prokaryotic and eukaryotic. Suitable host cells include bacteria such as E. coli, yeast, filamentous fungi, insect cells, mammalian cells, typically immortalized, e.g., mouse, CHO, human and monkey cell lines and derivatives thereof. Preferred host cells are able to process the variant gene product to produce an appropriate mature polypeptide. Processing includes glycosylation, ubiquitination, disulfide bond formation, general post-translational modification, and the like.

It is also contemplated that cells can be engineered to express the reference allele of the invention by gene therapy methods. For example, DNA encoding the reference TSP gene product, or an active fragment or derivative thereof, can be introduced into an expression vector, such as a viral vector, and the vector can be introduced into appropriate cells in an animal. In such a method, the cell population can be engineered to inducibly or constitutively express active reference TSP gene product. In a preferred embodiment, the vector is delivered to the bone marrow, for example as described in Corey et al. (Science 244:1275-1281 (1989)).

The invention further relates to the use of compositions (i.e., agonists) which enhance or increase the activity of the reference (or variant) TSP (e.g., TSP-1 or TSP-4) gene product, or a functional portion thereof, for use in the treatment of vascular disease. The invention also relates to the use of compositions (i.e., antagonists) which reduce or decrease the activity of the variant (or reference) TSP (e.g., TSP-1 or TSP-4) gene product, or a functional portion thereof, for use in the treatment of vascular disease.

The invention also relates to constructs which comprise a vector into which a sequence of the invention has been inserted in a sense or antisense orientation. For example, a vector comprising a nucleotide sequence which is antisense to the variant TSP-1 or TSP-4 allele may be used as an antagonist of the activity of the TSP-1 or TSP-4 variant allele. Alternatively, a vector comprising a nucleotide sequence of the TSP-1 or TSP-4 reference allele may be used therapeutically to treat vascular diseases. As used herein, the term “vector” refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a “plasmid”, which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors, expression vectors, are capable of directing the expression of genes to which they are operably linked. In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids (vectors). However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses) that serve equivalent functions.

Preferred recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell. This means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, which is operably linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, “operably linked” is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleotide sequence (e.g., in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell). The term “regulatory sequence” is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990). Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cell and those which direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc.

The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein. The recombinant expression vectors of the invention can be designed for expression of a polypeptide of the invention in prokaryotic or eukaryotic cells, e.g., bacterial cells such as E. coli, insect cells (using baculovirus expression vectors), yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, supra. Alternatively, the recombinant expression vector can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase.

Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms “host cell” and “recombinant host cell” are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but also to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein. A host cell can be any prokaryotic or eukaryotic cell. For example, a nucleic acid of the invention can be expressed in bacterial cells (e.g., E. coli), insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.

Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms “transformation” and “transfection” are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. (supra), and other laboratory manuals.

A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (i.e., express) a polypeptide of the invention. Accordingly, the invention further provides methods for producing a polypeptide using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of the invention (into which a recombinant expression vector encoding a polypeptide of the invention has been introduced) in a suitable medium such that the polypeptide is produced. In another embodiment, the method further comprises isolating the polypeptide from the medium or the host cell.

The host cells of the invention can also be used to produce nonhuman transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which a nucleic acid of the invention has been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous nucleotide sequences have been introduced into their genome or homologous recombinant animals in which endogenous nucleotide sequences have been altered. Such animals are useful for studying the function and/or activity of the nucleotide sequence and polypeptide encoded by the sequence and for identifying and/or evaluating modulators of their activity. As used herein, a “transgenic animal” is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, etc. A transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, an “homologous recombinant animal” is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, e.g., an embryonic cell of the animal, prior to development of the animal.

A transgenic animal of the invention can be created by introducing a nucleic acid of the invention into the male pronuclei of a fertilized oocyte, e.g., by microinjection, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. The sequence can be introduced as a transgene into the genome of a non-human animal. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequence(s) can be operably linked to the transgene to direct expression of a polypeptide in particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Pat. Nos. 4,736,866 and 4,870,009, U.S. Pat. No. 4,873,191 and in Hogan, Manipulating the Mouse Embryo (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986). Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the transgene in its genome and/or expression of mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene encoding the transgene can further be bred to other transgenic animals carrying other transgenes.

The invention also relates to the use of the variant and reference gene products to guide efforts to identify the causative mutation for vascular diseases or to identify or synthesize agents useful in the treatment of vascular diseases, e.g., CAD and MI. Amino acids that are essential for function can be identified by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham et al., Science, 244:1081-1085 (1989)). The latter procedure introduces single alanine mutations at every residue in the molecule. The resulting mutant molecules are then tested for biological activity in vitro, or in vitro activity. Sites that are critical for polypeptide activity can also be determined by structural analysis such as crystallization, nuclear magnetic resonance or photoaffinity labeling (Smith et al., J. Mol. Biol., 224:899-904 (1992); de Vos et al. Science, 255:306-312 (1992)).

Another aspect of the invention pertains to monitoring the influence of agents (e.g., drugs, compounds) on the expression or activity of proteins of the invention in clinical trials. An exemplary method for detecting the presence or absence of proteins or nucleic acids of the invention in a biological sample involves obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting the protein, or nucleic acid (e.g., mRNA, genomic DNA) that encodes the protein, such that the presence of the protein or nucleic acid is detected in the biological sample. A preferred agent for detecting mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to mRNA or genomic DNA sequences described herein, preferably in an allele-specific manner. The nucleic acid probe can be, for example, a full-length nucleic acid, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to appropriate mRNA or genomic DNA. Other suitable probes for use in the diagnostic assays of the invention are described herein.

The invention also encompasses kits for detecting the presence of proteins or nucleic acid molecules of the invention in a biological sample. For example, the kit can comprise a labeled compound or agent (e.g., nucleic acid probe) capable of detecting protein or mRNA in a biological sample; means for determining the amount of protein or mRNA in the sample; and means for comparing the amount of protein or mRNA in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect protein or nucleic acid.

The following Examples are offered for the purpose of illustrating the present invention and are not to be construed to limit the scope of this invention. The teachings of all references cited herein are hereby incorporated herein by reference.

EXAMPLES

Identification of Single Nucleotide Polymorphisms

The polymorphisms shown in the Table were identified by resequencing of target sequences from individuals of diverse ethnic and geographic backgrounds by hybridization to probes immobilized to microfabricated arrays. The strategy and principles for design and use of such arrays are generally described in WO 95/11995.

A typical probe array used in this analysis has two groups of four sets of probes that respectively tile both strands of a reference sequence. A first probe set comprises a plurality of probes exhibiting perfect complementarily with one of the reference sequences. Each probe in the first probe set has an interrogation position that corresponds to a nucleotide in the reference sequence. That is, the interrogation position is aligned with the corresponding nucleotide in the reference sequence, when the probe and reference sequence are aligned to maximize complementarily between the two. For each probe in the first set, there are three corresponding probes from three additional probe sets. Thus, there are four probes corresponding to each nucleotide in the reference sequence. The probes from the three additional probe sets are identical to the corresponding probe from the first probe set except at the interrogation position, which occurs in the same position in each of the four corresponding probes from the four probe sets, and is occupied by a different nucleotide in the four probe sets. In the present analysis, probes were 25 nucleotides long. Arrays tiled for multiple different references sequences were included on the same substrate.

Publicly available sequences for a given gene were assembled into Gap4, which can be found on the world wide web at biozentrum.unibas.ch/biocomp/staden/Overview.html. PCR primers covering each exon were designed using Primer 3, which can be found on the world wide web at genome.wi.mit.edu/cgi-bin/primer/primer3.cgi. Primers were not designed in regions where there were sequence discrepancies between reads. Genomic DNA was amplified in at least 50 individuals using 2.5 pmol each primer, 1.5 mM MgCl₂, 100 μM dNTPs, 0.75 μM AmpliTaq GOLD polymerase, and 19 ng DNA in a 15 μl reaction. Reactions were assembled using a PACKARD MultiPROBE robotic pipetting station and then put in MJ 96-well tetrad thermocyclers (96° C. for 10 minutes, followed by 35 cycles of 96° C. for 30 seconds, 59° C. for 2 minutes, and 72° C. for 2 minutes). A subset of the PCR assays for each individual were run on 3% NuSieve gels in 0.5×TBE to confirm that the reaction worked.

For a given DNA, 5 μL (about 50 ng) of each PCR or RT-PCR product were pooled (Final volume=150-200 μl). The products were purified using QiaQuick PCR purification from Qiagen. The samples were eluted once in 35 μl sterile water and 4 μl 10× One-Phor-All buffer (Pharmacia). The pooled samples were digested with 0.2μ DNaseI (Promega) for 10 minutes at 37° C. and then labeled with 0.5 mmols biotin-N-6-ddATP and 15μ Terminal Transferase (GibcoBRL Life Technology) for 60 minutes at 37° C. Both fragmentation and labeling reactions were terminated by incubating the pooled sample for 15 minutes at 100° C.

Low-density DNA chips (Affymetrix, Calif.) were hybridized following the manufacturer's instructions. Briefly, the hybridization cocktail consisted of 3M TMACl, 10 mM Tris pH 7.8, 0.01% Triton X-100, 100 mg/ml herring sperm DNA (Gibco BRL), 200 pM control biotin-labeled oligo. The processed PCR products were denatured for 7 minutes at 100° C. and then added to prewarmed (37° C.) hybridization solution. The chips were hybridized overnight at 44° C. Chips were washed in 1×SSPET and 6×SSPET followed by staining with 2 μg/ml SARPE and 0.5 mg/ml acetylated BSA in 200 μl of 6×SSPET for 8 minutes at room temperature. Chips were scanned using a Molecular Dynamics scanner.

Chip image files were analyzed using Ulysses (Affymetrix, Calif.) which uses four algorithms to identify potential polymorphisms. Candidate polymorphisms were visually inspected and assigned a confidence value: high confidence candidates displayed all three genotypes, while likely candidates showed only two genotypes (homozygous for reference sequence and heterozygous for reference and variant). Some of the candidate polymorphisms were confirmed by ABI sequencing. Identified polymorphisms were compared to several databases to determine if they were novel. Results are shown in the Table.

Association of Thrombospondin Gene Polymorphisms with Vascular Disease

Genbankor TIGRPositionMuta-PolyWIAFAccessioninGeneFlankingtionRefAltRefAltIDIDNumberSequenceDescriptionSeqTypeNTNTAAAAAT3a7WIAF-13246U1127011918AT3,CTGCAGGAGT[G/A]GCTGGATGAANGAW*antithrombin IIIDRD5u22WIAF-12913M67439310DRD1,CATCTGGACC[C/T]TGCTGGGCAASCTLLdopamine receptorD1DRD5u23WIAF-12914M67439332DRD1,GTGCTGGTGT[G/C]CGCAGCCATCMGCCSdopamine receptorD1DRD5u24WIAF-12915M67439369DRD1,TGCGCGCCAA[C/G]ATGACCAACGMCGNKdopamine receptorD1DRD5u25WIAF-12916M67439522DRD1,TGTGCTCCAC[T/C]GCCTCCATCCSTCTTdopamine receptorD1DRD5u26WIAF-12917M67439953DRD1,GCAGAGCACG[C/T]GCAGAGCTGCMCTAVdopamine receptor D1DRD5u27WIAF-12918M67439635DRD1,ATGGTCGGCC[T/C]GGCATGGACCMTCLPdopamine receptorD1DRD5u2BWIAF-129l9M67439606DRD1,GCAAGATGAC[T/C]CAGCGCATGGSTCTTdopamine receptorD1DRD5u29WIAF-12920M67439845DRD1,TCGCTCATCA[G/A]CTTCTACATCMGASNdopamine receptorD1DRD5u30WIAF-12921M67439720DRD1,CGGGCCGGCT[G/T]GACCTGCCAASGTLLdopamine receptorD1DRD5u31WIAF-12922M674391044DRD1,AGACCCTGTC[G/A]GTGATCATGGSGASSdopamine receptorD1DRD5u32WIAF-12923M67439766DRD1,GGAGGAGGAC[T/G]TTTGGGAGCCMTGFVdopamine receptorD1DRD5u33WIAF-12924N67439777DRD1,TTTCCGAOCC[C/T]GACCTCAATGSCTPPdopamine receptorD1DRD5u34WIAF-12925M67439786DRD1,CCGACGTGAA[T/C]GCACACAACTMTGNKdopamine receptorD1DRD5u35WIAF-12926M67439881DRD1,ACCTACACGC[G/A]CATCTACCGCMGARHdopamine receptorD1DRD5u36WIAF-12927M674391279DRD1,GTGCACCCAC[T/G]TCTGCTCCCGMTGFVdopamine receptorD1DRD5u37WIAF-12928M674391370DRD1,GAAATCGCAG[C/T]TGCCTACATCMCTAVdopamine receptorD1DRD5u38WIAF-12929M674391500DRD1,ACCCTGTTGC[T/A]GAGTCTGTCTSTAAAdopamine receptorD1DRD5u39WIAF-12930M674391338DRD1,TCTCCTACAA[C/T]CAAGACATCGSCTNNdopamine receptorD1DRD5u40WIAF-12931M674391215DRD1,CACTCAACCC[C/A]CTCATCTATGSCAPPdopamine receptorD1DRD5u41WIAF-12932M674391242DRD1,ACGCCGACTT[T/C]CAGAAGGTGTSTCPFdopamine receptorD1DRD5u42WIAF-12933M674391441DRD1,CGAGGAGGAC[G/A]GTCCTTTCGAMGAGSdopamine receptorD1DRD5u43WIAF-12934M674391460DRD1,GATCGCATGT[T/C]CCAGATCTATMTCFSdopamine receptorD1DRD5u44WIAF-12960M67439399DRD1,TGTCTCTGGC[C/T]GTGTCTGACCSCTAAdopamine receptorD1DRD5u45WIAF-12961M467439162DRD1,TGCCGCCAGC[C/G]AGcAAcOCCASCGGGdopamine receptorD1DRD5u46WIAF-12962M67439195DRD1,GGCAGTTCGC[T/G]CTATACCAGCSTGAAdopamine receptorD1DRD5u47WIAF-12963M67439264DRD1,TGGGGCCCTC[A/C]CAGCTCCTCASAGSSdopamine receptorD1DRD5u48WIAF-12964M61439465DRD1,TGGCCGGTTA[C/T]TGCCCCTTTCSCTYYdopamine receptorD1DRD5u49WIAF-12965M67439511DRD1,CTTCGACATC[A/T]TGTGCTCCACMATMLdopamine receptorD1DRD5u50WIAF-12966M67439557DRD1,ATCAGCGTGG[A/C]CCCCTACTGGMAGDGdopamine receptorD1DRD5u51WIAF-12967M67439476DRD1,TGGCCCTTTG[C/A]AGCGTTCTGCMGAGEdopamine receptorD1DRD5u52WIAF-12968M674391004DRD1,AGCCTGCGCG[C/T]TTCCATCAACMCTAVdopamine receptorD1DRD5u53WIAF-12969M674391036DRD1,GGTTCTCAAG[A/C]CCCTGTCGGTMACTPdopamine receptorD1DRD5u54WIAF-12970M67439859DRD1,CTACATCCCC[G/A]TTGCCATCATMGAVIdopamine receptorD1DRD5u55WIAF-12971M67439931DRD1,GATTTCCTCC[C/T]TGGAGAGGGCSCTLLdopamine receptorD1G10u1WIAF-10234J041111308JUN, v-jun avianCCCTCAACGC[C/T]TCGTTCCTCCSCTAAsarcoma virus 17oncogene homologG10u2WIAF-10235J041111471JUN, v-jun avianGCTGCTCAAG[C/T]TGGCGTCGCCSCTLLsarcoma virus 17oncogene homologG10u3WIAF-10253J041112010JUN, v-jun avianTGGAGTCCCA[G/A]GAGCCGATCASGAQQsarcoma virus 17oncogene homologG1001u1WIAF-13746D26135993DGKG, diacyl-CCCCAGTCGT[C/A]TACCTGAAGGSGAVVglycerol kinase,gamma (90 kD)G1001u2WIAF-13764D261352313DGKG, diacyl-ATGTGATGAG[A/T]GAGAAACATCMATRSglycerol kinase,gamma (90 kD)G1002u1WIAF-13918X57206334ITPKB, inositolCCCCAACATC[A/C]GGACAAGCCTMACQP1,4,5-trisphosphate3-kinase BG1002u2WIAF-13925X57206575ITPKB, inositolCCAACTCAGC[T/C]TTCCTGCATASTCAA1,4,5-trisphosphate3-kinase BG1004u1WIAF-13567L361511854PIK4CA, phospha-GCCGCTCAGA[C/T]TCCGAGGATGSCTDDtidylinositol 4-kinase, catalytic,alpha polypeptideG1006u1WIAF-12375HT2690858PRKCA, proteinGGTACAAGTT[G/A]CTTAACCAAGSGALLkinase C, alphaG1008u1WIAF-12397HT2136300PRKCZ, proteinCTGGCCTGCC[A/C]TCTCCCCGACSAGPPkinase C, zetaC1008u2WIAF-12398HT2136246PRKCZ, proteinAGTGCAGGGA[T/C]GAAGGCCTCASTCDDkinase C, zetaG1008u3WIAF-12399HT2136504PRKCZ, proteinGCTCCCACCC[C/T]CTCGTCCCCCSCTGGkinase C, zetaG1008u4WIAF-12403HT2136807PRKCZ, proteinAGAAGAATGA[C/T]CAAATTTACGSCTDDkinase C, zetaG1008u5WIAF-12404HT21361514PRKCZ, proteinGGATTTTCTG[A/T]CATCAACTCCMATDVkinase C, zetaG1008u6WIAF-12412HT2136166PRKCZ, proteinCAAGTGGGTC[C/A]ACACCGAAGGMGADNkinase C, zetaC1008u7WIAF-12418HT2136560PRKCZ, proteinTCCCAACAGC[C/T]TCCACTACACMCTPLkinase C, zetaC1009u1WIAF-12396L051862495PTK2, PTK2 proteinTCATCAACAA[G/A]ATGAAACTCGSGAKKtyrosine kinase 2G1011u1WIAF-11988X078761250WNT2, wingless-typeTCCCATCTCA[C/A]CCGCATGACCMCATNMMTV integrationsite family member2G1011u2WIAF-11997X07876788WNT2, wingless-typeCACTATGGGA[T/C]CAAATTTGCCMTCITMMTV integrationsite family member2G1011u3WIAF-12014X078761338WNT2, wingless-typeTGCACACATG[C/A]AAGGCCCCCANCAC*MMTV integrationsite family member2C1011u4WIAF-13475X07876856WNT2, wingless-typeCCTGATGAAT[C/T]TTCACAACAAMCTLFMMTV integrationsite family member2C1011u5WIAF-13476X07876958WNT2, wingless-typeGACATGCTGG[C/T]TGGCCATGGCSCTLLMMTV integrationsite family member2G1011u6WIAF-13477X07876789WNT2, wingless-typeACTATCCGAT[C/T]AAATTTCCCCSCTIIMMTV integrationsite family member2G1011u7WIAF-13478X07876823WNT2, wingless-typeTGCAAAGGAA[A/C]GCAAACCAAAMAGRGMMTV integrationsite family member2G1012u1WIAF-12408HT489101574WNT2B, wingless-typeATACTTGCAA[A/C]GCCCCCAAGASAGKKMMTV integrationsite family, member2BG1016a1WIAF-12125Z22534793ACVR1, activin ACCCAAGCCGA[A/C]AATGTTCCCGSAGEEreceptor, type IG1016u2WIAF-12392Z22534373ACVR1, activin ACTGGCCAACC[T/C]GTGGACTGCTSTCAAreceptor, type IG1018u1WIAF-12413X742101150ADCY2, adenylateCAAATTCCGA[C/T]TGCGTATTAAMGTVLcyclase 2 (brain)G1019u1WIAF-12394U838675475SPTAN1, spectrin,GCGACCTAAC[T/C]CGCCTCCACASTCTTalpha, nonerythro-cytic 1 (alpha-fodrin)G1019u2WIAF-12406U838671223SPTAN1, spectrin,GCCCTCATCA[A/G]TGCACATCACMAGNSalpha, nonerythro-cytic 1 (alpha-fodrin)G1019u3WIAF-12409U838673555SPTAN1, spectrin,CTCAAGCTCT[T/C]ATCCCACACCSTCLLalpha, nonerythro-cytic 1 (alpha-fodrin)G1019u4WIAF-12415U838673369SPTAN1, spectrin,TCCCTCAACC[C/A]AATGAACTACSGAAAalpha, nonerythro-cytic 1 (alpha-fodrin)C1019u5WIAF-12417U838675839SPTAN1, spectrin,TCACACACAC[T/A]TCACCCTCCAMTAFIalpha, nonerythro-cytic 1 (alpha-fodrin)G1022u1WIAF-12393U45945631ATP1B2, ATPase,CATCAATCTT[A/C]CCTCTCCTCCMAGTANa+/K+transporting, beta2 polypeptideG1022u2WIAF-12400U45945432ATP1B2, ATPase,GCCGCCCTGG[G/A]CGCTATTACGSGAGGNa+/K+transporting, beta2 polypeptideG1023u1WIAF-12401D89722395ARNTL, aryl hydro-AACATTAAGA[C/C]GTGCCACCAAMGCGRcarbon receptornucleartranslocator-likeG1023u2WIAF-12407D89722681ARNTL, aryl hydro-CTCATAGATC[C/T]AAAAACTGGAMCTAVcarbon receptornucleartranslocator-likeG1024u1WIAF-12410U85946731Homo sapiens brainCATACATTTT[C/T]ACAACTTAAAMCTSLsecretory proteinhSec10p (HSEC10)mRNA, complete cds.G1027u1WIAF-12402L476471135CKB, creatineTCGAGATGGA[A/G]CAGCGGCTGGSAGEEkinase, brainG1027u2WIAF-12405L47647499CKB, creatineCCGAGCCCCG[A/C]GCCATCGACASACRRkinase, brainG103u1WIAF-10427HT2269335ERCC5, excisionGGGATCCCCA[T/C]CCGAACTCAASTCHHrepair cross-complementingrodent repairdeficiency,complementationgroup 5 (xerodermapigmentosum,complementationgroup G (Cockaynesyndrome))G103u2WIAF-10429HT22691221ERCC5, excisionCCCTCCTTCT[C/T]CAAGAACTTTMCTPSrepair cross-complementingrodent repairdeficiency,complementationgroup 5 (xerodermapigmentosum,complementationgroup G (Cockaynesyndrome))G103u3WIAF-10431HT22691783ERCC5, excisionTCTCCAACTT[C/C]TACAAATTCTMGCCSrepair cross-complementingrodent repairdeficiency,complementationgroup 5 (xerodermapigmentosum,complenientationgroup G (Cockaynesyndrome))G103u4WIAF-10432HT22692077ERCC5, excisionACTGAATCTG[C/A]AGGCCAGGATMCAAErepair cross-complementingrodent repairdeficiency,complementationgroup 5 (xerodermapigmentosum,complementationgroup G (Cockaynesyndrome))G103u5WIAF-10446HT22693338ERCC5, excisionAATTTGAGCT[A/T]CTTGATAAGGSATLLrepair cross-complementingrodent repairdeficiency,complementationgroup 5 (xerodermapigmentosum,complementationgroup G (Cockaynesyndrome))G103u6WIAF-10447HT22693487ERCC5, excisionTCAGAATCAT[C/T]TGATGGATCTMCTSFrepair cross-complementingrodent repairdeficiency,complementationgroup 5 (xerodermapigmentosum,complementationgroup G (Cockaynesyndrome))G103u7WIAF-10448HT22693507ERCC5, excisionTTCAAGTGAA[C/G]ATGCTGAAAGMCGHDrepair cross-complementingrodent repairdeficiency,complementationgroup 5 (xerodermapigmentosum,complementationgroup G (Cockaynesyndrome))G103u8WIAF-10457HT22691388ERCC5, excisionCTCTTCACGAE[T/G]CACCAAGATCMTGDErepair cross-complementingrodent repairdeficiency,complementationgroup 5 (xeroderma-pigmentosum,complementationgroup G (Cockaynesyndrome))G103u9WIAF-10458HT22691362ERCC5, excisionCCGGACTCTT[T/C]CAGCCATTAAMTCSPrepair cross-complementingrodent repairdeficiency,complementationgroup 5 (xerodermapigmentosum,complementationgroup G (Cockaynesyndrome))G103u10WIAF-10459HT22692357ERCC5, excisionCTGAGAAAGA[T/C]GCCGAACATTSTCDDrepair cross-complementingrodent repairdeficiency,complementationgroup 5 (xerodermapigmentosum,complementationgroup G (Cockaynesyndrome))G103u11WIAF-10462HT22693109ERCC5, excisionTGGAACAGAA[C/T]GAAGACAGATMCTTMrepair cross-complementingrodent repairdeficiency,complementationgroup 5 (xerodermapigmentosum,complementationgroup G (Cockaynesyndrome))G103u12WIAF-10463HT22693138ERCC5, excisionGTTTCCTGTA[T/C]TAAAGCAACTSTCLLrepair cross-complementingrodent repairdeficiency,complementationgroup 5 (xerodermapigmentosum,complementationgroup G (Cockaynesyndrome))G103u14WIAF-10484HT22693553ERCC5, excisionAGAACAGCTG[C/T]GAAAGAGCCAMCTAVrepair cross-complementingrodent repairdeficiency,complementationgroup 5 (xerodermapigmentosum,complementationgroup G (Cockaynesyndrome))G103u15WIAF-10485HT22691429ERCC5, excisionCATCTCCACA[C/T]CCGACCGCCAMCTTMrepair cross-complementingrodent repairdeficiency,complementationgroup 5 (xerodermapigmentosum,complementationgroup G (Cockaynesyndrome))G103a16WIAF-12097HT22693335ERCC5, excisionAACAATTTGA[G/T]CTACTTCATAMGTEDrepair cross-complementingrodent repairdeficiency,complementationgroup 5 (xerodermapigmentosum,complementationgroup G (Cockaynesyndrome))G1030u1WIAF-12411U07358203ZPK, zipperACACTTCTGA[C/T]TGCACTCCCGSCTDD(leucine) proteinkinaseG1030u2WIAF-12416U073581806ZPK, zipperGCCACCCCAT[G/T]AACCTGGACGNGTE*(leucine) proteinkinaseG1031a1WIAF-12124U874602825GPR37, G protein-GAGTCACCAC[C/T]TTCACCTTATSCTTTcoupled receptor 37(endothelinreceptor typeB-like)G1032u1WIAF-12381U57911926C110RF8, chromosomeACGTACATCA[A/C]TGCCTCGACGMACNT11 open readingframe 8G1033u1WIAF-12437M65188431GJA1, gap junctionTCTGTACCCA[C/T]ACTCTTCTACMCTTIprotein, alpha 1,43 kD (connexin 43)G1033u2WIAF-12438M65188169GJA1, gap junctionACGCAACATG[G/C]GTGACTGGAGMGCGRprotein, alpha 1,43 kD (connexin 43)G1033u3WIAF-12439M65188467GJA1, gap junctionTATCTCATGC[C/A]AAAGGAACAGMGARQprotein, alpha 1,43 kD (connexin 43)G1033u4WIAF-12440M65188263GJA1, gap junctionTTCATTTTCC[C/A]AATCCTGCTGMCARQprotein, alpha 1,43 kD (connexin 43)G1033u5WIAF-12441M65188218GJA1, gap junctionCAAGCCTACT[C/T]AACTGCTCGAMCTSLprotein, alpha 1,43 kD (connexin 43)G1033u6WIAF-12442M65188498GJA1, gap junctionAGAAAGAGGA[A/G]GAACTCAAGCSAGEEprotein, alpha 1,43 kD (connexin 43)G1033u7WIAF-12465M65188550GJA1, gap junctionGCACTTGAAG[C/A]AGATTGAGATMCAQKprotein, alpha 1,43 kD (connexin 43)G1033u8WIAF-12466M65188548GJA1, gap junctionATGCACTTGA[A/G]GCACATTGACMAGKRprotein, alpha 1,43 kD (connexin 43)G1033u9WIAF-12486M65188933GJA1, gap junctionCCCTGAGCCC[T/C]GCCAAACACTSTCPPprotein, alpha 1,43 kD (connexin 43)G1033u10WIAF-12487M65188990GJA1, gap junctionCCTCACCAAC[C/T]GCTCCCCTCTSCTTTprotein, alpha 1,43 kD (connexin 43)G1033u11WIAF-12488M651881034GJA1, gap junctionAACCTGCTTA[C/A]TCGCGACAGAMCATNprotein, alpha 1,43 kD (connexin 43)G1033u12WIAF-12489M651881158GJA1, gap junctionCTAACTCCCA[T/C]CCACAGCCTTSTCHHprotein, alpha 1,43 kD (connexin 43)G1033u13WIAF-12490M651881222GJA1, gap junctionTGGACATGAA[T/C]TACAGCCACTSTCLLprotein, alpha 1,43 kD (connexin 43)G1033u14WIAF-12491M651881069GJA1, gap junctionCCGCAATTAC[A/C]ACAAGCAAGCMAGNDprotein, alpha 1,43 kD (connexin 43)G1033u15WIAF-12492M651881250GJA1, gap junctionCTCCACCACC[G/A]ACCTTCAAGCMGARQprotein, alpha 1,43 kD (connexin 43)G1033u16WIAF-12496M65188423GJA1, gap junctionTATTTCTCTC[T/C]GTACCCACACSTCSSprotein, alpha 1,43 kD (connexin 43)G1033u17WIAF-12503M65188880GJA1, gap junctionCCTTAAGGAT[C/T]GGGTTAACCGMCTRWprotein, alpha 1,43 kD (connexin 43)G1033u18WIAF-12504M65188855GJA1, gap junctionAACTCTTCTA[T/C]GTTTTCTTCASTCYYprotein, alpha 1,43 kD (connexin 43)G1033u19WIAF-12505M65188576GJA1, gap junctionAGTTCAAGTA[C/T]GGTATTGAAGSCTYYprotein, alpha 1,43 kD (connexin 43)G1033u20WIAF-12512M651881255GJA1, gap junctionCCACCCACCT[T/G]CAACCACACCMTGSAprotein, alpha 1,43 kD (connexin 43)G1033u21WIAF-12513M651881078GJA1, gap junctionCAACAAGCAA[C/A]CAAGTGACCAMGAATprotein, alpha 1,43 kD (connexin 43)G1033u22WIAF-12514M651881097GJA1, gap junctionCAAAACTCCG[C/G]TAATTACACTMCGAGprotein, alpha 1,43 kD (connexin 43)G1034u1WIAF-12443J035441201PYGB, phosphory-AGACCTGTGC[A/G]TACACCAACCSAGAAlase, glycogen;brainG1034u2WIAF-12469J03544771PYGB, phosphory-GACACCCCAG[T/C]CCCCGGCTACMTCVAlase, glycogen;brainG1034u3WIAF-12470J035441465PYGB, phosphory-TCCACTCCGA[C/C]ATCGTCAAACMGCEDlase, glycogen;brainG1034u4WIAF-12471J035441583PYGB, phosphory-CCCGCTCCCC[G/A]ATACCATCCTMGADNlase, glycogen;brainG1034u5WIAF-12472J035441774PYGB, phosphory-CCATGTTCGA[T/C]GTGCATGTGASTCDDlase, glycogen;brainG1034u6WIAF-12474J035442449PYGB, phosphory-AGGTGGACCA[G/A]CTGTACCGGASGAQQlase, glycogen;brainG1034u7WIAF-12508J03544718PYGB, phosphory-CCCCCGACGG[C/T]GTGAAGTGGCSCTGGlase, glycogen;brainG1035u1WIAF-12484U971051962DPYSL2, dihydro-GCAGAGGAGC[A/G]GCAGACGATCMAGQRpyrimidinase-like 2G1035u2WIAF-12485U971052842DPYSL2, dihydro-ATGACGGACC[T/C]GTGTGTGAAGSTCPPpyrimidinase-like 2G1035u3WIAF-12511U971052062DPYSL2, dihydro-CCATCACCAT[C/T]GCCAACCAGASCTIIpyrimidinase-like 2G1036u1WIAF-12444D88460311WASL, Wiskott-ACGTGGGGTC[C/T]CTGTTGCTCASCTSSAldrich syndromelikeG1038u1WIAF-12445HT2746994PCTK2, PCTAIRETAGAAGAAAG[C/A]TATTGCATCGMGAVIprotein kinase 2G1039u1WIAF-12429HT2747955serine/threonineATCCAAGAGT[C/T]GCATGTCAGCMCTRCkinase, PCTAIRE-3G1039u2WIAF-12458HT2747808serine/threonineCACAGAAGAG[A/T]CGTGGCCCGGMATTSkinase, PCTAIRE-3G1041u1WIAF-12459X72886544H.sapiens TYRO3CAAGTGGCTG[G/C]CCCTGGAGAGMGCAPmRNA.G1041u2WIAF-12460X72886693H.sapiens TYRO3TTGGCGGGAA[C/T]CGCCTGAAACSCTNNmRNA.G1041u3WIAF-12502X72886561H.sapiens TYRO3AGAGCCTGGC[C/T]GACAACCTGTSCTAAmRNA.G1043u1WIAF-12448M940555481Human voltage-gatedCTCTGAGTGA[G/A]GATGACTTTGSGAEEsodium channelmRNA, complete cds.G1043u2WIAF-12449M940555205Human voltage-gatedTTGACACCTT[T/C]GGCAACAGCASTCFFsodium channelmRNA, complete cds.G1043u3WIAF-12450M940555224Human voltage-gatedCATGATCTGC[C/T]TGTTCCAAATSCTLLsodium channelmRNA, complete cds.G1043u4WIAF-12451M940555514Human voltage-gatedAGGTTTGGGA[C/A]AACTTTCATCSCAEEsodium channelmRNA, complete cds.G1043u5WIAF-12452M940555217Human voltage-gatedCCAACAGCAT[G/C]ATCTCCCTGTMGCMIsodium channelmRNA, complete cds.G1043u6WIAF-12453M940555334Human voltage-gatedCCTCACTTAA[A/G]CCAGACTCTGSAGKKsodium channelmRNA, complete cds.G1043u7WIAF-12454M540555424Human voltage-gatedTGTACATCGC[G/C]GTCATCCTGGSGCAAsodium channelmRNA, complete cds.G1043u8WIAF-12455M940555322Human voltage-gatedATCACCCTGG[A/C]AGCTCAGTTASACGGsodium channelmRNA, complete cds.G1043u9WIAF-12456M940551200Human voltage-gatedATGGCTACAC[G/A]AGCTTTGACASGATTsodium channelmRNA, complete cds.G1043u10WIAF-12499M940551170Human voltage-gatedTCTGTGTGAA[G/T]GCTCGTAGAAMGTKNsodium channelmRNA, complete cds.G1046a1WIAF-13187U50352267ACCN1, amiloride-TCCCACCTGT[C/A]ACCCTCTCTASGAVVsensitive cationchannel 1, neuronal(degenerin)G1046a2WIAF-13188U50352282ACCN1, amiloride-TCTGTAACCT[C/g]AATGGCTTCCSCgLLsensitive cationchannel 1, neuronal(degenerin)G1046a3WIAF-13189U50352315ACCN1, amiloride-TCACCACCAA[C/t]CACCTGTACCSCtNNsensitive cationchannel 1, neuronal(degenerin)G1046a4WIAF-13190U50352386ACCN1, amiloride-CCCCATCTGG[C/a]TGACCCCTCCMCaADsensitive cationchannel 1, neuronal(degenerin)G1046a5WIAF-13191U50352417ACCN1, amiloride-CCCTCCGGCA[C/A]AACCCCAACTSGAQQsensitive cationchannel 1, neuronal(degenerin)G1048u1WIAF-12641HT5174S3214REST, RE1-silencingCAGTCAAACC[G/A]CCTAAGGCACSGAAAtranscriptionfactorG1048u2WIAF-12642HT5174S3199REST, RE1-silencingCAAAGGAAGC[C/G]TTGGCAGTCASCGAAtranscriptionfactorG1048u3WIAF-12657HT5174S2125REST, RE1-silencingCTCCCATCGA[C/T]ACTCCTCAGAMGTEDtranscriptionfactorG1048u4WIAF-12660HT5174S2333REST, RE1-silencingCGAACCTCTT[A/C]ACATACACCTMACKQtranscriptionfactorG1051u1WIAF-12431HT28321658SCNN1G, sodiumATGACACCTC[C/T]GACTGTGCCASCTSSchannel, non-voltage gated 1,gammaG1051u2WIAF-12434HT283211735SCNN1G, sodiumAAGCCAAGGA[G/A]TGGTCCGCCTSCAEEchannel, non-voltage gated 1,gammaG1051u3WIAF-12473HT28321409SCNN1G, sodiumAGTCCCTGTA[T/C]GCCTTTCCACSTCYYchannel, non-voltage gated 1,gammaG1051u4WIAF-12475HT28321953SCNN1G, sodiumAGTCATTTTG[T/C]ACATAAACGAMTCYHchannel, non-voltage gated 1,gammaG1051u5WIAF-12476HT28321975SCNN1G, sodiumGAGCAATACA[A/C]CCCATTCCTCMAGNSchannel, non-voltage gated 1,gammaG1051u6WIAF-12477HT283211192SCNN1G, sodiumCTGCCTACTC[C/A]CTCCAGATCTSGASSchannel, non-voltage gated 1,gammaG1053a1WIAF-13192HT22014085SCN5A, sodiumCGTCCTCTGA[C/A]AGCTCTCTCAMGARKchannel, voltage-gated, type V,alpha polypeptide(long (electro-cardiographic)QT syndrome 3)G1053a2WIAF-13193HT22015607SCN5A, sodiumACTTTCCCCA[C/T]CCCCTGTCTGSCTDDchannel, voltage-gated, type V,alpha polypeptide(long (electro-cardiographic)QT syndrome 3)G1053a3WIAF-13194HT22015828SCN5A, sodiumGACCCCATCA[C/T]CACCACACTCMCTTIchannel, voltage-gated, type V,alpha polypeptide(long (electro-cardiographic)QT syndrome 3)G1053a4WIAF-13202HT2201713SCN5A, sodiumGCGTTCACTT[T/A]CCTTCCGGACMTAFYchannel, voltage-gated, type V,alpha polypeptide(long (electro-cardiographic)QT syndrome 3)G1053a5WIAF-13203HT22016148SCN5A, sodiumCCACACTGAA[G/T]ATCTCGCCGAMGTDYchannel, voltage-gated, type V,alpha polypeptide(long (electro-cardiographic)QT syndrome 3)G1053a6WIAF-13204HT22016217SCN5A, sodiumGCCCTCGCTC[C/T]CCACGACACA—GT——channel, voltage-gated, type V,alpha polypeptide(long (electro-cardiographic)QT syndrome 3)G1053a7WIAF-13205HT22016324SCN5A, sodiumAATCCCCCTC[G/A]CCCCCGCCCA—GA——channel, voltage-gated, type V,alpha polypeptide(long (electro-cardiographic)QT syndrome 3)G1054u1WIAF-12419HT22022252SCN4A, sodiumTTGGCAAGAG[C/T]TACAAGGAGTSCTSSchannel, voltage-gated, type IV,alpha polypeptideG1054u2WIAF-12423HT22024559SCN4A, sodiumTGGTCATGTT[C/T]ATCTACTCCASCTFFchannel, voltage-gated, type IV,alpha polypeptideG1054u3WIAF-12424HT22024856SCN4A, sodiumTCAACATGTA[C/G]ATCGCCATCANCGY*channel, voltage-gated, type IV,alpha polypeptideG1054u4WIAF-12425HT22024777SCN4A, sodiumGTCAAGGCTC[A/G]CTGCGGCAACMAGDGchannel, voltage-gated, type IV,alpha polypeptideG1054u5WIAF-12426HT22024863SCN4A, sodiumGTACATCGCC[A/G]TCATCCTGGAMAGIVchannel, voltage-gated, type IV,alpha polypeptideG1054u6WIAF-12427HT22024566SCN4A, sodiumGTTCATCTAC[T/G]CCATCTTCGGMTGSAchannel, voltage-gated, type IV,alpha polypeptideG1054u7WIAF-12428HT22024923SCN4A, sodiumTGGTGAAGAT[G/T]ACTTTGAGATMGTDYchannel, voltage-gated, type IV,alpha polypeptideG1054u8WIAF-12446HT22023595SCN4A, sodiumTTCTGGCTGA[T/C]CTTCAGCATCMTCITchannel, voltage-gated, type IV,alpha polypeptideG1054u9WIAF-12447HT22024203SCN4A, sodiumGGAGACAGAC[G/A]ACCAGAGCCAMGADNchannel, voltage-gated, type IV,alpha polypeptideG1054u10WIAF-12495HT22024811SCN4A, sodiumTCTGCTTCTT[C/A]TGCAGCTATAMCAFLchannel, voltage-gated, type IV,alpha polypeptideG1054u11WIAF-12497HT22025555SCN4A, sodiumCAGGGCAGAC[T/G]GTGCGCCCAGSTGTTchannel, voltage-gated, type IV,alpha polypeptideG1054u12WIAF-12498HT22025480SCN4A, sodiumCACGGGACGC[C/T]GGACCCACTASCTAAchannel, voltage-gated, type IV,alpha polypeptideG1059u1WIAF-12432HT33704112APLP1, amyloid betaCGCTGCTGCT[G/A]CCACTATTGCSGALL(A4) precursor-likeprotein 1G1059u2WIAF-12433HT33704140APLP1, amyloid betaTCTGCGCGCG[C/T]AGCCCGCCATNCTQ*(A4) precursor-likeprotein 1G1059u3WIAF-12435HT337041344APLP1, amyloid betaCACCATGTGG[C/T]CGCCCTGGATMCTAV(A4) precursor-likeprotein 1G1059u4WIAF-12457HT337041687APLP1, amyloid betaATCACCGAAA[C/A]CTGAATGCGTSCAKK(A4) precursor-likeprotein 1G1059u5WIAF-12500HT33704976APLP1, amyloid betaCGTTCCTGAG[A/C]GCCAAGATGGSAGRR(A4) precursor-likeprotein 1G1059u6WIAF-12501HT337041786APLP1, amyloid betaGTCAGGCTCT[A/G]TCGGGTCTGCSAGVV(A4) precursor-likeprotein 1G1060u1WIAF-12436HT14181744APLP2, amyloid betaCCAAGAAATT[C/C]AAGAGGAAATMCGQE(A4) precursor-likeprotein 2G1060u2WIAF-12467HT14182213APLP2, amyloid betaATCACCCTGC[T/C]GATGCTGACCMTGVG(A4) precursor-likeprotein 2G1060u3WIAF-12468HT14182256APLP2, amyloid betaGCCACGGGAT[C/T]CTGGAGGTTGSCTII(A4) precursor-likeprotein 2G1066a1WIAF-13195HT3538566CCKBR, cholecysto-CTTTGGCACC[G/A]TCATCTGCAAMGAVIkinin B receptorG1066a2WIAF-13196HT3538607CCKBR, cholecysto-GGGTGTCTGT[G/A]AGTGTGTCCASGAVVkinin B receptorG1066a3WIAF-13206HT3538864CCKBR, cholecysto-CTGCTGCTTC[T/A]GCTCTTGTTCMTALQkinin B receptorG1067u1WIAF-12478HT0830684KCNA1, potassiumAAACGCTGTG[C/T]ATCATCTGGTSCTCCvoltage-gatedchannel, shaker-related subfamily,member 1 (episodicataxia withmyokymia)G1067u2WIAF-12479HT0830722KCNA1, potassiumGTGCGCTTCT[T/C]CGCCTGCCCCMTCFSvoltage-gatedchannel, shaker-related subfamily,member 1 (episodicataxia with myo-kymia)G1067u3WIAF-12480HT0830804KCNA1, potassiumATTTCATCAC[C/C]CTCGCCACCGSCGTTvoltage-gatedchannel, shaker-related subfamily,member 1 (episodicataxia with myo-kymia)G1067u4WIAF-12509HT0830690KCNA1, potassiumTGTGCATCAT[C/T]TGGTTCTCCTSCTIIvoltage-gatedchannel, shaker-related subfamily,member 1 (episodicataxia with myo-kymia)G1068u1WIAF-12493HT0831774KCNA2, potassiumTGAACATCAT[T/A]GACATTGTGGSTAIIvoltage-gatedchannel, shaker-related subfamily,member 2G1070a1WIAF-13197HT27728522KCNJ6, potassiumCACAGTGACC[T/C]GGCTCTTTTTMTCWRinwardly-rectifyingchannel, subfamilyJ, member 6G1070a2WIAF-13201HT277281244KCNJ6, potassiumCCCTGGAGGA[T/C]GGGTTCTACGSTCDDinwardly-rectifyingchannel, subfamilyJ, member 6G1070a3WIAF-13207HT27728707KCNJ6, potassiumATAAATGCCC[C/A]GACCGAATTASGAPPinwardly-rectifyingchannel, subfamilyJ, member 6G1071u1WIAF-12422HT486721534KCNJ3, potassiumTTCCGGGCAA[C/T]TCAGAACAAASCTNNinwardly-rectifyingchannel, subfamilyJ, member 3G1073u1WIAF-12461HT45561127KCNJ1, potassiumCACTGTGCCA[T/C]GTGCCTTTATMTCMTinwardly-rectifyingchannel, subfamilyJ, member 1G1074u1WIAF-12462HT27804289KCNAB2, potassiumACCTCTTCGA[T/C]ACACCAGAAGSTCDDvoltage-gatedchannel, shaker-related subfamily,beta member 2G1079u1WIAF-12463HT273831130potassium channel,ACCTGGCCGA[T/A]GAGATCCTGTMTADEinwardly rectifing(GB:D50582)G1079u2WIAF-12464HT273831192potassium channel,CCTTACTCTG[T/G]GGACTACTCCMTGVGinwardly rectifing(GB:D50582)G1079u3WIAF-12481HT27383708potassium channel,CCTTCCCTCC[A/G]TCTTCATCAAMAGIVinwardly rectifing(GB:D50582)G1079u4WIAF-12482HT27383779potassium channel,CGGTCATCGC[T/C]CTCCCCCACGSTCAAinwardly rectifing(GB:D50582)G1079u5WIAF-12483HT27383276potassium channel,GCACCCTGCC[C/A]ACCCCACCTAMGAEKinwardly rectifing(GB:D50582)G1079u6WIAF-12510HT27383489potassium channel,CTGCCTCATC[C/A]CCTTCCCCCAMGAATinwardly rectifing(GB:D50582)G1080u1WIAF-12536HT44121099KCNJ4, potassiumTCGACTACTC[A/G]CGTTTTCACASAGSSinwardly rectifyingchannel, subfamilyJ, member 4G1080u2WIAF-12537HT44121050KCNJ4, potassiumGGCCACCGCT[T/A]TGAGCCTGTGMTAFYinwardly-rectifyingchannel, subfamilyJ, member 4G1081u1WIAF-12538HT277241090KCNJ2, potassiumGGCCACCGCT[A/T]TGAGCCTGTGMATYFinwardly-rectifyingchannel, subfamilyJ, member 2G1082u1WIAF-12662HT28319768potassium channel,CGCGGGTCAC[C/T]GACGAGGGCGSCTTTinwardly rectify-ing, highconductance,alpha subunitG1082u2WIAF-12663HT28319854potassium channel,CTGGTGTCGC[C/T]CATCACCATCMCTPLinwardly rectify-ing, highconductance, alphasubunitG1082u3WIAF-12679HT28319471potassium channel,TCTCCATCGA[G/C]ACGCAGACCAMGCEDinwardly rectify-ing, highconductance, alphasubunitG1084a1WIAF-13198HT03832028KCNB1, potassiumCACTCCCCAG[C/A]AAGACTCCGGMCASRvoltage-gatedchannel, Shab-related subfamily,member 1G1084a2WIAF-13199HT03832033KCNB1, potassiumCCCAGCAAGA[C/G]TGGGCGCAGCMCGTSvoltage-gatedchannel, Shab-related subfamily,member 1G1084a3WIAF-13200HT03832321KCNB1, potassiumGAGTGTGCCA[C/A]GCTTTTGGACMCATKvoltage-gatedchannel, Shab-related subfamily,member 1G1084a4WIAF-13208HT0383870KCNB1, potassiumACAACCCCCA[G/A]CTGGCCCACGSCAQQvoltage-gatedchannel, Shab-related subfamily,member 1G1088u1WIAF-12516HT05221503KCNA5, potassiumTCCTGGGCAA[G/A]ACCTTCCAGCSGAKKvoltage-gatedchannel, shaker-related subfamily,member 5G1088u2WIAF-12519HT05221249KCNA5, potassiumCGAGCTGCTC[G/A]TGCGCTTCTTMGAVMvoltage-gatedchannel, shaker-related subfamily,member 5G1088u3WIAF-12520HT0522973KCNA5, potassiumCTCTGGGTCC[G/A]CGCGGGCCATMGAATvoltage-gatedchannel, shaker-related subfamily,member 5G1088u4WIAF-12521HT05221013KCNA5, potassiumGTTATCCTCA[T/C]CTCCATCATCMTCITvoltage-gatedchannel, shaker-related subfamily,member 5G1090u1WIAF-12651HT14971836KCNA5, potassiumCAACCAGCCA[G/A]TGGAGGAGGCMGASNvoltage-gatedchannel, shaker-related subfamily,member 6G1091u1WIAF-12714HT0222843KCNA3, potassiumCATCATCTGG[T/C]TCTCCTTCGAMTCFLvoltage-gatedchannel, shaker-related subfamily,member 3G1094a1WIAF-13218HT273811280KCNJ8, potassiumGTGTATTCTG[T/A]GGATTACTCCMTaVEinwardly-rectifyingchannel, subfamilyJ, member 8G1095u1WIAF-12532HT2629765KCNMA1, potassiumTTCTCTACTT[C/T]GGCTTGCGGTSCTFFlarge conductancecalcium-activatedchannel, subfamilyM, alpha member 1G1095u2WIAF-12533HT26292441KCNMA1, potassiumGTGGTCTGCA[T/C]CTTTGCCCACMTCITlarge conductancecalcium-activatedchannel, subfamilyM, alpha member 1G1095u3WIAF-12534HT26292714KCNMA1, potassiumGATGATACTT[C/C]GCTCCACCACMCGSWlarge conductancecalcium-activatedchannel, subfamilyM, alpha member 1G1095u4WIAF-12535HT26292439KCNMA1, potassiumTCGTGGTCTG[C/T]ATCTTTGGCGSCTCClarge conductancecalcium-activatedchannel, subfamilyM, alpha member 1G1095u5WIAF-12539HT26293048KCNMA1, potassiumCACTCATGAG[C/T]GCGACGTACTSCTSSlarge conductancecalcium-activatedchannel, subfamilyM, alpha member 1G1095u6WIAF-12544HT26292352KCNMA1, potassiumGGATGTTTCA[C/T]TGGTGTGCACSCTHHlarge conductancecalcium-activatedchannel, subfamilyM, alpha member 1G1095u7WIAF-12545HT26292392KCNMA1, potassiumCATCCTGACT[C/T]GAAGTGAAGCNCTR*large conductancecalcium-activatedchannel, subfamilyM, alpha member 1G1095u8WIAF-12546HT26292295KCNMA1, potassiumCTGGCAATGA[T/C]CAGATTGACASTCDDlarge conductancecalcium-activatedchannel, subfamilyM, alpha member 1G1095u9WIAF-12548HT26292949KCNMA1, potassiumAGTTTTTGGA[C/T]CAAGACGATGSCTDDlarge conductancecalcium-activatedchannel, subfamilyM, alpha member 1G1095u10WIAF-12549HT26292865KCNMA1, potassiumTGCACGGCAT[G/A]TTACGTCAACMCAMIlarge conductancecalcium-activatedchannel, subfamilyM, alpha member 1G1095u1WIAF-12547L26318930PRKMB, proteinTGCTGGTAAT[A/T]CATCCATCTASATIIkinase mitogenactivated 8(MAP kinase)G1098u1WIAF-12515L197112650DAG1, dystroglycanTCTACCTGCA[C/T]ACAGTCATTCSCTHH1 (dystrophin-associatedglycoprotein 1)G110u1WIAF-10385HT27392230meiosis-specificCAAAGGTATA[C/T]AGATGACAACNCTQ*recA homolog,HsLim15G110u2WIAF-10397HT273921050meiosis-specificCCTGAAAATG[A/G]AGCCACCTTCMAGEGrecA homolog,HsLim15G110u3WIAF-10399HT27392674meiosis-specificTGAACATCAG[A/G]TGGACCTACTMAGMVrecA homolog,HsLim15G1106u1WIAF-12647HT50735781MAP1B, microtubule-ACTATGAGAA[G/A]ATAGACAGAASCAKKassociated protein1BG1106u2WIAF-12648HT50735916MAP1B, microtubule-CTGAACAGCG[C/T]GGGTACTCATSCTGGassociated protein1BG1106u3WIAF-12650HT50731837MAP1B, microtubule-AGACAAGCCA[G/A]TAAAAACAGAMGAVIassociated protein1BG1105u4WIAF-12653HT50732476MAP1B, microtubule-CACCACACCA[G/A]CTGTCATGGCMGAATassociated protein1BG1106u5WIAF-12656HT50733913MAP1B, microtubule-GCCCAATGAG[A/C]TTAAACTCTCMAGIVassociated protein1BG1106u6WIAF-12667HT5073559MAP1B, microtubule-GATTTTCACC[G/A]ATCAAGAGATMGADNassociated protein1BG1106u7WIAF-12668HT5073570MAP1B, microtubule-ATCAAGAGAT[C/T]CCGGAGTTACSCTIIassociated protein1BG1106u8WIAF-12669HT50736175MAP1B, microtubule-TACTTCCACA[T/C]ACTCTTACCAMTCYHassociated protein1BG1106u9WIAF-12670HT50731215MAP1B, microtubule-TCACTCTCCA[C/C]TACCTAAACAMGCQHassociated protein1BG1106u10WIAF-12672HT50731821MAP1B, microtubule-AGGTAATGGT[G/A]AAAAAAGACASGAVVassociated protein1BG1106u11WIAF-12673HT50732727MAP1B, microtubule-CTCCTGCCGA[G/T]TCCCCTGATGMGTEDassociated protein1BG1106u12WIAF-12674HT50732739MAP1B, microtubule-CCCCTCATGA[G/A]GGAATCACTASGAEEassociated protein1BG1106u13WIAF-12676HT50733643MAP1B, microtubule-ACATGCCACT[C/A]ATCCCAAGCAMGADNassociated protein1BG1106u14WIAF-12677HT50733609MAP1B, microtubule-CACCCCTCAA[C/T]CCATTTTCTGSCTNNassociated protein1BG1106u15WIAF-12682HT50734752MAP1B, microtubule-TTCCACACCC[A/T]ACAACAGATGSATppassociated protein1BG1110u1WIAF-12517HT10961527myelin associatedGCCCCCTCGT[G/C]CTCACCAGCASGCVVglycoproteinG1110u2WIAF-12518HT10961678myelin associatedTGTGCGCCCC[G/T]TGGTCGCCTTMGTVLglycoproteinG1110u3WIAF-12522HT10961271myelin associatedGCCGTGTCAC[C/T]CCACGATGATMCTP LglycoproteinG1113u1WIAF-12523HT2242353myelin transcrip-AATTCCGATC[C/T]GATCCTCACCMCTRLtion factor 1G1116a1WIAF-13217HT28451417myelin oligodendro-CAACCTTATC[G/A]ACACCCTCTCSGASScyte glycoprotein(MOG)G1116a2WIAF-13219HT28451913myelin oligodendro-GCAGATCACT[C/G]TTGGCCTCGTMCGLVcyte glycoprotein(MOG)G1116a3WIAF-132201HT28451922myelin oligodendro-TCTTGGCCTC[G/A]TCTTCCTCTGMGAVIcyte glycoprotein(MOG)G1120u1WIAF-12525HT36951200neurofilament,TAGAGATAGC[T/C]GCTTACAGAASTCAAsubunit HG1123u1WIAF-12542HT25692269OMG, oligodendro-CAGCTGCAAC[T/C]CTAACTATTCSTCTTcyte myelinglycoproteinG1126u1WIAF-12526HT28354626PSEN2, presenilin 2GAGCGAAGCA[T/C]GTGATCATGCSTCHH(Alzheimer disease4)G1126u2WIAF-12527HT28354494PSEN2, presenilin 2ATGGAGAGAA[T/C]ACTGCCCAGTSTCNN(Alzheimer disease4)G1126u3WIAF-12528HT28354434PSEN2, presenilin 2TAATGTCGGC[C/T]GAGAGCCCCASCTAA(Alzheimer disease4)G1126u4WIAF-12543HT28354550PSEN2, presenilin 2GACCCTGACC[G/A]CTATGTCTGTMGARH(Alzheimer disease4)G117u1WIAF-10391HT27765156GTBP, G/T mismatch-ACTTCTCACC[A/G]GGAGATTTGGSAGPPbinding proteinG117u2WIAF-10392HT27765420GTBP, G/T mismatch-AACGTGCAGA[T/C]GAAGCCTTAASTCSSbinding proteinG117u3WIAF-10407HT27765939GTBP, G/T mismatch-CCCACGTTAG[T/C]GGAGGTGGTGSTCSSbinding proteinG117u4WIAF-10411HT277651622GTBP, G/T mismatch-binding proteinCATTGTTCGA[G/A]ATTTAGGACTMGARKG117u5WIAF-10412HT277652405GTBP, G/T mismatch-GACAGCAGGG[C/T]TATAATGTATMCTAVbinding proteinG117u6WIAF-10413HT277652387GTBP, G/T mismatch-AAGAGTCAGA[A/T]CCACCCAGACMATNIbinding proteinG125u1WIAF-10371HT286321999ATM, ataxiaCAGTAATTTT[C/T]CTCATCTTGTMCTPStelangiectasiamutated (includescomplementationgroups A, C and D)G125u2WIAF-10372HT286322631ATM, ataxiaTAATGAATGA[C/A]ATTGCAGATAMCADEtelangiectasiamutated (includescomplementationgroups A, C and D)G125u3WIAF-10373HT286323084ATM, ataxiaCAATGGAAGA[T/G]GTTCTTGAACMTGDEtelangiectasiamutated (includescomplementationgroups A, C and D)G125Su5WIAF-10375HT286324767ATM, ataxiaCACTTATACC[C/T]CTTGTGTATGSCTPPtelangiectasiamutated (includescomplementationgroups A, C and D)G125u6WIAF-10383HT286328713ATM, ataxiaATTCTTGGAT[C/T]CAGCTATTTGMCTPStelangiectasiamutated (includescomplementationgroups A, C and D)G125u7WIAF-10396HT286321825ATM, ataxiaCACTTTGGCA[C/G]TGACCACCAGMCGLVtelangiectasiamutated (includescomplementationgroups A, C and D)G125u8WIAF-10398HT286322924ATM, ataxiaACTACTGCTC[A/G]GACCAATACTMAGQRtelangiectasiamutated (includescomplementationgroups A, C and D)G125u9WIAF-10405HT286328967ATM, ataxiaTTCAACGTGT[C/T]TTCACAAGATSCTVVtelangiectasiamutated (includescomplementationgroups A, C and D)G125u10WIAF-10408HT286326954ATM, ataxiaCCAAACACCT[T/C]GTACAACTCTSTCLLtelangiectasiamutated (includescomplementationgroups A, C and D)G125u11WIAF-10409HT286326855ATM, ataxiaTTCACCACCC[T/C]ATCATCGCTCSTCPPtelangiectasiamutated (includescomplementationgroups A, C and D)G125u12WIAF-10410HT286326801ATM, ataxiaTATATATTAA[G/T]TGGCAGAAACMGTKNtelangiectasiamutated (includescomplementationgroups A, C and D)G125u13WIAF-10421HT28632335ATM, ataxiaCATTCAGATT[C/C]CAAACAAGCAMCGSCtelangiectasiamutated (includescomplementationgroups A, C and D)G125u14WIAF-11607HT286323966ATM, ataxiaTTCCACATCT[C/A]GTCATTAGAASGALLtelangiectasiamutated (includescomplementationgroups A, C and D)G125a15WIAF-13130HT286328642ATM, ataxiaCAGAAATATC[A/C]ACTCTTCATGMACEAtelangiectasiamutated (includescomplementationgroups A, C and D)G136u1WIAF-10388HT3337535MLH1, mutLAGGAGAAAAG[C/T]TTTAAAAAATMCTAV(E. coli) homolog 1(colon cancer, non-polyposis type 2)G136u2WIAF-10389HT3337769MLH1, mutLTTCAAAATGA[A/G]TGGTTACATAMAGNS(E. coli) homolog 1(colon cancer, non-polyposis type 2)G144u1WIAF-11638HT36251129FOS, v-fos FBJCCTCTGCACT[C/T]CGGTCGTCACMCTPSmurine osteo-sarcoma viraloncogene homologG1461u1WIAF-12562HT0329684pRB-binding proteinTTGCCAAGAA[C/A]TCCAAGAACCSGAKKG1466u1WIAF-12571HT278492128API2, apoptosisATGATCCATG[G/C]GTAGAACATGMGCWCinhibitor 2G1468u1WIAF-12563HT49861928apoptosisCCACCAGACC[A/T]GACGAGGGGCSATPPinhibitor, neuronalG1468u2WIAF-12564HT49863057apoptosisTTTGCAATTC[C/C]TTCAAGGGAGMCGLVinhibitor, neuronalG1472u1WIAF-12565HT28478242BAK1, BCL2-GGCACCAGTC[C/T]GGAGAGCCTGSCTCCantagonist/killer 1G1472u2WIAF-12572HT28478509BAK1, BCL2-TGCACCCCAC[G/A]GCAGAGAATGSGATTantagonist/killer 1G1473u1WIAF-12568HT28606394CASP6, caspase 6,GGTGTCAACT[G/C]TTAGCCACGCMGCVLapoptosis-relatedcysteine proteaseG1473u2WIAF-12576HT28606411CASP6, caspase 6,ACGCAGATGC[C/T]GATTGCTTTGSCTAAapoptosis relatedcysteine proteaseG1479u1WIAF-12550Y09077711ATR, ataxiaACTTTATTAA[T/C]GGTTCTTACTMTCMTtelangiectasis andRad3 relatedG1479u2WIAF-12551Y090774303ATR, ataxiaTTGCGTATGC[T/C]GATAATAGCCSTCAAtelangiectasia andRad3 relatedG1479u3WIAF-12552Y090771894ATR, ataxiaATTCTGATGA[T/C]CCCTGTTTAASTCDDtelangiectasia andRad3 relatedG1479u4WIAF-12553Y090771855ATR, ataxiaATTTATGTGG[T/A]ATGCTCTCACSTAGGtelangiectasia andRad3 relatedG1479u5WIAF-12558Y090775287ATR, ataxiaTCATTCATTA[T/C]CATGGTCTAGSTCYYtelangiectasia andRad3 relatedG1479u6WIAF-12559Y090775539ATR, ataxiaCAGCTTTTTA[T/C]GACTCACTGASTCYYtelangiectasia andRad3 relatedG1479u7WIAF-12569Y090771540ATR, ataxiaATCCTGTTAT[T/C]GAGATGTTAGSTCIItelangiectasia andRad3 relatedG1479u8WIAF-12570Y090772521ATR, ataxiaATTTAATGGA[A/C]GATCCAGACASAGEEtelangiectasia andRad3 relatedG1482u1WIAF-12560HT278703176BLM, Bloom syndromeAAAATATAAC[G/A]GAATCCAGGASGATTG1482u2WIAF-12561HT278703605BLM, Bloom syndromeGAAATAAAGC[C/A]CAAACTGTACSCAAAG1482u3WIAF-12573HT278702677BLM, Bloom syndromeTATCTATTAC[C/T]GAAAAACCCTMCTPLG1483u1WIAF-12597HT14701910MYBL2, v-myb avianGGATGAGGAT[C/A]TGAAGCTGATMGAVMmyeloblastosisviral oncogenehomolog-like 2G14B3u2WIAF-12610HT1470244MYBL2, v-myb avianATGAGGAGGA[C/T]GAGCAGCTGASCTDDmyeloblastosisviral oncogenehomolog-like 2G1483u3WIAF-12611HT14701406MYBL2, v-myb avianCACTCAGAAT[A/G]GCACCAGTCTMAGSGmyeloblastosisviral oncogenehomolog-like 2G1485u1WIAF-12581HT14321941BCR, breakpointTGGAGATGAG[A/G]AAATGGGTCCSAGRRcluster regionG1485u2WIAF-12582HT14323144BCR, breakpointTGACCATCAA[T/C]AAGGAAGATGSTCNNcluster regionG1485u3WIAF-12583HT14323777BCR, breakpointATAACAAGGA[T/C]GTGTCGGTGASTCDDcluster regionG1485u4WIAF-12603HT14322831BCR, breakpointCAGATCAAGA[C/A]TGACATCCAGMGASNcluster regionG1485u5WIAF-12608HT14324217BCR, breakpointATCCCTGCCC[C/T]GGACAGCAAGMCTPLcluster regionG1486u1WIAF-12578HT337701909BRCA2, breastATTGATAATG[G/A]AAGCTGGCCAMGAGEcancer 2, earlyonsetG1486u2WIAF-12579HT337703623BRCA2, breastAGTTTAGAAA[A/G]CCAAGCTACASAGKKcancer 2,early onsetG1486u3WIAF-12586HT337701341BRCA2, breastAAATGTAGCA[A/C]ATCAGAAGCCMACNHcancer 2, earlyonsetG1486u4WIAF-12594HT33770446BRCA2, breastCTTATAATCA[G/A]CTGGCTTCAASGAQQcancer 2, earlyonsetG1486u5WIAF-12598HT337703013BRCA2, breastACCATGGTTT[T/C]ATATGGAGACMTCLScancer 2, earlyonsetG1486u6WIAF-12599HT337703187BRCA2, breastGAAAAAAATA[A/T]TGATTACATGMATNIcancer 2, earlyonsetG1486u7WIAF-12604HT337704971BRCA2, breastAGCATGTGAG[A/C]CCATTGAGATMACTPcancer 2, earlyonsetG1486u8WIAF-12607HT337704034BRCA2, breastATGATTCTGT[C/T]GTTTCAATGTSCTVVcancer 2, earlyonsetG1487u1WIAF-12584HT276322536BRCA1, breastAGTCAGTGTG[C/G]AGCATTTGAAMCGAGcancer 1, earlyonsetG1487u2WIAF-12587HT276324697BRCA1, breastCATCTCAAGA[G/C]GAGCTCATTAMGCEDcancer 1, earlyonsetG1487u3WIAF-12595HT27632469BRCA1, breastTCTCCTGAAC[A/G]TCTAAAAGATMAGHRcancer 1, earlyonsetG1487u4WIAF-12600HT276323667BRCA1, breastAGCGTCCAGA[A/G]AGGAGAGCTTMAGKRcancer 1, earlyonsetG1487u5WIAF-12601HT276323537BRCA1, breastTATGGGAAGT[A/G]GTCATGCATCMAGSGcancer 1, earlyonsetG1487u6WIAF-12602HT276324956BRCA1, breastATCTGCCCAG[A/G]GTCCAGCTGCMAGSGcancer 1, earlyonsetG1487u7WIAF-12605HT276322090BRCA1,breastAGTACAACCA[A/G]ATGCCAGTCASAGQQcancer 1, earlyonsetG1487u8WIAF-12614HT27632233BRCA1,breastTCTCCACAAA[G/A]TGTGACCACASGAKKcancer 1, earlyonsetG1492u1WIAF-12585HT35063912cell death-TCCAGGTCCG[T/C]GGCCTGGAGASTCRRassociated kinaseG1492u2WIAF-12593HT35064352cell death-TACAACACCA[A/G]TAACGGGGCTMAGNSassociated kinaseG1492u3WIAF-12606HT35062127cell death-GCAATTTGGA[C/T]ATCTCCAACASCTDDassociated kinaseG1492u4WIAF-12612HT35061605cell death-TCAAATTTCT[C/T]ACTGACAACASCTLLassociated kinaseG1494u1WIAF-12589HT28507366cell death-inducingTTCACCACAC[T/C]TAAGGAGAACMTCLPprotein BikG1495u1WIAF-12580HT27803759CSE1L, chromosomeTTTCTTCCCT[G/C]ATCCTGATCTSGCLLsegregation 1(yeast homolog)-likeG1501u1WIAF-13502HT19491181MCC, mutated inCAGCAATGAC[A/C]TTCCCATCGCMACILcolorectal cancersG1501u2WIAF-13503HT19491753MCC, mutated inCAGCTGAGAA[C/T]GCTGCCAAGGSCTNNcolorectal cancersG1501u3WIAF-13504HT19492344MCC, mutated inTGTCCCTAGC[T/C]GAACTCAGGASTCAAcolorectal cancersG1501u4WIAF-13521HT1949445MCC, mutated inAGCGAACGAC[G/A]CTTCGCTATGSGATTcolorectal cancersG1501u5WIAF-13522HT19491504MCC, mutated inAAAGCAATGC[T/C]GAGAGGATGASTCAAcolorectal cancersG1501u6WIAF-13527HT19492511MCC, mutated inTTCGTGAATG[A/G]TCTAAAGCGGMAGDGcolorectal cancersG1502u1WIAF-12633HT1547870CCND1, cyclin D1AGTGTGACCC[A/G]GACTGCCTCCSAGPP(PRAD1: para-thyroid adeno-matosis 1)G1503u1WIAF-13741U370221151CDK4, cyclin-CATGCCAATT[G/A]CATCGTTCACMGACYdependent kinase 4G1503u2WIAF-13742U370221410CDK4, cyclin-CTGAAGCCCA[C/T]CAGTTGGGCASCTDDdependent kinase 4G1503u3WIAF-13743U370221328CDK4, cyclin-TATGCAACAC[C/T]TGTGGACATGMCTPLdependent kinase 4G1503u4WIAF-13780U370221194CDK4, cyclin-TTCTGGTCAC[A/G]AGTGGTCCAASAGTTdependent kinase 4G1503u5WIAF-13781U370221443CDK4, cyclin-TGATTGGGCT[G/A]CCTCCAGAGGSGALLdependent kinase 4G1503u6WIAF-13787U370221633CDK4, cyclin-CTCTTATCTA[C/T]ATAAGGATGAMCTHYdependent kinase 4G1517u1WIAF-12618HT11323894ERBB3, v-erb-b2CAGACCTCAG[T/C]GCCTCTCTGGSTCSSavian erythro-blastic leukemiaviral oncogenehomolog 3G152u1WIAF-11608HT38541673HSPA1L, heat shockGTGAGTGATG[A/C]AGGTTTCAAGMACEA70 kD protein like1G152u2WIAF-11629HT38541683HSPA1L, heat shockAAGGTTTGAA[G/A]GGCAAGATTASGAKK70 kD protein like1G152u3WIAF-11609HT38541478HSPA1L, heat shockGTCACAGCCA[C/T]GGACAAGAGCMCTTM70 kD protein like1G152u4WIAF-11610HT38541443HSPA1L, heat shockTGACGTTTCA[C/T]ATTGATGCCASCTDD70 kD protein like1G1520u1WIAF-12162HT11752211DNA excision repairTGACCGTGGA[C/T]GAGGGTGTCCSCTDDprotein ERCC2, 5′endG1520u2WIAF-12166HT1175546DNA excision repairCCCACTGCCG[A/C]TTCTATGAGGSACRRprotein ERCC2, 5′endG1527u1WIAF-12168HT0086577GSTM2, glutathioneTCATCTCCCG[A/C]TTTGAGGGCTSACRRS-transferase M2(muscle)G1527u2WIAF-12169HT0086644GSTM2, glutathioneACCTGTGTTC[A/T]CAAAGATGGCMATTSS-transferase M2(muscle)G1527u3WIAF-12171HT0086100GSTM2, glutathioneACTCAAGCTA[C/T]GAGGAAAAGASCTYYS-transferase M2(muscle)G1527u4WIAF-12172HT008641GSTM2, glutathioneGGGGTACTGG[A/G]ACATCCGCGGMAGNDS-transferase M2(muscle)G1527u5WIAF-12173HT0086215GSTM2, glutathioneGATTGATGGG[A/G]CTCACAAGATMAGTAS-transferase M2(muscle)G1527u6WIAF-12194HT0086238GSTM2, glutathioneCCCAGAGCAA[T/C]GCCATCCTGCSTCNNS-transferase M2(muscle)G1528u1WIAF-11950HT1811529GSTM3, glutathioneGTATATTTGA[C/G]CCCAAGTGCCMCGDES-transferase M3(brain)G1528u2WIAF-11951HT1811674GSTM3, glutathioneCAACAAGCCT[C/A]TATGCTGAGCMGAVIS-transferase M3(brain)G1528u3WIAF-11989HT1811572GSTM3, glutathioneGGCTTTCATG[T/C]GCCGTTTTGAMTGCGS-transferase M3(brain)G1528u4WIAF-13470HT1811240GSTM3, glutathioneCAGAGCAATG[C/A]CATCTTGCGCMCAADS-transferase M3(brain)G1529u1WIAF-14146HT2006797GSTM4, glutathioneTGGACGCCTT[C/T]CCAAATCTGASCTFFS-transferase M4G153u1WIAF-12163HT38561212HSPA1B, heat shockTGGGGCTGGA[G/A]ACGGCCGGAGSGAEE70 kD protein 1G153u2WIAF-12182HT3856676HSPA1B, heat shockGGCCGGGGAC[A/G]CCCACCTGGGMAGTA70 kD protein 1G153u3WIAF-12183HT38561695HSPA1B, heat shockTCAGCGAGGC[C/G]GACAAGAAGASCGAA70 kD protein 1G153u4WIAF-12189HT3856330HSPA1B, heat shockACAAGGGGGA[G/C]ACCAAGGCATMGCED70 kD protein 1G153u5WIAF-12190HT38561053HSPA1B, heat shockAGCTGCTGCA[A/G]GACTTCTTCASAGQQ70 kD protein 1G1530u1WIAF-11964HT3010673GSTM5, glutathioneATTCCTCCGA[G/A]GTCTTTTGTTMGAGSS-transferase M5G1530u2WIAF-11995HT3010593GSTM5, glutathioneGACGCCTTCC[T/C]AAACTTGAAGMTCLPS-transferase M5G1530u3WIAF-13473HT3010693GSTM5, glutathioneTTGGAAAGTC[A/G]GCTACATGGASAGSSS-transferase M5G1533u1WIAF-13458HT27460543GSTT2, glutathioneCTCTCGGCTA[C/T]GAACTGTTTGSCTYYS-transferasetheta 2G1533u2WIAF-13460HT27460417GSTT2, glutathioneGGACTGCCAT[G/A]GACCAGGCCCMGAMIS-transferasetheta 2G1533u3WIAF-13461HT27460359GSTT2, glutathioneCAGGTGTTGG[G/A]GCCACTCATTMGAGES-transferasetheta 2G1533u4WIAF-13462HT27460363GSTT2, glutathioneTGTTGGGGCC[A/C]CTCATTGGGGSACPPS-transferasetheta 2G1533u5WIAF-13463HT27460385GSTT2, glutathioneCCAGGTGCCC[G/A]AGGAGAAGGTMGAEKS-transferasetheta 2G1535u1WIAF-11952HT0436517HCK, hemopoieticCCGCGTTGAC[T/C]CTCTGGACACMTCSPcells kinaseG1535u2WIAF-12013HT0436783HCK, hemopoieticTGGACCACTA[C/T]AAGAAGGGGASCTYYcells kinaseG1535u3WIAF-13464HT0436357HCK, hemopoieticTCATCGTGGT[T/C]GCCCTGTATGSTCVVcells kinaseG1535u4WIAF-13465HT0436387HCK, hemopoieticCCATTCACCA[C/T]GAAGACCTCASCTHHcells kinaseG1535u5WIAF-13466HT0436471HCK, hemopoieticCCCTGGCCAC[C/G]CGGAAGGACGSCGTTcells kinaseG1535u6WIAF-13467HT0436240HCK, hemopoieticCCAGCGCCAG[C/T]CCACACTCTCSCTSScells kinaseG1535u7WIAF-13468HT0436394HCK, hemopoieticCCACGAAGAC[C/T]TCAGCTTCCAMCTLFcells kinaseG1537u1WIAF-12020U040451514MSH2, mutSGTGAATTAAG[A/C]GAAATAATCASAGRR(E. coli) homolog 2(colon cancer, non-polyposis type 1)G1537u2WIAF-12044U04045599MSH2, mutSGACTGTGTGA[A/T]TTCCCTGATAMATED(E. coli) homolog 2(colon cancer, non-polyposis type 1)G1537u3WIAF-12045U040451452MSH2, mutSAGATATGGAT[C/T]AGGTGGAAAANCTQ*(E. coli) homolog 2(colon cancer, non-polyposis type 1)G1537u4WIAF-12076U04045938MSH2, mutSGACACTTTGA[A/T]CTGACTACTTMATED(E. coli) homolog 2(colon cancer, non-polyposis type 1)G1537u5WIAF-12077U040451878MSH2, mutSTCAGCTAGAT[G/A]CTGTTGTCAGMGAAT(E. coli) homolog 2(colon cancer, non-polyposis type 1)G1543u1WIAF-13856J00119553MOS, v-mos MoloneyGAGTTTCTGG[G/T]CTGAGCTCAAMGTASmurine sarcomaviral oncogenehomologG1543u2WIAF-13857J00119621MOS, v-mos MoloneyGCACGCGCAC[G/A]CCCGCAGGGTSGATTmurine sarcomaviral oncogenehomologG1544u1WIAF-12018U594643821PTCH, patchedCATCCCGAAT[C/T]CAGGCATCACMCTSF(Drosophila)homologG1544u2WIAF-12019U594643618PTCH, patchedGCGTGGTCCG[C/T]TTCGCCATGCSCTRR(Drosophila)homologG1544u3WIAF-12027U594641761PTCH, patchedATTTTGCCAT[G/T]GTTCTGCTCAMGTMI(Drosophila)homologG1544u4WIAF-12029U594644074PTCH, patchedCTGCCATGGG[C/T]AGCTCCGTGCSCTGG(Drosophila)homologG1544u5WIAF-12043U594643845PTCH, patchedCCCTCGAACC[C/T]GAGACAGCAGMCTPL(Drosophila)homologG1544u6WIAF-12056U594641433PTCH, patchedCTGCTGGTTG[C/T]ACTGTCAGTGMCTAV(Drosophila)homologG1544u7WIAF-12058U594643298PTCH, patchedCACCGTTCAC[G/C]TTGCTTTGGCMGCVL(Drosophila)homologG1544u8WIAF-12062U594643986PTCH, patchedTCTACTGAAG[G/A]GCATTCTGGCMGAGE(Drosophila)homologG1544u9WIAF-13489U594641665PTCH, patchedCCATCAGCAA[T/C]GTCACAGCCTSTCNN(Drosophila)homologG1544u10WIAF-13490U594642396PTCH, patchedAAATACTTTT[C/T]TTTCTACAACMCTSF(Drosophila)homologG1544u11WIAF-13491U594642199PTCH, patchedGGACACTCTC[A/G]TCTTTTGCTGSAGSS(Drosophila)homologG1544u12WIAF-13492U594642222PTCH, patchedAAGCACTATG[C/T]TCCTTTCCTCMCTAV(Drosophila)homologG1544u13WIAF-13500U594641686PTCH, patchedTCTTCATGGC[C/T]GCGTTAATCCSCTAA(Drosophila)homologG1545u1WIAF-12032HT04731835RAG1, recombina-GGACATGGAA[G/A]AAGACATCTTMGAEKtion activatinggene 1G1545u2WIAF-12035HT04732519RAG1, recombina-TGACATTGGC[A/G]ATGCAGCTGAMAGNDtion activatinggene 1G1545u3WIAF-12046HT04733045RAG1, recombina-CGGAAAATGA[A/G]TGCCAGGCAGMAGNStion activatinggene 1G1545u4WIAF-12047HT04733146RAG1, recombina-TCATAATGCA[T/C]TAAAAACCTCSTCLLtion activatinggene 1G1545u5WIAF-12075HT04732513RAG1, recombina-CCACTGTGAC[A/T]TTGGCAATGCMATIFtion activatinggene 1G1545u6WIAF-13484HT04731322RAG1, recombina-GTCGCTGACT[C/T]GGAGAGCTCAMCTRWtion activatinggene 1G1545u7WIAF-13494HT04732571RAG1, recombina-GAAGTGTATA[A/C]GAATCCCAATMAGKRtion activatinggene 1G1545u8WIAF-13498HT04731018RAG1, recombina-TTCTGGCTGA[C/A]CCTGTGGAGAMCADEtion activatinggene 1G1545u9WIAF-13499HT04732782RAG1, recombina-ATCTTTACCT[G/C]AAGATGAAAC SGCLLtion activatinggene 1G1548u1WIAF-12015HT4999133IF127, interferon,CTCTGCCGTA[G/A]TTTTGCCCCTMGAVIalpha-inducibleprotein 27G1548u2WIAF-13482HT4999380IFI27, interferon,ATCCTGGGCT[C/T]CATTGGGTCTMCTSFalpha-inducibleprotein 27G1548u3WIAF-13483HT4999135IF127, interferon,CTGCCGTAGT[T/C]TTGCCCCTGGSTCVValpha-inducibleprotein 27G155u1WIAF-11634HT3962991CHCl, chromosomeAGCTGGATGT[G/A]CCTGTGGTAASGAVVcondensation 1G155u2WIAF-11635HT39621271CHCl, chromosomeCGGCTTCGGC[C/T]TCTCCAACTAMCTLFcondensation 1G155u3WIAF-11636HT39621192CHCl, chromosomeGCCGGGGCCA[C/T]GTGAGATTCCSCTHHcondensation 1G155u4WIAF-11637HT39621267CHCl, chromosomeTGTACGGCTT[C/T]GGCCTCTCCASCTFFcondensation 1G155u5WIAF-11649HT39621657CHCl, chromosomeTGATGGGCAA[A/G]CAGCTGGAGASAGKKcondensation 1G1550u1WIAF-12057M16038611LYN, v-yes-1 Yama-GCAAAGTCCC[T/G]TTTAACAAAAMTGLRguchi sarcoma viralrelated oncogenehomologG1550u2WIAF-12061M160381371LYN, v-yes-1 Yama-TGGCATACAT[C/T]GAGCGGAAGASCTIIguchi sarcoma viralrelated oncogenehomologG1550u3WIAF-12080M160381059LYN, v-yes-1 Yama-AAAGGCTTGG[C/T]GCTGGGCAGTSCTGGguchi sarcoma viralrelated oncogenehomologG1550u4WIAF-12081M16038996LYN, v-yes-1 Yama-AGCCACAGAA[G/A]CCATGGGATASGAKKguchi sarcoma viralrelated oncogenehomologG1552u1WIAF-12030HT45782355PMS1, postmeioticCCTGCTATTT[A/T]AAAGACTTCTNATK*segregationincreased(S. cerevisiae) 1G1552u2WIAF-12031HT45782231PMS1, postmeioticsegregationACAAAGTTGA[C/T]TTAGAAGAGASCTDDincreased(S. cerevisiae) 1G1552u3WIAF-12040HT4578617PMS1, postmeioticTCATGAGCTT[T/C]GGTATCCTTASTCFFsegregationincreased(S. cerevisiae) 1G1552u4WIAF-12063HT45781723PMS1, postmeioticTCATGTAACA[A/C]AAAATCAAATMAGKRsegregationincreased(S. cerevisiae) 1G1552u5WIAF-12064HT45781732PMS1, postmeioticAAAAAATCAA[A/G]TGTAATAGATMAGNSsegregationincreased(S. cerevisiae) 1G1552u6WIAF-12065HT45781660PMS1, postmeioticTTACCATGTA[A/G]AGTAAGTAATMAGKRsegregationincreased(S. cerevisiae) 1G1552u7WIAF-12066HT45781975PMS1, postmeioticGAACGATACA[A/G]TAGTCAAATGMAGNSsegregationincreased(S. cerevisiae) 1G1552u8WIAF-12067HT45781881PMS1, postmeioticTTTAGAGGAT[G/T]CAACACTACAMGTASsegregationincreased(S. cerevisiae) 1G1552u9WIAF-12068HT45782454PMS1, postmeioticTTTAGACGTT[T/A]TATATAAAATMTALIsegregationincreased(S. cerevisiae) 1G1552u10WIAF-12069HT45782457PMS1, postmeioticAGACGTTTTA[T/C]ATAAAATGACMTCYHsegregationincreased(S. cerevisise) 1G1552u11WIAF-12082HT45782557PMS1, postmeioticATACCAGGAC[T/C]TTCAATTACTMTCVAsegregationincreased(S. cerevisiae) 1G1552u12WIAF-12083HT4578971PMS1, postmeioticsegregationTTTTCTTTCT[G/T]AAAATCGATGSGTLLincreased(S. cerevisiae) 1G1554u1WIAF-12028HT41611500ELK3, ELK3, ETS-CTCAGAAATC[C/T]TGATGACCTCSCTSSdomain protein (SRFaccessory protein2) NOTE: Symboland nameprovisional.G1554u2WIAF-12059HT41611380ELK3, ELK3, ETS-CTGCCAGGCT[G/A]CAAGGGCCAASGALLdomain protein (SRFaccessory protein2) NOTE: Symboland nameprovisional.G1554u3WIAF-12060HT41611436ELK3, ELK3, ETS-CACATGCCAG[T/C]GCCAATCCCCMTCVAdomain protein (SRFaccessory protein2) NOTE: Symboland nameprovisional.G1562u1WIAF-12024HT28220804PDCD1, programmedGGGGCTCAGC[T/C]GACGGCCCTCSTCAAcell death 1G1562u2WIAF-13488HT28220644PDCD1, programmedGACCCCTCAG[C/T]CGTGCCTCTGMCTAVcell death 1G1563u1WIAF-13493HT11871748EGFR, epidermalCCGGAGCCCA[G/A]GGACTGCGTCMGARKgrowth factorreceptor (avianerythroblasticleukemia viral(v-erb-b) oncogenehomolog)G1563u2WIAF-13497HT11872073EGFR, epidermalACGGATGCAC[T/A]GGGCCAGGTCSTATTgrowth factorreceptor (avianerythroblasticleukemia viral(v-erb-b) oncogenehomolog)G1566u1WIAF-12016HT27594235PDCD2, programmedGCGCCGCTGC[C/G]TGGCCGCCCGMCGPRcell death 2G1566u2WIAF-12033HT27594904PDCD2, programmedTTGGAATTCC[A/G]GGTCATGCCTMAGQRcell death 2G1566u3WIAF-12041HT27594331PDCD2, programmedAATCAACTAC[C/T]CAGGAAAAACMCTPLcell death 2G1566u4WIAF-12071HT27594649PDCD2, programmedCCTGAGGTTG[T/C]GGAAAAGGAAMTCVAcell death 2G1566u5WIAF-12072HT27594633PDCD2,programmedAGAAGATGAG[A/T]TTATGCCTGAMATIFcell death 2G1567u1WIAF-12042M95936293AKT2, v-akt murineGAGAGGCCGC[G/A]ACCCAACACCMGARQthymoma viraloncogene homolog 2G1572u1WIAF-12212HT39981894proto-oncogene c-TGTTCCAGGA[A/G]TCCAGTATCTSAGEEabl, tyrosineprotein kinase,alt. transcript 2G1572u2WIAF-12233HT39983694proto-oncogene c-AGCTTCAGAT[C/T]TGCCCGGCGASCTIIabl, tyrosineprotein kinase,alt. transcript 2G1572u3WIAF-12234HT39983721proto-oncogene c-GCAGTGGTCC[G/A]GCGGCCACTCSGAPPabl, tyrosineprotein kinase,alt. transcript 2G1573u1WIAF-12021HT0642343CBL, Cas-Br-MTCATGGACAA[G/C]CTGGTGCGGTMGCKN(murine) ecotropicretroviraltransformingsequenceG1573u2WIAF-12022HT0642363CBL, Cas-Br-MTTGTGTCAGA[A/T]CCCAAAGCTGMATNI(murine) ecotropicretroviraltransformingsequenceG1573u3WIAF-12034HT06422364CBL, Cas-Br-MAATATTCAGT[C/T]CCAGGCGCCAMCTSP(murine) ecotropicretroviraltransformingsequenceG1573u4WIAF-12049HT0642387CBL, Cas-Br-MCTAAAGAATA[G/A]CCCACCTTATMGASN(murine) ecotropicretroviraltransformingsequenceG1573u5WIAF-12050HT0642947CBL, Cas-Br-MAACTCATCCT[G/A]GCTACATGGCMGAGS(murine) ecotropicretroviraltransformingsequenceG1573u6WIAF-12070HT06422740CBL, Cas-Br-MTCGAGAACCT[C/T]ATGAGTCAGGSCTLL(murine) ecotropicretroviraltransformingsequenceG1573u7WIAF-12073HT0642661CBL, Cas-Br-MTCTTTCCAAG[T/C]GGACTCTTTCSTCSS(murine) ecotropicretroviraltransformingsequenceG1573u8WIAF-12074HT06422569CBL, Cas-Br-MCTCTGGATGG[T/C]GATCCTACAASTCGG(murine) ecotropicretroviraltransformingsequenceG1573u9WIAF-13486HT06422006CBL, Cas-Br-MCCGGCACTCA[C/T]TTCCATTTTCMCTLF(murine) ecotropicretroviraltransformingsequenceG1574u1WIAF-12037HT15082493FES, feline sarcoma(Snyder-Theilen)AGCGGCCCAG[C/T]TTCAGCACCASCTSSviral (v-fes)/Fujinami aviansarcoma (PRCII)viral (v-fps) oncogenehomologG1574u2WIAF-12051HT1508189FES, feline sarcoma(Snyder-Theilen)CCCAGCGGGT[C/T]AAGAGTGACASCTVVviral (v-fes)/Fujinami aviansarcoma (pRCII)viral (v-fps) oncogenehomologG1574u3WIAF-12052HT15081441FES, feline sarcomaGAAGCCCCTG[C/T]ATGAGCAGCTMCTHY(Snyder-Theilen)viral (v-fes)/Fujinami aviansarcoma (PRCII)viral (v-fps) oncogenehomologG1574u4WIAF-12053HT15082202FES, feline sarcomaGAGAGGAAGC[C/T]GATGGGGTCTSCTAA(Snyder-Theilen)viral (v-fes)/Fujinami aviansarcoma (PRCII)viral (v-fps)oncogene homologG1574u5WIAF-12054HT15082088FES, feline sarcomaCTGCTGGCAT[G/T]GAGTACCTGGMGTMI(Snyder-Theilen)viral (v-fes)/Fujinami aviansarcoma (PRCII)viral (v-fps)oncogene homologG1574u6WIAF-12078HT15081577FES, feline sarcomaGATGGTCTGC[C/T]CCGGCACTTCMCTPL(Snyder-Theilen)viral (v-fes)/Fujinami aviansarcoma (PRCII)viral (v-fps)oncogene homologG1574u7WIAF-13495HT1508579FES, feline sarcomaGTGACAAGGC[T/C]AAGGACAAGTSTCAA(Snyder-Theilen)viral (v-fes)/Fujinami aviansarcoma (PRCII)viral (v-fps)oncogene homologG1575u1WIAF-12079HT1052963FGR, Gardner-TGGGCACCGG[C/T]TGCTTCGGGGSCTGGRasheed felinesarcoma viral(v-fgr) oncogenehomologG1575u2WIAF-13487HT1052232FGR, Gardner-CAGAAGCTAC[G/A]GGGCAGCAGAMGAGRRasheed felinesarcoma viral(v-fgr) oncogenehomologG1585u1WIAF-12017HT1675996CRK, v-crk avianTGGATCAACA[G/A]AATCCCGATGSGAQQsarcoma virus CT10oncogene homologG1585u2WIAF-12036HT1675446CRK, v-crk avianACTACAACGT[T/C]GATAGAACCAMTCLSsarcoma virus CT10oncogene homologG1587u1WIAF-12023HT05901473proto-oncogene dblGGCCAATCCA[A/G]TTTGTGGTACSAGQQG1587u2WIAF-12025HT05902549proto-oncogene dblGTCCAGGCTT[C/T]TAATGTAGATMCTSFG1587u3WIAF-12026HT05902828proto-oncogene dblGCATCACAAT[C/T]TGCAGAAATCMCTSFG1587u4WIAF-12038HT0590982proto-oncogene dblAAATTCTCAG[G/C]AGCTATTATCMGCEQG1587u5WIAF-12039HT05902343proto-oncogene dblAACCAATGCA[G/T]CGACACCTTTMGTQHG1587u6WIAF-12048HT0590683proto-oncogene dblGACACTGAAG[G/A]AGCTGTCAGTMGAGEG1587u7WIAF-12055HT05902686proto-oncogene dblTTCTCTTCAG[C/T]AGAATGATGANCTQ*G1587u8WIAF-13485HT05902136proto-oncogene dblACTGTGAAGG[T/A]TCTGCTCTGTSTAGGG1587u9WIAF-13496HT05901566proto-oncogene dblAAAATCAGAG[C/T]AACTTAAAAASCTSSG159u1WIAF-11616HT42091059RAD23B, RAD23AGTACTGGGG[C/T]TCCTCAGTCTMCTAV(S. cerevisiae)homolog BG1590u1WIAF-13897HT24551257ETS2, v-ets avianGCCAGTCTCT[C/G]TGCCTCAATASCGLLerythroblastosisvirus E26 oncogenehomolog 2G1590u2WIAF-13913HT24551107ETS2, v-ets avianATTCTGGGAC[T/G]CCCAAAGACCSTGTTerythroblastosisvirus E26 oncogenehomolog 2G1590u3WIAF-13914HT24551314ETS2, v-ets avianGGAGTGACCC[A/G]GTGGAGCAAGSAGPPerythroblastosisvirus E26 oncogenehomolog 2G1591u1WIAF-13924HT2333417HRAS, v-Ha-rasTCCAGAACCA[T/C]TTTGTGGACGSTCHHHarvey rat sarcomaviral oncogenehomologG1595u1WIAF-12262HT337781302proto-oncogeneGCATACCTCA[G/C]TGGCTACTAAMGCST1-myc, alt.transcript 1G1597u1WIAF-12243HT0410900MAS1, MAS1 oncogeneCCATCTTGGT[C/T]GTGAAGATCCSCTVVG150u1WIAF-11630HT4247690RAD23A, RAD23AGAGCCAGGT[A/G]TCGGAGCAGCSAGVV(S. cerevisiae)homologG1602u1WIAF-14180HT19031321proto-oncogeneGTCGCCGGGG[C/A]CCAGCAAATAMCAPTpim-1G1604u1WIAF-12319HT27881182REL, v-rel avianCCTCCCAAAG[T/C]GCTGGGATTASTCSSreticuloendo-theliosis viraloncogene homologG1609u1WIAF-12358HT33646348RIPK1, receptorGACGCACGGT[C/T]TCCCATGACCSCTVV(TNFRSF) interact-ing serine-threonine kinase1G161u1WIAF-11654HT42511522DNA repair andTATGATCCAT[C/T]TTAACTGAGGMCTSFrecombinationhomolog RAD52G1610a1WIAF-12101HT27727501replicationTGCAACTCCT[G/A]CTATTAAGACMGAATprotein Rpa4,30 kDaG1610a2WIAF-12102HT27727554replicationTACCGTGTAA[C/T]GTGAACCAGCSCTNNprotein Rpa4,30 kDaG1610u3WIAF-12307HT27727450replicationTTCTGCTGCT[G/A]ATGGAGCGAGMGADNprotein Rpa4,30 kDaG1610u4WIAF-12320HT277271037replicationTGATTCATGA[G/C]TGTCCTCATCMGCEDprotein Rpa4,30 kDaG1610u5WIAF-12321HT27727857replicationTAGAGGACAT[G/A]AACGAGTTCAMGAMIprotein Rpa4,30 kDaG1610u6WIAF-12343HT27727539replicationGAATTCAGGA[C/T]GTTGTACCGTSCTDDprotein Rpa4,30 kDaG1630u1WIAF-12302HT35634312DCC, deleted inACTCATGAAG[C/T]AGCTTAATGCNCTQ*colorectalcarcinomaG1632u1WIAF-13572HT27355742tumor suppressor,TTTATGACAT[G/C]AAGCGGGGCTMGCMIPDGF receptorbeta-likeG1632u2WIAF-13584HT273551102tumor suppressor,TGGAAGACTT[C/T]GAGACGATTGSCTFFPDGF receptorbeta-likeG1632u3WIAF-13601HT27355258tumor suppressor,AAGACGCAGT[C/T]TATCATGATGMCTSFPDGF receptorbeta-likeG1633u1WIAF-13957HT17781263FER, fer (fps/TTCAGGCAAA[T/C]GAGATCATGTSTCNNfes related)tyrosine kinase(phosphoproteinNCP94)G1633u2WIAF-13958HT17782407F2R, fer (fps/TATGTTGTAT[C/T]TCGAGAGTAAMCTLFfes related)tyrosine kinase(phosphoproteinNCP94)G1634u1WIAF-13505HT32161569ELK1, ELK1, memberTCTCGACCCC[C/T]GTGGTGCTCTSCTPPof ETS oncogenefamilyG1634u2WIAF-13858HT3216456ELK1, ELK1, memberGGCTGTGGGG[A/G]CTACGCAAGASAGGGoncogene familyG1634u3WIAF-13859HT3216745ELK1, ELK1, memberAGGCCCAGGC[G/A]GTTTGGCACGMGAGSof ETS oncogenefamilyG1638u1WIAF-14172HT122498uracil-DNAGCTGGGACCT[G/C]TTCCACAAAT—GC——glycosylaseG1643u1WIAF-13517HT3751629DXS648E, DNA seg-TACATCCCCA[G/A]TCGTGGCCCTMGASNment on chromosomeX (unique) 648expressed sequenceG1645u1WIAF-14087D21089363XPC, xerodermaAAAACCTCAA[G/A]GTTATAAAGGSGAKKpigmentosum, com-plementation groupCG1645u2WIAF-14088D210892166XPC, xerodermaTGCATTCCAG[G/A]CACACGTGGCSGARRpigmentosum, com-plementation groupCG1645u3WIAF-14089D210891580XPC, xerodermaGGGAGCCATC[G/A]TAAGGACCCAMGARHpigmentosum, com-plementation groupCG1645u4WIAF-14090D210891601XPC, xerodermaAGCTTGCCAG[T/C]GGCATCCTCAMTCVApigmentosum, com-plementation groupCG1645u5WIAF-14091D210892920XPC, xerodermaCCCATTTGAG[A/C]AGCTGTGAGCMACKQpigmentosum, com-plementation groupCG1645u6WIAF-14103D21089405XPC, xerodermaATGACCTCAG[G/A]GACTTTCCAASGARRpigmentosum, com-plementation groupCG1645u7WIAF-14104D21089151XPC, xerodermaGGGACGCGAA[C/G]TGCGCAGCCAMCGLVpigmentosum, com-plementation groupCG1645u8WIAF-14105D210892133XPC, xerodermaAAGCGGTCTA[C/T]TCCAGGGATTSCTYYpigmentosum, com-plementation groupCG167u1WIAF-11632HT457983PMS2L8, postmeioticCCTATTCATC[G/A]GAAGTCAGTCMGARQsegregationincreased 2-like 8G167u2WIAF-11633HT4579219PMS2L8, postmeioticGAGTGGATCT[T/C]ATTGAAGTTTSTCLLsegregationincreased 2-like 8G167u3WIAF-11644HT4579768PMS2L8, postmeioticTGCCCCCTAG[T/C]GACTCCGTGTSTCSSsegregationincreased 2-like 8G161u4WIAF-11622HT45791645PMS2L8, postmeioticGAAAGCGCCT[G/A]AAACTGACGAMGAEKsegregationincreased 2-like 8G167u5WIAF-11645HT45791512PMS2L8, postmeioticACTCGGGGCA[C/T]GGCAGCACTTSCTHHsegregationincreased 2-like 8G167u6WIAF-11646HT45791619PMS2L8, postmeioticTCGCAGGAAC[A/C]TGTGGACTCTMAGHRsegregationincreased 2-like 8G167u7WIAF-11647HT45791432PMS2L8, postmeioticCGTCCTGAGA[C/T]CTCAGAAAGAMCTPSsegregationincreased 2-like 8G167u8WIAF-11625HT45792490PMS2L8, postmeioticGGACTGCTCT[T/C]AACACAAGCGSTCLLsegregationincreased 2-like 8G167u9WIAF-11619HT4579804PMS2L8, postmeioticTGAGCTGTTC[G/C]GATGCTCTGCSGCSSsegregationincreased 2-like 8G167u10WIAF-11623HT45791555PMS2L8, postmeioticCATCCCAGAC[A/G]CGGGCAGTCAMAGTAsegregationincreased 2-like 8G167u11WIAF-11624HT45752364PMS2L8, postmeioticCCTTCGGACC[C/T]CAGGACGTCGSCTPPsegregationincreased 2-like 8G167u12WIAF-11626HT45792348PMS2L8, postmeioticACTAGTAAAA[A/G]CTGGACCTTCMAGNSsegregationincreased 2-like 8G181u1WIAF-11697HT48793311ERCC4, excisionATATTTGCGA[C/T]AAGTAGGATAMCTTIrepair cross-complementingrodent repairdeficiency,complementationgroup 4G181u2WIAF-11698HT48793295ERCC4, excisionCACACAAGGT[G/C]GTGTTATATTMGCGRrepair cross-complementingrodent repairdeficiency,complementationgroup 4G181u3WIAF-11699HT48793234ERCC4, excisionTTGAACACCT[C/T]CCTCCCCCTCSCTLLrepair cross-complementingrodent repairdeficiency,complementationgroup 4G181u4WIAF-11704HT48793808ERCC4, excisionTTTGTGGCAC[C/T]AGCTTGGAGCNCTQ*repair cross-complementingrodent repairdeficiency,complementationgroup 4G181u5WIAF-11705HT48793640ERCC4, excisionTTCTATGACA[C/T]CTACCATGCTMCTPSrepair cross-complementingrodent repairdeficiency,complementationgroup 4G181u6WIAF-11670HT487931117ERCC4, excisionAGAAAGCAAC[C/T]CAAAGTGGGAMCTPSrepair cross-complementingrodent repairdeficiency,complementationgroup 4G185u1WIAF-11668HT5122319ACVR2B, activin ATCTGCAACGA[G/A]CGCTTCACTCSGAEEreceptor, type IIBG185u2WIAF-11707HT512270ACVR2B, activin AAGACACGGGA[G/C]TGCATCTACTMGCEDreceptor, type IIBG185u3WIAF-11672HT5122812ACVR2B, activin ACCTCACGGAT[T/C]ACCTCAAGGGMTCYHreceptor, type IIBG185u4WIAF-13542X775331109ACVR2B, activin AGGCTCCTGAG[G/A]TGCTCGAGGGMGAVMreceptor, type IIBG185u5WIAF-13558X77533997ACVR2B, activin ATGCTGAAGAG[C/T]GACCTCACAGSCTSSreceptor, type IIBG187u1WIAF-11669HT97400183androgenCCAGAGACAG[C/T]GCGACCCGGAMCTRCG191u1WIAF-10176AF025375414CXCR4, chemokineACCTGGCCAT[C/T]GTCCACGCCASCTII(C-X-C motif),receptor 4 (fusin)G193u1WIAF-10178D29984231CCR2, chemokineAGTGCTTGAC[T/A]GACATTTACCSTATT(C-C motif)receptor 2G193u2WIAF-10179D29984190CCR2, chemokineCATGCTGGTC[G/A]TCCTCATCTTMGAVI(C-C motif)receptor 2G194u1WIAF-10211D43767121SCYA17, smallACATCCACCC[A/C]GCTCGAGGGASACAAinducible cytokinesubfamily A(Cys-Cys), member17G197u1WIAF-10167D504031515NRAMP1, naturalGGTGCTAGTC[T/C]GCGCCATCAAMTCCRresistance-associatedmacrophage protein1 (might includeLeishmaniasis)G197u2WIAF-10173D504031629NRAMP1, naturalCACCTACCTG[G/C]TCTGGACCTGMGCVLresistance-associatedmacrophage protein1 (might includeLeishmaniasis)G20u1WIAF-10249U14722896ACVR1B, activin ACGGTACACAG[T/C]GACAATTGAGMTCVAreceptor, type IBG20u2WIAF-10250U14722866ACVR1B, activin AGAGCACGGGT[C/T]CCTGTTTGATMCTSFreceptor, type IBG20u3WIAF-10251U147221391ACVR1B, activin ACAGAGTTATG[A/T]GGCACTGCGGMATEVreceptor, type IBG20u4WIAF-10252U147221236ACVR1B, activin ATATATTGGGA[G/C]ATTGCTCGAAMGCEDreceptor, type IBG20u5WIAF-10261U14722518ACVR1B, activin AGAGATGTGTC[T/C]CTCCAAAGACMTCLPreceptor, type IBG207a1WIAF-10516L25259866Human CTLA4AGCTGTACTT[C/T]CAACAGTTATMCTPScounter-receptor(B7-2) mRNA,complete cds.G208u1WIAF-10204L3158185CCR7, chemokineGGGGAAACCA[A/G]TGAAAAGCGTMAGMV(C-C motif)receptor 7G211u1WIAF-10213M24545174SCYA2, small,TCACCTGCTG[T/C]TATAACTTCASTCCCinducible cytokineA2 (monocytechemotactic protein1, homologous tomouse Sig-je)G214u1WIAF-10191M27533452CD80, CD80 antigenTGAAAGAAGT[G/A]GCAACGCTGTSGAVV(CD28 antigenligand 1, B7-1antigen)G215u1WIAF-11659M28393822PRF1, perforin 1GCATCTCTGC[C/T]GAAGCCAAGGSCTAA(preformingprotein)G215u2WIAF-11723M28393159PRF1, perform 1TGACCAGCCT[C/T]CGCCGCTCGGSCTLL(preformingprotein)G215u3WIAF-11724M2839396PRF1, perform 1CAGAGTGCAA[G/A]CGCAGCCACASGAKK(preformingprotein)G215u4WIAF-11725M283931377PRF1, perform 1ATAACAACCC[C/T]ATCTGGTCAGSCTPP(preformingprotein)G215u5WIAF-11726M283931326PRF1, perform 1TGAAGCTCTT[C/T]TTTGGTGGCCSCTFF(preformingprotein)G215u6WIAF-11727M283931076PRF1, perform 1CGGCGGGAGG[C/T]ACTGAGGAGGMCTAV(preformingprotein)G217u1WIAF-11691M31932649FCGR2B, Fc fragmentGCAGCTCTTC[A/C]CCAATGGGGASAGSSof IgG, lowaffinity IIb,receptor for (CD32)G217u2WIAF-11692M31932625FCGR2B, Fc fragmentTCACTGTCCA[A/G]GTGCCCAGCASAGQQof IgG, lowaffinity IIb,receptor for (CD32)G217u3WIAF-11712M31932332FCGR2B, Fc fragmentGACTGGCCAG[A/C]CCAGCCTCAGMACTPof IgG, lowaffinity IIb,receptor for (CD32)G217u4WIAF-11713M31932101FCGR2B, Fc fragmentGGCTTCTGCA[G/T]ACAGTCAAGCMGTDYof IgG, lowaffinity IIb,receptor for (CD32)G218u1WIAF-10184M36712677CD8B1, CD8 antigen,TTTTACAAAT[A/G]AGCAGAGAATNAG**beta polypeptide 1(p37)G218u2WIAF-10188M36712326CD8B1, CD8 antigen,GCTGTGTTTC[G/C]GGATGCAAGCMGCRPbeta polypeptide 1(p37)G218u3WIAF-10189M36712196CD8B1, CD8 antigen,CAGTAACATG[C/T]GCATCTACTGMCTRCbeta polypeptide 1(p37)G218u4WIAF-10190M36712225CD8B1, CD8 antigen,AGCGCCAGGC[A/C]CCGAGCAGTGSACAAbeta polypeptide 1(p37)G218u5WIAF-10194M36712583CD8B1, CD8 antigen,GGTGGCTGGC[G/A]TCCTGGTTCTMGAVIbeta polypeptide 1(p37)G218u6WIAF-10208M36712372CD8B1, CD8 antigen,TGAAGCCGGA[A/G]GACAGTGGCASAGEEbeta polypeptide 1(p37)G218u7WIAF-10209M36712400CD8B1, CD8 antigen,CTGCATGATC[G/T]TCGGGAGCCCMGTVFbeta polypeptide 1(p37)G218u8WIAF-10210M36712270CD8B1, CD8 antigen,TCTGGGATTC[C/T]GCAAAAGGGASCTSSbeta polypeptide 1(p37)G218a9WIAF-10518M36712618CD8B1, CD8 antigen,GAGTGGCCAT[C/G]CACCTGTGCTMCGIMbeta polypeptide 1(p37)G218a10WIAF-13223M36712556CD8B1, CD8 antigen,TTGTAGCCCC[A/G]TCACCCTTGGMAGIVbeta polypeptide 1(p37)G218a11WIAF-13224M36712836CD8B1, CD8 antigen,CTGTGTGTGA[T/C]GTGCATGGGA—TC——beta polypeptide 1(p37)G22u1WIAF-10301U861366719Human telomerase-GGTGGTAACC[G/A]TCGGGCTAGAMGAVIassociated proteinTP-1 mRNA, completecds.G22u2WIAF-10302U861367537Human telomerase-CTGATGGGAT[C/G]CTATGGAACCMCGIMassociated proteinTP-1 mRNA, completecds.G22u3WIAF-10311U861361798Human telomerase-ATGATGCCAT[T/C]GATGCCCTCGSTCIIassociated proteinTP-1 mRNA, completecds.G22u4WIAF-10312U861362397Human telomerase-CTGTCTCTGG[C/T]TGGCCAAAGGMCTAVassociated proteinTP-1 mRNA, completecds.G22u5WIAF-10313U861363289Human telomerase-AGAAAGGGAT[A/C]ACCTGCCGCASACIIassociated proteinTP-1 mRNA, completecds.G22u6WIAF-10314U861363242Human telomerase-AGAGGCCGCA[T/C]GTCGGATCTCMTCCRassociated proteinTP-1 mRNA, completecds.G22u7WIAF-10315U861364482Human telomerase-CCGTTTGCCT[G/A]CCTCGTCCAGMGACYassociated proteinTP-1 mRNA, completecds.G22u8WIAF-10316U861364363Human telomerase-GTTTGACTGT[G/A]GACCAGCTGCSGAVVassociated proteinTP-1 mRNA, completecds.G22u9WIAF-10317U861364230Human telomerase-GTGTCTGAGA[G/A]ACTCCGGACCMGARKassociated proteinTP-1 mRNA, completecds.G22u10WIAF-10318U861364419Human telomerase-GGGACTAAGA[G/C]CTGGGAAGAAMGCSTassociated proteinTP-1 mRNA, completecds.G22u11WIAF-10319U861365269Human telomerase-TCTCCGATGA[T/C]ACACTCTTTCSTCDDassociated proteinTP-1 mRNA, completecds.G22u12WIAF-10320U861365015Human telomerase-GCTGCTCTCC[C/T]GGAGATGGCAMCTRWassociated proteinTP-1 mRNA, completecds.G22u13WIAF-10321U861365133Human telomerase-GTGGCCTTCT[C/T]CACCAATGGGMCTSFassociated proteinTP-1 mRNA, completecds.G22u14WIAF-10322U861367764Human telomerase-ACAGCCCTCC[A/G]TGTCCTACCTMAGHRassociated proteinTP-1 mRNA, completecds.G22u15WIAF-10323U861367884Human telomerase-TGCCTGGAAC[C/T]TTGCCTGGGCMCTPLassociated proteinTP-1 mRNA, completecds.G22u16WIAF-10324U861367744Human telomerase-AGATTCACTC[C/A]GCCTCTGTCASGASSassociated proteinTP-1 mRNA, completecds.G22u17WIAF-10337U861361018Human telomerase-CCATTGCTGC[T/C]TTCTTGCCGGSTCAAassociated proteinTP-1 mRNA, completecds.G22u18WIAF-10338U861361000Human telomerase-TGGCCAATAA[C/A]ATCTTGGCCAMCANKassociated proteinTP-1 mRNA, completecds.G22u19WIAF-10339U861361182Human telomerase-ATGACGGACA[A/G]ATTTGCCCAGMAGKRassociated proteinTP-1 mRNA, completecds.G22u20WIAF-10340U861361939Human telomerase-AGCAGCTTCG[T/G]ATGGCAATGASTGRRassociated proteinTP-1 mRNA, completecds.G22u21WIAF-10341U861362227Human telomerase-TCACGAGGGC[G/A]GAGCAGGTGGSGAAAassociated proteinTP-1 mRNA, completecds.G22u22WIAF-10342U861362776Human telomerase-GGCGCAGCAT[C/T]CGGCTTTTCASCTIIassociated proteinTP-1 mRNA, completecds.G22u23WIAF-10343U861362877Human telomerase-GCCCCTCACC[C/A]TATCAGCCTTMGARHassociated proteinTP-1 mRNA, completecds.G22u24WIAF-10344U861363087Human telomerase-TCAGGGCGCT[C/T]TGTGACAGAGMCTSFassociated proteinTP-1 mRNA, completecds.G22u25WIAF-10345U861363662Human telomerase-CAAGGTGGCA[C/T]CATTAGTCTTMCTPSassociated proteinTP-1 mRNA, completecds.G22u26WIAF-10346U861364762Human telomerase-TTTCGAAGTT[C/T]CTTACCAACCSCTFFassociated proteinTP-1 mRNA, completecds.G22u27WIAF-10351U861361737Human telomerase-CTCCAGCATG[G/C]GAAGTCGGTGMGCGAassociated proteinTP-1 mRNA, completecds.G22u28WIAF-10352U861363543Human telomerase-ACAGTGCAAC[A/G]GCTGATGCTGMAGQRassociated proteinTP-1 mRNA, completecds.G22u29WIAF-10353U861364232Human telomerase-GTCTGAGAGA[C/T]TCCGGACCCTMCTLFassociated proteinTP-1 mRNA, completecds.G22u30WIAF-10354U861364523Human telomerase-GGAGGGCCCT[C/T]TGGAGCGCCCSCTLLassociated proteinTP-1 mRNA, completecds.G22u31WIAF-10355U861365333Human telomerase-TGGTTGTCGG[G/T]TGCTGCAGACMGTVLassociated proteinTP-1 mRNA, completecds.G22u32WIAF-10356U861366208Human telomerase-AGCTGCTGAC[G/A]CGGCCACACASGATTassociated proteinTP-1 mRNA, completecds.G22u33WIAF-10357U861367703Human telomerase-TAGTCAGCCA[A/G]CACCACATCTMAGTaassociated proteinTP-1 mRNA, completecds.G22u34WIAF-10360U861363881Human telomerase-CATCGATGGG[G/A]CTGATAGGTTMGAATassociated proteinTP-1 mRNA, completecds.G222u1WIAF-11700M57230697IL6ST, interleukinTGAGTGGGAT[G/C]GTGGAAGGGAMGCGR6 signal transducer(gp130, oncostatinM receptor)G222u2WIAF-11701M57230708IL6ST, interleukinGTGGAAGGGA[A/G]ACACACTTGGSAGEE6 signal transducer(gp130, oncostatinM receptor)G222u3WIAF-11702M57230677IL6ST, interleukinGAGGGGAACA[A/G]AATGAGGTGTMAGKR6 signal transducer(gp130, oncostatinM receptor)G222u4WIAF-11706M572301616IL6ST, interleukinAAGAAATATA[T/C]ACTTGAGTGGMTCIT6 signal transducer(gp130, oncostatinM receptor)G222u5WIAF-11667M572301444IL6ST, interleukinTGATCGCTAT[C/G]TAGCAACCCTMCGLV6 signal transducer(gp130, oncostatinM receptor)G222u6WIAF-11708M57230981IL6ST, interleukinTCTTAAAATT[G/C]ACATGGACCAMGCLF6 signal transducer(gp130, oncostatinM receptor)G226u1WIAF-11714M85079869TGFBR2, transform-CACTGGGAGT[T/C]GCCATATCTGSTCVVing growth factor,beta receptor II(70-80 kD)G226u2WIAF-11715H850791749TGFBR2, transform-ACATTATCAC[C/T]CTCCATTTCCMCTPSing growth factor,beta receptor II(70-80 kD)G226u3WIAF-11716M850791601TGFBR2, transform-TCCCAACTCC[A/C]ACATACATCCSAGAAing growth factor,beta receptor II(70-80 kD)G226u4WIAF-11721H850791256TGFBR2, transform-TACTCCACTT[C/C]CTCACCCCTCMCGFLing growth factor,beta receptor II(70-80 kD)G226u5WIAF-11722M850791502TGFBR2, transform-TCCTCAACAA[C/T]CACCTAACCTSCTNNing growth factor,beta receptor II(70-80 kD)G226u6WIAF-11671M85079888TGFBR2, transform-TCTCATCATC[A/C]TCTTCTACTCMACILing growth factor,beta receptor II(70-80 kD)G226u7WIAF-11674M850791425 TGFBR2, transform-CCTCCACAGT[G/A]ATCACACTCCMGADNing growth factor,beta receptor II(70-80 kD)G227u1WIAF-10197M86511685CD14, CD14 antigenCCTGTCTGAC[A/G]ATCCTGGACTMAGNDG227u2WIAF-10212M86511497CD14, CD14 antigenGAAGCCACAG[G/A]ACTTGCACTTMGAGEG2278u1WIAF-14117AF034611959CUBN, cubilinACATAAATAA[T/C]CGCCCCTGTTSTCNN(intrinsic factor-cobalamn receptor)G2278u2WIAF-14118AF034611781CUBN, cubilinCCGTGGATGT[C/T]TTCACCCAACMCTSF(intrinsic factor-cobalain receptor)G2278u3WIAF-14119AF034611641CUBN, cubilinCTCAGACGTA[C/T]CCACCCCAGTSCTYY(intrinsic factor-cobalamin receptor)G2278u4WIAF-14121AF0346111185CUBN, cubilinTCCTTATCCG[C/A]CAAATGCATGMCAPT(intrinsic factor-cobalamin receptor)G2278u5WIAF-14133AF0346111532CUBN, cubilinTCTGCGTTAT[C/G]AAAACTGAAAMCGIM(intrinsic factorcobalamin receptor)G2278u6WIAF-14134AF0346112208CUBN, cubilinGCCTTTCACT[C/T]ACACCAGGCAMCTHY(intrinsic factorcobalamin receptor)G228u1WIAF-10199U00672586IL10RA, interleukinCCAACGTCCC[G/A]CCAAACTTCASGAPP10 receptor, alphaG228u2WIAF-10200U00672731IL10RA, interleukinAGAGCAGTGC[A/G]TCTCCCTCACMAGIV10 receptor, alphaG2280u1WIAF-13970AJ0015151747RYR3, ryanodineCAGGTATCTT[G/A]GAAGTTTTGCSGALLreceptor 3G2280u2WIAF-13974AJ0015158593RYR3, ryanodineTAGAAGCCAT[T/C]GTCAGCAGTGSTCIIreceptor 3G2282u1WIAF-12694D00726263FECH,ACATGGGAGG[C/T]CCTGAAACTGSCTGGferrochelatase(protoporphyria)G2282u2WIAF-12695D00726514FECH,TACTATATTG[G/A]ATTTCGGTACMGAGEferrochelatase(protoporphyria)G2285u1WIAF-12688D16611673CPO, copropor-AGAAGACGCT[G/A]TCCATTTTCAMGAVIphyrinogen oxidase(coproporphyria,harderoporphyria)G2285u2WIAF-12689D16611783CPO, copropor-ATCGTGGAGA[G/A]CGGCGGGGCASGAEEphyrinogen oxidase(coproporphyria,harderoporphyria)G2287u1WIAF-12687D28472502PTGER4, prosta-GGGCCTCACG[C/T]TCTTTGCAGTMCTLFglandin E receptor4 (subtype EP4)G2287u2WIAF-12691D284721309PTGER4, prosta-TGAAAATGGC[C/T]TTGGAGGCAGMCTLFglandin E receptor4 (subtype EP4)G2287u3WIAF-12707D28472243PTGER4, prosta-AGGAGACGAC[C/T]TTCTACACGCSCTTTglandin E receptor4 (subtype EP4)G2287u4WIAF-12710D284721342PTGER4, prosta-GGTGTGCCTG[G/A]CATGGGCCTGMGAGDglandin E receptor4 (subtype EP4)G229u1WIAF-10185U16752202SDF1, stromal cell-CATGTTGCCA[G/A]AGCCAACCTCMGARKderived factor 1G2295u1WIAF-12727D89079613LTB4R, leukotrieneCTATGTCTGC[G/C]GAGTCAGCATMGCGRb4 receptor (chemo-kine receptor-like1)G2295u2WIAF-1272BD890791248LTB4R, leukotrieneAGGGCACGGG[T/C]TCCGAGGCGTSTCGGb4 receptor (chemo-kine receptor-like1)G2295u3WIAF-12753D890791348LTB4R, leukotrieneCCTCACTGCC[T/G]CCAGCCCTCTMTGSAb4 receptor (chemo-kine receptor-like1)G230u1WIAF-10201U31628627IL15RA, interleukinACAGCCAAGA[A/C]CTGGGAACTCMACNT15 receptor, alphaalphaG2300u1WIAF-12735J02959102LTA4H, leukotrieneACCTGCACCT[C/T]CGCTGCACGCSGTLLA4 hydrolaseG2300u2WIAF-12738J029591380LTA4H, leukotrieneCCTGGCTCTA[C/T]TCTCCTGGACSCTYYA4 hydrolaseG2302u1WIAF-12741J03037627CA2, carbonicTCCTGAATCC[C/T]TGGATTACTGSCTLLanhydrase IIG2302u2WIAF-12742J03037819CA2, carbonicGCCACTGAAG[A/G]ACAGGCAAATMAGNDanhydrase IIG2303u1WIAF-12751J03571304ALOX5, arachidonateCGCTGAAGAC[G/A]CCCCACGGGGSGATT5-lipoxygenaseG2303u2WIAF-12752J03571794ALOX5, arachidonateAGAGCTGCCC[G/A]AGAAGCTCCCMGAEK5-lipoxygenaseG2304u1WIAF-12772J03575840PDHA1, pyruvateTCCGAGAGGC[A/C]ACAAGGTTTGSAGAAdehydrogenase(lipoamide) alpha 1G2304u2WIAF-12779J035751044PDHA1, pyruvateCCAGTGTGGA[A/C]GAACTAAAGGMACEDdehydrogenase(lipoamide) alpha 1G2305u1WIAF-12763J03576456PDHB, pyruvateTCTTCAGGGG[A/G]CCCAATGGTGSAGGGdebydrogenase(lipoamide) betaG2305u2WIAF-12764J03576650PDHB, pyruvateGTTCCTTTTG[A/C]ATTTCTCCCGMACEAdehydrogenase(lipoamide) betaG231u1WIAF-10202U32324734IL11RA, interleukinCCAGGGCCTG[C/T]GGGTAGAGTCMCTRW11 receptor, alphaG2312u1WIAF-12762J050963726ATP1A2, ATPase,TCAAGAACCA[C/T]ACAGAGATCGSCTHHNa+/K+transporting,alpha 2 (+)polypeptideG2313u1WIAF-12760J052006141RYR1, ryanodineTGCAATTCAA[A/G]GATGGTACAGSAGKKreceptor 1(skeletal)G2313u2WIAF-12767J052003048RYR1, ryanodineCGGCGCAGAC[A/G]ACACTGGTGGSAGTTreceptor 1(skeletal)G2313u3WIAF-12768J052003084RYR1, ryanodineATGGCCACAA[C/T]GTGTGGGCCCSCTNNreceptor 1(skeletal)G2313u4WIAF-12777J052005667RYR1, ryanodineGCATCTTTGG[C/T]GATGAGGATGSCTGGreceptor 1(skeletal)G2313u5WIAF-12780J052006600RYR1, ryanodineGCTCGCTGCT[C/T]ATCGTGCAGASCTLLreceptor 1(skeletal)G2313u6WIAF-12781J052007191RYR1, ryanodineAGCCTGAGTG[C/T]TTCGHACCCGSCTCCreceptor 1(skeletal)G2313u7WIAF-12782J052007602RYR1, ryanodineACCACAAGGC[G/A]TCCATGGTGCSGAAAreceptor 1(skeletal)G2313u8WIAF-12784J052009288RYR1, ryanodineCAGACGCCCC[A/G]GCTCTGGTCASAGPPreceptor 1(skeletal)G2313u9WIAF-12786J0520013690RYR1, ryanodineTCCAAAGAAG[G/A]AGGAAGCTGGMGAEKreceptor 1(skeletal)G2313u10WIAF-12789J052003147RYR1, ryanodineACATCCCAGC[G/A]CGCCCAAACCSGAAAreceptor 1(skeletal)G23144u1WIAF-12771J052721920IMPDH1, IMPTGAAGATCGC[A/G]CAGGGTGTCTSAGAA(inosine mono-phosphate)dehydrogenase 1G2319u1WIAF-12814K03191651CYP1A1, cytochromeCCCCTACAGG[T/C]ATGTGGTGGTMTCYHP450, subfamily I(aromatic compoundinducible), poly-peptide 1G232u1WIAF-11657U589171490Homo sapiens IL,-17TGAACATGAT[C/T]CTCCCGGACTSCTIIreceptor mRNA,complete cds.G232u2WIAF-11677U589171293Homo sapiens IL-17GCAGGCCATC[T/C]CGGAGGCAGGMTCSPreceptor mRNA,complete cds.G232u3WIAF-11658U589171132Homo sapiens IL-17GGCCTGCCTG[C/T]GGCTCACCTGMCTAVreceptor mRNA,complete cds.G232u4WIAF-11679U58917905Homo sapiens IL-17GCAGCTGCCT[C/T]AATGACTGCCSCTLLreceptor mRNA,complete cds.G232u5WIAF-11682U589171794Homo sapiens IL-17GTTCGAATGTE[G/T]AGAACCTCTANGTE*receptor mRNA,complete cds.G232u7WIAF-11660U58917743Homo sapiens IL-17TGACCAGTTT[T/C]CCGCACATGGSTCFFreceptor mRNA,complete cds.G2322u1WIAF-12853L014061316GHRHR, growthCTGACATCTA[T/C]GTGCTAGGCTMTCMThormone releasinghormone receptorG2328u1WIAF-12845L203161285GCGR, glucagonTGCGGGCACG[G/C]CAGATGCACCSGCRRreceptorG2329u1WIAF-12850L22214713ADORA1, adenosineTGCTGGCAAT[T/C]GCTGTGGACCSTCIIA1 receptorG2329u2WIAF-12851L22214716ADORA1, adenosineTGGCAATTGC[T/G]GTGGACCGCTSTGAAA1 receptorG2335a1WIAF-12136L32961265ABAT, 4-amino-CCTAGATCTC[A/G]GGAGTTAATGMAGQRbutyrate amino-transferaseG2335a2WIAF-12137L32961407ABAT, 4-amino-TCTCCTCTGT[T/C]CCCATAGGTTSTCVVbutyrate amino-transferaseG2335u3WIAF-12838L32961365ABAT, 4-amino-TTGATGTGGA[C/T]GGCAACCGAASCTDDbutyrate amino-transferaseG2335u4WIAF-12839L32961583ABAT, 4-amino-ATCACCATGG[C/T]CTGCGGCTCCMCTAVbutyrate amino-transferaseG2335u5WIAF-12841L329611082ABAT, 4-amino-TGGACGAGGT[C/A]CAGACCGGAGSCAVVbutyrate amino-transferaseG2335u6WIAF-12852L32961227ABAT, 4-amino-ATTATGATGG[C/A]CCTCTGATGASGAGGbutyrate amino-transferaseG2337u1WIAF-13577L34820149ALDH5A1, aldehydeTGTTCTCGAA[A/C]GAATGCCAAGMAGKRdehydrogenase 5family, member A1(succinate-semi-aldehydedehydrogenase)G2342a1WIAF-12138M125301602TF, transferrinGCCTAAACCT[G/C]TGTGAACCCASGCLLG2342a2WIAF-12139M125301795TF, transferrinTACCAGGAAA[C/T]CTGTGGAGGAMCTPSG2346u1WIAF-12829M13928234ALAD, aminolevuli-TGGCCAGGTA[T/C]GGTGTGAAGCSTCYYnate, delta-,dehydrataseG2346u2WIAF-12830M13928529ALAD, aminolevuli-TGAGGTGGCA[T/C]TGGCGTATGCSTCLLnate, delta-,dehydrataseG2346u3WIAF-12843M13928480ALAD, aminolevuli-TGAGTGAAAA[C/T]GGAGCATTCCSCTNNnate, delta-,dehydrataseG2348u1WIAF-12835M14016621UROD, uroporphyrino-CTCTGGTCCC[A/G]TATCTGGTAGSAGPPgen decarboxylaseG235u1WIAF-11678U83171100SCYA22, smallCAGGCCCCTA[C/T]GGCGCCAACASCTYYinducible cytokinesubfamily A (Cys-Cys), member 22G2363a1WIAF-10519M37435596CSF1, colonyGACAAGGACT[G/T]GAATATTTTCMGTWLstimulating factor1 (macrophage)G2363a2WIAF-13225M37435498CSF1, colonyAAGAGCATGA[C/T]AAGGCCTGCGSCTDDstimulating factor1 (macrophage)G2363a3WIAF-13226M37435712CSF1, colonyCAGTGACCCG[G/T]CCTCTGTCTCMGTASstimulating factor1 (macrophage)G2369u1WIAF-12854M30773857PPP3R1, proteinTTGATTTGCA[C/T]AATTCTCGTTSCTDDphosphatase 3 (formerly 2B),regulatory subunitB (19 kD), alphaisoform(calcineurin B,type I)G2369u2WIAF-12855M307731274PPP3R1, proteinATGTGTGACT[C/T]TTATCAGAGA-CT--phosphatase 3(formerly 25),regulatory subunitB (19 kD), alphaisoform(calcineurin B,type I)G237u1WIAF-11662U86358311SCYA25, smallCACCACAACA[T/C]GCAGACCTTCMTCMTinducible cytokinesubfamily A (Cys-Cys), member 25G237u2WIAF-11680U86358134SCYA25, smallGTGCTCCGGC[G/A]CGCCTGGACTMGARHinducible cytokinesubfamily A (Cys-Cys), member 25G237u3WIAF-11681U86358133SCYA25, smallTGTGCTCCGG[C/T]GCGCCTGGACMCTRCinducible cytokinesubfamily A (Cys-Cys), member 25G237u5WIAF-11661U86358302SCYA25, smallGCAAAGCTCC[A/G]CCACAACATGMAGHRinducible cytokinesubfamily A (Cys-Cys), member 25G237u6WIAF-11663U86358378SCYA25, smallAGTTATCATC[A/C]TCCAAGTTTASAGSSinducible cytokinesubfamily A (Cys-Cys), member 25G2373u1WIAF-12870M36035500BZRP, benzo-GCTGGCCTTC[G/A]CGACCACACTMGAATdiazapine receptor(peripheral)G2376u1WIAF-13025M57414979TACR2, tachykininCTGCTGCCCA[T/C]GGGTCACACCMTCWRreceptor 2G238u1WIAF-10177X01394239TNF, tumor necrosisGCTCCAGGCG[G/T]TGCTTGTTCCSGTRRfactor (TNF super-family, member 2)G2381u1WIAF-12894M59941730CSF2RB, colonyCAGAGGTTTG[C/T]TGGGACTCCCSCTCCstimulating factor2 receptor, beta,low-affinity(granulocyte-macrophage)G2381u2WIAF-12896M599411306CSF2RB, colonyGGATCTGGAG[C/T]GAGTGGAGTGSCTSSstimulating factor2 receptor, beta,low-affinity(granulocyte-macrophage)G2381u3WIAF-12900M599411972CSF2RB, colonyCGATGGGACCC[G/A]GGACAGGCCGSGAPPstimulating factor2 receptor, beta,low-affinity(granulocyte-macrophage)G2381u4WIAF-12901M599411982CSF2RB, colonyGGGACAGGCC[G/A]TGGAACTGGAMGAVMstimulating factor2 receptor, beta,low-affinity(granulocyte-macrophage)G2381u5WIAF-12942M59941773CSF2RB, colonyCCAGAACCTG[G/C]AGTGCTTCTTMGCEQstimulating factor2 receptor, beta,low-affinity(granulocyte-macrophage)G2381u6WIAF-12946M599412458CSF2RB, colonyCCCCACAGCC[C/A]GAGGGCCTCCSCAPPstimulating factor2 receptor, beta,low-affinity(granulocyte-macrophage)G2384u1WIAF-12908M618311000AHCY, S-adenosyl-GCCGTGGAGA[A/C]GGTGAACATCMACKThomocysteinehydrolaseG2387u1WIAF-12910M639672585ALDH5, aldehydeCTGCTGAACC[T/G]CCTGGCAGACMTGLRdehydrogenase 5G2387u2WIAF-12911M639672996ALDH5, aldehydeTATGGCCCAA[C/G]AGCAGGTGCGMCGTRdehydrogenase 5G2387u3WIAF-12954M639672522ALDH5, aldehydeGCCCGGGAAG[C/T]CTTCCGCCTGMCTAVdehydrogenase 5G2387u4WIAF-12955M639672448ALDH5, aldehydeACCCTACCAC[C/T]GGGGAGGTCASCTTTdehydrogenase 5G2387u5WIAF-12956M639672460ALDH5, aldehydeGGGAGGTCAT[C/T]GGGCACGTGGSCTIIdehydrogenase 5G2387u6WIAF-12957M639672991ALDH5, aldehydeCGGGGTATGG[C/T]CCAACAGCAGSCTGGdehydrogenase 5G2387u7WIAF-12958M639673022ALDH5, aldehydeCGCCCAGCAC[A/G]TGGATGTTGAMAGMVdehydrogenase 5G2387u8WIAF-12959M639672943ALDH5, aldehydeCCCTCATCAA[G/C]GAGGCAGGCTMGCKNdehydrogenase 5G2388u1WIAF-12888M64590588GLDC, glycineTGCCACAGAC[G/A]ATTTTGCCGASCATTdehydrogenase(decarboxylating;glycine decarboxyl-ase, glycine cleav-age system proteinP)G2388u2WIAF-12889M64590651GLDC, glycineACCAGCCTGA[G/A]GTGTCTCAGGSGAEEdehydrogenase(decarboxylating;glycine decarboxyl-ase, glycine cleav-age system proteinP)G2388u3WIAF-12890M64590698GLDC, glycineCAGACCATGG[T/C]GTGTGACATCMTCVAdehydrogenase(decarboxylating;glycine decarboxyl-ase, glycine cleav-age system proteinP)G2388u4WIAF-12891M64590557GLDC, glycineTATATTGGCA[T/C]GGGCTATTATMTCMTdehydrogenase(decarboxylating;glycine decarboxyl-ase, glycine cleav-age system proteinP)G2388u5WIAF-12938M64590587GLDC, glycineGTGCCACAGA[C/G]GATTTTGCGGMCGTRdehydrogenase(decarboxylating;glycine decarboxyl-ase, glycine cleav-age system proteinP)G2388u6WIAF-12939M64590518GLDC, glycineCTGCATGCCA[T/C]TTCAAGCAAAMTCITdehydrogenase(decarboxylating;glycine decarboxyl-ase, glycine cleav-age system proteinP)G2388u7WIAF-12940M64590810GLDC, glycineGGAAATTTCT[C/T]GTTGATCCCCSCTLLdehydrogenase(decarboxylating;glycine decarboxyl-ase, glycine cleav-age system proteinP)G2388u8WIAF-12941M645901481GLDC, glycineCATTGTGGCT[G/A]CTCAGTGAAGMGACYdehydrogenase(decarboxylating;glycine decarboxyl-ase, glycine cleav-age system proteinP)G2388u9WIAF-12947M645901841GLDC, glycineAAACTGAACA[C/A]TTCGTCTGAAMGASNdehydrogenase(decarboxylating;glycine decarboxyl-ase, glycine cleavage system proteinP)G2388u10WIAF-12948M645902325GLDC, glycineGACAGGTCTA[C/T]CTACACCGGGSCTYYdehydrogenase(decarboxylating;glycine decarboxyl-ase, glycine cleav-age system proteinP)G2388u11WIAF-12949M645902362GLDC, glycineGGTGGGAATC[T/A]GTCCCCCTGGMTACSdehydrogenase(decarboxylating;glycine decarboxyl-ase, glycine cleav-age system proteinP)G2388u12WIAF-12950M645903220GLDC, glycineTTAGTCCTCT[C/G]TCCCTAAGTT-CG--dehydrogenase(decarboxylating;glycine decarboxyl-ase, glycine cleav-age system proteinP)G2391u1WIAF-12998M69238623ARNT, aryl hydro-TGGTGTATGT[G/C]TCTGACTCCGSGCVVcarbon receptornucleartranslocatorG2391u2WIAF-13002M692381072ARNT, aryl hydro-TGCCTAGTGG[C/T]CATTGGCAGAMCTAVcarbon receptornucleartranslocatorG2391u3WIAF-13021M69238966ARNT, aryl hydro-ACCTCACTTC[G/A]TGGTGGTCCAMGAVMcarbon receptornucleartranslocatorG2394u1WIAF-13003M737472061TSHR, thyroidTTGCTCGTAC[T/A]CTTCTATCCAMTALHstimulating hormonereceptorG2394u2WIAF-13004M737472248TSHR, thyroidTTACCCACGA[C/G]ATGAGGCAGGMCGDEstimulating hormonereceptorG2396u1WIAF-12995M745421027ALDH3, aldehydeCCCCCAGTCC[C/G]CGGTGATGCAMCGPAdehydrogenase 3G2396u2WIAF-13019M745421295ALDH3, aldehydeGGCAACAACA[G/A]CTTCGAGACTMGASNdehydrogenase 3G2403u1WIAF-13583M83670280CA4, carbonicTACGATAAGA[A/T]GCAAACGTGGMATKManhydrase IVG2409u1WIAF-10010HT21561268AGTR1, angiotensinCCACTCAAAC[C/T9 TTTCAACAAAMCTLFreceptor 1G2411u1WIAF-13541M97759210ADORA2B, adenosineTGGCGGGCAA[C/T]GTGCTGGTGTSCTNNA2b receptorG2422u1WIAF-14077S90469375POR, P450GCAGCCTGCC[A/G]GAGATCGACASAGPP(cytochrome)oxidoreductaseG2422u2WIAF-14078S90469852POR, P450TCCTGGCTGC[A/G]GTCACCACCASAGAA(cytochrome)oxidoreductaseG2422u3WIAF-14082S904691496POR, P450AAGGAGCCTG[T/C]CGCCGAGAACMTCVA(cytochrome)oxidoreductaseG2422u4WIAF-14099S904691443POR, P450AGACCAAGGC[C/T]GGCCGCATCASCTAA(cytochrome)oxidoreductaseG2422u5WIAF-14100S904691704POR, P450GCCGCCGCTC[G/A]GATGAGGACTSGASS(cytochrome)oxidoreductaseG2427u1WIAF-14079U079191369ALDH6, aldehydeACTATGGACT[C/T]ACAGCAGCCGSCTLLdehydrogenase 6G2427u2WIAF-14096U079191347ALDH6, aldehydeATAAAAAGAG[C/T]GAATACCACCMCTAVdehydrogenase 6G243u1WIAF-11684X57522926TAP1, transporterATAGCCAGTG[C/G]AGTGCTGGAGMCGAG1, ABC (ATPbinding cassette)G243u2WIAF-11685X57522627TAP1, transporterACCCTACCGC[C/T]TTCGTTGTCASCTAA1, ABC (ATPbinding cassette)G243u3WIAF-11686X57522538TAP1, transporterCCTGCCGGGA[C/G]TTCCCTTGTTMCGLV1, ABC (ATPbinding cassette)G243u4WIAF-11687X57522798TAP1, transporterTGGTGGTCCT[C/G]TCCTCTCTTGSCGLL1, ABC (ATPbinding cassette)G243u5WIAF-11689X575221465TAP1, transporterTAGTATTTCA[G/T]GTATCCTGCTMGTGC1, ABC (ATPbinding cassette)G243u6WIAF-11690X57522177TAP1, transporterAGAGTCCCAG[A/G]CCCGGCCGGGSAGRR1, ABC (ATPbinding cassette)G243u7WIAF-11693X575221067TAP1, transporterAACATCATGT[C/T]TCGGGTAACAMCTSF1, ABC (ATPbinding cassette)G243u8WIAF-11665X575221207TAP1, transporterGGTCACCCTG[A/G]TCACCCTGCCMAGIV1, ABC (ATPbinding cassette)G243u9WIAF-11664X575221757TAP1, transporterCCAAACCCCC[C/T]ACATGTCTTANCTPL1, ABC (ATPbinding cassette)G244u1WIAF-10174X60592239TNFRSF5, tumorCTTGCGGTCA[A/C]AGCGAATTCCSAGEEnecrosis factorreceptor super-family, member 5G2441u1WIAF-13682U302461355SLC12A2, soluteTGCTTAAGGA[A/G]CATTCCATACSAGEEcarrier family 12(sodium/potassium/chloride trans-porters), member 2G2441u2WIAF-13714U302462691SLC12A2, soluteAGCCAAATAT[C/G]AGCCATGGCTMCGQEcarrier family 12(sodium/potassium/chloride trans-porters), member 2G2443u1WIAF-14004U371431456CYP2J2, cytochromeCTGAAGTTTA[G/A]AATGGGTATCMGARKP450, subfamily IIJ(arachidonic acidepoxygenase)polypeptide 2G2443u2WIAF-14032U37143376CYP2J2, cytochromeTTTAAGAAAA[A/G]TGGATTGATTMAGNSP450, subfamily IIJ(arachidonic acidepoxygenase)polypeptide 2G2443u3WIAF-14033U371431502CYP2J2, cytochroneTCTGCGCTGT[T/A]CCTCAGGTGTSTAVVP450, subfamily IIJ(arachidonic acidepoxygenase)polypeptide 2G2444u1WIAF-14065U37519771ALDH3, aldehydeCCCGCACGGA[A/G]TTGCCTCGTGMAGNSdehydrogenase 3G2444u2WIAF-14066U375191698ALDH3, aldehydeAAGGAGATCC[G/A]CTACCCACCCMGARHdehydrogenase 3G2445u1WIAF-14114U38178236CNP, 2′,3′-cyclicTGCCGGGCGC[C/A]CCTCTCGCTGMGARHnucleotide 3′phosphodiesteraseG2445u2WIAF-14115U38175849CNP, 2′,3′-cyclicGTGCCGCCGA[A/G]GAAAAAGTGCSAGGEnucleotide 3′phosphodiesteraseG2445u3WIAF-14122U381781655CNP, 2′,3′-cyclicGTTATCTTGC[A/T]GAGATCTCTGMATQLnucleotide 3′phosphodiesteraseG2445u4WIAF-14241X95520941CNP, 2′,3′-cyclicTGCAAAATAT[T/C]CAGGAGACCG?TC??nucleotide 3′phosphodiesteraseG2445u5WIAF-14242X955201057CNP, 2′,3′-cyclicTCGAGTTGAT[C/T]TTTCAGTGCT?CT??nucleotide 3′phosphodiesteraseG2445u6WIAF-14243X955201583CNP, 2′,3′-cyclicTCTACTGGCT[C/G]TCTAACTAAT?CG??nucleotide 3′phosphodiesteraseG2448u1WIAF-13973U466891895ALDH10, aldehydeTTGTCAAGGC[A/T]GAATATTACTSATAAdehydrogenase 10(fatty aldehydedehydrogenase)G2457u1WIAF-13898U902771304GRIN2A, glutamateGGTCCCGATG[C/T]ACACCTTGCAMCTHYreceptor, iono-tropic, N-methylD-aspartate 2AG2457u2WIAF-13899U902771934GRIN2A, glutamateAAGAAGTAAT[G/T]GCACCGTCTCMGTGCreceptor, iono-tropic, N-methylD-aspartate 2AG2457u3WIAF-13900U902772230GRIN2A, glutamateTCGCTGTCAT[A/G]TTCCTGGCTAMAGIMreceptor, iono-tropic, N-methylD-aspartate 2AG2457u4WIAF-13902U902772916GRIN2A, glutamateGGCATCTACA[G/A]CTGCATTCATMGASNreceptor, iono-tropic, N-methylD-aspartate 2AG2457u5WIAF-13903U902773251GRIN2A, glutamateCTATGTATTC[C/T]AGGCACAACANCTQ*receptor, iono-tropic, N-methylD-aspartate 2AG2457u6WIAF-13917U902772756GRIN2A, glutamateGGACATTGAC[A/C]ACATCCCGGGMAGNDreceptor, iono-tropiC, N-methylD-aspartate 2AG2468u1WIAF-13642X040111017CYBB, cytochromeAGGTGTCCAA[G/A]CTGGAGTGGCSGAKKb-245, beta poly-peptide (chronicgranulomatousdisease)G2473u1WIAF-13670X069901417ICAM1, inter-GGTCACCCGC[G/A]AGGTGACCGTMGAEKcellular adhesionmolecule 1 (CD54),human rhinovirusreceptorG2473u2WIAF-13695X06990179ICAM1, inter-GACCAGCCCA[A/T]GTTGTTGGGCMATKMcellular adhesionmolecule 1 (CD54),human rhinovirusreceptorG2480u1WIAF-14148X55330800AGA, aspartylgluco-TTGGCATGGT[T/G]GTAATCCATASTGVVsaminidaseG2480u2WIAF-14149X55330852AGA, aspartylgluco-AAATGGTATA[A/T]AATTCAAAATMATK*saminidaseG2480u3WIAF-14158X55330616AGA, aspartylgluco-TTATCTACCA[G/C]TGCTTCTCAAMGCSTsaminidaseG2485u1WIAF-13612X595432301RRM1, ribo-ATTGATCAAA[C/A]CCAATCTTTGMGASNnucleotidereductase M1polypeptideG2485u2WIAF-43613X595432410RRM1, ribo-ATTTAAGGAC[G/A]AGACCAGCAGSGATTnucleotidereductase M1polypeptideG2485u3WIAF-13651X59543548RRM1, ribo-CAAGTCAACA[T/C]TGGATATTGTSTCLLnucleotidereductase M1polypeptideG2485u4WIAF-13652X59543199RRM1, ribo-TGCATGTGAT[C/T]AAGCGAGATGSCTIInucleotidereductase M1polypeptideG2485u5WIAF-13653X595431037RRM1, ribo-CAACACAGCT[C/A]GATATGTGGASCARRnucleotidereductase M1polypeptideG2485u6WIAF-13660X595431955RRM1, ribo-GAAGATTGCA[A/C]ADTATGGTATMACKQnucleotidereductase M1polypeptideG2485u7WIAF-13877X59543860RRM1, ribo-GAGTATGAAA[G/C]ATGACAGCATMGCEQnucleotidereductase M1polypeptideG2486u1WIAF-14075X59618543RRM2, ribo-TCAGCACTGG[G/C]AATCCCTGAAMGCEQnucleotidereductase M2polypeptideG2486u2WIAF-14076X59618189RRM2, ribo-TCGCTGCGCC[T/G]CCACTATGCT-TG--nucleotidereductase M2polypeptideG2486u3WIAF-14092X59618524RRM2, ribo-TTGACCTCTC[C/G]AACGACATTCSCGSSnucleotidereductase M2polypeptideG2488u1WIAF-13585X635631633POLR2B, polymeraseCCTTGATGGC[C/A]TATATTTCAGSGAAA(RNA) II (DNAdirected) poly-peptide B (140 kD)G2488u2WIAF-13586X635632452POLR2B, polymeraseCTGTAGACCG[C/T]GGCTTCTTCASCTRR(RNA) II (DNAdirected) poly-peptide B (140 kD)G2488u3WIAF-13587X635632740POLR2B, polymeraseTCAGAACTAG[T/C]GAGACCGGCASTCSS(RNA) II (DNAdirected) poly-peptide B (140 kD)G2488u4WIAF-13602X635631411POLR2B, polymeraseGGGGTGATCA[A/G]AAGAAAGCTCSAGQQ(RNA) II (DNAdirected) poly-peptide B (140 kD)G2488u5WIAF-13603X635632386POLR2B, polymeraseCAATTGTGGC[C/T]ATTGCATCATSCTAA(RNA) II (DNAdirected) poly-peptide B (140 kD)G2489u1WIAF-14181X635641346POLR2A, polymeraseTGGTGGACAA[T/C]GAGCTGCCTGSTCNN(RNA) II (DNAdirected) poly-peptide A (220 kD)G2489u2WIAF-14236X635641647POLR2A, polymeraseTGAATCTTAG[C/T]GTGACAACTC?CT??(RNA) II (DNAdirected) poly-peptide A (220 kD)G2489u3WIAF-14237X635642678POLR2A, polymeraseCTGAATACAA[C/T]AACTTCAAGT?CT??(RNA) II (DNAdirected) poly-peptide A (220 kD)G2489u4WIAF-14238X635643059POLR2A, polymeraseAGCTGCGCTA[C/T]GGCGAACACG?CT??(RNA) II (DNAdirected) poly-peptide A (220 kD)G2489u5WIAF-14239X635643827POLR2A, polymeraseTGGGCCAGTC[C/T]GCTCGAGATG?CT??(RNA) II (DNAdirected) poly-peptide A (220 kD)G2489u6WIAF-14240X635643992POLR2A, polymeraseTGCCTGACTT[T/C]GATGTGGCCC?TC??(RNA) II (DNAdirected) poly-peptide A (220 kD)G2489u7WIAF-14245X635643938POLR2A, polymeraseCCCAGAGCAC[G/A]GTGGTGGCAG?GA??(RNA) II (DNAdirected) poly-peptide A (220 kD)G250u1WIAF-11696HT01551113IL3RA, interleukinCTGTGTCTTC[G/C]TGATCTGCAGMGCVL3 receptor, alpha(low affinity)G251u1WIAF-11666HT0240179interleukin 1TGGATAAGAC[C/T]CGAGCTTTGASCTTTbeta convertaseG251u2WIAF-11694HT0240973interleukin 1GATGCTATTA[A/G]GAAAGCCCACMAGKRbeta convertaseG251u3WIAF-11695HT0240783interleukin 1CCCAGATATA[C/T]TACAACTCAASCTLLbeta convertaseG2513u1WIAF-13736HT273651721PLCB3, phospho-AACTATCTAT[G/A]AAAAGCCAAAMGAMIlipase C, beta 3(phosphatidylino-sitol-specific)G2513u2WIAF-13737HT273651741PLCB3, phospho-AACTATTGGG[A/T]AATCTGTTCAMATEVlipase C, beta 3(phosphatidylino-sitol-specific)G2513u3WIAF-13738HT273651697PLCB3, phospho-AATCTGTTCA[A/G]TACACGGATTSAGQQlipase C, beta 3(phosphatidylino-sitol-specific)G2513u4WIAF-13739HT273651908PLCB3, phospho-CTGTCAGATT[C/A]TAGCAATGAAMGAVIlipase C, beta 3(phosphatidylino-sitol-specific)G2513u5WIAF-13740HT273652172PLCB3, phospho-TATACAGATA[C/T]ACGGAATTCCMCTHYlipase C, beta 3(phosphotidylino-sitol-specific)G2513u6WIAF-13744HT273653019PLCB3, phospho-TTGAAGGGCC[A/C]AGGAGATCTGMAGQRlipase C, beta 3(phosphatidylino-sitol-specific)G2513u7WIAF-13745HT273653024PLCB3, phospho-GGGCCAAGCA[G/A]ATCTGTTGAAMGADNlipase C, beta 3(phosphatidylino-sitol-specific)G2513u8WIAF-13771HT273651079PLCB3, phospho-ACATTTTTGA[T/C]CCTGAGCAAASTCDDlipase C, beta 3(phosphatidylino-sitol-specific)G2513u9WIAF-13772HT273651546PLCB3, phospho-AAGTTGCCTT[C/T]TGATCCAGATMCTSFlipase C, beta 3(phosphatidylino-sitol-specific)G2513u10WIAF-13773HT273651514PLCB3, phospho-AATTAAAAAG[A/T]ATGATCATTGMATRSlipase C, beta 3(phosphatidylino-sitol-specific)G2513u11WIAF-13774HT273651445PLCB3, phospho-AGGTCTTTGG[C/T]AATAAACTCTSCTGGlipase C, beta 3(phosphatidylino-sitol-specific)G2513u12WIAF-13778HT273652087PLCB3, phospho-TTCATATCAA[G/A]ATCATCAGTGSGAKKlipase C, beta 3(phosphotidylino-sitol-specific)G2513u13WIAF-13779HT273652367PLCB3, phospho-TGAATGTTTG[C/T]ACCCTGGATANCTQ*lipase C, beta 3(phosphatidylino-sitol-specific)G2513u14WIAF-13782HT273652719PLCB3, phospho-CTCATCACCA[G/A]TGACAATACTMGASNlipase C, beta 3(phosphatidylino-sitol-specific)G2513u15WIAF-13783HT273652567PLCB3, phospho-TTGATGACAT[C/T]TTTAAAATAGSCTIIlipase C, beta 3(phosphatidylino-sitol-specific)G2513u16WIAF-13784HT273652864PLCB3, phospho-TAGAAATGGC[G/A]GACACACTCCSGAAAlipase C, beta 3(phosphatidylino-sitol-specific)G2513u17WIAF-13785HT273652571PLCB3, phospho-TGACATCTTT[A/T]AAATAGCGGTNATK*lipase C, beta 3(phosphatidylino-sitol-specific)G2513u18WIAF-13786HT273652706PLCB3, phospho-TCTGTCATCT[C/T]GCCTCATCACMCTRWlipase C, beta 3(phosphatidylino-sitol-specific)G252u1WIAF-10195HT0425397FCER2, Fc fragmentGAGGGCTGCC[C/T]GGAACGTCTCMCTRWof IgE, lowaffinity II,receptor for(CD23A)G252u2WIAF-10206HT0425930FCER2, Fc fragmentATGGGAGCCA[T/C]GTGGACTACASTCHHof IgE, lowaffinity II,receptor for(CD23A)G253u1WIAF-10175HT0573228IFNB1, interferon,GGCTTGAATA[C/T]TGCCTCAACGSCTYYbeta 1, fibroblastG254u1WIAF-10196HT0611466IL4R, interleukinTCAGTGCGGA[T/C]AACTATACACSTCDD4 receptorG254u2WIAF-10198HT06111474IL4R, interleukinCATGCCTTCT[T/C]CCACCTTCGGSTCLL4 receptorG254u3WIAF-10207HT06111902IL4R, interleukinAGTGGCTATC[A/G]GGAGTTTGTAMAGQR4 receptorG260u1WIAF-10186HT1090453IL4R, interleukinTGTTATAATC[C/G]ACAACCCATAMCGAG1 receptor, type IG261u1WIAF-10187HT1101434IL7R, interleukinCCTCACTGTC[A/G]TCTATCCCCAMAGIV7 receptorG261u2WIAF-10203HT1101517IL7R, interleukinTTTTAATCCA[T/C]CATCTAGCTTSTCHH7 receptorG267u1WIAF-11735HT1877881IL2RB, interleukinTCCTCGTGGG[C/T]CTCAGCGGGGSCTGG2 receptor, betaG267u2WIAF-11759HT1877379IL2RB, interleukinAGTCAAGCAT[C/T]CTGCGCCTGCMGTSF2 receptor, betaG268u1WIAF-11758HT1985568CD19 antigenGCCTCCGTGT[G/C]TCCCACCGAGMGCVLG268u2WIAF-11734HT1985783CD19 antigenACGATCGCCC[G/T]GCCAGAGATASGTPPG270u1WIAF-11736HT2415530IL6R, interleukinAGGAGGTGGC[A/G]AGAGCCGTGCSAGAA6 receptorG270u2WIAF-11760HT24151590IL6R, interleukinCATTGCCATT[G/A]TTCTGAGGTTMGAVI6 receptorG270u3WIAF-11737HT24151510IL6R, interleukinCCAGTGCAAG[A/C]TTCTTCTTCAMACDA6 receptorG270u4WIAF-11761HT24151451IL6R, interleukinCTACTAATAA[A/T]GACGATGATAMATKN6 receptorG270u5WIAF-11766HT24151843IL6R, interleukinTTCCCCAGAT[A/C]CCTGGCTGGGNAG*W6 receptorG270u6WIAF-11767HT24151829IL6R, interleukinATACAGACTA[C/T]TTCTTCCCCASCTYY6 receptorG271u1WIAF-11762HT2531577CD2, CD2 antigenTCAGAGGCTC[A/G]TCACACACAAMAGIV(p50), sheep redblood cell receptorG271u2WIAF-11739HT2531861CD2, CD2 antigenGGAAGCCCCA[A/C]CAAATTCCAGMACXH(p50), sheep redblood cell receptorG271u3WIAF-11768HT2531818CD2, CD2 antigenCTGGAGACAA[G/A]AGCCCACAGAMGARK(p50), sheep redblood cell receptorG271u4WIAF-11738HT2531736CD2, CD2 antigenCCTCTTGATG[G/A]TCTTTGTGGCMGAVI(p50), sheep redblood cell receptorG273u1WIAF-11763HT3139667IL2RA, interleukinATCATCGTGC[C/T]TGGCTGCCAGMCTPL2 receptor, alphaG273u2WIAF-11764HT3139956IL2RA, interleukinAAACTCCAAT[G/C]CACCCACTGCMGCMI2 receptor, alphaG273u3WIAF-11765HT3139701IL2RA, interleukinACGATGACCC[G/A]CCAGAGATCCSGAPP2 receptor, alphaG273u4WIAF-11740HT31391133IL2RA, interleukinAAATGACCCA[C/T]GGGAAGACAASCTHH2 receptor, alphaG273u5WIAF-11769HT31391163IL2RA, interleukinAGCCCCAGCT[C/A]ATATGCACAGSCALL2 receptor, alphaG276u1WIAF-10192HT3670644CD4 antigenCTCCTAGTAG[C/G]CCCTCAGTGCMCGSRG276u2WIAF-10193HT36701535CD4 antigenCCTGCCAGTG[T/C]CCTCACCGCTSTCCCG276u3WIAF-10205HT36701217CD4 antigenTGATCCTGAC[T/C]TTCAAACTCGSTCSSG277u1WIAF-10007D10232851RENBP, renin-CACGTGATTG[A/G]CAAGTTCCTAMAGDGbinding proteinG277u2WIAF-10032D10232842RENBP, renin-CTTCGAGCCC[A/G]CGTGATTGACMAGHRbinding proteinG277u3WIAF-10042D10232634RENBP, renin-CCTGGCGGCC[A/G]AATACGCAGAMAGKEbinding proteinG279u1WIAF-10047K017401658F8C, coagulationACTGATGTCC[G/A]TCCTTTGTATMGARHfactor VIIIc,procoagulantcomponent(hemophilia A)G279u2WIAF-10049K017402328F8C, coagulationCCTTACTGAA[G/A]GTTTCTAGTTSGAKKfactor VIIIc,procoagulantcomponent(hemophilia A)G279u3WIAF-10050K017404650F8C, coagulationCTGTTCTCCC[G/A]AAACCAGACTSGAPPfactor VIIIc,procoagulantcomponent(hemophilia A)G279u4WIAF-10050K017406919F8C, coagulationCCAGAAGACA[A/C]TGAAAGTCACMAGMVfactor VIIIc,procoagulantcomponent(hemophilia A)G279u5WIAF-10080K01740480F8C, coagulationTTAAGAACAT[G/A]GCTTCCCATCMGAMIfactor VIIIc,procoagulantcomponent(hemophilia A)G279u6WIAF-10082K017402129F8C, coagulationTACATTCTAA[G/A]CATTGGAGCAMGASNfactor VIIIc,procoagulantcomponent(hemophilia A)G279u7WIAF-10084K017402533F8C, coagulationGTTTGCACAC[A/G]CAACACCTATMAGRGfactor VIIIc,procoagulantcomponent(hemophilia A)G279u8WIAF-10086K017406639F8C, coagulationACCCTCCAAT[T/C]ATTGCTCGATSTCIIfactor VIIIc,procoagulantcomponent(hemophilia A)G279u9WIAF-10087K017405957F8C, coagulationGAGAATTATC[G/A]CTTCCATGCAMGARHfactor VIIIc,procoagulantcomponent(hemophilia A)G279a10WIAF-10495K017405829F8C, coagulationTGACAGTACA[G/A]GAATTTGCTCSGAQQfactor VIIIc,procoagulantcomponent(hemophilia A)G279a11WIAF-10496K017405852F8C, coagulationTTTTTCACCA[T/G]CTTTCATGAGMTGISfactor VIIIc,procoagulantcomponent(hemophilia A)G279a12WIAF-10502K017402492F8C, coagulationACCACAATTC[C/T]AGAAAATGACMCTPLfactor VIIIc,procoagulantcomponent(hemophilia A)G279a13WIAF-10503K017406906F8C, coagulationTGCAAGTGGA[C/T]TTCCAGAAGASCTDDfactor VIIIc,procoagulantcomponent(hemophilia A)G279a14WIAF-13120K017401980F8C, coagulationCAGAGAATAT[A/C]CAACGCTTTCSAcIIfactor VIIIc,procoagulantcomponent(hemophilia A)G279a15WIAF-13121K017401982F8C, coagulationGAGAATATAC[A/C]ACGCTTTCTCMAcQPfactor VIIIc,procoagulantcomponent(hemophilia A)G282u1WIAF-10067L25615976AVPR1A, arginineCGCCTTTCTT[C/A]ATCATCCAGAMCAFFvasopressinreceptor 1AG282u2WIAF-10070L25615460AVPR1A, arginineTCGGCATGTT[T/C]GCGTCGGCCTSTCFFvasopressinreceptor 1AG282u3WIAF-10071L25615343AVPR1A, arginineGCCTGGCCGA[C/T]CTGGCCGTGGSCTDDvasopressionreceptor 1AG282u4WIAF-10072L2561568AVPR1A, arginineTCTCTCCGCC[G/A]GTCCCGACGCMGAGSvasopressionreceptor 1AG282u5WIAF-10073L25615535AVPR1A, arginineAGACTCTGCA[A/G]CAGCCCGCGCSAGQQvasopressinreceptor 1AG282u6WIAF-10092L256151075AVPR1A, arginineCCTTGAATAG[C/A]TGCTGTAATCMCASRvasopressinreceptor 1AG282a7WIAF-10499L256151089AVPR1A, arginineTGTAATCCCT[G/A]GATATACATGNGAW*vasopressinreceptor 1AG284u1WIAF-10182M168271179ACADM, acyl-AATATCCTGT[A/G]GAAAAACTAASAGVVCoenzyme Adehydrogenase,C-4 to C-12straight chainG284a2WIAF-10515M16827696ACADM, acyl-TTGTGGAACC[A/G]GATACCCCAGSAGAACoenzyme Adehydrogenase,C-4 to C-12straight chainG285u1WIAF-10108M28372258ZNF9, zinc fingerCTCTTCCAGA[T/C]ATTTGTTATCSTCDDprotein 9 (acellular retroviralnucleic acidbinding protein)G289u1WIAF-10041M63012172PON1, paraoxonase 1CTCTGAAGAC[A/T]TGGAGATACTMATMLG290u1WIAF-10085M63959354LRPAP1, low densityCTCATACGCA[A/G]CCTCAATGTCMAGNSlipoprotein-relatedprotein-associatedprotein 1 (alpha-2-macroglobulinreceptor associatedprotein 1)G290a2WIAF-13122M63959223LRPAP1, low densityAGCGACTGCA[T/A]CTTCCTCCCGMTAHQlipoprotein-relatedprotein-associatedprotein 1 (alpha-2-macroglobulinreceptor associatedprotein 1)G292u1WIAF-10180M740961002ACADL, acyl-AGTGCAACAT[A/C]AATTAGCAGAMACKQCoenzyme Adehydrogenase,long chainG293u1WIAF-10068M74775723LIPA, lipase A,AAGGACTTAT[T/C]TGGACACAAAMTCFSlysosomal acid,cholesterolesterase (Wolmandisease)G293a2WIAF-10497M74775107LIPA, lipase A,TGAGGGGTCT[G/A]GAGGGAAACTMGAGRlysosomal acid,cholesterolesterase (Wolmandisease)G293a3WIAF-10498M7477586LIPA, lipase A,GGTTCTCTGG[C/A]CCCTGCATTCMCAPTlysosomal acid,cholesterolesterase (Wolmandisease)G295u1WIAF-10057U042701282KCNH2, potassiumAAAGGAGCGA[A/T]CCCACAATGTMATTSvoltage-gatedchannel, subfamilyH, member 2G295u2WIAF-10062U042701875KCNH2, potassiumCGCACTGGCT[A/G]GCCTGCATCTSAGLLvoltage-gatedchannel, subfamilyH, member 2G295u3WIAF-10064U042702040KCNH2, potassiumACTTCACCTT[C/T]AGCAGCCTCASCTFFvoltage-gatedchannel, subfamilyH, member 2G295u4WIAF-10088U042701650KCNH2, potassiumCCGGCCGCAT[C/T]GCCCTCCACTSCTIIvoltage-gatedchannel, subfamilyH, member 2G295u5WIAF-10090U042702139KCNH2, potassiumCCCTCATGTA[T/C]GCTAGCATCTSTCYYvoltage-gatedchannel, subfamilyH, member 2G2951u1WIAF-14147HT00301334ZNF42, zinc fingerCCCTGCTCTG[A/G]TCACCACCCGMAGIVprotein 42(myeloid-specificretinoic acidresponsive)G2951u2WIAF-14157HT00301558ZNF42, zinc fingerACCAGCTTAC[G/A]CACACCGAGGSGATTprotein 42(myeloid-specificretinoic acidresponsive)G2959u1WIAF-13501HT01341014GRLP1, gluco-GTGGAGAGAC[T/C]CTGCATAGCTSTCTTcorticoid receptorDNA binding factor 1G2959u2WIAF-13518HT01341853GRLF1, gluco-GAGCCATCTT[A/C]CAGCCTGTTTMACYScorticoid receptorDNA binding factor 1G296a1WIAF-10514U12778961ACADSB, acyl-TATTCCATAT[A/G]TTAAAGAAAGMAGIVCoenzyme Adehydrogenase,short/branchedchainG2968u1WIAF-12699HT02441754SMARCA1, SWI/SNFCAGAACAAAC[C/T]ACTACGTGTAMCTPLrelated, matrixassociated, actindependent regulatorof chromatin, sub-family a, member 1G2968u2WIAF-12716HT02442624SMARCA1, SWI/SNFTGGGAACGTT[G/T]CAATGAATTAMGTCFrelated, matrixassociated, actincdependent regulatorof chromatin, sub-family a, member 1G297u1WIAF-10109U516660402ECH1, enoylACATGGCTTC[G/A]GACATCCTCCSGASSCoenzyme Ahydratase1, peroxisomalG297u2WIAF-10110U16660149ECH1, enoylGCACAAGAGG[A/C]GGCTTCCGGAMACEACoenzyme A hydratase1, peroxisomalG2970u1WIAF-12746HT0281682BR140: bromodomain-ATGACATGGA[C/T]GAGCAGGACTSCTDDcontaining protein,140 kD (peregrin)G2975U1WIAF-12729HT03341104B-cell-specificACTTTTCCGG[G/A]ACTCCCTACASGACGtranscriptionfactorG2975u2WIAF-12730HT03341185B-cell-specificGCTCCCCCTA[C/T]TATTATACCCSCTYYtranscriptionfactorG2976a1WIAF-12129HT03401600SATB1, specialGTCCTGCCCC[C/A]CTCATCAGCASCAPPAT-rich sequencebinding protein 1(binds to nuclearmatrix/scaf fold-associating DNA's)G2976u2WIAF-12743HT03402116SATB1, special AT-TGGCCTCTCC[A/G]GCACAGTCAGSAGPPrich sequencebinding protein 1(binds to nuclearmatrix/scaf fold-associating DNA's)G2978u1WIAF-12721HT03461140MSX1, msh (Droso-CATAGAGGGT[C/T]CCAGGTCCCC-CT--phila) homeo boxhomolog 1 (formerlyhomeo box 7)G298u1WIAF-10048U338378995Human glycoproteinCCGGACAGGA[G/A]GTGCATTCCCMGARKreceptor gp330precursor, mRNA,complete cds.G298u2WIAF-10051U3383713217Human glycoproteinATGCAGCCAT[C/T]GAACTGCCTASCTIIreceptor gp330precursor, mRNA,complete cds.G298u3WIAF-10077U338376298Human glycoproteinAACTCTTTCA[T/C]TGTTGTTTCAMTCITreceptor gp330precursor, mRNA,complete cds.G298u4WIAF-10078U338376371Human glycoproteinCCATGGTCCC[G/A]GTGGCAGGCCSGAPPreceptor gp330precursor, mRNA,complete cds.G298u5WIAF-10079U338376914Human glycoproteinACTCTGAAGT[G/A]ATTCGTTATGSGAVVreceptor gp330precursor, mRNA,complete cds.G298u6WIAF-10081U338378718Human glycoproteinGTTCCAATGC[G/A]CATCTGGGCGMGAATreceptor gp330precursor, mRNA,complete cds.G298u7WIAF-10083U338379088Human glycoproteinACTTGCTCTG[A/G]AAATGAATTCMAGEGreceptor gp330precursor, mRNA,complete cds.G298u8WIAF-10096U338376949Human glycoproteinACTCCTTATC[G/C]CATCACTCTTMGCGAreceptor gp330precursor, mRNA,complete cds.G298u9WIAF-10097U338377149Human glycoproteinTTCCTTCCAA[A/C]ACAATCGTGGMAGNDreceptor gp330precursor, mRNA,complete cds.G298u10WIAF-10100U338378590Human glycoproteinTACACAAAAT [C/A]TCATAATTCAMGACYreceptor gp330precursor, mRNA,complete cds.G298u11WIAF-10101U3383712948Human glycoproteinCATCTTTCAA[G/C]ACCACTTATAMGCDHreceptor gp330precursor, mRNA,complete cds.G2980u1WIAF-12723HT0356437TLE1, transducin-TCATGGCCAC[G/A]GACCCCCACTMGAGRlike enhancer ofsplit 1, homolog ofDrosophila E(sp1)G2980u2WIAF-12726HT03562044TLE1, transducin-AGTGGCTGGC[A/G]GTGGGCATGGSAGAAlike enhancer ofsplit 1, homolog ofDrosophila E(sp1)G2980u3WIAF-12747HT0356379TLE1, transducin-CCATGGCAGA[G/A]TTGAATGCCASGAEElike enhancer ofsplit 1, homolog ofDrosophila E(sp1)G2980u4WIAF-12748HT0356276TLE1, transducin-ATCGCCAAGA[G/A]ATTGAATACGMGARKlike enhancer ofsplit 1, homolog ofDrosophila E(sp1)G2980u5WIAF-12749HT03561876TLE1, transducin-GCCACACAGA[C/T]GGAGCCAGCTSCTDDlike enhancer ofsplit 1, homolog ofDrosophila E(sp1)G2980u6WIAF-12750HT03561759TLE1, transducin-CCGCCTGCTA[C/T]GCCCTGGCCASCTYYlike enhancer ofsplit 1, homolog ofDrosophila E(sp1)G2981u1WIAF-12720HT03572206TLE2, transducin-ACAAATACAT[T/C]GTGACAGSCTSTCIIlike enhancer ofsplit 2, homolog ofDrosophila E(sp1)G2981u2WIAF-12737HT03571036TLE2, transducin-CGGACAGCGT[C/T]GCCCTCACCASCTVVlike enhancer ofsplit 2, homolog ofDrosophila E(sp1)G2981u3WIAF-12740HT03572181TLE2, transducin-CTGAGTTGTG[A/T]CATCTCCAGAMATDVlike enhancer ofsplit 2, homolog ofDrosophila E(sp1)G2983u1WIAF-12833HT0360636TLE3, transducin-TGTCACCCTC[G/C]GAAAGCCTCCSGCSSlike enhancer ofsplit 3, homolog ofDrosophila E(sp1)G2983u2WIAF-12834HT03601944TLE3, transducin-TGGACAACAC[G/A]GTGCGCTCCTSGATTlike enhancer ofsplit 3, homolog ofDrosophila E(sp1)G2983u3WIAF-12848HT03601710TLE3, transducin-ACCTGGCCTC[C/A]CCCACGCCCCSGASSlike enhancer ofsplit 3, homolog ofDrosophila E(sp1)G2985u1WIAF-12724HT0421995homeotic protein D3CGCTTCGCCA[G/A]CGCCAACCTCMGASNG2985u2WIAF-12725HT04211003homeotic protein D3CACCGCCAAC[C/T]TGCAGGCCACSCTLLG2986u1WIAF-14124HT04681197CSDA, cold shockGCCGTGGATA[C/T]CGGCCTCCCTSCTYYdomain protein AG2987u1WIAF-12758HT04742068ZNF7, zincAGTGCTTTTA[C/T]GAATATGCGASCTYYfinger protein 7(KOX 4, cloneHF.16)G2987u2WIAF-12773HT0474985ZNF7, zincGAGAGAAGCC[G/C]TACGAATGTGSGCPPfinger protein 7(KOX 4, cloneHF.16)G2987u3WIAF-12775HT04741278ZNF7, zincAGCCAGCAGT[C/T]GCAGCTGGTTMCTSLfinger protein 7(KOX 4, cloneHF.16)G3005a1WIAF-12133HT07351441homeotic proteinGAGGCAGCGG[C/T]CCCGGGCCTGSCTGG5.1G3008a1WIAF-12134HT07531850ATF4, activatingTAAAAGAGAG[C/A]GCGGATTCCCSGARRtranscriptionfactor 4 (tax-responsive enhancerelement B67)G3008u2WIAF-12798HT0753946ATF4, activatingCCCTTCGACC[C/A]GTCGGGTTTGMCAPQtranscriptionfactor 4 (tax-responsive enhancerelement B67)G3008u3WIAF-12812HT07531482ATF4, activatingCACTGCTTAC[G/A]TTGCCATGATMGAVItranscriptionfactor 4 (tax-responsive enhancerelement B67)G3008u4WIAF-12813HT07531847ATF4, activatingCTCTAAAAGA[G/C]AGGGCGGATTMGCEDtranscriptionfactor 4 (tax-responsive enhancerelement B67)G301u1WIAF-10127U712853639MTR, 5-methyltetra-TGTGGAGACT[C/T]GCAGACATCGSCTLLhydrofolate-homocysteinemethyltransferaseG3012u1WIAF-12794HT0873402MAD, MAXTGGTGCCACT[C/T]GGACCCGAATSGTLLdimerizationproteinG3014u1WIAF-14183HT0899274homeotic protein 2,AAAAGACTCA[G/A]TACTTGGCCTSGAQQdistal-lessG3020u1WIAF-12797HT0956852MLLT3, myeloid/GTGCCTTCAA[A/G]GAACCTTCCASAGKKlymphoid or mixed-lineage leukemia(trithorax(Drosophila)homolog);translocated to, 3G3023u1WIAF-13724HT0966381zinc finger, X-GCTGCAGCAA[G/A]CAATATGACASGAKKlinked, duplicatedAG3023u2WIAF-13725HT0966220zinc finger, X-GGCCAAACTC[G/A]GCGCCCACCAMGAGSlinked, duplicatedAG3023u3WIAF-13726HT096669zinc finger, X-AGTCGCACGA[T/C]AAACTGCGGCSTCDDlinked, duplicatedAG3023u4WIAF-13727HT0966249zinc finger, X-ACTTCGAACC[C/T]CACACCCCTTSCTPPlinked, duplicatedAG3023u5WIAF-13765HT0966661zinc finger, X-CAGGTTCTCT[G/A]CTCGCAGTAGMGAATlinked, duplicatedAG3023u6WIAF-13766HT09661302zinc finger, X-TGACTCCTTC[C/T]AGCACCCTTTSGTSSlinked, duplicatedAG3027u1WIAF-12800HT1035124HOXB7, homeo box B7TTATGCGAAT[G/A]CTTTATTTTCMGAATG3027u2WIAF-12816HT1035450HOXB7, homeo box B7GCCACTCGCA[C/T]TTCGCGCCCCSCTDDG3028u1WIAF-12806HT1037701homeotic protein C8AGACCCTCGA[A/G]CTCCAGAACCSAGEEG3029u1WIAF-14153HT1100441zinc fingerTCAGACTCAG[G/A]CAAAACTCCGSGARRprotein 8G3029u2WIAF-14155HT11001416zinc fingerGCCGTCAACA[A/G]TCCTCGACCASAGQQprotein 8G303u1WIAF-10000X139164110LRP1, low densityATGGAGCTGG[C/A]GCCCGACAACMGAGElipoprotein-related protein 1(alpha-2-macro-globulin receptor)G303u2WIAF-10001X139164012LRP1, low densityGCGAGCTCTG[C/T]GACCACTGCTSCTCClipoprotein-related protein 1(alpha-2-macro-globulin receptor)G303u3WIAF-10002X139164702LRP1, low densityGCCTGCCCCG[C/T]ATTGAGGCAGSCTRRlipoprotein-related protein 1(alpha-2-macro-globulin receptor)G303u4WIAF-10003X139166395LRP1, low densityCTGGATCGCA[G/A]GCAACATCTAMGAGSlipoprotein-related protein 1(alpha-2-macro-globulin receptor)G303u5WIAF-10004X139166937LRP1, low densityAAGGCACCAA[C/T]GTGTGCGCGGSCTNNlipoprotein-related protein 1(alpha-2-macro-globulin receptor)G303u6WIAF-10005X139169391LRP1, low densityGGCTGAAGGA[T/C]GACGGCCGCASTCDDlipoprotein-related protein 1(alpha-2-macro-globulin receptor)G303u7WIAF-10011X13916766LRP1, low densityACTGCATCGA[C/T]GGCTCAGATGSCTDDlipoprotein-related protein 1(alpha-2-macro-globulin receptor)G303u8WIAF-10015X139169040LRP1, low densityACCCGACCTG[C/T]GGCCCCAGTGSCTCClipoprotein-related protein 1(alpha-2-macro-globulin receptor)G303u9WIAF-10019X1391611749LRP1, low densityCCCTGCGCTG[C/T]AACATGTTCGSCTCClipoprotein-related protein 1(alpha-2-macro-globulin receptor)G303u10WIAF-10020X139161917LRP1, low densityGACCAGTATG[G/A]GAAGCCGGGTMGAGElipoprotein-related protein 1(alpha-2-macro-globulin receptor)G303u11WIAF-10021X139164810LRP1, low densityAGAAGCGCAT[C/T]CTTTGGATTGSCTIIlipoprotein-related protein 1(alpha-2-macro-globulin receptor)G303u12WIAF-10022X139166367LRP1, low densityTTGGCCGTGT[G/C]GAGGGCATTGSGCVVlipoprotein-related protein 1(alpha-2-macro-globulin receptor)G303u13WIAF-10023X139166247LRP1, low densityCTGTCCGCAT[C/T]GACTTCCACGSCTIIlipoprotein-related protein 1(alpha-2-macro-globulin receptor)G303u14WIAF-10024X139168371LRP1, low densityACGCCTCAGA[T/C]GAGATGAACTSTCDDlipoprotein-related protein 1(alpha-2-macro-globulin receptor)G303u15WIAF-10030X1391611395LRP1, low densityACGGCAGCGA[C/T]GAGGAGGCCTSCTDDlipoprotein-related protein 1(alpha-2-macro-globulin receptor)G303u16WIAF-10031X1391612763LRP1, low densityACGTCTTTGA[G/A]GATTACATCTSGAEElipoprotein-related protein 1(alpha-2-macro-globulin receptor)G303u17WIAF-10035X13916640LRP1, low densityACGGATCTGA[C/T]GAGGCCCCTGSCTDDlipoprotein-related protein 1(alpha-2-macro-globulin receptor)G303u18WIAF-10037X139161609LRP1, low densityGCCGCCTTGT[C/T]TACTGGGCAGSCTVVlipoprotein-related protein 1(alpha-2-macro-globulin receptor)G303u19WIAF-10038X139161629LRP1, low densityGATGCCTATC[T/G]GGACTATATTMTGLRlipoprotein-related protein 1(alpha-2-macro-globulin receptor)G303u20WIAF-10039X139162210LRP1, low densityCACCAGCTAC[C/T]TCATTGGCCGMCTLFlipoprotein-related protein 1(alpha-2-macro-globulin receptor)G303u21WIAF-10043X139167287LRP1, low densityGATGGCTCCA[G/A]GAGGATCACCMGARKlipoprotein-related protein 1(alpha-2-macro-globulin receptor)G303u22WIAF-10044X139168258LRP1, low densityCTCTGACGAC[A/G]TCCCTTGCAAMAGIVlipoprotein-related protein 1(alpha-2-macro-globulin receptor)G303u23WIAF-10045X1391611871LRP1, low densityGTGCGCACCG[A/G]GAAAGCCGCCMAGEGlipoprotein-related protein 1(alpha-2-macro-globulin receptor)G3031u1WIAF-14097HT1128611PSMC3, proteasomeTGGGGATCCA[A/C]CCTCCAAAAGSAGQQ(prosome, macro-pain) 26S subunit,ATPase, 3G3034u2WIAF-12837HT1182421TCF12, tran-ATCTTCAATT[A/C]TGGGTTCCTTMAGMVscription factor 12(HTF4, helix-loop-helix transcriptionfactors 4)G3038u1WIAF-12864HT13731700NFKB1, nuclearAGAGAAGGCT[A/G]TGCAGCTTGCMAGMVfactor of kappalight polypeptidegene enhancer inB-cells 1 (p105)G3038u2WIAF-12881HT13731936NFKB1, nuclearTGTACCAGAC[G/A]CCCTTGCACTSGATTfactor of kappalight polypeptidegene enhancer inB-cells 1 (p105)G3038u3WIAF-12882HT13732641NFKB1, nuclearAGCTGCACCT[G/C]TATAAGTTACSGCLLfactor of kappalight polypeptidegene enhancer inB-cells 1 (p105)G3039u1WIAF-13027HT13753761GLI3, GLI-KruppelAACAGCCCCG[G/T]AACTCCCACCMGTGVfamily memberGLI3 (Greigcephalopoly-syndactylysyndrome)G3039u2WIAF-13028HT13753963GLI3, CLI-KruppelCGCCAAATGA[G/T]TCAGCTGGCAMGTEDfamily memberGLI3 (Greigcephalopoly-syndactylysyndrome)G304u1WIAF-12242HT637158FABP3, fatty acidCTCACCCTAA[A/C]AACACACAGCMAGKRbinding protein3, muscle and heart(mammary derivedgrowth inhibitor)G3043u1WIAF-12867HT1486842IRF2, interferonGTGCCGAGGG[G/A]CGGCCACACTSGAGGregulatoryfactor 2G3047u1WIAF-12875HT15181233transcriptionTCCGTTTCCT[C/T]GAGAGCCTGCSCTLLfactor 1, nucleolarG3047u2WIAF-12876HT15181746transcriptionGGATTAAGAA[G/A]GCACCCGAAGSGAKKfactor 1, nucleolarG3047u3WIAF-12877HT15181829transcriptionTCCAAGAAGA[T/C]GAAATTCCAGMTCMTfactor 1, nucleolarG3048u1WIAF-12884HT1530628transcriptionAGTGGAGCGT[C/T]GCCGCCGAGAMCTRCfactor USFG305u1WIAF-10150HT0034777prolyl 4-hydroxy-CCCTTGTCAT[C/T]GAGTTCACCGSCTIIlase, beta subunit/protein disulfideisomerase/thyroidhormone-bindingprotein, alt.transcript 1G305u21WIAF-10154HT0034186prolyl 4-hydroxy-TGGCCGCCCA[C/A]AAGTACCTCCMCAHQlase, beta subunit/protein disulfideisomerase/thyroidhormone-bindingprotein, alt.transcript 1G305u3WIAF-10155HT00341428prolyl 4-hydroxy-GGACGGTCAT[T/C]GATTACAACGSTCIIlase, beta subunit/protein disulfideisomerase/thyroidhormone-bindingprotein, alt,transcript 1G3050u1WIAF-12860HT15582098PSRG1: femaleAACATTGCAA[T/C]GGCATTTTGASTCNNsterile homeoticrelated gene 1(mouse homolog)G3050u2WIAF-12861HT15582845FSRG1: femaleTAGGCCCTTC[T/C]GGCTTTGGACSTCSSsterile homeoticrelated gene 1(mouse homolog)G3050u3WIAF-12862HT15583409FSRG1: femaleCCTCGTCGTC[G/A]TCTTCAGACASGASSsterile homeoticrelated gene 1(mouse homolog)G3050u4WIAF-12874HT15581699FSRG1: femaleTCTCTTCTGT[G/C]TCACACACAGSGCVVsterile homeoticrelated gene 1(mouse homolog)G3050u5WIAF-12878HT15582093FSRG1: femaleGTTAAAACAT[T/G]GCAATGGCATMTGCGsterile homeoticrelated gene 1(mouse homolog)G3050u6WIAF-12879HT15582746FSRG1: femaleCTGGGGCCGA[C/T]GAAGATGACASCTDDsterile homeoticrelated gene 1(mouse homolog)G3051u1WIAF-12866HT15691423MEF2B, MADS boxCTTGGCCGAC[G/A]GCTGGCCCCGSGATTtranscriptionenhancer factor 2,polypeptide B(myocyte enhancerfactor 2B)G3051u2WIAF-13022HT1569661MEF2B, MADS boxCAGACTACAG[C/T]GAGCCCCACGSCTSStranscriptionenhancer factor 2,polypeptide B(myocyte enhancerfactor 2B)G3057a1WIAF-12142HT16695565alpha-fetoproteinAGACTGCTCT[T/C]GAGGCTCATASTCLLenhancer-bindingproteinG3057a2WIAF-12143HT16695634alpha-fetoproteinCTCTGTCTGC[C/A]ATGCTCTTAGSGAAAenhancer-bindingproteinG3057a3WIAF-12144HT16695664alpha-fetoproteinGGGGACTCCA[G/T]ATGAAAGGAGMGTQHenhancer-bindingproteinG3057a4WIAF-12145HT16695703alpha-fetoproteinGCTTTTCCCA[C/T]CTACCCCCAASCTHHenhancer-bindingproteinG3057u5WIAF-12885HT16692227alpha-fetoproteinTCTGGAGATC[C/T]ATATGAGGTCMCTHYenhancer-bindingproteinG3057u6WIAF-12892HT16693720alpha-fetoproteinAGACCTTGCC[G/A]GCTCAGCTACSGAPPenhancer-bindingproteinG3057u7WIAF-12893HT16694137alpha-fetoproteinCAAGGTTTAC[G/A]GACTACCACCSGATTenhancer-bindingproteinG3057u8WIAF-12897HT16694783alpha-fetoproteinGAAGACCAAC[A/C]CTCCCCAGCAMACTPenhancer-bindingproteinG3057u9WIAF-12898HT16695215alpha-fetoproteinTCCAACCTCC[A/C]CAATGAACACMACTPenhancer-bindingproteinG3057u10WIAF-12904HT16697266alpha-fetoproteinCCCTGCAGCC[C/TI GCGTTGACTTSCTAAenhancer-bindingproteinG3057u11WIAF-12907HT16698345alpha-fetoproteinCCAACACACG[A/C]CTATTCGGAGMACDAenhancer-bindingproteinG3057u12WIAF-12943HT16694257alpha-fetoproteinTGGTGTGGTT[T/C]CAGAATGCCCSTCFFenhancer-bindingproteinG057u13WIAF-12951HT16697333alpha-fetoproteinACCAGGCTTT[T/A]CTCCTTATTAMTASTenhancer-bindingproteinG3057u14WIAF-13030HT1669303alpha-fetoproteinGCAHCCTGTC[C/A]GAGGACGAGTSGASSenhancer-bindingproteinG3057u15WIAF-13031HT1669777alpha-fetoproteinGCCTTCCAGA[G/A]GACGACGAGGSGAEEenhancer-bindingproteinG306u1WIAF-10118HT00401618CPT2, carnitineCTCTACTGCC[C/A]TCCACTTTGAMGAVIpalmitoyl-transferase IIG307u1WIAF-10076HT0114110EDN2, endothelin 2CGTTGCGCTA[G/A]CCCTGCTCGTMGAATG3070u1WIAF-12972HT2085625pre-B-cell leukemiaAGAAATATGA[A/C]CAGGCATGTASAGEEtranscriptionfactor 3G3070u2WIAF-12973HT2085841pre-B-cell leukemiaGTAACTTCAG[T/C]AAACAGGCCASTCSStranscriptionfactor 3G3071u1WIAF-12886HT2086995AGER, advancedCCTGCGAGGC[T/C]GTGATGATCCSTCAAglycosylation endproduct-specificreceptorG3071u2WIAF-12887HT20861475AGER, advancedGAGGCCAGAT[C/G]TACAGCCCACMCGIMglycosylation endproduct-specificreceptorG3071u3WIAF-12935HT2086933AGER, advancedACGCATGGTG[A/G]GCATCATCCAMAGSGglycosylation endproduct-specificreceptorG3071u4WIAF-12936HT20861052AGER, advancedGTAACTTCAC(C/T]AAACAGGCCASCTSSglycosylation endproduct-specificreceptorG3071u5WIAF-12937HT2086836AGER, advancedAGAAGTATGA[G/A]CAGGCATGTASGAEEglycosylation endproduct-specificreceptorG308u1WIAF-10094HT0192484ANX4, annexin IVATGGACGGAG[C/G]CTTGAAGATGMCGSR(placental anti-coagulant proteinII)G308u2WIAF-10095HT0192333ANX4, annexin IVGGGATCATGA[C/T]GCCCACGGTCMCTTM(placental anti-coagulant proteinII)G3081u1WIAF-12997HT2188689PSMC2, proteasomeGGCATTGAGC[C/T]TCCCAAGGGCMCTPL(prosome, macro-pain) 26S subunit,ATPase, 2G3083u1WIAF-12976HT2228106IGHMBP2, immuno-TGCTGGAGCT[T/C]GAGAGAGACGSTCLLglobulin mubinding protein 2G3083u2WIAF-12985HT22282260IGHMBP2, immuno-TGGAGTTCAT[G/C]GCCAGCAAGAMGCMIglobulin mubinding protein 2G3083u3WIAF-12986HT22282060IGHMBP2, inmuno-GGGACCTGCT[A/G]CGTCCACCAGMAGTAglobulin mubinding protein 2G3083u4WIAF-12987HT22282365IGHMBP2, immuno-ACGACAGTTC[C/T]GGGGAAGGGASCTSSglobulin mubinding protein 2G3083u5WIAF-13005HT2228411IGHMBP2, immuno-TTTGATGAGT[C/T]CCACGATTTCMCTSFglobulin mubinding protein 2G3083u6WIAF-13006HT2228272IGHMBP2, immuno-ATACGGGTCC[G/A]CGGCAGCTCTMGAATglobulin mubinding protein 2G3083u7WIAF-13010HT22282581IGHMBP2, immuno-TCAGGAGCGC[G/A]CAGGGGCAGCSGAAAglobulin mubinding protein 2G3083u8WIAF-13011HT22282594IGHMBP2, immuno-GGGGCAGCCC[G/A]CCAGCAAGGAMGAATglobulin mubinding protein 2G3088u1WIAF-12984HT2318884HIVEP1, humanTGTGGCACTA[C/T]GTCCCCCTCCMCTTMimmunodeficiencyvirus type Ienhancer-bindingprotein 1G3088u2WIAF-12988HT23182469HIVEP1, humanTCTTGTCACC[A/G]CGTCAACACCSAGPPimmunodeficiencyvirus type Ienhancer-bindingproteinG3088u3WIAF-12989HT23183066HIVEP1, humanTTCTTGGTAC[T/C]GGACAGTCCCSTCTTimmunodeficiencyvirus type Ienhancer-bindingprotein 1G3088u4WIAF-12991HT23184008HIVEP1, humanTTATCCGGCA[G/T]CACAACATCCMGTQHimmunodeficiencyvirus type Ienhancer-bindingprotein 1G3088u5WIAF-12992HT23184880HIVEP1, humanCAAATCCATG[C/G]ACCGCCTAGCMCGAGimmunodeficiencyvirus type Ienhancer-bindingprotein 1G3088u6WIAF-12993HT23185148HIVEP1, humanTTGACAGCAT[G/A]TCTAATTCGCMGAMIimmunodeficiencyvirus type Ienhancer-bindingprotein 1G3088u7WIAF-12999HT23185834HIVEP1, humanCCAGCTGATA[A/C]TTCATCAACAMAGNSimmunodeficiencyvirus type Ienhancer-bindingprotein 1G3088u8WIAF-13000HT23186065HIVEP1, humanCAAAGTCAAC[G/A]GCCAGTCACTMGARQimmunodeficiencyvirus type Ienhancer-bindingprotein 1G3088u9WIAF-13001HT23187652HIVEP1, humanCATAGGAATA[C/T]GGTCACACAAMCTTMimmunodeficiencyvirus type Ienhancer-bindingprotein 1G30B8u10WIAF-13008HT2318741HIVEP1, humanTTCTGCAGCA[A/G]CCATCTGAACSAGQQimmunodeficiencyvirus type Ienhancer-bindingprotein 1G3088u11WIAF-13009HT2318948HIVEP1, humanCAGAACTGAG[C/T]ACCTTGTCACSCTSSimmunodeficiencyvirus type Ienhancer-bindingprotein 1G3088u12WIAF-13012HT23181909HIVEP1, humanTGAAACTTTA[C/T]TAAAATCAAGSCTLLimmunodeficiencyvirus type Ienhancer-bindingprotein 1G3088u13WIAF-13013HT23182803HIVEP1, humanTCTTCTGTCT[G/A]TACCTTCACTMGAVIimmunodeficiencyvirus type Ienhancer-bindingprotein 1G3088u14WIAF-13015HT23183342HIVEP1, humanGCGGTCTGCA[A/G]CCTCAGATTCSAGQQimmunodeficiencyvirus type Ienhancer-bindingprotein 1G3088u15WIAF-13016HT23183542HIVEP1, humanCCTAAACATA[G/A]TGTTACCATAMGASNimmunodeficiencyvirus type Ienhancer-bindingprotein 1G3088u16WIAF-13017HT23184972HIVEP1, humanTGGGTCTTCT[A/G]AAAGTGAGGAMAGKEimmunodeficiencyvirus type Ienhancer-bindingprotein 1G3095u1WIAF-12994HT2435701TCF2, transcriptionCCGCTCTGTA[C/T]ACCTGGTACGSCTYYfactor 2, hepatic;LF-B3; varianthepatic nuclearfactorG3095u2WIAF-13018HT2435362TCF2, transcriptionGGGCCGAGCC[C/T]GACACCAAGCSCTPPfactor 2, hepatic;LF-B3; varianthepatic nuclearfactorG3095u3WIAF-13020HT24351620TCF2, transcriptionCCAGTTCTCC[C/T]AGCAGCTGCANCTQ*factor 2, hepatic;LF-B3; varianthepatic nuclearfactorG3100a1WIAF-12147HT2483526ZNF141, zinc fingerGAATGAGTGT[A/G]AGTTGCAGAAMAGKEprotein 141 (dionepHZ-44)G3102u1WIAF-12975HT2508259NRF1, nuclearCGCCTTCTTC[G/T]CCCGAGGACASGTSSrespiratory factor1G3103u1WIAF-13617HT25111106E2F2, E2FCCTTGGACCA[G/T]CTCATCCAGAMHTQHtranscriptionfactor 2C3103u2WIAF-13659HT25111154E2F2, E2FCTGAGGACAA[G/A]GCCAACAAGASGAKKtranscriptionfactor 2G311u1WIAF-10291HT04021339A2M, alpha-2-macro-GTCCCTGTTA[C/T]GGCTACCAGTSCTYYglobulinG311u2WIAF-10292HT04021201A2M, alpha-2-macro-TCATATTCAT[C/T]AGAGGAAATGSCTIIglobulinG311u3WIAF-10293HT04023041A2M, alpha-2-macro-TACTCCAGAG[C/A]TCAACTCCAAMGAVIglobulinG311u4WIAF-10294HT04023676A2M, alpha-2-macro-TGACATCCTA[T/C]GTGCTCCTCCSTCYYglobulinG311u5WIAF-10296HT04023364A2M, alpha-2-macro-ATATCACCAT[C/T]GCCCTTCTGGSCTIIglobulinG311u6WIAF-10297HT04023203A2M, alpha-2-macro-CCAAGCTCGA[G/T]CCTACATCTTMGTASglobulinG311a7WIAF-10494HT04021122A2M, alpha-2-macro-TCACACTTTC[G/A]ACAGGGAATTMGARQglobulinG3119u1WIAF-13947HT26542876GLI, glioma-TTTCTGGGCG[G/A]TTCCCAGGTTMGAGDassociated oncogenehomolog (zincfinger protein)G3119u2WIAF-13959HT2654654GLI, glioma-AGTGCCGGGA[G/A]GAACCCTTGGSGAEEassociated oncogenehomolog (zincfinger protein)G3119u3WIAF-13965HT26543376GLI, glioma-TGGGGAAACA[G/C]AATTCCTCAAMGCEQassociated oncogenehomolog (zincfinger protein)G312u1WIAF-10006HT0428898PLAU, plasminogenCTCACCACAA[C/T]CACATTCCCTSCTNNactivator,urokinaseG312u2WIAF-10029HT0428498PLAU, plasminogenGGCCTAAACC[C/T]GCTTGTCCAAMCTPLactivator,urokinaseG312a3WIAF-10521HT0428767PLAU, plasminogenTGATTACCCA[A/C]AGAAGGACGAMACKQactivator,urokinaseG3125u1WIAF-13675HT2674740GTF2F2, generalACATCACAAA[A/G]CAACCTGTGGSAGKKtranscriptionfactor hF, poly-peptide 2 (30 kDsubunit)G313u1WIAF-10129HT04623086platelet-derivedCATGCGTGTG[C/A]ACTCAGACAAMGADNgrowth factor,alpha polypeptide(GB:M21574)G313u2WIAF-10130HT04621078platelet-derivedATGAGAAAGG[T/C]TTCATTGAAASTGGGgrowth factor,alpha polypeptide(CB:M21574)G313u3WIAF-10133HT04621571platelet-derivedGGAGATCCAC[T/C]CCCCAGACAGMTCSPgrowth factor,alpha polypeptide(CB:M21574)G313u4WIAF-10135HT04622611platelet-derivedCTCGCAACGT[C/T]CTCCTGGCACSCTVVgrowth factor,alpha polypeptide(CB:M21574)C314u1WIAF-10069HT04671890ALOX15,TCAGCCAGGA[G/A]CTGGCTGCCCSGAEEarachidonate 15-lipoxygenaseG3141u1WIAF-13934HT27498878NFATC3, nuclearCCAGAGGATA[G/A]CTGGCTACTCMGASNfactor of activatedT-cells,cytoplasmic 3G3141u2WIAF-13936HT274981189NFATC3, nuclearGCCTGCCTCA[T/C]GCAATGGGAAMTCCRfactor of activatedT-cells,cytoplasmic 3G3141u3WIAF-13938HT274982241NFATC3, nuclearCTCTGCGGGG[T/C]TTCCCTTCAGSTCGGfactor of activatedT-cells,cytoplasmic 3C3141u4WIAF-13944HT27498702NFATC3, nuclearATGCCTCTGA[C/T]CACGCAGCCCSCTDDfactor of activatedT-cells,cytoplasmic 3G3159u1WIAF-13891HT2757523SP4, Sp4 tran-CTTCAAAAGA[C/A]AATAACGTTTSGAEEscription factorG3159u2WIAF-13892HT27571514SP4, Sp4 tran-ACAGAATGTT[C/T]AACTTCAAGCNCTQ*scription factorG3159u3WIAF-13893HT27572236SP4, Sp4 tran-TGTTTTGTGG[C/T]AAAAGATTCASCTGGscription factorG3165u1WIAF-13860HT27636437transcriptionAGCAGCTCAC[A/G]GAGGAACTGASAGTTfactor B-ATFG3165u2WIAF-13861HT27636512transcriptionCCACCACGCC[C/G]TCGCCCCCCGSCGPPfactor B-ATFG3173u1WIAF-13556HT27721686ZNF74, zinc fingerTGCACAGCGA[G/A]GGGAAGCCCTSGAEEprotein 74 (Cos52)G3175u1WIAF-13948HT27762037transcriptionalTGTTCGGACC[A/G]GAAGCACCCASAGPPregulator, viaglucocorticoidreceptorG3182u1WIAF-14036HT27831614MHC2TA, MHC classATCCTAGACG[C/G]CTTCGAGGAGMCGAGII transactivatorG3182u2WIAF-14037HT27832791MHC2TA, MHC classTGAGCGACAC[G/A]GTGGCGCTGTSGATTII transactivatorC3182u3WIAF-14059HT27831657MHC2TA, MHC classTGCACAGCAC[C/A]TGCGGACCGGSGATTII transactivatorG3182u4WIAF-14060HT27831606MHC2TA, MHC classTTCTGCTCAT[C/T]CTAGACGCCTSCTIIII transactivatorG3183u1WIAF-13950HT27861392zinc finger proteinTACTCTAGAG[G/A]AGCCTGTTGGMGAEKC2H2-150G3184u1WIAF-13864HT27862271zinc finger proteinGAAACTCCAG[T/G]TCAAAGACTTMTGFVC2H2-171G3184u2WIAF-13865HT27862248zinc finger proteinCTGCTTGAAT[T/C]CATGTATGARMTCFSC2H2-171G320u1WIAF-10136HT0791552ANX7, annexin VIICCAACTTCCA[T/C]GCTATAAGAGSTCDD(synexin)G320u2WIAF-10137HT07911350ANX7, annexin VIITTGACCTTGT[A/G]CAAATAAAACSAGVV(synexin)G3208u1WIAF-14186HT27930485zinc fingerGTCACAAGTC[A/C]GCCCTAATTGSAGSSprotein ZNF37AG3218u1WIAF-13526HT28104187zinc fingerCCCGACAGCT[C/T]ATTAAGAAAGMCTHYprotein ZNF169,Krueppel-typeG323u1WIAF-10066HT09151361Homo sapiensACTTCTGTGA[C/T]GTCCAGCGCTSCTDDinducible nitricoxide synthase(NOS) mRNA,complete cds.G325u1WIAF-10106HT09623817FBN1, fibrillin 1TGTGAATGCC[C/T]GCCTGGCCATMCTPL(Marfan syndrome)G325u2WIAF-10113HT0962722FBN1, fibrillin 1AGATACCTCC[T/C]TCCTCTGGCTSTGPP(Marfan syndrome)G325u3WIAF-10114HT09622022FBN1, fibrillin 1GATCTGCAAT[A/C]ATGGACGCTGMACNH(Marfan syndrome)G325u4WIAF-10116HT09623603FBN1, fibrillin 1GAACTGCACA[G/C]ACATTGACGAMGCDH(Marfan syndrome)C325u5WIAF-10117HT09622270FBN1, fibrillin 1TCTGCATCAA[C/T]GGGCGTTGCGSCTNN(Marfan syndrome)G326u1WIAF-10036HT10091854KLKB1, kallikreimGCAAACACAA[C/T]GGAATGTGGCSCTNNB plasma (Fletcherfactor) 1G327u1WIAF-10052HT10111599HRG, histidine-AAGCCAGACA[A/T]TCAGCCCTTTMATNIrich glycoproteinG327u2WIAF-10054HT10111083HRG, histidine-CCACTATTGC[C/T]CATGTCCTGCMCTPLrich glycoproteinG327u3WIAF-10055HT10111140HRG, histidine-GCCCAAAGAC[A/G]TTCTCATAATMAGHRrich glycoproteinG328u1WIAF-10145HT1087255SAA1, serum amyloidGTGCCTGGGC[T/C]GCAGAAGTGASTCAAA1G328a2WIAF-10511HT1087248SAA1, serum amyloidCCTGGGGGTC[C/T]CTGGGCTGCAMCTAVA1G328a3WIAF-10512HT1087305SAA1, serum amyloidTTCTTTGGCC[A/G]TGGTGCGGACMAGHRA1G328a4WIAF-13126HT1087295SAA1, serum amyloidTATCCAGAGA[T/C]TCTTTGGCCAMTCFLA1G328a5WIAF-13127HT108782SAA1, serum amyloidCTTGGTCCTG[C/A]GTGTCAGCAGMGAGSA1G329u1WIAF-10140HT11412514PLCG1, phospho-CTGACCTTCA[T/C]CAAGAGCGCCMTCITlipase C, gamma 1(formerly subtype148)G329u2WIAF-10162HT11411036PLCG1, phospho-TATGCCCGGA[C/A]ACCATGAACAMCADElipase C, gamma 1(formerly subtype148)G329u3WIAF-10163HT1141911PLCG1, phospho-GTTCATGCTC[A/G]GCTTCCTCCGMAGSGlipase C, gamma 1(formerly subtype148)G3295u1WIAF-14017HT34601229FUBP, far upstreamCCATAAAAAG[C/T]ATAACCCAGCSCTSSelement bindingproteinG3296u1WIAF-14168HT34666289transcriptionCAGCCTGGAC[G/A]AGAGCCCCATMGAEKfactor TFIIIC, RNApolymerase III,alpha subunitG3296u2WIAF-14179HT3466235transcriptionGGCCATCAGC[T/A]TCTATGAGGAMTAFIfactor TFIIIC, RNApolymerase III,alpha subunitG3298u1WIAF-13523HT35041803DNA-binding proteinACTTTGCCAA[C/T]GTGCAGGAGCSCTNNHRFX2G3298u2WIAF-13524HT35041743DNA-binding proteinGGGCGGTGCT[G/A]CAGAACACGTSGALLHRFX2G3298u3WIAF-13528HT35042002DNA-binding proteinGTTCTTGCTG[A/G]AATGGTCCTTMAGKEHRFX2G33u1WIAF-10254X825401044INHBC, inhibin,AAGGCCAACA[C/T]AGCTGCAGGCMCTTIbeta CG33u2WIAF-10255X825401136INHBC, inhibin,CAGCAACATT[G/A]TCAAGACTGAMGAVIbeta CG33u3WIAF-10256X825401185INHBC, inhibin,GGGTGCAGTT[A/G]GTCTATGTGTNAG*Wbeta CG33u4WIAF-10259X82540892INHBC, inhibin,TTTTTGTGGA[C/T]TTCCGTGAGASCTDDbeta CG3303u1WIAF-13566HT3523981POU6F1, POUCAGGCCAGGA[G/A]ATCACTGAAASGAEEdomain, class 6,transcriptionfactor 1G3304u1WIAF-13932HT3544970SP2, Sp2 transcrip-TCAACAACCT[C/T]GTGAACGCCASCTLLtion factorG3304u2WIAF-13935HT35441891SP2, Sp2 transcrip-AGAAGCACGT[T/G]TGCCACATCCSTGVVtion factorG3304u3WIAF-13943HT3544920SP2, Sp2 transcrip-TGTGGTGAAG[T/C]TGACAGGTGGSTCLLtion factorG3311u1WIAF-13839HT3585757GATA3, GATA-CCCACTCCCG[T/C]GGCAGCATGASTCRRbinding protein 3G3311u2WIAF-13840HT3585901GATA3, GATA-TCGGATGCAA[G/A]TCCAGGCCCASGAKKbinding protein 3G3316u1WIAF-13818HT3607282zinc fingerAAAGAGTTTC[A/G]GTCACACTTCMAGSGprotein HKE-T1,Kruppel-likeG3319u1WIAF-14214HT36131086SMARCA3, SWI/SNFAAACTCTTAC[A/C]GCCATTGCAGSAGTTrelated, matrixassociated, actindependent regulatorof chromatin,subfamily a, member3G3319u2WIAF-14221HT36131261SMARCA3, SWI/SNFTAGATCTAGT[G/C]AACAACCCAGMGCEQrelated, matrixassociated, actindependent regulatorof chromatin,subfamily a, member3G3320u1WIAF-13692HT3622624BCL6, B-cell CLL/ATTTGCGGGA[G/C]GGCAACATCAMGCEDlymphoma 6 (zincfinger protein 51)G3320u2WIAF-13717HT36221062BCL6, B-cell CLL/ACAGCCGGCC[C/A]ACTTTGGAGGSGAPPlymphoma 6 (zincfinger protein 51)G3321u1WIAF-13761HT3641235STAT2, signalTCTTGGATCA[G/C]CTGAACTATGMGCQHtransducer andactivator oftranscription 2,113 kDG3321u2WIAF-13762HT3641774STAT2, signalCAAAAAGCCT[G/C]CATCAGAGCTMGCCStransducer andactivator oftranscription 2,113 kDG3328u1WIAF-13543HT36811550transcriptionCCACAATGGT[A/C]TCAGAGCAGGSAGVVfactor znf6G3328u2WIAF-13544HT36811389transcriptionAGAGGATTTA[G/C]AGGAAGATGAMGCEQfactor znf6G3336u1WIAF-13848HT3732216XBP1, X-box bindingACCTGAGCCC[C/T]GAGGAGAAGGSCTPPprotein 1G334u1WIAF-1008HT1220893THBS1, thrombo-TACATTCGCC[A/C]CAAGACAAAGMACHPspondin 1G334u2WIAF-10009HT12202000THBS1, thrombo-TCACAGCCCT[T/C]CGGCCAGCCTMTCFSspondin 1G334u3WIAF-10016HT12201521THBS1, thrombo-CCCAGATGAA[T/C]GGCAAACCCTSTCNNspondin 1G334u4WIAF-10017HT12202210THBS1, thrombo-GGCTGGCCCA[A/G]TGAGAACCTGMAGNSspondin 1G334u5WIAF-10018HT12202979THBS1, thrombo-GTGAGACCGA[T/C]TTCCGCCGATSTCDDspondin 1G334u6WIAF-10033HT12201136THBS1, thrombo-TGTCACTGTC[A/G]GAACTCACTTMAGQRspondin 1G334u7WIAF-10034HT12201859THBS1, thrombo-AGTGGAAATG[C/A]CATCCAGTGCMGAGDspondin 1G3343u1WIAF-13545HT37701104ZNF76, zinc fingerGCACTGCCCA[C/T]GGCGAGCTGGSCTHHprotein 76(expressed intestis)G3343u2WIAF-13561HT3770425ZNF76, zinc fingerGAGCAGTATG[C/A]CAGCAAGGTTMCAADprotein 76(expressed intestis)G3343u3WIAF-13562HT3770143ZNF76, zinc fingerCACCAGGTGA[C/T]GGTACAGAAAMCTTMprotein 76(expressed intestis)G3343u4WIAF-13563HT3770646ZNF76, zinc fingerGAAGACCCAC[G/T]TTCGTACCCAMGTVFprotein 76(expressed intestis)G3343u5WIAF-13564HT3770611ZNF76, zinc fingerAGCTGTGGAA[A/G]GGCCTTTGCCMAGKRprotein 76(expressed intestis)G3344u1WIAF-13664HT3772925zinc finger proteinAGCTCTCGCA[C/T]TCGGACGACASCTHHHAZG3345u1WIAF-13508HT3823315TCF6L1, transcrip-TTCGATTTTC[T/C]AAAGAACAACSTCSStion factor 6-like 1 (mito-chondrialtranscriptionfactor 1-like)G3345u2WIAF-13509HT3823167TCF6L1, transcrip-GGCGTGCTGA[G/CITGCCCTGGGAMGCSTtion factor 6-like 1 (mito-chondrialtranscriptionfactor 1-like)G3345u3WIAF-13531HT3623625TCF6L1, transcrip-TTATAACGTT[T/G]ATGTAGCTGAMTGYDtion factor 6-like 1 (mito-chondrialtranscriptionfactor 1-like)G3352u1WIAF-13589HT40051190MITF, micro-CTCGGAACTG[G/A]GACTCAGGCCMGAGEphthalmia-associatedtranscription factorG3352u2WIAF-13604HT40051156MITF, micro-TCTCACGGAT[G/A]GCACCATCACMGAGSphthalmia-associatedtranscription factorG3353u1WIAF-13937HT4010360GTF2H3, generalATCTAATGAC[C/A]AAAAGTGACASCATTtranscriptionfactor IIH,polypeptide 3(34 kD subunit)G3358u1WIAF-13671HT4187398ETV5, ets variantGATGATGAAC[A/C]GTTTGTCCCAMAGQRgene 5 (ets-relatedmolecule)G3358u2WIAF-13672HT4187223ETV5, ets variantTCAGCAAGTC[C/T]CTTTTATGGTMCTPSgene 5 (ets-relatedmolecule)G3358u3WIAF-13673HT41871236ETV5, ets variantGACTGGAAGC[C/G]AAAGTCAAACSCGGGgene 5 (eta-relatedmolecule)G3358u4WIAF-13674HT41871678ETV5, ets variantTTACCTCCTC[G/A]ACATGGACCGMGADNgene 5 (ets-relatedmolecule)G3358u5WIAF-13706HT4187414ETV5, ets variantTCCCAGATTT[T/C]CAGTCTGATASTCFFgene 5 (ets-relatedmolecule)G3358u6WIAF-13707HT41871238ETV5, ets variantCTGGAAGGCA[A/C]AGTCAAACAGMAGKRgene 5 (ets-relatedmolecule)G336u1WIAF-10152HT1258566ACAT1, acetyl-AGAGCATCTC[C/A]AATGTTCCATSCASSCoenzyme A acetyl-transferase 1(acetoacetylCoenzyme A thiolase)G3369u1WIAF-14047HT4302614zinc fingerATCTCAATCG[A/G]CACAAGCTCTSAGRRprotein DB1G337u1WIAF-10268HT1259464EDNRB, endothelinAAAGCAGACA[G/T]GACGGCAGGAMGTRMreceptor type BG337u2WIAF-10298HT12591281EDNRB, endothelinTGAAGCTCAC[T/A]CTTTATAATCSTATTreceptor type BG3373u1WIAF-14203HT43421253MTF1, metal-CTCAACAGAC[A/G]GCTTCCTTGASAGTTregulatorytranscriptionfactor 1G3390u1WIAF-14182HT4483680ZNF133, zinc fingerAGAGCCAGAG[C/T]TCTACCTCGAMCTLFprotein 133 (clonepHZ-13)G3390u2WIAF-14184HT44831026ZNF133, zinc fingerGCTCACACAG[G/A]GAACCCTGAGMGAGEprotein 133 (clonepHZ-13)G3390u3WIAF-14185HT44831423ZNF133, zinc fingerAAAAGCCTTA[T/C]GTGTGCCGGGSTCYYprotein 133 (clonepHZ-13)G3390u4WIAF-14197HT4483811ZNF133, zinc fingerCTGGGGATCC[A/G]GGCCCAGGGGSAGPPprotein 133 (clonepHZ-13)G3390u5WIAF-14198HT44831420ZNF133, zinc fingerGGGAAAAGCC[T/G]TATGTCTCCCSTGPPprotein 133 (clonepHZ-13)G3390u6WIAF-14199HT44832143ZNF133, zinc fingerCAGCTCTAAT[C/T]ACACACAAGCSCTIIprotein 133(clone pHZ-13)G3391u1WIAF-13631HT4484391ZNF136, zinc fingerAGCATTGTAT[A/G]TGGAGAAGTCMAGYCprotein 136(clone pHZ-20)G3396u1WIAF-13978HT44911283ZNF135, zinc fingerCACACCTCCT[C/T]GCTCAGCCAGMCTSLprotein 135(clone pHZ-17)G3396u2WIAF-13979HT44911296ZNF135, zinc fingerTCAGCCAGCA[C/T]GAAAGGACGCSCTHHprotein 135(clone pHZ-17)G3396u3WIAF-13980HT44911028ZNF135, zinc fingerAGTCACAGCT[C/T]CTCCCTCACCMCTSLprotein 135(clone pHZ-17)G3396u4WIAF-13981HT44911057ZNF135, zinc fingerGCGAATCCAC[A/C]CTGGGGAGAAMAGTAprotein 135(clone pHZ-17)G3396u5WIAF-13982HT44911152ZNF135, zinc fingerCAGGAGAGAA[A/G]CCCTATGAATSAGKKprotein 135(clone pHZ-17)G3396u6WIAF-13983HT44911243ZNF135, zinc fingerAAAGCCGTAT[G/C]GGTGCAATGAMGCGRprotein 135(clone pHZ-17)G3396u7WIAF-13984HT44911045ZNF135, zinc fingerCACCAAACAT[C/T]AGCGAATCCANCTQ*protein 135(clone pHZ-17)G340u1WIAF-10139HT1386459CYP27A1, cytochromeCCTATGGGCC[G/A]TTCACCACGGSGAPPP450, subfamilyXXVIIA (steroid 27-hydroxylase,cerebrotendinousxanthomatosis),polypeptide 1G340u2WIAF-10160HT1386801CYP27A1, cytochromeTCCCCAAGTG[G/A]ACTCGCCCCGNGAW*P450, subfamilyXXVIIA (steroid 27-hydroxylase,cerebrotendinousxanthomatosis),polypeptide 1G341u1WIAF-10121HT1388912MUT, methylmalonylGAGCTGGCCT[A/G]TACTTTAGCAMAGYCCoenzyme AmutaseG341u2WIAF-10128HT13882087MUT, methylmalonylTGCTCTGGGC[G/A]TAAGCACCCTMGAVICoenzyme AmutaseG3410u1WIAF-13749HT45501720zinc fingerTGAGTCCTCT[G/T]TTTCATCAGCMGTVFhomeodomain proteinG3410u2WIAF-13750HT45502843zinc fingerAAACATCATT[T/C]GATTGAACAC MTCLShomeodonain proteinG3410u3WIAF-13751HT45502745zinc fingerAGATATTCCA[A/T]AAGAGTAGTTMATQHhomeodomain proteinG3410u4WIAF-13775HT4550236zinc fingerAGAGAAGGGA[A/C]TGCTAACAACMACNThomeodomain proteinG3410u5WIAF-13776HT4550195zinc fingerTGCCAACAGA[C/T]CAGACAGTGTSCTDDhomeodomain proteinG3410u6WIAF-13777HT4550606zinc fingerATAACTTTAG[T/C]TGCTCCCTGTSTCSShomeodomain proteinG3410u7WIAF-13793HT45502073zinc fingerCAGTTTTACC[A/C]GTGCCATCAASAGPPhomeodomain proteinG343u1WIAF-10120HT1552561HK1, hexokinase 1CTTGCCAACA[A/C]TCCAAAATAGSAGQQC343u2WIAF-10124HT1552159HK1, hexokinase 1ACAAGTATCT[G/C]TATGCCATCCSGCLLG348u1WIAF-10269HT19062212PECAM1, platelet/TGACGATGTC[A/G]GAAACCATCCSAGGGendothelial celladhesion molecule(CD31 antigen)G348u2WIAF-10277HT19061656PECAM1, platelet/GCCATTCCCA[C/T]GCCAAAATGTSCTHHendothelial celladhesion molecule(CD31 antigen)G348u3WIAF-10283HT1906577PECAM1, platelet/AGAGTACCAG[C/G]TGTTGGTGGASCGVVendothelial celladhesion molecule(CD31 antigen)G348a5WIAF-13119HT1906?PECAM1, platelet/ATTCTTCCC[C/G]?CGendothelial celladhesion molecule(CD31 antigen)G351u1WIAF-10123HT19901047OSBP, oxysterolTGCTCGCAGA[C/A]TCAGATGAATSGAEEbinding proteinG351u2WIAF-10132HT19901023OSBP, oxysterolTGGCCAAGGC[C/A]AAAGCTGTGASCAAAbinding proteinG355u1WIAF-10146HT21431670THBS4,AACTCCCTGA[C/A]TGTCTTAAATMGASNthrombospondin 4G355u2WIAF-10165HT21431186THBS4,TCGAAATCCA[G/C]CGTGCGTTCCMGCAPthrombospondin 4G355a3WIAF-10510HT21431962THBS4,ACTGCCCCAC[C/G]GTCATTAACASCGTTthrombospondin 4G355a4WIAF-13125HT21431963THBS4,CTGCCCCACC[G/a]TCATTAACAGMCaVIthrombospondin 4G3552u1WIAF-12701HT281011006CLCN2, chlorideAAGAGACTAT[T/C]ACAGCCCTCTSTCIIchannel 2G3552u2WIAF-12731HT281011823CLCN2, chlorideCCGCCACCAG[C/T]AGTACCCGGTNCTQ*channel 2G3552u3WIAF-12736HT281012254CLCN2, chlorideGGAGCGCAGA[G/C]TCGGCAGGCAMGCEDchannel 2G3565u1WIAF-12744HT2896334calcyclinGCCCTCAAGG[G/A]CTGAAAATAAMGAGDG357u1WIAF-10267HT22444300C4B, complementATGAGTACGA[T/C]GAGCTTCCAGSTCDDcomponent 4BG357u2WIAF-10280HT22445095C4B, complementTCATGGGTCT[G/A]GATGGGGCCASGALLcomponent 4BG357u3WIAF-10295HT22442996C4B, complementCTCAGATCCA[T/C]TGGACACTTTSTCLLcomponent 4BG359u1WIAF-10026HT2411936PLAT, plasminogenCGCAGGCTCA[A/C]GTGGGAGTACMAGTMactivator, tissueG359a2WIAF-10520HT24111444PLAT, plasminogenAGGCCTTGTC[T/C]CCTTTCTATTSTCSSactivator, tissueG3592u1WIAF-12759HT4214743CLCN4, chlorideCTTCTAACGA[C/A]ACCACTTTTGSGAEEchannel 4G3592u2WIAF-12761HT4214835CLCN4, chlorideGCTTACATTC[T/G]GAATTACTTAMTGLRchannel 4G361u1WIAF-10053HT2479857cystathionine betaTGGCTCACTA[C/T]GACACCACCGSCTYYsynthase, alt.transcript 1G361u2WIAF-10056HT24791097cystathionine betaTCATCCCCAC[G/A]GTGCTGGACASGATTsynthase, alt.transcript 1G362u1WIAF-10058HT2638223ADRB2, adrenergic,GGCACCCAAT[G/A]GAACCCATCCMGAGRbeta-2-, receptor,surfaceG362u2WIAF-10059HT2638429ADRS2, adrenergic,TCATGGGCCT[G/A]CCAGTGGTGCSGALLbeta-2-, receptor,surfaceG362u3WIAF-10060HT2638256ADRB2, adrenergic,CGTCACGCAG[G/C]AAAGGGACCAMGCEQbeta-2-, receptor,surfaceG362u4WIAF-10093HT26381230ADRB2, adrenergic,AGGCCTATGG[G/C]AATGGCTACTSGCGGbeta-2-, receptor,surfaceG3620u1WIAF-12808HT97200458ACATN, acetyl-CACTCTCTGG[A/G]TATGAAGAGCMAGDGCoenzyme AtransporterG3627u1WIAF-12820HT97387347NAPG, N-ethyl-GCACAAACTA[C/T]CAGAGGCCGTMCTPSmaleimide-sensitivefactor attachmentprotein, gammaG366u1WIAF-10046HT2764987BDKRB2, bradykininGCCTCCTTCA[T/C]CGCCTACAGCMTCMTreceptor B2G366a2WIAF-10500HT2764820BDKRB2, bradykininAGATCCAGAC[C/A]GAGAGGAGGGSGATTreceptor B2G366a3WIAF-10501HT2764961BDKRB2, bradykininGCATCATCGA[T/C]GTAATCACACSTCDDreceptor B2G367u1WIAF-10156HT276856965ACACA, acetyl-ATCATCCATA[T/C]GACGCAGCACNTC*CCoenzyme Acarboxylase alphaG370u1WIAF-10281HT278883250LEPR, leptinAAAATTCTCC[G/A]TTGAAGGATTSGAPPreceptorG370u2WIAF-10282HT278883229LEPR, leptinTCACCAAGTG[C/T]TTCTCTAGCASCTCCreceptorG370u3WIAF-10284HT278881005LEPR, leptinCAATATCAAG[T/C]GAAATATTCAMTCVAreceptorG370u4WIAF-10285HT278881894LEPR, leptinCAGAGAATAA[C/TI CTTCAATTCCSCTNNreceptorG370u5WIAF-10299HT278881222LEPR, leptinTTCTGACAAG[T/C]GTTGGGTCTASTCSSreceptorG370u6WIAF-10300HT278882161LEPR, leptinCTATGAAAAA[G/C]GAGAAAAATGMGCKNreceptorG371u1WIAF-10107HT27943349CRAT, carnitineTCATCTACTC[G/C]AGCCCAGGCGSGCSSacetyltransferaseG371a2WIAF-12093HT27943287CRAT, carnitineGGAGAACTGG[C/T]TGTCTGAGTGSCTLLacetyltransferaseG372a1WIAF-10506HT282471099HADHA, hydroxyacyl-TGGAGCTCCA[C/A]AGAAGGATGTMCAQKCoenzyme A dehydro-genase dehydro-genase/3-ketoacyl-Coenzyme Athiolase/enoyl-Coenzyme Ahydratase (tri-functionalprotein), alphasubunitG374u1WIAF-10103HT284964435FASN, fatty acidCACCTCCCAC[G/A]TCCCGGAGGTMGAVIsynthaseG374u2WIAF-10104HT284965996FASN, fatty acidCTGGACAGGG[T/C]GACCCGAGAGMTCVAsynthaseG374u3WIAF-10105HT284965644FASN, fatty acidCAAGAGCTAC[A/G]TCATCGCTGGMAGIVsynthaseG374u4WIAF-10115HT284966387FASN, fatty acidTGGCACACAT[C/T]CTGGGCATCCSCTIIsynthaseG374u5WIAF-10119HT28496567FASN, fatty acidGGGGCATCAA[C/T]GTCCTGCTGASCTNNsynthaseG374a6WIAF-12094HT284965520FASN, fatty acidACATGGCCCA[A/G]GGGAAGCACASAGQQsynthaseG377u1WIAF-10142HT2996929PCCB, propionylGGACCCGGCT[T/C]CCGTCCGTGAMTCSPCoenzyme Acarboxylase,beta polypeptideG377u2WIAF-10143HT29961416PCCB, propionylCACCTTTGTG[G/A]TGATACCAACNGAGDCoenzyme Acarboxylase,beta polypeptideG380u1WIAF-10122HT3159831INSR, insulinTCTACCTCCA[C/T]GGCAGGTGTGSCTDDreceptorG380u2WIAF-10126HT31591698INSR, insulinGGCAGGATCC[A/G]TGTGGTTCCASAGAAreceptorG380u4WIAF-11605HT31592382INSR, insulinGCGTGCCCAC[G/A]AGTCCGGAGGSGATTreceptorG383u1WIAF-10125HT335463633phospholipase C,AGCAGCGGGC[G/A]AGGCTCCCCCMGARQbeta 3, alt.transcript 2G385u1WIAF-10141HT33831505PRCP,ATGACAGTGC[A/G]GGAAAGCAGCSAGAAprolylcarboxy-peptidase(angiotensinase C)G385u2WIAF-10157HT33831360PRCP,ATCACAGACA[C/G]TCTGGTTGCAMCGTSprolylcarboxy-peptidase(angiotensinase C)G387u1WIAF-11729HT34392697SREBF2, sterolCACTCTCCAG[G/C]AGCTCCGTGCMGCRSregulatory elementbinding tran-scription factor 2G387u2WIAF-11770HT34391901SREBF2, sterolGCTGCTGCCC[C/G]CAACCTACAAMCGAGregulatory elementbinding tran-scription factor 2G388u1WIAF-10270HT3440245SELPLG, selectinCTCCAGAAAT[G/A]CTGAGGAACAMGAMIP ligandG390u1WIAF-10276HT35682049NOS3, nitric oxideTTGCTCGTGC[C/G]GTGGACACACSCGAAsynthase 3(endothelial cell)G391u1WIAF-10013HT36306205VWF, von WillebrandAGCACCTGCA[G/C]GTGATTCTCCMGCEDfactorG391u2WIAF-10265HT36304554VWF, von HillebrandGCCCCTCACA[A/C]CAACGCCTTCMAGNSfactorG391u3WIAF-10266HT36307489VWF, von WillebrandTGGCCTCAAC[C/T]GCCACCAATCSCTTTfactorC391u4HIAF-10272HT36302470VWF, von WillebrandACTGTACCAT[G/A]AGTGCAGTCCMGAMIfactorG391u5WIAF-10273HT36302615VWF, von WillebrandGCTCGAGTGT[A/G]CCAAAACGTGMAGTAfactorG391u6WIAF-10274HT36302635VWF, von WillebrandGCCAGAACTA[T/C]GACCTGGACTSTCYYfactorG391u7WIAF-10275HT36304045VWF, von WillebrandTCTCGGAACC[G/A]CCGTTGCACGSGAPPfactorG391u8WIAF-10278HT36304446VWF, von WillebrandAACTTTGTCC[C/A]CTACGTCCAGMGARHfactorG391u9WIAF-10279HT36305152VWF, von WillebrandGCCCTAATGC[C/T]AACGTGCACGSCTAAfactorG391u10WIAF-10286HT36303448VWF, von WillebrandTTACCAGTGA[C/T]GTCTTCCAGGSCTDDfactorG391u11WIAF-10287HT36304891VWF, von WillebrandACATGGTCAC[C/T]GTGGAGTACCSCTTTfactorG391u12WIAF-10288HT36304805VWF, von WillebrandCAGGAGCAAG[G/A]AGTTCATGGAMGAEKfactorG391u13WIAF-10289HT36304943VWF, von WillebrandCCTGCAGCCC[G/T]TGCGAGAGATMGTVLfactorG391u14WIAF-10290HT36304915VWF, von WillebrandTCAGCGAGGC[A/C]CAGTCCAAAGSACAAfactorG391a15WIAF-10517HT36306194VWF, von WillebrandAAACAAGGAG[C/T]AGGACCTGGANCTQ*factorG391a16WIAF-13222HT36306419VWF, von WillebrandTCACCTTGGT[C/T]ACATCTTCACMCTHYfactorG3941u1WIAF-14123HT34641265mannosidase, alpha,CACGTCTGCA[A/G]CCAGCTGGAGMAGNSlysosomalG3941u2WIAF-14135HT3464965mannosidase, alpha,ACCAACCACA[C/T]TGTGATGACCMCTTIlysosomalG395u1WIAF-10271HT41581627ECE1, endothelinTCACTGCCGA[T/C]CAGCTCAGGASTCDDconverting enzyme 1G395a2WIAF-13110HT41581493ECE1, endothelinCATCTACAAC[A/T]TGATAGGATAMATMLconverting enzyme 1G3959u1WIAF-13634HT4490250ADTB1, adaptin,TGAAGAAGCT[G/A]GTATACCTCTSGALLbeta 1 (betaprime)G3959u2WIAF-13640HT44902029ADTB1, adaptin,TTCTTGGCGG[T/C]GCCCTTGACASTCGGbeta 1 (betaprime)G3959u3WIAF-13641HT44902395ADTB1, adaptin,AGGTCCACGC[C/A]CCACTCACCCSGAAAbeta 1 (betaprime)G3967u1WIAF-13997HT2958918ACTC, actin,GAGGCACCAC[T/C]ATGTACCCTGSTCTTalpha, cardiacmuscleG3968u1WIAF-14159HT19861747ACTN3, actinin,CGAGGCTGAC[C/T]GAGAGCGAGGNCTR*alpha 3G3968u2WIAF-14164HT19861900ACTN3, actinin,GGTGCCCAGC[C/T]GTGACCAGACMCTRCalpha 3G3968u3WIAF-14165HT19862184ACTN3, actinin,ACACCGTCTA[C/T]AGCATGGAGCSCTYYalpha 3G3968u4WIAF-14167HT19862557ACTN3, actinin,GATCTTGCCA[G/A]GAGACAAGAAMGAGRalpha 3G3968u5WIAF-14175HT19861212ACTN3, actinin,GGCTGCTCTC[G/A]GAGATCCGGCSGASSalpha 3G3979u1WIAF-13884HT0623776GPC1, glypican 1TGCTGCTGCC[T/G]GATCACTACCSTGPPG3979u2WIAF-13885HT0623680GPC1, glypican 1TCTACTACCC[C/TI GCTGCCAACCSCTRRG3979u3WIAF-13886HT06231361GPC1, glypican 1AGCTGCTCTC[T/C]GAACCCAAGGSTCSSG3979u4WIAF-13887HT06231163GPC1, glypican 1ACAGTCTCAT[C/T]GGCAGCGTCCSCTIIG3979u5WIAF-13888HT06231670GPC1, glypican 1ACGCCAGTGA[C/T]GACGGCACCGSCTDDG3979u6WIAF-13905HT06231069GPC1, glypican 1CTTCCCAACC[A/T]CGCCGACCTGMATQLG3979u7WIAF-13906HT06231514GPC1, glypican 1TCATCCCTCA[C/T]GCCCTCCCCASCTDDG3979u8WIAF-13907HT06231720GPC1, glypican 1GACCTCTCCC[G/C]CCCCAAGGTCMGCGAG3979u9WIAF-13908HT06231676GPC1, glypican 1CTCACCACGG[C/T]AGCGGCTCGGSCTGGG3979u10WIAF-13909HT06231719GPC1, glypican 1TGACCTCTCC[G/A]GCCGCAACGTMGAGSG399u1WIAF-10102HT48511450AQP3, aquaporin 3TCTGGCACTT[T/C]GCCCACAACCSTCAAG399u2WIAF-10111HT48511192AQP3, aquaporin 3CCTCCCTCCC[C/T]CAGGTTGTGCSCTAAG399u3WIAF-10112HT48511165AQP3, aquaporin 3CCCTCATCCT[C/G]GTGATGTTTGSCGLLG3997u1WIAF-13649HT27682473MFAP2, micro-TGTGTGCCCA[C/T]GAGGAGCTCCSCTHHfibrillar-associatedprotein 2G3997u2WIAF-13650HT27682377MFAP2, micro-CCATACACAG[G/T]CCTTCCAAACMGTRSfibrillar-associatedprotein 2G3997u3WIAF-13876HT27682453MFAP2, micro-GGAGATCTGT[G/T]TTCGTACAGTMGTVFfibrillar-associatedprotein 2G4022u1WIAF-14020HT2426240TGM1, trans-TGGCTGCTGT[T/C]CATGCCGAAAMTCSPglutaminase 1 (Kpolypeptide epi-dermal type I,protein-glutamine-gamma glutamyl-transferase)G4022u2WIAF-14021HT2426371TGM1, trans-CCCGGGGCAG[C/TI GGTGTCAATGSCTSSglutaminase 1 (Kpolypeptide epi-dermal type I,protein-glutamine-gamma-glutamyl-transferase)G4022u3WIAF-14022HT2426506TGM1, trans-ACGAGCTGAT[A/GIGTGCGCCGCGMAGIMglutaminase 1 (Kpolypeptide epi-dermal type I,protein-glutamine-gamma-glutamyl-transferase)G4022u4WIAF-14031HT24262491TGM1, trans-GGTGGAGGTG[A/T]CAGTCACTTAMATDVglutaminase 1 (Kpolypeptide epi-dermal type I,protein-glutamine-gamma-glutamyl-transferase)G4038u1WIAF-13998HT4211411LAMB3, laminin,GGTGGCAGTC[C/A]CAGAATGATGSCASSbeta 3 (nicein(125 kD), kalinin(140 kD), BM600(125 kD))G4038u2WIAF-13999HT4211258LAMB3, laminin,CTTCATCTAC[C/T]TGTGGACTGASCTTTbeta 3 (nicein(125 kD), kalinin(140 kD), BM600(125 kD))G4038u3WIAF-14002HT42111830LAMB3, laminin,GAGGCTACTG[C/T]AATCGCTACCSCTCCbeta 3 (nicein(125 kD), kalinin(140 kD), BM600(125 kD))G4038u4WIAF-14003HT42112668LAMB3, laminin,GACCACGCAG[A/T]TGATTAGGCCMATMLbeta 3 (nicein(125 kD), kalinin(140 kD), BM600(125 kD))G4038u5WIAF-14018HT4211248LAMB3, laminin,TTTCTCCGAG[C/T]TTCATCTACCMCTAVbeta 3 (nicein(125 kD), kalinin(140 kD), BM600(125 kD))G4038u6WIAF-14019HT4211887LAMB3, laminin,CACGGCCATG[C/T]TGATCGCTGCMCTAVbeta 3 (nicein(125 kD), kalinin(140 kD), BM600(125 kD))G4038u7WIAF-14023HT42111266LAMB3, laminin,AGTGTGATCC[G/A]GATGGGGCAGSGAPPbeta 3 (nicein(125 kD), kalinin(140 kD), BM600(125 kD))G4038u8WIAF-14025HT42111693LAMB3, laminin,CTATGGAGAC[G/A]TGGCCACAGGMGAVMbeta 3 (nicein(125 kD), kalinin(140 kD), BM600(125 kD))G4038u9WIAF-14026HT42111553LAMB3, laminin,GGCTGTGAAC[C/T]GTGTGCCTGCMCTPLbeta 3 (nicein(125 kD), kalinin(140 kD), BM600(125 kD))G4038u10WIAF-14029HT42113562LANB3, laminin,CCTGACAGGA[C/T]TGGAGAAGCGSCTLLbeta 3 (nicein(125 kD), kalinin(140 kD), BM600(125 kD))G4038u11WIAF-14030HT42113546LAMB3, laminin,TGCTGCGCTC[A/G]GCGGACCTGASAGSSbeta 3 (nicein(125 kD), kalinin(140 kD), BM600(125 kD))G4045u1WIAF-13571HT06521266adducin, beta sub-TGGAGCAGGA[G/T]AAGCACCGGCMGTEDunitG4050u1WIAF-14106HT14661366villinCGTTTGCCAG[G/A]GCAGCCAGGCMGAGSG4050u2WIAF-14107HT14661468villinGGTCCCAATG[G/A]GCAAGGAGCCMGAGSG4050u3WIAF-14108HT14661932villinCCACAGAGAT[C/T]CCTGACTTCASCTIIG4050u4WIAF-14110HT14662438villinTTTGGGATGA[C/T]TCCACCTGCCMCTTIG4057u1WIAF-13648HT33633371CNN3, calponin 3,TTCAGGCTTA[T/C]GGTATGAAGCSTCYYacidicG4066u1WIAF-13676HT4301654troponin T, beta,AGATTGACAA[G/A]TTCGACTTTGSGAKKskeletalG4066u2WIAF-13677HT4301774troponin T, beta,GCAAAGTCGG[C/T]GCGCGCTGGASCTGGskeletalG4066u3WIAF-13708HT4301625troponin T, beta,GGAGCTCTGG[G/C]AGACCCTGCAMGCEQskeletalG4080u1WIAF-14142HT139613130HSPG2, heparanGATTCTCCTC[G/A]GCCATCACACSGASSsulfate proteo-glycan 2 (perlecan)G4080u2WIAF-14150HT139610340HSPG2, heparanTTGAGTTCCA[C/T]TGTCCTCTGCSCTHHsulfate proteo-glycan 2 (perlecan)G4080u3WIAF-14151HT139612392HSPG2, heparanAATGCTATGA[T/C]AGCTCCCCATSTCDDsulfate proteo-glycan 2 (perlecan)G4080u4WIAF-14152HT13963416HSPG2, heparanTCCCTCTGCC [C/T]GAGCAAACCGSCTPPsulfate proteo-glycan 2 (perlecan)G4080u5WIAF-14154HT13964588HSPG2, heparanGTGCCGCTGG[T/C]GGCCAGCATCMTCVAsulfate proteo-glycan 2 (perlecan)G4080u6WIAF-14156HT13969582HSPG2, heparanGCACAGCCAC[C/A]CCGTGCTGCAMGAATsulfate proteo-glycan 2 (perlecan)G4096u1WIAF-13890HT4237394motor proteinCAAAGAAATC[G/A]ATTCAGTCGCSGASSG4096u2WIAF-13910HT4237455motor proteinATCTAAACAC[C/T]CTGCCTCACAMCTPSG4096u3WIAF-13911HT42371150motor proteinCTAACCTTGT[A/G]TCTCAGTATCSAGVVG4109u1WIAF-14034HT282231238phosphoglucomutase-TACACCGTCC[C/T]GAAGACGCATMCTAVrelated proteinG4109u2WIAF-14035HT282231043phosphoglucomutase-ATTATTCCTG[C/A]CCGGAACCAGMCAADrelated proteinG4112u1WIAF-13615HT4401374KIF5A, kinesinAGATGTCCTT[G/A]CTCGCTACAAMGAATfamily member 5AG4112u2WIAF-13623HT44012767KIF5A, kinesinAGAGAGTTAA[G/T]GCCCTCCACCMGTKNfamily member 5AG4114u1WIAF-14113HT4160830fibrinogen-likeAACTTCACCA[G/A]AACATGGCAAMGARKprotein pT49G4118u1WIAF-14010HT0841564MYL5, myosin,TCGATGTGGC[G/A]GGCAACCTGGSGAAAlight polypeptide5, regulatoryG4118u2WIAF-14011HT0841368MYL5, myosin,TTCACCATGT[T/C]TCTGAACCTGMTCFSlight polypeptide5, regulatoryG4118u3WIAF-14012HT0841533MYL5, myosin,GAGGTGGACC[A/G]GATGTTCCAGMAGQRlight polypeptide5, regulatoryG4122u1WIAF-13955HT97538161myosin-ITCGAGAACCT[A/G]CGCCCCCGATSAGLLG4124u1WIAF-13895HT09251517TCM3, transgluta-TCGCTCGCAT[G/A]CTGGCACTAGMGAMIminase 3 (E poly-peptide, protein-glutamine gamma-glutamyl-transferase)G4124u2WIAF-13896HT09251433TCM3, transgluta-AACCCAACAC[G/A]CCATTTGCCCSGATTminase 3 (E poly-peptide, protein-glutamine-gamma-glutamyl-transferase)G4126u1WIAF-13830HT24651035myosin bindingACTCGTACTC[C/G]TTCCGGCTCTSCGSSprotein HG4126u2WIAF-13853HT2465369myosin bindingAGAGAGGCAC[G/C]CTCGGAGTGGMGCGAprotein HG4130u1WIAF-13614HT1657198CFL1, cofilin 1CTGTCCACGA[T/C]CCCTACGCCASTCDD(non-muscle)G4138u1WIAF-13598HT33664601MAGP2: Microfibril-GAAAGATGAG[C/T]TTTCCCGTCAMCTLFassociated glyco-protein-2G4138u2WIAF-13599HT33664405MAGP2: Microfibril-ATGACTTGGC[C/T]TCCCTCAGTCSCTAAassociated glyco-protein-2G4138u3WIAF-13600HT33664327MAGP2: Microfibril-AAGATCCTAA[T/C]CTGCTGAATGSTCNNassociated glyco-protein-2G4159u1WIAF-14048HT34431119SNL, singedGCTGCTACTT[T/C]GACATCGACTSTCFF(Drosophila)-like(sea urchin fascinhomolog like)G4170u1WIAF-13580HT50691131Golgi protein,GAAATATACC[A/G]TAAGTATCGAMAGIVperipheral,brefeldin A-sensitiveG4170u2WIAF-13581HT5069930Golgi protein,GTATAATAAA[C/T]TCCTGGACTTMCTLFperipheral,brefeldin A-sensitiveG4170u3WIAF-13582HT50692312Golgi protein,AGCAGCCTTA[A/G]GCATCTTGGANAG**peripheral,brefeldin A-sensitiveG4170u4WIAF-13596HT5069359Golgi protein,TCAACCACGT[T/G]TCTGTGCCTTSTGLLperipheral,brefeldin A-sensitiveG4170u5WIAF-13597HT50691007Golgi protein,AAAAAGCCAA[T/A]ACTGTTCCTGMTANKperipheral,brefeldin A-sensitiveG4171u1WIAF-13688HT1587667KIF5B, kinesinTTTTTAATTA[T/C]ATTTACTCCASTCYYfamily member 5BG4171u2WIAF-13689HT15871036KIF5B, kinesinTTAGTAAAAC[T/C]GGAGCTGAAGSTCTTfamily member SBG4176u1WIAF-14204HT33754130TNR, tenascin RGCTCATTGGC[G/A]TCAACCTGATMGAVI(restrictin,janusin)G4176u2WIAF-14205HT33754463TNR, tenascin RCTGTCCATGT[G/T]CCAGTTCAGCMGTAS(restrictin,janusin)G4176u3WIAF-14206HT33754249TNR, tenascin RACTACAACAC[G/A]TCCAGCAAACSGATT(restrictin,janusin)G4176u4WIAF-14208HT337542009TNR, tenascin RCTGGTCCCCA[G/A]CGCCATTGGTMGARK(restrictin,janusin)G4176u5WIAF-14209HT337542175TNR, tenascin RCAGCCTCCTC[G/A]GAGACCTCCASGASS(restrictin,janusin)G4176u6WIAF-14210HT337543318TNR, tenascin RAATCCACCGA[C/T]GGAAGCCGCASCTDD(restrictin,janusin)G4176u7WIAF-14211HT337543221TNR, tenascin RCCGGCAAACC[T/C]GACAGCCAGTMTCLP(restrictin,janusin)G4176u8WIAF-14217HT337541635TNR, tenascim RTCTCGGACAC[C/TI GTGGCTTTTGSCTTT(restrictin,janusin)G4178u1WIAF-14138HT02242827ACTN2, actinin,GCTGCGTTCT[C/T]TTCCGCACTCMCTSFalpha 2G4178u2WIAF-14139HT02242818ACTN2, actinin,CTGGATTACG[C/T]TGCGTTCTCTMCTAValpha 2G418u1WIAF-11750L075942370TGFBR3, trans-GAGTGCACTT[C/T]CCTATCCCGCSCTFFforming growthfactor, betareceptor III(betaglycan, 300 kD)G418u2WIAF-11751L075942586TGFBR3, trans-AGAAGACGTT[C/T]ACCAACCCCCSCTFFforming growthfactor, betareceptor III(betaglycan, 300 kD)G418u3WIAF-11752L075942671TGFBR3, trans-AATTTCTCCA[C/T]CAATTTTCCAMCTPSforming growthfactor, betareceptor III(betaglycan, 300 kD)G418u4WIAF-11771L07594438TGFBR3, trans-TGTCTGAACT[C/T]TCACCTCTCASGTLLforming growthfactor, betareceptor III(betaglycan, 300 kD)G418u5WIAF-11744L07594392TGFBR3, trans-CTGATCAGCT[T/C]CTGTTTAGCCMTCFSforming growthfactor, betareceptor III(betaglycan, 300 kD)G418u6WIAF-11772L075941470TGFBR3, trans-AGCTACGGAT[C/T]CTGCTGGACCSCTIIforming growthfactor, betareceptor III(betaglycan, 300 kD)G418u7WIAF-11773L075941170TGFBR3, trans-TCTTGAAGTG[C/A]AAAAACTCTGNCAC*forming growthfactor, betareceptor III(betaglycan, 300 kD)G418u8WIAF-11745L075941463TGFBR3, trans-CCTCCTGAGC[T/C]ACGGATCCTCMTCLPforming growthfactor, betareceptor III(betaglycan, 300 kD)G418u9WIAF-11746L075942211TGFBR3, trans-ATGTTGAGGT[A/G]TCTGTTACTASAGVVforming growthfactor, betareceptor III(betaglycan, 300 kD)G4181u1WIAF-14207HT2008425SPTBN1, spectrin,CTCTGCGCGG[C/T]TTTTTCAGCGMCTLFbeta, non-erythrocytic 1G4181u2WIAF-14213HT20083565SPTBN1, spectrin,ACACAGCGAT[C/T]GCCTCGGAGGSCTIIbeta, non-erythrocytic 1G4181u3WIAF-14218HT20081258SPTBN1, spectrin,ACCTTCTGGA[A/G]TGCATTGAACSAGEEbeta, non-erythrocytic 1G4181u4WIAF-14219HT20081780SPTBN1, spectrin,AGCTCGAGGC[C/T]GAGAATTACCSCTAAbeta, non-erythrocytic 1G4181u5WIAF-14220HT20063637SPTBN1, spectrin,ACATCAAGAA[T/C]GAGATCGACASTCNNbeta, non-erythrocytic 1G4183u1WIAF-13976HT2640404TPM4, tropomyosin 4CCAAGCACAT[T/C]GCGGAAGAGGSTCIIG4185u1WIAF-13554HT3451257MFAP1, micro-AAGGCCAGAC[T/C]ATGCCCCTATMTGYDfibrillar-associatedprotein 1G4185u2WIAF-13555HT34511108MFAP1, micro-CCAACAAAGC[T/C]GTTAAGGGCASTGAAfibrillar-associatedprotein 1G4185u3WIAF-13570HT3451274MFAP1, micro-CTATGCAGTC[C/T]TCAGATCACGSCTSSfibrillar-associatedprotein 1G4196u1WIAF-13665HT97558941NUP88, nucleoporinGGGTCCATTG[C/A]CCATGCATCTMCAAD88 kDG4196u2WIAF-13666HT975581092NUP8B, nucleoporinATGACCACAC[G/A]TCAGAAAACTSGATT88 kDG4196u3WIAF-13667HT975581551NUP88, nucleoporinTCCATCCAGC[C/A]TCTCCTCCCCSGAAA88 kDG4196u4WIAF-13668HT975582220NUP88, nucleoporinAGGGTGAACA[T/C]ATAAGCCAAASTCHH88 kDG4196u5WIAF-13669HT975582205NUP88, nucleoporinCCATCCTGAA[A/G]GAGGAGGGTGSAGKK88 kDG4208u1WIAF-13921HT11221329VCL, vinculinTCATCCTAAA[G/C]AAAGAGATCAMGCEQG4208u2WIAF-13922HT11222438VCL, vinculinCCATCTCCCC[A/G]ATGGTGATGCSAGPPG4208u3WIAF-13941HT1122818VCL, vinculinGCCATCAAGA[T/C]GCCTGCGCCASTCDDG4208u4WIAF-13942HT11221556VCL, vinculinAACCACAGCG[C/A]TCGATTGATASGARRG4213u1WIAF-13605HT2813163NUP153, nucleoporinGCCAGGCTCC[T/C]TACAAAGATASTCLL153 kDG4213u2WIAF-13606HT2813742NUP153, nucleoporinGAATTCTTCA[A/C]TCCTTAAAACMAGIV153 kDG4213u3WIAF-13609HT28131800NUP153, nucleoporinTTACACCTGC[A/C]GAAATCCTCASACAA153 kDG4213u4WIAF-13627HT28131829NUP153,nucleoporinAGTGTTCTAG[A/C]TATTCTCAAAMACDA153 kDG4213u5WIAF-13632HT28133258NUP153, nucleoporinCTTTTCCCAA[C/T]GTGGAGCCTCSCTNN153 kDG4213u6WIAF-13635HT28134162NUP153, nucleoporinCTCTGCAACA[A/C]CTCCTAATTCMAGTA153 kDG4218u1WIAF-13854HT16811122phosphatidyl-AACCTTATTA[T/C]TTTATCTCACMTCITinositol glycan,class AG4223u1WIAF-14160HT16841434CD36L2, CD36ATTAGATGAC[T/C]TTGTTGAAACMTCFLantigen (collagentype I receptor,thrombospondinreceptor)-like 2(lysosomal integralmembrane proteinII)G4223u2WIAF-14173HT1684696CD36L2, CD36GTGGTCCCAC[G/A]TGCACTTCCTMGAVMantigen (collagentype I receptor,thrombospondinreceptor)-like 2(lysosomal integralmembrane proteinII)G4223u3WIAF-14174HT1684986CD36L2, CD36CAGACAAGTC[C/T]AATATCATTASCTCCantigen (collagentype I receptor,thrombospondinreceptor)-like 2(lysosomal integralmembrane proteinII)G4223u4WIAF-14176HT16841437CD36L2, CD36AGATGACTTT[G/A]TTGAAACGCGMGAVIantigen (collagentype I receptor,thrombospondinreceptor)-like 2(lysosomal integralmembrane proteinII)G4227u1WIAF-14056HT1929912proteoglycan 2ATCCCTCCAA[C/A]AAACATCCCCSCAKKG4227u2WIAF-14057HT19291254proteoglycan 2CGAACTTTCC[C/A]TACTCCCCTCSCAAAG4227u3WIAF-14058HT19291321proteoglycan 2CCCAGCACCC[T/C]ACTCCCCTCCMTCYHG4229u1WIAF-13961HT168974SDC4, syndecan 4CCTGCTCCTC[T/C]TCTTCCTACCMTCFL(amphiglycan,ryudocan)G4230u1WIAF-13525HT4995602TRAM proteinCCATAACCTC[A/C]TGACATTTCAMACMLG4243u1WIAF-14169HT2901406KRT17, keratin 17ACCTCCACCT[C/A]AACATCCCTCSGAVVG4243u2WIAF-14170HT2901478KRT17, keratin 17ACACCACAAT[T/C]CACCACCTCCSTCIIG4243u3WIAF-14171HT2901389KRT17, keratin 17GGAGGAGGCC[A/C]ACACTGAGCTMAGNDG4243u4WIAF-14178HT2901564KRT17, keratin 17CTGGCTGCTC[A/C]TGACTTCCGCMACDAG4244u1WIAF-14086HT1056386clathrin, lightATCGATTGCA[G/C]TCAGAGCCTGMGCQHpolypeptide aG4246u1WIAF-14044HT97492259SLN, sarcolipinGTCCTATCAC[T/C]ACTGAGAGGCMTCYHG4246u2WIAF-14045HT97492189SLN, sarcolipinACACCCGGGA[G/A]CTGTTTCTCASGAEEG4254u1WIAF-13546HT339386TNNI2, troponin I,ACCTGAAGAG[C/T]CTGATCCTGCSCTSSskeletal, fastG4254u2WIAF-13553HT3393530TNNI2, troponin I,skeletal, fastTCGAGGAGAA[G/C]TCTGGCATGGMGCKNG4255u1WIAF-13644HT2907562CRYAB, crystallin,AGTTCCACAG[G/A]AAATACCGGASGARRalpha BG4255u2WIAF-13645HT2907367CRYAB, crystallin,CCTCCTTCCT[G/A]CGGCCACCCASGALLalpha BG4255u3WIAF-13872HT2907271CRYAB, crystallin,CCAGCCGCCT[C/T]TTTGACCAGTSCTLLalpha BG4255u4WIAF-13873HT2907580CRYAB, crystallin,GGATCCCAGC[T/C]GATGTAGACCSTCAAalpha BG4257u1WIAF-14052HT1694394PIGF,TAGAGTTGGC[A/G]TTGGAAACATSAGAAphosphatidylinositolglycan, class FG4257u2WIAF-14053HT1694252PIGF,TATTTAGTAG[T/C]GAAACCAAATMTCVAphosphatidylinositolglycan, class FG4257u3WIAF-14069HT1694291PIGF,TCATTATCAC[A/G]CAAGGTAACTMAGHRphosphatidylinositolglycan, class FG4264u1WIAF-13519HT09681720TJP1, tightCGGTCAGTGG[C/T]TTCCAGCCAGMCTAVjunction protein 1(zona occludens 1)G4264u2WIAF-13520HT09682272TJP1, tightCATGCTGATG[A/C]TCACACACCTMAGDGjunction protein 1(zona occludens 1)G4264u3WIAF-13529HT09685408TJP1, tightAGCCTCCTGA[A/T]GCTGATGGTGMATEDjunction protein 1(zona occiudens 1)G434u1WIAF-11748M21121286SCYA5, smallTACATCAACT[C/T]TTTGGAGATGMCTSFinducible cytokineA5 (RANTES)G434u2WIAF-11749M21121137SCYA5, smallGCTTTGCCTA[C/T]ATTGCCCGCCSCTYYinducible cytokineA5 (RANTES)G435u1WIAF-11741M31933754FCGR2B, Fc fragmentGTCACTGGGA[T/C]TGCTGTAGCCMTCITof IgG, lowaffinity IIb,receptor for (CD32)G435u2WIAF-11743M31933395FCGR2B, Fc fragmentGGGAGTACAC[G/A]TGCCAGACTGSGATTof IgG, lowaffinity IIb,receptor for (CD32)G435u3WIAF-11742M31933673FCGR2B, Fc fragmentTACACGCTGT[T/A]CTCATCCAAGMTAFYof IgG, lowaffinity IIb,receptor for (CD32)G4369u1WIAF-13728HT09001176GBE1, glucanTTACGTCCAT[G/A]CTTTATCATCMGAMI(1,4-alpha-),branching enzyme 1(glycogen branchingenzyme, Andersendisease, glycogenstorage diseasetype IV)G4369u2WIAF-13729HT09001609GBE1, glucanGAGTGTCCTG[A/G]CTCCTTTTACMAGTA(1,4-alpha-),branching enzyme 1(glycogen branchingenzyme, Andersendisease, glycogenstorage diseasetype IV)G4373u1WIAF-13559HT09401117HSD17B2, hydroxy-GCCAGCAAGG[A/T]CTTCTCTCCGMATDVsteroid (17-beta)dehydrogenase 2G4373u2WIAF-13560HT09401195HSD17B2, hydroxy-CCAGGGAAAG[G/A]CGCTTACTTGMGAGDsteroid (17-beta)dehydrogenase 2G438u1WIAF-11830M63121583TNFRSF1A, tumorACCGTGTGTG[G/A]CTGCAGGAAGMGAGDnecrosis factorreceptor super-family, member 1AG438u2WIAF-11790M63121618TNFRSF1A, tumorTTATTGGACT[G/A]AAAACCTTTTMGAEKnecrosis factorreceptor super-family, member 1AG440u1WIAF-11806M74447261TAP2, transporterTGCTAAAGCT[A/G]AGAGGGCTGCSAGLL2, ABC (ATPbinding cassette)G440u2WIAF-11807M744472089TAP2, transporterCAGGCTGCAG[G/A]CAGTTCAGCGMGAAT2, ABC (ATPbinding cassette)G440u3WIAF-11808M744472155TAP2, transporterTGCCCAGCTC[C/T]AGGAGGGACANCTQ*2, ABC (ATPbinding cassette)G440u4WIAF-11818M744471789TAP2, transporterGAACAACATT[G/A]CTTATGGGCTMGAAT2, ABC (ATPbinding cassette)G440u5WIAF-11819M744471565TAP2, transporterAAGGGGCTGA[C/T]GTTTACCCTAMCTTM2, ABC (ATPbinding cassette)G440u6WIAF-11820M744471254TAP2, transporterTGCACTTGGG[G/T[GTCCACATCCSCTGG2, ABC (ATPbinding cassette)G440u7WIAF-11788M744471231TAP2, transporterGTACCTGCTC[A/C]TAACCAGGCTMAGIV2, ABC (ATPbinding cassette)G440u8WIAF-11821M744471404TAP2, transporterTGCTCAGCAA[C/T]GTGGGAGCTCSCTNN2, ABC (ATPbinding cassette)G440u9WIAF-11783M744472187TAP2, transporterCCCGCCTGGT[T/C]CAGCACCGGCSTGVV2, ABC (ATPbinding cassette)G440u10WIAF-11786M744471825TAP2, transporterTGATAAGGTG[A/G]TGGCGGCTGCMAGMV2, ABC (ATPbinding cassette)G4400u1WIAF-14007HT97396839A33GCCAATCAAA[G/T]GACGGCTCACMGTKNG4404u1WIAF-14013HT1215109ACP2, acidCCGCCCACCC[G/A]GGCCCGGAGTMGARQphosphatase 2,lysosomalG4404u2WIAF-14016HT12151271ACP2, acidACCGCCACGT[C/T]GCAGATGGGGSCTVVphosphatase 2,lysosomalG4406u1WIAF-13661HT3564872ACPP, acidACAAAAAACT[T/C]ATCATGTATTSTCLLphosphatase,prostateG4406u2WIAF-13662HT3564839ACPP, acidATCACATGAA[G/A]AGAGCAACTCSGAKKphosphatase,prostateG4406u3WIAF-13881HT3564741ACPP, acidAGAATTGTCA[G/T]AATTGTCCCTNGTE*phosphatase,prostateG441u1WIAF-10166M77349698TGFBI, transformingGTGCCCGGCT[C/G]CTGAAAGCCGSCGLLgrowth factor,beta-induced, 68 kDG441u2WIAF-10168M773491028TGFBI, transformingGCCTCTCTGT[A/G]CAGACCCTGGSAGVVgrowth factor,beta-induced, 68 kDG441u3WIAF-10169M773491667TGFBI, transformingACACAGTCTT[T/C]GCTCCCACAASTCFFgrowth factor,beta-induced, 68 kDG441u4WIAF-10171M773491463TGFBI, transformingGTAATAGCCT[C/T]TGCATTGAGASCTLLgrowth factor,beta-induced, 68 kDG4411u1WIAF-14005HT97468492acyl-CoAGCTCACCAAT[A/G]AGGCCACCCTMAGKEG4411u2WIAF-14008HT974681076acyl-CoATGCCCCACAC[C/T]GAGGACGAGASCTTTG4412u1WIAF-13576HT1882657ACADS, acyl-GCAAAACAAG[G/A]GCATCAGTGCMGAGSCoenzyne Adehydrogenase, C-2to C-3 short chainG4412u2WIAF-13579HT18821022ACADS, acyl-TGACCTGGCC[C/T]GCTGCCATGCSCTRRCoenzyme Adehydrogenase, C-2to C-3 short chainG4415u1WIAF-14080HT25032170acyl-Coenzyme A:TCATTATATT[C/T]GAGCAGATTCSCTFFcholesterolacyltransferaseG4415u2WIAF-14081HT25031993acyl-Coenzyme A:TTTCAGTTCC[C/T]TATTTTCTGTSCTPPcholesterolacyltransferaseG4415u3WIAF-14098HT25032006acyl-Coenzyme A:TTTTCTGTTT[C/G]AACATTGGCGMCGQEcholesterolacyltransferaseG4415u4WIAF-14101HT25032365acyl-Coenzyme A:GGGGTTATGT[C/T]GCTATGAAGTSCTVVcholesterolacyltransferaseG4417u1WIAF-13819HT0542356AOAH, acyloxyacylTCCAGCCAAC[G/A]ATGACCAGTCMGADNhydrolase (neutro-phil)G4417u2WIAF-13820HT0542340AOAH, acyloxyacylTTCAGTCCTC[G/A]GCCTCTCCAGSGASShydrolase(neutrophil)G4417u3WIAF-13824HT05421595AOAH, acyloxyacylGCTAAATAAA[G/A]ACATGACCTAMGADNhydrolase(neutrophil)G4417u4WIAF-13841HT0542382AOAH, acyloxyacylCCAGCCTCTC[G/A]AATGGGCACASGASShydrolase(neutrophil)G4417u5WIAF-13842HT0542458AOAH, acyloxyacylCAACTCGACG[G/A]TCCAGGCCTCMGAVIhydrolase(neutrophil)G4417u6WIAF-13843HT05421201AOAH, acyloxyacylGATTTCTGGA[C/T]TCCACTGTTGSCTDDhydrolase(neutrophil)G4417u7WIAF-13844HT05421321AOAH, acyloxyacylACCTGAAGAA[A/G]TTTATAGAAASAGKKhydrolase(neutrophil)G4417u8WIAF-13845HT05421404AOAH, acyloxyacylGATGTCTCCA[G/A]TCGGAACAGTMGASNhydrolase(neutrophil)G4417u9WIAF-13846HT05421759AOAH, acyloxyacylAATTTACAAA[C/T]TTCAATCTTTSCTNNhydrolase(neutrophil)G4417u10WIAF-13847HT05421644AOAH, acyloxyacylCTCCAGGTCA[G/A]CCCCTGCCACMGASNhydrolase(neutrophil)G442u1WIAF-11828M94582933IL8RA, interleukinCACATCGACC[G/A]GGCTCTCGATMGARQ8 receptor, alphaG442u2WIAF-11829M94582721IL8RA, interleukinTCATCGTGCC[A/G]CTGCTGATCASAGPP8 receptor, alphaG442u3WIAF-11780M945821027IL8RA, interleukinGCCATGGACT[C/T]CTCAAGATTCSCTLL8 receptor, alphaG442u4WIAF-11792M9458278IL8RA, interleukinATGGACAGTC[A/C]CAGCTTTGAAMAGDG8 receptor,alphaG4423u1WIAF-13752HT221671ADSL,GCTATGCCAG[C/T]CCGGAGATGTSCTSSadenylosuccinatelyaseG4423u2WIAF-13794HT2216126ADSL,ATGGCGCCAG[C/T]TGTGGCTGTGSCTLLadenylosuccinatelyaseG4423u3WIAF-13795HT2216674ADSL,AGCTTGACAA[G/A]ATGGTCACAGSGAKKadenylosuccinatelyaseG4428u1WIAF-13954HT9752457ADFP, adiposeTGGTCAACCT[C/A]CCCTTGGTGASGALLdifferentiationrelated protein;adipophilinG4434u1WIAF-13506HT0863551ARF3, ADP-TCTGGAGACA[C/T]TACTTCCAGASCTHHribosylation factor3G444u1WIAF-10172U28694398CCR3, chemokineCGACATCTTT[T/G]TCATAATCCTMTGFV(C-C motif)receptor 3G444u2WIAF-10181U28694214CCR3, chemokineTCCTCATAAA[A/C]TACAGGAGGCSAGKK(C-C motif)receptor 3G4440u1WIAF-14054HT1392136ADRBK1, adrenergic,GCAAGAAGAT[A/C]CTGCTGCCCGSAGIIbeta, receptorkinase 1G445u1WIAF-10183U40373319Human cellTAGAAGGCCA[C/T]CTGGTGATTCSCTHHsurface glyco-protein CD44 mRNA,complete cds.G4456u1WIAF-13629HT0626796ALDOC, aldolase C,CCCTGCTCAA[G/A]CCCAACATCCSGAKKfructose-bisphosphateG446u1WIAF-11832U64198754IL12RB2, inter-TGAACCCTTC[C/G]CATGTAATTTSCGSSleukin 12 receptor,beta 2G446u2WIAF-11795U641982569IL12RB2, inter-TTTTCTCAAC[G/A]CATTACTTCCSGATTleukin 12 receptor,beta 2G446u3WIAF-11833U641982500IL12RB2, inter-TGCAACGTAA[A/C]CCCAATTGCASAGKKleukin 12 receptor,beta 2G446u4WIAF-11835U641981918IL12RB2, inter-CTCCTCGCCA[G/C]CTCTCTGCAAMGCQHleukin 12 receptor,beta 2G446u5WIAF-11793U64198991IL12RB2, inter-GTGGAGCAGA[C/A]ATCTTCGTTCSGAEEleukin 12 receptor,beta 2G446u6WIAF-11794U641982469IL12RB2, inter-AGTTCCCACC[G/C]AAATGAGAGGMGCGAleukin 12 receptor,beta 2G446a7WIAF-13128U641981964IL12RB2, inter-GGTGACTTGG[C/g]AGCCTCCCAGMCgQEleukin 12 receptor,beta 2G446a8WIAF-13129U641982060IL12RB2, inter-TCTAAACTGG[C/G]TACCCACTCGMCGLVleukin 12 receptor,beta 2G447u1WIAF-11796X03663384CSF1R, colonyCCAGTGTCCC[C/T]GAGCTGGTCGSCTPPstimulating factor1 receptor,formerly McDonoughfeline sarcomaviral (v-fms)oncogene homologG447u2WIAF-11836X036631026CSF1R, colonyACAACAACAC[T/C]AAGCTGCCAASTCTTstimulating factor1 receptor,formerly McDonoughfeline sarcomaviral (v-fms)oncogene homologG447u3WIAF-11837X03663886CSF1R, colonyCCTCAAAGTG[C/A]ACAAACTCATMCAQKstimulating factor1 receptor,formerly McDonoughfeline sarcomaviral (v-fms)oncogene homologG447u4WIAF-11797X036632425CSF1R, colonyGAAGAAATAT[G/A]TCCGCAGGGAMGAVIstimulating factor1 receptor,formerly McDonoughfeline sarcomaviral (v-fms)oncogene homologG4473u1WIAF-13904HT1352860FUCA1,TTCAAGCCAC[A/G]GAGCTTGCCAMAGQRfucosidase,alpha-L- 1,tissueG4473u2WIAF-13916HT1352440FUCA1,ACAAACTGGC[C/T]GAGTCCTGTGMCTPLfucosidase,alpha-L- 1,tissueG4479u1WIAF-13637HT19952465AMPD2, adenosineGCCTCAATGA[G/T]CCTGGTCCAT—GT——monophosphatedeaminase 2(isoform L)G4479u2WIAF-13866HT19951258AMPD2, adenosineTGGATGTGCA[T/C]GCGGACAGGASTCHHmonophosphatedeaminase 2(isoform L)G4479u3WIAF-13867HT19951280AMPD2, adenosineCACTTTCCAT[C/T]CCTTTGACAAMCTRCmonophosphatedeaminase 2(isoform L)G4479u4WIAF-13868HT19951201AMPD2, adenosineTGCGGGAGGT[C/T]TTTGAGAGCASCTVVmonophosphatedeaminase 2(isoform L)G4479u5WIAF-13869HT19951579AMPD2, adenosineGTACCAAGGG[C/T]CAGCTGGCCASCTGGmonophosphatedeaminase 2(isoform L)G4492u1WIAF-14084HT3390866ANX11, annexinCCTGGGGAGT[C/T]GCTCCAACAAMCTRCXI (56 kDautoantigen)G4492u2WIAF-14085HT3390850ANX11, annexinAGGCCATCAT[T/C]GACTGCCTGGSTCIIXI (56 kDautoantigen)G450u1WIAF-10170X857401196CCR4, chemokineTCCAAATTTA[C/T]TCTGCTGACASCTYY(C-C motif)receptor 4G4502u1WIAF-13510HT4840165ASS,AAGCCTATGA[C/T]GTCATTGCCTSCTDDargininosuccinatesynthetaseG4502u2WIAF-13511HT4840369ASS,GGCCCTGCAT[C/T]GCCCGCAAACSCTIIargininosuccinatesynthetaseG4502u3WIAF-13512HT484073ASS,AATCCCAGAC[G/A]CTATGTCCAC—GA——argininosuccinatesynthetaseG4502u4WIAF-13513HT4840129ASS,TGGACACCTC[G/C]TGCATCCTCGSGCSSargininosuccinatesynthetaseG4502u5WIAF-13514HT4840285ASS,AGTTTGTGGA[G/A]GAGTTCATCTSGAEEargininosuccinatesynthetaseG4502u6WIAF-13515HT4840234ASS,AGGCACTGAA[C/A]CTTGGGGCCASGAKKargininosuccinatesynthetaseG4502u7WIAF-13516HT4840316ASS,CCAGTCCAGC[G/A]CACTGTATGANGAATargininosuccinatesynthetaseG4502u8WIAF-13537HT4840426ASS,TGTCCCACGG[C/T]GCCACAGGAASCTGGargininosuccinatesynthetaseG4502u9WIAF-13538HT4840530ASS,GAATTCTACA[A/C]CCGGTTCAAGMAGNSargininosuccinatesynthetaseG4502u10WIAF-13539HT4840750ASS,TTCTCGACAT[C/T]GAGTTCAAAASCTIIargininosuccinatesynthetaseG4502u11WIAF-13540HT4840960ASS,ATGCTCATTT[A/G]GACATCGAGGSAGLLargininosuccinatesynthetaseG4508u1WIAF-13663HT285571767ARSD,CAGTTTTCCA[T/C]GAGCAACATCMTCMTarylsulfatase DG4508u2WIAF-13693HT28557433ARSD,TTCAGTGGAA[C/T]GCAGGCTCAGSCTNNarylsulfatase DG4508u3WIAF-13694HT28557747ARSD,GGTTTCTTCT[C/G]TGTCTCCGCGMCGSCarylsulfatase DG4508u4WIAF-13696HT285571012ARSD,CCAGCACTGC[A/C]TTCCTGGGGASAGAAarylsulfatase DG4508u5WIAF-13697HT285571302ARSD,CGAGTGATTG[G/A]AGAGCCCACGMGAGEarylsulfatase DG4508u6WIAF-13698HT285571285ARSD,GGGTGCTCCC[G/A]GCCCGCCGAGSGAPParylsulfatase DG4508u7WIAF-13699HT285571807ARSD,AGCCGTGCTG[C/T]GGACATTTCCSCTCCarylsulfatase DG4508u8WIAF-13718HT28557483ARSD,GCAAGAATCT[T/C]GCAGCAGCATMTCLSarylsulfatase DG4518u1WIAF-13809HT3430515ASPA,ACAACACCAC[C/T]TCTAACATGGSCTTTaspartoacylase(aminoacylase 2,Canavan disease)G4518u2WIAF-13810HT3430851ASPA,AACTTCATTA[C/T]CCCCGGGATCSCTYYaspartoacylase(aminoacylase 2,Canavan disease)G4518u3WIAF-13811HT3430787ASPA,CATCATTTCA[A/G]TGAAGGAAAAMAGNSaspartoacylase(aminoacylase 2,Canavan disease)G4518u4WIAF-13837HT3430618ASPA,ACCCTGCTAC[G/A]TTTATCTGATMGAVIaspartoacylase(aminoacylase 2,Canavan disease)G452a1WIAF-10509HT0695553APOA4,ACCCAGGTCA[A/C]CACGCAGGCCMAGNSapolipoprotein A-IVG452a2WIAF-13124HT0695563APOA4,ACACGCAGGC[C/T]GAGCAGCTGCSCTAAapolipoprotein A-IVG4524u1WIAF-14120HT1541726ATP5A1, ATPCTCAATTGCT[A/G]TTGACACAATMAGIVsynthase, H+transporting, mito-chondrial F1complex, alphasubunit, isoform 1,cardiac muscleG4524u2WIAF-14131HT1541153ATP5A1, ATPATCTTTCATT[G/T]CTGCAAGGAAMGTASsynthase, H+transporting, mito-chondrial F1complex, alphasubunit, isoform 1,cardiac muscleG4526u1WIAF-14130HT4994400ATP5D, ATPTCCATCGCAG[T/C]GAACGGCGACMTCVAsynthase, H+transporting, mito-chondrial F1complex, deltasubunitG453u1WIAF-10138HT07681747PDGFRB, platelet-CTGCCGCCCA[C/T]GCTGCTGGGGMCTTMderived growthfactor receptor,beta polypeptideG453u2WIAF-10147HT07682957PDGFRB, platelet-TTTTGCCTTT[A/G]AAGTGGATGGSAGLLderived growthfactor receptor,beta polypeptideG453u3WIAF-10148HT07683608PDGFRB, platelet-AGCCGGAGCC[A/G]GAGCTGGAACSAGPPderived growthfactor receptor,beta polypeptideG453u4WIAF-10149HT0768457PDGFRB, platelet-CAGGGCCTGG[T/G]CGTCACACCCMTGVGderived growthfactor receptor,beta polypeptideG453u5WIAF-10151HT07681505PDGFRB, platelet-AGCTGACACT[G/C]GTTCGCGTGASGCLLderived growthfactor receptor,beta polypeptideG453u6WIAF-10153HT07683446PDGFRB, platelet-ACCCCAAACC[C/T]GAGCTTGCTGSCTPPderived growthfactor receptor,beta polypeptideG453u7WIAF-10161HT07682030PDGFRB, platelet-TTTGGCAGAA[G/A]AAGCCACGTTSGAKKderived growthfactor receptor,beta polypeptideG4533u1WIAF-13616HT1618343ATP synthase, H+GTTACATGAT[C/T]GACAACGTGASCTIItransporting,subunit D,vacuolarG4534u1WIAF-13569HT3556654ATP6E, ATPase, H+TAAAGGTTTC[C/T]AACACCCTGGSCTSStransporting,lysosomal(vacuolarproton pump) 31 kDG4535u1WIAF-13747HT27972357ATP50, ATPTCACTACCAA[C/T]CTGATCAATTSCTNNsynthase, H+transporting,mitochondrial F1complex, O subunit(oligomycinsensitivityconferringprotein)G4535u2WIAF-13748HT27972144ATP50, ATPAGGTATACGG[T/C]ATTGAAGGTCSTCGGsynthase, H+transporting,mitochondrial F1complex, O subunit(oligomycinsensitivityconferringprotein)G4535u3WIAF-13792HT27972329ATP50, ATPATCACAGCAA[A/G]AGAGAGGTTCMAGKRsynthase, H+transporting,mitochondrial F1complex, O subunit(oligomycinsensitivityconferringprotein)G45439u1WIAF-13711HT48520288ATPase, 14 kDaTGCCCTGGAC[G/A]CCCACCAGCAMGAATsubunit, vacuolarG4548u1WIAF-14127HT15743138ATPase, Ca2+ trans-CGCAATGTCT[T/C]TGACGGCATCMTCFSporting membrane,isoform 2G4548u2WIAF-14137HT15742089ATPase, Ca2+ trans-GCACTATCTG[C/T]GTGGCCTACCSCTCCporting membrane,isoform 2G4548u3WIAF-14140HT15742924ATPase, Ca2+ trans-CAGGACCATG[A/T]TGAAGAACATMATMLporting membrane,isoform 2G4549u1WIAF-14161HT1346524ATP2B4, ATPase,TGCACTGACC[C/T]AGATTAATGTNCTQ*Ca++ transporting,plasma membrane 4G4549u2WIAF-14162HT1346715ATP2B4, ATPase,ATGTCACGCT[C/T]ATCATCCTGCSCTLLCa++ transporting,plasma membrane 4G4549u3WIAF-14163HT1346508ATP2B4, ATPase,AGCTGCGTTC[G/A]ACGGATOCACSGASSCa++transporting,plasma membrane 4G4549u4WIAF-14166HT13461084ATP2B4, ATPase,TGATCCAACG[G/A]AATGATCTCASGAGGCa++ transporting,plasma membrane 4G4552u1WIAF-13630HT0867710ATP7A, ATPase,TACTAGCACT[A/G]TTGAAGGAAAMAGIVCu++ transporting,alpha polypeptide(Menkes syndrome)G456u1WIAF-100741HT2834408EDN1, endothelin 1CCTGGCGGCT[T/G]CGCCGGTCCASTGLLG456u2WIAF-10075HT2834585EDN1, endothelin 1CAGACCGTGA[A/G]AATAGATGCCSAGEEG456a3WIAF-10507HT2834861EDN1, endothelin 1TGAAAGGCAA[T/G]CCCTCCAGAGMTGKNG4565u1WIAF-14041HT28561320ATP1G1, ATPase,CGAGGCTGCT[G/A]TTACGGCTCASGALLNa+/K+transporting, gamma1 polypeptideG4565u2WIAF-14062HT28561216ATP1G1, ATPase,CAGTGACGGG[G/A]ACAAAGGTCTMGADNNa+/K+transporting, gamma1 polypeptideG4565u3WIAF-14063HT28561315ATP1G1, ATPase,ACCGCCGAGG[C/A]TGCTGTTACGMCALMNa+/K+transporting, gamma1 polypeptideG4565u4WIAF-14064HT28561531ATP1G1, ATPase,TTTCCCCAGG[T/C]GAATGGGCTGNTC*RNa+/K+transporting, gamma1 polypeptideG4568u1WIAF-14212HT0082717AMFR, autocrineTGCCTCATGC[A/G]TACGTCCCACMAGIVmotility factorreceptorG457a1WIAF-10489HT2903321SELL, selectin LACAAATCTCT[C/T]ACTGAAGAAGSCTLL(lymphocyteadhesionmolecule 1)G457a2WIAF-10490HT2903577SELL, selectin LCCAGTGTCAG[T/C]TTGTGATTCAMTCFL(lymphocyteadhesionmolecule 1)G457a3WIAF-10491HT2903601SELL, selectin LTGAGCCTTTG[G/C]AGGCCCCAGAMGCEQ(lymphocyteadhesionmolecule 1)G457a4WIAF-10492HT2903637SELL, selectin LCTGTACTCAC[C/T]CTTTGGGAAAMCTPS(lymphocyteadhesionmolecule 1)G4573u1WIAF-13568HT28320943NCAT2, mannosylCGGACAACCT[G/T]ACCCTGCGCTSGTLL(alpha-1,6-)-glycoprotein beta-1,2-N-acetylgluco-saminyltransferaseG4574u1WIAF-13805HT0198163beta-1,4 N-CGGCCTCCGG[C/G]TACCTCTTGCMCGLVacetylgalacto-saminyltransferaseG4574u2WIAF-13806HT0198415beta-1,4 N-TGCCACAAGA[G/A]AGCAGGAGTTMGAEKacetylgalacto-saminyltransferaseG4574u3WIAF-13807HT0196726beta-1,4 N-AACTACAACT[G/T]GTCACTTACASGTLLacetylgalacto-saminyltransferaseG4574u4WIAF-13836HT0198559beta-1,4 N-AGGGCTGAGC[C/A]TTCAGGCAGCMCALIacetylgalacto-saminyltransferaseG4575u1WIAF-13626HT03411251GCNT1, glucosaminylAGTATGATCT[A/G]TCTGACATGCSAGLL(N-acetyl)transferase 1,core 2 (beta-1,6-N-acetylgluco-saminyltransferase)G4577u1WIAF-13971HT14951268SIAT1, sialyl-ATTTCTTTAA[C/T]AACTACAAGASCTNNtransferase 1(beta-galactosidealpha-2, 6-sialytransferase)G458u1WIAF-10063HT29681464ALB, albuminGTGCAGAAGA[C/A]TATCTATCCGMCADEG458u2WIAF-10089HT29681470ALB, albuminAAGACTATCT[A/C]TCCGTGGTCCSACLLG458u3WIAF-10091HT29681707ALB, albuminTTGTTGAGCT[C/T]GTGAAACACASCTLLG458a4WIAF-10504HT2968889ALB, albuminCAGGGCGGAC[C/T]TTGCCAAGTAMCTLFG458a5WIAF-10508HT29681475ALB, albuminTATCTATCCG[T/A]GGTCCTGAACMTAVEG458a6WIAF-12091HT29681330ALB, albuminCCAGAATGCG[C/T]TATTAGTTCGSCTLLG458a7WIAF-12092HT29681408ALB, albuminCCTAGGAAAA[G/a]TGGGCAGCAAMGaVMG4592u1WIAF-14126HT2128985branched-chain ketoACCAGCCCTT[T/C]CTCATCGAGGSTCFFacid dehydrogenaseE1, alpha poly-peptideG4593u1WIAF-13574HT973731743BARD1, ERCA1GCTAGCCACT[G/C]CTCAGTAATGMGCCSassociated RINGdomain 1G4593u2WIAF-13592HT973731167BARD1, ERCA1TGTTCTTCAC[C/T]ACCTTCATGCMCTPLassociated RINGdomain 1G4593u3WIAF-13593HT973731591BARD1, ERCA1AGAATGGGCA[C/TI GTGGATATAGSCTHHassociated RINGdomain 1G4593u4WIAF-13594HT973732030BARD1, ERCA1AAAGTATGAA[A/G]TTCCTGAAGGMAGIVassociated RINGdomain 1G4593u5WIAF-13595HT973732006BARD1, ERCA1AAGAAAAGTA[T/C]GTGAACAGGAMTCCRassociated RINGdomain 1G4599u1WIAF-13920HT42731803CDH13, cadherin 13,TCGTACCCGA[C/T]GTCTCCTACGSCTDDH-cadherin(heart)G4614u1WIAF-13733HT483591S100A3, S100AGGATGGCCA[G/A]GCCTCTGGAGMGARKcalcium-bindingprotein A3G4614u2WIAF-13734HT4835203S100A3, S100TGCTGCAGAA[G/A]GAGCTGGCCASGAKKcalcium-bindingprotein A3G4614u3WIAF-13769HT4835344S100A3, S100TCTACTGCCA[C/T]GAGTACTTCASCTHHcalcium-bindingprotein A3G462u1WIAF-10134HT4753600PDGFA, platelet-ACGGGGTCCA[C/T]GCCACTAAGCSCTHHderived growthfactor alphapolypeptideG4627u1WIAF-14042HT0771186ANX6, annexin VIGGAGGCCATA[C/T]TGGACATAATSCTLL(p68)G4627u2WIAF-14043HT07711664ANX6, annexin VICAGACACACC[T/C]AGTGGAGACASTCPP(p68)G4627u3WIAF-14067HT07711498ANX6, annexin VIAAGGAGCACT[A/G]TCACAAGTCCMAGYC(p68)G4644u1WIAF-13801HT17361990CPS1, carbamoyl-TGGTGGAGAA[G/A]TCAGTGACAGSGAKKphosphatesynthetase 1,mitochondrialG4644u2WIAF-13802HT17361866CPS1, carbamoyl-ATTGGCTACC[C/T]AGTGATGATCMCTPLphosphatesynthetase 1,mitochondrialG4644u3WIAF-13803HT17361993CPS1, carbamoyl-TGGAGAAGTC[A/C]GTGACAGGTTSACSSphosphatesynthetase 1,mitochondrialG4644u4WIAF-13804HT17361860CPS1, carbamoyl-GACACCATTG[G/A]CTACCCAGTGMGAGDphosphatesynthetase 1,mitochondrialG4644u5WIAF-13831HT17361087CPS1, carbamoyl-AGCCTGTTTT[C/T]AATATCACAAMGTLFphosphatesynthetase 1,mitochondrialG4644u6WIAF-13835HT17361958CPS1, carbamoyl-CACAAAGGCC[T/C]TTGCTATGACMTCFLphosphatesynthetase 1,mitochondrialG4644u7WIAF-13855HT17361332CPS1, carbamoyl-AAAGCTACCA[C/A]CATTACATCAMCATNphosphatesynthetase 1,mitochondrialG4659u1WIAF-14143HT11831830catenin, alphaGTGCCAACGT[T/C]CCTCAACCGTSTCVVG466u1WIAF-10164U009682403SREBF1, sterolAGCAGTGCCC[C/A]CCAGGCCTGCMGARHregulatory elementbinding transcrip-tion factor 1G4662u1WIAF-13710HT21422183CTNNB1, cateninTTTTGTTCCG[A/C]ATGTCTGAGGSACRR(cadherinassociatedprotein), beta 1(88 kD)G467a1WIAF-13304X72861827ADRB3, adrenergic,GGCCATCGCC[T/C]GGACTCCGAGMTCWRbeta-3-,receptorG467a2WIAF-13305X72861832ADRB3, adrenergic,TCGCCTGGAC[T/A]CCGAGACTCCSTATTbeta-3-,receptorG467a3WIAF-13306X72861870ADRB3, adrenergic,TTCGTCACTT[C/T]CCTGGCCGCAMCTSLbeta-3-,receptorG467a4WIAF-13307X728611761ADRB3, adrenergic,TGCGCCGCCG[C/T]CCGCCCCGCCMCTAVbeta-3-,receptorG467a5WIAF-13305X728611899ADRB3, adrenergic,TCTGTTGATC[A/C]GAACCTGTCG—AC——beta-3-,receptorG4671u1WIAF-13956HT1925161NDUFB7, NADHTGGTGGCCAC[A/C]CAGCAGGACASAGTTdehydrogenase(ubiquinone) 1beta subcomplex, 7(18 kD, B18)G4673u1WIAF-13889HT01911349CDC25A, cellTCTCGGGCCA[G/C]CCCCAAAGACMGCSTdivision cycle 25AG4674u1WIAF-13821HT1393261CDC25B, cellACCACCTCCC[C/T]GGGCTCGGCASCTAAdivision cycle 25BG4674u2WIAF-13822HT13931297CDC25B, cellGATGGTCCCC[C/T]TATTCACGGGSCTLLdivision cycle 25BG4674u3WIAF-13823HT13931083CDC25B, cellATAACCCCAG[C/A]CGGAGCCTGASGARRdivision cycle 25BG4674u4WIAF-13827HT13931446CDC25B, cellAGAGCCCCAT[C/T]CCCCCCTGTASCTIIdivision cycle 25BG468a1WIAF-13309L37019192ASIP, agoutiAAATCCAAAC[C/A]CATCGGCACAMCAPQ(mouse)-signalingproteinG4691u1WIAF-13753HT97602179CMKBR9, chemokineTATAGCCTGA[T/A]TTTTGTGTTGMTAIN(C-C motif)receptor 9G4691u2WIAF-13754HT97602134CMKBR9, chemokineAAGGATGCAG[T/C]GGTCTCCTTTMTCVA(C-C motif)receptor 9G4691u3WIAF-13755HT97602193CMKBR9, chemokineTGTGTTGGGC[C/T]TCAGCGGGAAMCTLF(C-C motif)receptor 9G4691u4WIAF-13756HT97602770CMKBR9, chemokineAAAATAGCTC[C/T]AGCCTTGGTGMCTAV(C-C motif)receptor 9G4691u5WIAF-13759HT976021130CMKBR9, chemokineTCTCAGAACT[A/C]CCCTAACAAGMACYS(C-C motif)receptor 9G4691u6WIAF-13796HT97602482CMKBR9, chemokineAGGCTGAGGA[C/A]CCCGGCCAAGMCATN(C-C motif)receptor 9G4691u7WIAF-13797HT97602259CMKBR9, chemokineGATGGTTGAG[A/G]TCTATCTGCTMAGIV(C-C motif)receptor 9G4691u8WIAF-13798HT97602434CMKBR9, chemokineATGACCCTGG[A/G]CAAGTACCTGMAGDG(C-C motif)receptor 9G4691u9WIAF-13799HT97602755CMKBR9, chemokineCAGGGCCGGG[C/T]TTTAAAAATAMCTAV(C-C motif)receptor 9G4699u1WIAF-14040HT42771426BAAT, bile acidTTCCAGATGT[C/T]ACCAGTCAACSGTVVCoenzyme A: aminoacid N-acyl-transferase(glycine N-choloyltransferase)G4726u1WIAF-14128HT486141606AOC3, amineTCCACCCCAG[T/C]GGGGCCATAGSTCSSoxidase, coppercontaining 3(vascular adhesionprotein 1)G4726u2WIAF-14129HT486142242AOC3, amineTTCCTAACAC[A/G]GTGACTGTGGSAGTToxidase, coppercontaining 3(vascular adhesion.protein 1)G4726u3WIAF-14141HT48614659AOC3, amineCCTGCCCTAT[C/T]ACCGACGCCCMCTHYoxidase, coppercontaining 3(vascular adhesionprotein 1)G4744u1WIAF-13683HT2599564CTH, cystathionaseATATTGTCCA[T/C]AAGCATGGAGSTCHH(cystathioninegamma-lyase)G4748u1WIAF-14144HT1061242CYBA, cytochromeGGGACAGAAG[C/T]ACATGACCGCMCTHYb-245, alphapolypeptideG4748u2WIAF-14145HT1061265CYBA, cytochromeTGGTGAAGCT[G/C]TTCGGGCCCTSGCLLb-245, alphapolypeptideG4750u1WIAF-14116HT48417156CYB5, cytochromeTGAAGTACTA[C/T]ACCCTAGAGGSCTYYb-5G4751u1WIAF-13770HT1285495UQCRC2, ubiquinol-AGAATTTCGT[C/A]GTTGGGAAGTMCARScytochrome creductase coreprotein IIG4788u1WIAF-13931HT282491864DSC3, desmocollin 3CTGTTGATCC[T/C]GATGAACCTGSTCPPG4788u2WIAF-13933HT282492000DSC3, desmocollin 3TGGATTTCAA[G/T]AATATACCATNGTE*G4788u3WIAF-13945HT282492524DSC3, desmocollin 3ACACTTACTC[G/A]GAGTGGCACASGASSG479u1WIAF-12567U36310894GPD2, glycerol-3-GGGAAAGTCC[A/G]TGTGACCGGCMAGHRphosphatedehydrogenase 2(mitochondrial)G479u2WIAF-12574U363101657GPD2, glycerol-3-CTGGCAAAAG[G/T]TGGCCTATTGMGTRSphosphatedehydrogenase 2(mitochondrial)G479u3WIAF-12575U363101131GPD2, glycerol-3-GTTATTTTCT[T/C]CTTACCCTGGMTCFSphosphatedehydrogenase 2(mitochondrial)G480u1WIAF-12175HT336250GRB2, growthAATGAAACCA[C/A]ATCCGTGGTTMCAHNfactor receptor-hound protein 2G4819u1WIAF-13985HT975761804EYA1, eyes absentCCCTGCACCA[T/C]GCCTTGGAACSTCHH(Drosophila)homolog 1G482u1WIAF-12181J045011186GYS1, glycogenCTGACGTCTT[T/C]CTGGAGGCATSTCFFsynthase 1(muscle)G482u2WIAF-12195J045011406GYS1, glycogenCCTTCCCGAC[A/G]TGAACAAGATMAGMVsynthase 1(muscle)G4827u1WIAF-14177HT9747768elongationCGAGCTGGCC[A/G]TCATGGTCATMAGHRG483a1WIAF-12113HT43411850GSY2TTACCAGCAT[C/T]CCAGACACCTMGTASG483u2WIAF-12148HT43411130GSY2GTTTTTCATT[A/C]TCCCTGCCAAMACMLG483u3WIAF-12149HT4341880GSY2CCTTCAATGT[T/C]AAGAAATTTTSTGVVG483u4WIAF-12150HT43411115GSY2CATCACACTC[C/A]TGGTGTTTTTMGAVMG483u5WIAF-12156HT43411230GSY2GAAAACTTTG[C/A]AAAAAAACTCMGAGEG483u6WIAF-12159HT43412033GSY2TCACAGATAC[G/A]ATGACGAACAMGADNG483u7WIAF-12160HT43411836GSY2TACTTACGCA[G/C]ATATTACCACMGCRTG483u8WIAF-12161HT43411678GSY2CTTACGGTAT[T/C]TACATCGTTGSTCIIG483u9WIAF-12177HT4341790GSY2GCGCTCACGT[G/C]TTCACCACGGSGCVVG483u10WIAF-12188HT43411728GSY2TCCAATCACC[T/C]GACTAAGTTTMTCLPG484u1WIAF-12151HT5111487GSY3CATCAAAGTG[A/G]TTGGCAATGGMAGIVG484u2WIAF-12187HT51111141GSY3AACCCCGCAA[C/T]AAATCCCAGANCTQ*G489u1WIAF-12152HT26071181IRS1, insulinAAGAAGTGGC[G/A]GCACAAGTCGMGARQreceptorsubstrate 1G489u2WIAF-12184HT26071031IRS1, insulinATGGCCAGCC[C/T]TCCGGAGAGCMCTPLreceptorsubstrate 1G492a1WIAF-13345L08603307MC4R, melanocortinAGAAACCATT[A/C]TCATCACCCTMAGIV4 receptorG493u1WIAF-12154X67594346MC1R, melanocortinCGCGCTGGTG[G/T]TGGCCACCATMGTVL1 receptor(alpha melanocytestimulatinghormone receptor)G493u2WIAF-12167X67594646MC1R, melanocortinGACCCTGCCG[C/T]GGGCGCGGCAMCTRW1 receptor(alpha melanocytestimulatinghormone receptor)G493u3WIAF-12170X675941110MC1R, melanocortinAGGTCCTGAC[A/G]TGCTCCTGGTSAGTT1 receptor(alpha melanocytestimulatinghormone receptor)G493u4WIAF-12186X67594442MC1R, melanocortinCGGGAGCAAC[C/T]TGCTCGAGACMGTVL1 receptor(alpha melanocytestimulatinghormone receptor)G498u1WIAF-11809J041271305CYP19, cytochromeCTTATAGGTA[C/T]TTTCAGCCATSCTYYP450, subfamilyXIX (aromatizationof androgens)G498u2WIAF-11810J041271377CYP19, cytochromeTGAAAGCCAT[C/T]CTCGTTACACSCTIIP450, subfamilyXIX (aromatizationof androgens)G498u3WIAF-11811J041271406CYP19, cytochromeCGATTCCACG[T/C]GAAGACATTGMTCVAP450, subfamilyXIX (aromatizationof androgens)G498u4WIAF-11838J041271055CYP19, cytochromeATTGCTGACA[G/A]AGACATAAAGMGARKP450, subfamilyXIX (aromatizationof androgens)G498u5WIAF-11800J041271001CYP19, cytochromeATTGCAAAGC[A/C]CCCTAATGTTMAGHRP450, subfamilyXIX (aromatizationof androgens)G499u1WIAF-11785HT14392142ESR1, estrogenTCCCTGCCAC[A/G]GTCTGAGAGCSAGTTreceptor 1G499u2WIAF-11801HT1439443ESR1, estrogenCCCCTGAACC[G/A]TCCGCAGCTCMGARHreceptor 1G500u1WIAF-11803X99101793ESR1, estrogenCATGATCAGC]T/C]GGGCCAAGAAMTCWRreceptor 1G500u2WIAF-11816X99101489ESR1, estrogenGGAAGTGTTA[C/T]GAAGTGGGAASCTYYreceptor 1G500u3WIAF-11817X99101474ESR1, estrogenAGGCCTGCCG[A/G]CTTCGGAAGTSAGRRreceptor 1G505u1WIAF-11824HT11131063PRLR, prolactinGCTTTCAAGC[C/A]CTATAGCATCMGAGDreceptorG505u2WIAF-11827HT11132083PRLR, prolactinGCAACATCAA[C/A]CAAGTCCAGGMGASNreceptorG505u3WIAF-11787HT1113582PRLR, prolactinGAGGACATAC[A/G]TCATGATGGTMAGIVreceptorG505u4WIAF-11802HT1113792PRLR, prolactinCCTGTATGAA[A/C]TTCGATTAAAMACILreceptorG509u1WIAF-11789M32313378SRD5A1, steroid-S-CACTGTTCGC[A/G]TGTACAATGGSAGAAalpha-reductase,alpha polypeptide 1(3-oxo-5 alpha-steroid delta 4-dehydrogenasealpha 1)G510a1WIAF-13348U17280582STAR, steroidogenicCCAATGTCAA[C/A]GAGATCAAGGSGAKKacute regulatoryproteinG52u1WIAF-10224HT04881139inhibin, beta BCCAACATGAT[T/C]GTGGAGGAGTSTCIIG520u1WIAF-13507D31770517ACVR2, activin ACTTATTTTCC[G/A]GAGATGGAAGSGAPPreceptor, typeIIG520u2WIAF-13532D317701177ACVR2, activin ACAGCTTGCAT[T/G]GCTGACTTTGMTGIMreceptor, typeIIG520u3WIAF-13533D317701189ACVR2, activin ACTGACTTTGG[G/C]TTGGCCTTAASGCGGreceptor, typeIIG520u4WIAF-13534D317701024ACVR2, activin ATCTCTTCGAA[T/C]GAACTGTGTCSTCNNreceptor, typeIIG523u1WIAF-12155HT4996538OXTR, oxytocinTGACGGGGAA[C/T]GCGTGTGTGCSCTNNreceptorG523u2WIAF-12180HT49961057OXTR, oxytocinTCTGGCAGAA[C/T]TTGCGGCTCASCTNNreceptorG524a1WIAF-13349L05144190PCK1, phosphoenol-TGGACAGCCT[G/A]CCCCAGGCAGSGALLpyruvate carboxy-kinase 1 (soluble)G528u1WIAF-11831V00572988PGK1, phospho-AAGCCACTGT[G/C]GCTTCTGGCASGCVVglycerate kinase 1G53u1WIAF-10307HT0508723DNA repair proteinCCAGCGACCC[G/A]GCAGGACCTASGAPPXRCC1G53u2WIAF-10308HT0508746DNA repair proteinTATGCAGCTG[C/T[TACCCTCCAGMCTAVXRCC1G53u3WIAF-10309HT05081884DNA repair proteinGGGATCCCAG[C/T]TTTGAGGAGGSCTSSXRCC1G53u4WIAF-10362HT0508425DNA repair proteinAACCCCAACC[G/A]CGTTCGCATGMGARHXRCC1G534a1WIAF-13311U282811284SCTR, secretinGCTTCCTCAA[T/C]GGGGAGGTGCSTCNNreceptorG534a2WIAF-13311U282811404SCTR, secretinAGCACAGCCA[G/A]GGCACCTGCASGAQQreceptorG535u1WIAF-12157HT50011158SHC1ATGCTCTTCG[G/C]GTGCCTCCACSGCRRG535u2WIAF-12196HT5001774SHC1ATGAGGAGGA[G/A]GAAGAGCCACSGAEEG536u1WIAF-13923M20747535SLC2A4, soluteGCCTGCCCAA[C/T]GCTGCTGCCTSCTNNcarrier family 2(facilitatedglucosetransporter),member 4G538u1WIAF-11812M55531438SLC2A5, soluteGCAGCAGAGT[C/T]GCCACATCATSCTVVcarrier family 2(facilitatedglucosetransporter),member 5G538u2WIAF-11813M55531124SLC2A5, soluteGACGCTTGTG[C/T]TTGCCCTGGCMCTLFcarrier family 2(facilitatedglucosetransporter)member 5G538u3WIAF-11791M55531816SLC2A5, soluteACAGGGAGGT[C/A]GCCGAGATCCSGAVVcarrier family 2(facilitatedglucosetransporter),member 5G539u1WIAF-12158K03195224Human (HepG2) glu-TCATGCTGCC[T/C]GTCCGAGGACSTCAAcose transportergene mRNA,complete cds.G539u2WIAF-12191K031951244Human (HepG2) glu-CCATCGCGCT[A/C]CCACTCCTGGSAGLLcose transportergene mRNA,complete cds.G540a1WIAF-12114HT9601100SOS1AGTGAAGATC[A/C]ACAACACAAGMACQPG540u2WIAF-12165HT950933SOS1ATGATCGTTT[C/T]CTTAGTCAGTSCTFFG540u3WIAF-12178HT960399SOS1TACTACCAGT[C/T]TTACAATACASCTVVG540u4WIAF-12193HT960195SOS1CTCAGCCCCG[A/C]AGTCCTTCAGSACRRG540u5WIAF-12197HT9601329SOS1GTTGTAATCA[A/C]TTTATAATCCSAGEEG540u6WIAF-12198HT9601339SOS1ATTTATAATC[C/A]AACCAACTCTMGAEKG543a1WIAF-13312J003061373SST, somatostatinAACCAGGAAC[T/C]CCCCAACTACMTCLPG543a2WIAF-13313J003061603SST, somatostatinACTATTGTCC[A/G]TATCACACCT—AG——G544u1WIAF-12174HT27489982SUR, sulfonylureaCCATTGACAT[G/C]GCCACGGAAAMGCMIreceptor(hyperinsulinemia)G546u1WIAF-13618HT225426TKT, transketolaseGCTACATTGC[C/T]CAGCAGAACASCTAA(Wernicke Korsakoffsyndrome)G551u1WIAF-11709HT1118257TNFRSF1B, tumorGCTGCAGCAA[A/G]TGCTCGCCGGSAGKKnecrosis factorreceptor super-family, member 1BG551u2WIAF-11710HT1118449TNFRSF1B, tumorTCTGCACCTG[C/T]AGGCCCGGCTSCTCCnecrosis factorreceptor super-family, member 1BG551u3WIAF-11719HT1118648TNFRSF1B, tumorGATCTGTAAC[G/A]TGGTGGCCATMGAVMnecrosis factorreceptor super-family, member 1BG551u4WIAF-11673HT1118676TNFRSF1B, tumorAATGCAACCA[T/C]CCATGCAGTCMTGMRnecrosis factorreceptor super-family, member 1BG551u5WIAF-11720HT1118808TNFRSF1B, tumorCCAAGCACCT[C/T]CTTCCTGCTCMCTSFnecrosis factorreceptor super-family, member 1BG552u1WIAF-12229HT5108384TRAP3GCCGCTGCCC[G/AICTCATGCTGASGAPPG555u1WIAF-12211U94592478UCP2, uncouplingCGCGCTACAG[T/C]CAGCGCCCAGMTCVAprotein 2(mitochondrial,proton carrier)G556u1WIAF-11804AF001787480UCP2, uncouplingTCGGCCTCTA[T/C]GACTCCCTCASTCYYprotein 2(mitochondrial,proton carrier)G556u2WIAF-11805AF001787563UCP2, uncouplingTGCACCACAG[G/A]AGCCATGGCGMGAGEprotein 2(mitochondrial,proton carrier)G556u3WIAF-11823AF0017871113UCP2, uncouplingTACGCCAATC[A/C]CCCTTTTGAASAGSSprotein 2(mitochondrial,proton carrier)G556u4WIAF-11782AF001787386UCP2, uncouplingATCCTGACCA[T/C]GGTGCGGACTMTCMTprotein 2(mitochondrial,proton carrier)G561a1WIAF-12111HT11762430IDE, insulin-ACTCTGGCAT[C/A]GAGATATACTSCAIIdegrading enzymeG561u2WIAF-12222HT11763099IDE, insulin-ATATTAACTT[C/G]ATGGCTGCAAMCGFLdegrading enzymeGSG2u1WIAF-12223HT27503680tumor necrosisCCTGTAGTGA[A/C]TCGGCCGCTGMACNTfactor receptortype 1 associatedproteinG562u2WIAF-12224HT27503900tumor necrosisCGCTCCAGCG[C/A]CTGGTGGAGGSCARRfactor receptortype 1 associatedproteinG573u1WIAF-12199HT28094469SSTR1, somatostatinGGACCGCTAC[G/C]TGGCCGTGGTMGCVLreceptor 1G573u2WIAF-12208HT28094480SSTR1, somatostatinTGGCCCTGGT[G/A]CATCCCATCASGAVVreceptor 1G573u3WIAF-12209HT28094879SSTR1, somatostatinTGCAGCTGGT[T/C]AACGTGTTTGSTCVVreceptor 1G574u1WIAF-11822HT40581054SSTR5, somatostatinGCCACGGAGC[C/T]GCGTCCAGACMCTPLreceptor 5G575u1WIAF-12200HT2809599SSTR3, somatostatinACGTGTCGGC[C/A]GGCCCAAGCCSGAAAreceptor 3G575u2WIAF-12217HT28095453SSTR3, somatostatinCCACCCGGTC[G/A]GCCCGCTGGCSGASSreceptor 3G585u1WIAF-12204HT10221133PYGL,AGCTGAATGA[T/C]ACTCACCCTCSTCDDphosphorylase,glycogen;liver (Hersdisease, glycogenstorage diseasetype VI)G585u2WIAF-12205HT10221988PYGL,AGCTGATCAC[T/C[TCAGTGGCAGSTCTTphosphorylase,glycogen;liver (Hersdisease, glycogenstorage diseasetype VI)G585u3WIAF-12225HT10221883PYGL,TGTACAACCC[C/T]ATTAAGAAAGSCTRRphosphorylase,glycogen;liver (Hersdisease, glycogenstorage diseasetype VI)G585u4WIAF-12226HT10222037PYGL,AAGCAAGTTG[A/G]AAGTCATCTTMAGKEphosphorylase,glycogen;liver (Hersdisease, glycogenstorage diseasetype VI)G585u5WIAF-12231HT10221387PYGL,GATGTGGACC[C/G]TCTGAGAAGGMCGPRphosphorylase,glycogen;liver (Hersdisease, glycogenstorage diseasetype VI)G586a1WIAF-12112HT18782410PFKM,CCGGGGAAGC[T/G]GCCGTCTAAASTGAAphosphofructo-kinase, muscleG586u2WIAF-12206HT1878375PFKM,GGACCACTCC[G/A]AGCTCCCTACMGARQphosphofructo-kinase, muscleG586u3WIAF-12207HT1878322PFKM,TGCGAGGCAC[C/A]GTGATTGGAASGATTphosphofructo-kinase, muscleG586u4WIAF-12227HT1878334PFKM,TGATTGGAAG[T/C]GCCCGGTGCASTCSSphosphofructo-kinase, muscleG586u5WIAF-12228HT1878408PFKM,CGTCGGATCA[C/G]CAATCTCTGTMCGTSphosphofructo-kinase, muscleG586u6WIAF-12235HT1878717PFKM,CACTGTGGAT[A/G]CCTGGCCCTTMAGYCphosphofructo-kinase, muscleG587u1WIAF-12615HT3847366phosphofructo-ATGCCAGCCT[T/C]ACAGGTGCCASTCLLkinase, liverG589u1WIAF-12210L392111327CPT1A, carnitineCAGCGTTCTT[C/T]GTGACGTTAGSCTFFpalmitoyl-transferase I,liverG589u2WIAF-12215L392112080CPT1A, carnitineAATATCTCGC[T/C]GTGGAGTCCCSTCAApalmitoyl-transferase I,liverG589u3WIAF-12216L39211679CPT1A, carnitineACTTCAAACG[C/T]ATGACAGCACSGTRRpalmitoyl-transferase I,liverG589u4WIAF-12218L392111844CPT1A, carnitineCCTCACATAC[G/C]AGGCCTCCATMGCEQpalmitoyl-transferase I,liverG592u1WIAF-11814X965861089NSMAF, neutralTCCGGGATCT[C/T]AGTAAGCCAGSCTLLsphingomyelinase(N-SMase)activationassociatedfactorG592u2WIAF-11815X965862020NSMAF, neutralAAGTATATCA[T/G]TTTCAAATATMTGFVsphingomyelinase(N-SMase)activationassociatedfactorG592u3WIAF-11834X965861673NSMAF, neutralGTAGCCATGC[T/C]TACGCAAATCMTCLPsphingomyelinase(N-SMase)activationassociatedfactorG592u4WIAF-11784X965861889NSMAF, neutralCACGAGCACT[A/G]TAAAATCCACMACYCsphingomyelinase(N-SMase)activationassociatedfactorG592u5WIAF-11798X965861677NSMAF, neutralCCATGCTTAC[G/A]CAAATCTTGGSGATTsphingomyelinase(N-SMase)activationassociatedfactorG592u6WIAF-11799X965862429NSMAF, neutralTGCCATTCAG[G/C]GATTCTATGTMGCGAsphingomyelinase(N-SMase)activationassociatedfactorG592a7WIAF-13156X965862205NSMAF, neutralATTCTGCATC[G/A]TGGGACTCTASGASSsphingomyelinase(N-SMase)activationassociatedfactorGS94u1WIAF-10065HT39211153annexin V, alt.TTGTGAAATC[T/A]ATTCGAAGTASTASStranscript 2G594u2WIAF-10098HT3921567annexin V, alt.CGAAGTAATG[C/T]TCACCGCCAGMCTAVtranscript 2G594u3WIAF-10099HT3921774annexin V, alt.ATTGCTTCAA[G/C]CACACCTCAAMGCRTtranscript 2G594a4WIAF-10505HT3921424annexin V, alt.GAGTAGTCGC[C/T]ATGCCACACG—CT——transcript 2G594a5WIAF-13123HT3921571annexin V, alt.GTAATGCTCA[G/C]CGCCAGGAAAMGCQHtranscript 2G595u1WIAF-12203HT279831008NRIP1, nuclearTGCAACATTA[C/T]AGGCTGTTGCNCTQ*receptorinteractingprotein 1G595u2WIAF-12220HT27983785NRIP1, nuclearCCCTCAGTCA[T/C]GATTCTTTAASTCHHreceptorinteractingprotein 1G595u3WIAF-12232HT279831231NRP1, nuclearGTTGGCAGTT[A/T]CCAGCTCCCAMATYFreceptorinteractingprotein 1G595u4WIAF-12261HT279832048NRIP1, nuclearGCAGTACTCA[G/A]TCTCAAAACCSGAQQreceptorinteractingprotein 1C595u5WIAF-12274HT279832376NRIP1, nuclearTCCTCAACCA[G/T]GGCTTTCTGGMGTGWreceptorinteractingprotein 1G595u6WIAF-12275HT279833498NRIP1, nuclearACTATATTAC[A/G]TGCTTCAAAAMAGMVreceptorinteractingprotein 1G595u7WIAF-12276HT279833671NRIP1, nuclearACAATAGCCA[T/C]ATGGGAAATASTCHHreceptorinteractingprotein 1G595u8WIAF-12294HT279832020NRIP1, nuclearATCAAATGGA[A/G]TTCCCCACCAMAGNSreceptorinteractingprotein 1G595u9WIAF-12295HT279833140NRIP1, nuclearATTTGTCCCC[G/A]CACAGAAGTASGAPPreceptorinteractingprotein 1G596u1WIAF-10144HT35373299PC, pyruvateTGCGGTCCAT[C/T]TTGGTCAAGGSCTIIcarboxylaseG596u2WIAF-10158HT35372662PC, pyruvateACCAACCTCC[A/C]CTTCCAGGCCMACHPcarboxylaseG596u3WIAF-10159HT35372156PC, pyruvateCCATCTCATA[C/A]ACGGGCGACGNCAY*carboxylaseG598a1WIAF-12118HT486665585HERC1, hectGGGACCTATG[C/T]TGATAAACTGMCTAV(homologous to theE6 AP (UBE3A)carboxyl terminus)domain and RCC1(CHC1)-like domain(RLD) 1G598u2WIAF-12236HT486664456HERC1, hectCCTGTTAATA[T/C]TAGGAGTAAGSTCLL(homologous to theE6 AP (UBE3A)carboxyl terminus)domain and RCC1(CHC1)-like domain(RLD) 1G598u3WIAF-12237HT486656356HERC1, hectGGTAATGAAG[G/T]CACGTGTGTTMGTGV(homologous to theE6 AP (UBE3A)carboxyl terminus)domain and RCC1(CHC1)-like domain(RLD) 1G598u4WIAF-12240HT4866612219HERC1, hectGTACCTTTGT[C/T]ATCCAGGCCASCTVV(homologous to theE6 AP (UBE3A)carboxyl terminus)domain and RCC1(CHC1)-like domain(RLD) 1G598u5WIAF-12241HT4866612480HERC1, hectCCAGGCAGAT[C/G]GAGGCCTTACMCGIM(homologous to theE6 AP (UBE3A)carboxyl terminus)domain and RCC1(CHC1)-like domain(RLD) 1G598u6WIAF-12244HT4866612975HERC1, hectGAGTAATCAT[T/A]GAAGATGTGGSTAII(homologous to theE6 AP (UBE3A)carboxyl terminus)domain and RCC1(CHC1)-like domain(RLD) 1G598u7WIAF-12245HT486661424HERC1, hectTCCAATAATC[A/T]GTCAACTTTAMATQL(homologous to theE6 AP (UBE3A)carboxyl terminus)domain and RCC1(CHC1)-like domain(RLD) 1G598u8WIAF-12250HT486665854HERC1, hectTTCAAAAGCA[A/T]TTCAATCAAAMATIF(homologous to theE6 AP (UBE3A)carboxyl terminus)domain and RCC1(CHC1)-like domain(RLD) 1G598u9WIAF-12251HT486666754HERC1, hectTATTCAGCTC[G/A]TCCGTATCCTMGAVI(homologous to theE6 AP (UBE3A)carboxyl terminus)domain and RCC1(CHC1)-like domain(RLD) 1G598u10WIAF-12252HT486667535HERC1, hectATCTTTACCT[C/T]GGTCCTATGASCTLL(homologous to theE6 AP (UBE3A)carboxyl terminus)domain and RCC1(CHC1)-like domain(RLD) 1G598u11WIAF-12254HT486669189HERC1, hectGTGGAAATCC[A/G]TACTACCTGTSAGPP(homologous to theE6 AP (UBE3A)carboxyl terminus)domain and RCC1(CHC1)-like domain(RLD) 1G598u12WIAF-12255HT4866610119HERC1, hectTTGTGGCATT[G/C]CTAGCAGACAMGCLF(homologous to theE6 AP (UBE3A)carboxyl terminus)domain and RCC1(CHC1)-like domain(RLD) 1G598u13WIAF-12257HT4866611109HERC1, hectATCCATCTAT[T/C]GTAAATGGCASTCII(homologous to theE6 AP (UBE3A)carboxyl terminus)domain and RCC1(CHC1)-like domain(RLD) 1G598u14WIAF-12258HT4866613513HERC1, hectCTATGGACCT[C/T]AGATAACTGTNCTQ*(homologous to theE6 AP (UBE3A)carboxyl terminus)domain and RCC1(CHC1)-like domain(RLD) 1G5958u15WIAF-12259HT4866613697HERC1, hectACCATCACAG[A/C]GATGTGCCAGMAGEG(homologous to theE6 AP (UBE3A)carboxyl terminus)domain and RCC1(CHC1)-like domain(RLD) 1G598u16WIAF-12255HT486661098HERC1, hectCCCTTTACGA[G/A]GCAGCATTATSGAEE(homologous to theE6 AP (UDE3A)carboxyl terminus)domain and RCC1(CHC1)-like domain(RLD) 1G598u17WIAF-12272HT486666079HERC1, hectTATGTGGGAG[A/G]CACCCATTGCMAGTA(homologous to theE6 AP (UHE3A)carboxyl terminus)domain and RCC1(CHC1)-like domain(RLD) 1G598u18WIAF-12273HT486669551HERC1, hectAAGAGCTCCT[C/T]TGGGAGAATAMCTSF(homologous to theE6 AP (UBE3A)carboxyl terminus)domain and RCC1(CHC1)-like domain(RLD) 1G598u19WIAF-12277HT48666666HERC1, hectGTCTTTGCAA[C/T]GATGTCATTCSCTNN(homologous to theE6 AP (UBE3A)carboxyl terminus)domain and RCC1(CHC1)-like domain(RLD) 1G598u20WIAF-12278HT48666882HERC1, hectGCTCATTGCG[A/G]TATCTTCTTGSAGRR(homologous to theE6 AP (UBE3A)carboxyl terminus)domain and RCC1(CHC1)-like domain(RLD) 1G598u21WIAF-12279HT48666893HERC1, hectTATCTTCTTC[A/T]ATGGATAGAAMATEV(homologous to theE6 AP (UBE3A)carboxyl terminus)domain and RCC1(CHC1)-like domain(RLD) 1G598u22WIAF-12280HT4866613276HERC1, hectAGAACTCAGC[A/C]TTCACACGGTMAGIV(homologous to theE6 AP (UBE3A)carboxyl terminus)domain and RCC1(CHC1)-like domain(RLD) 1G598u23WIAF-12283HT486666519HERC1, hectCCTGTCTGTT[A/T]GACATGGAACMATLF(homologous to theE6 AP (UBE3A)carboxyl terminus)domain and RCC1(CHC1)-like domain(RLD) 1G598u24WIAF-12284HT486668386HERC1, hectGGGGTTCTCT[C/T]TTCGGCAGATMCTLF(homologous to theE6 AP (UBE3A)carboxyl terminus)domain and RCC1(CHC1)-like domain(RLD) 1G598u25WIAF-12286HT4866610266HERC1, hectCAGCTCAGCA[A/T]CTCGTGCGCAMATQH(homologous to theE6 AP (UBE3A)carboxyl terminus)domain and RCC1(CHC1)-like domain(RLD) 1G598u26WIAF-12287HT4866610099HERC1, hectCTTTGTTGTA[A/G]CACAGGCCCTMAGTA(homologous to theE6 AP (UBE3A)carboxyl terminus)domain and RCC1(CHC1)-like domain(RLD) 1G598u27WIAF-12289HT4866611835HERC1, hectAGAACTGTCT[G/C]CCTGACCCTGSGCLL(homologous to theE6 AP (UBE3A)carboxyl terminus)domain and RCC1(CHC1)-like domain(RLD) 1G598u28WIAF-12290HT4866612689HERC1, hectTTAAACCACA[C/T]TTTGGCAGTGMCTTI(homologous to theE6 AP (UBE3A)carboxyl terminus)domain and RCC1(CHC1)-like domain(RLD) 1G598u29WIAF-12291HT4866614655HERC1, hectACGTGGACAA[C/T]GCCGAGGGCTSCTNN(homologous to theE6 AP (UBE3A)carboxyl terminus)domain and RCC1(CHC1)-like domain(RLD) 1G598u30WIAF-12296HT48666393HERC1, hectATTCCCCATT[T/C]GCCGGGGCACSTCFF(homologous to theE6 AP (UBE3A)carboxyl terminus)domain and RCC1(CHC1)-like domain(RLD) 1G598u31WIAF-12297HT48666479HERC1, hectGGCAAGGTGA[A/G]GCAGCAGCAGMAGKR(homologous to theE6 AP (UBE3A)carboxyl terminus)domain and RCC1(CHC1)-like domain(RLD) 1G598u32WIAF-12298HT486661197HERC1, hectATGCTCCCAT[T/C]GTCTCCGAAASTCII(homologous to theE6 AP (UBE3A)carboxyl terminus)domain and RCC1(CHC1)-like domain(RLD) 1G598u33WIAF-12300HT486663595HERC1, hectTCCAGAGGAA[C/T]AGCACACTGCNCTQ*(homologous to theE6 AP (UBE3A)carboxyl terminus)domain and RCC1(CHC1)-like domain(RLD) 1G598u34WIAF-12301HT486663661HERC1, hectCACTCCTCAA[T/C]TGGATAAATGSTCLL(homologous to theE6 AP (UBE3A)carboxyl terminus)domain and RCC1(CHC1)-like domain(RLD) 1G601u1WIAF-12246HT27734106PRKMK5, proteinTGGAGAACCA[G/A]GTGCTGGTAASGAQQkinase, mitogen-activated, kinase 5(MAP kinasekinase 5)G601u2WIAF-12247HT27734351PRKMK5, proteinGTAAATGGAC[A/G]GTTAATAGAGMAGQRkinase, mitogen-activated, kinase 5(MAP kinasekinase 5)G601u3WIAF-12292HT27734617PRKMK5, proteinAGCATATCAT[G/C]TCCCGAGTGGMGCVLkinase, mitogen-activated, kinase 5(MAP kinasekinase 5)G603u1WIAF-12248HT42911336mitogen-activatedAGTCATCAGC[T/C]TTGTGCCACCMTCFLprotein (MAP)kinase p38G603u2WIAF-12281HT42911230mitogen-activatedCTCAGTACCA[C/T]GATCCTGATGSCTHHprotein (MAP)kinase p38G610u1WIAF-12249HT486901012protein kinase,CCGAGCCATA[T/C]GATGAGAGCGSTCVYmitogen-activated,p38Beta (MAP kinasep38Beta)G610u2WIAF-12263HT48690799protein kinase,AAATCTCCTC[G/A]GAACACGCCCSGASSmitogem-activated,p38Beta (MAP kinasep38Beta)GS10u3WIAF-12264HT48690848protein kinase,GCCCCAGAAG[G/A]ACCTGAGCAGMGADNmitogen-activated,p38Beta (MAP kinasep38Beta)G610u4WIAF-12282HT48690439protein kinase,TCCTGGTTTA[C/T]CAGCTCCTGCSCTYYmitogen-activated,p38Beta (MAP kinasep38Beta)G612u1WIAF-12344HT14361513RAF1, v-raf-1TTTGCATGCA[A/G]AGAACATCATMAGKEmurine leukemiaviral oncogenehomolog 1G614u1WIAF-12267HT321603BRAF, v-raf murineGACAGTCTAA[A/G]GAAAGCACTGMAGKRsarcoma viraloncogene homolog 51G614u2WIAF-12268HT3212282BRAF, v-raf murineCCAAACAGAG[G/A]ATTTTAGTCTMGADNsarcoma viraloncogene homolog 51G614u3WIAF-12299HT321973BRAF, v-raf murineAGGAAGAGGC[G/A]TCCTTAGCACSGAAAsarcoma viraloncogene homolog 51G616u1WIAF-12253HT48746498TRAF-interactingAAGAAGACAA[G/T]AGGTTTCTTCNGTE*protein (I-TRAF)G616u2WIAF-12269HT487461338TRAF-interactingGCATATACCT[C/G]GAGTATGTGAMCGRGprotein (I-TRAF)G616u3WIAF-12285HT48746377TRAF-interactingATAACAATTA[T/C]GGCTGTGTCCSTCYYprotein (I-TRAF)G616u4WIAF-12288HT487461032TRAF-interactingTGAAATTCAG[G/A]GAATTGACCCMGAGRprotein (I-TRAF)G617u1WIAF-12256HT161452PPP1CA, proteinGAAGCTCAAC[C/T]TGGACTCGATSCTLLphosphatase 1,catalytic subunit,alpha isoformG617u2WIAF-12270HT1614792PPP1CA, proteinAAGACGGCTA[C/T]GAGTTCTTTGSCTYYphosphatase 1,catalytic subunit,alpha isoformG618u1WIAF-12238HT275081598proteinCATTGAACCA[A/C]CACAGTTCAAMACTPphosphatase, 2AB56-alphasubunitG618u2WIAF-12271HT275081135proteinATCAGAAATT[C/T]GTACAACAGCSCTFFphosphatase, 2AB56-alphasubunitG62u1WIAF-10369HT0855214ERCC6, excisionAGGAGTACCT[G/C]TCCTTTCGTTSGCLLrepair cross-complementing rodentrepair deficiency,complementationgroup 6G62u2WIAF-10370HT0855926ERCC6, excisionAAAACTGTCT[T/C]TTGAAAGGAAMTCFLrepair cross-complementing rodentrepair deficiency,complementationgroup 6G62u3WIAF-10428HT08552904ERCC6, excisionAGCACGGACA[C/T]GCAGGCCCGGMCTTMrepair cross-complementing rodentrepair deficiency,complementationgroup 6G62u4WIAF-10430HT08553368ERCC6, excisionTGACCCTCAC[A/G]TGAGTAGTAAMAGMVrepair cross-complementing rodentrepair deficiency,complementationgroup 6G62u5WIAF-10451HT08551376ERCC6, excisionTTCTGGGGAA[G/A]AAGCTGAAGCMGAEKrepair cross-complementing rodentrepair deficiency,complementationgroup 6G62u6WIAF-10452HT08553716ERCC6, excisionTAAGCATTGC[A/G]GACACGCCAAMAGRGrepair cross-complementing rodentrepair deficiency,complementationgroup 6G62u7WIAF-10453HT08553967ERCC6, excisionCCCTGAAAGC[A/C]CTGAGGCTCTSACAArepair cross-complementing rodentrepair deficiency,complementationgroup 6G62u8WIAF-10454HT08554016ERCC6, excisionTGGTGTTCCC[A/G]CCTGGACTGGMAGTArepair cross-complementing rodentrepair deficiency,complementationgroup 6G62u9WIAF-10455HT08553979ERCC6, excisionTGAGGCTCTC[T/C]CGTCAGCGGTSTCSSrepair cross-complementing rodentrepair deficiency,complementationgroup 6G62u10WIAF-10456HT08553729ERCC6, excisionGACCCCAAGT[T/C]TGAAGGAACTMTGFCrepair cross-complementing rodentrepair deficiency,complementationgroup 6G62u11WIAF-10476HT08551275ERCC6, excisionTCTGGAGATG[G/A]TACTGACTATMGAGDrepair cross-complementing rodentrepair deficiency,complementationgroup 6G62u12WIAF-10477HT08552017ERCC6, excisionTGATCTTGGA[C/T]GAAGGACACASCTDDrepair cross-complementing rodentrepair deficiency,complementationgroup 6G62u13WIAF-10479HT08553265ERCC6, excisionCTAACATATC[T/C]CTAAATCATGSTCSSrepair cross-complementing rodentrepair deficiency,complementationgroup 6G62u14WIAF-10481HT08554317ERCC6, excisionGGGCACCTGC[A/G]GGAAGCTTCTMAGQRrepair cross-complementing rodentrepair deficiency,complementationgroup 6G620a1WIAF-12116HT19431256PPP2CB, proteinTATCATGGAA[T/A]TAGATGACACMTALIphosphatase 2(formerly 2A),catalytic subunit,beta isoformG620a2WIAF-12117HT19431326PPP2CB, proteinCCTCATGTTA[C/G]ACGGCGCACCMCGTRphosphatase 2(formerly 2A),catalytic subunit,beta isoformG620u3WIAF-12239HT1943819PPP2CB, proteinTTTTATGATG[A/G]ATGTCTGCGAMAGEGphosphatase 2(formerly 2A),catalytic subunit,beta isoformG623u1WIAF-12260HT3979459PPP1CB, proteinTTCATCGACA[A/G]TATACACATTSAGQQphosphatase 1,catalytic subunit,beta isoformG625u1WIAF-12266HT19512279PPP2R2A, proteinCATTCTGGAG[A/G]ATTACTAGCAMAGEGphosphatase 2(formerly 2A),regulatory subunit(PR 52), alphaisoformG628a1WIAF-12104HT27801104PPP1CC, proteinAGGGGTATGA[T/A]CACAAAGCAAMTAINphosphatase 1,catalytic subunit,gamma isoformG628a2WIAF-12105HT2780973PPP1CC, proteinCCAATTATTG[C/T]GGACAGTTTGSCTCCphosphatase 1,catalytic subunit,gamma isoformG628u3WIAF-12311HT2780888PPP1CC, proteinGATCTTATAT[G/T]TAGAGCCCATMATCPphosphatase 1,catalytic subunit,gamma isofornG630a1WIAF-12103HT5086704protein phosphataseAAAGATGCAG[A/G]TCTGAACTCTMAGDG2A, 130 kDaregulatory subunitG630a2WIAF-12106HT50861015protein phosphataseCGATGGGAAC[G/T]CCCCATCCTTMGTAS2A, 130 kDaregulatory subunitG630a3WIAF-12107HT50861024protein phosphataseCGCCCCATCC[T/c]TTGGTTTACTMTcFL2A, 130 kDaregulatory subunitG630a4WIAF-12108HT5086837protein phosphataseACTTAAAGGA[T/C]ATTGCAGGAGSTCDD2A, 130 kDaregulatory subunitG630u5WIAF-12325HT50861200protein phosphataseTAAAGATGTG[C/T]TTGGACATCTSCTCC2A, 130 kDaregulatory subunitG630u6WIAF-12326HT50862810protein phosphataseATGTTCAGGG[C/TITGCAGGGGGAMCTAV2A, 130 kDaregulatory subunitG630u7WIAF-12351HT5086512protein phosphataseATTATGGCAG [C/T]AACTTACAGAMCTAV2A, 130 kDaregulatory subunitG630u8WIAF-12352HT5086703protein phosphataseCAAACATGCA[G/A]ATCTGAACTCMGADN2A, 130 kDaregulatory subunitG630u9WIAF-12353HT50861069protein phosphatasaACCTTTGTCT[C/T]ATAGAAACTCMCTHY2A, 130 kDaregulatory subunitG634u1WIAF-11825X044342283IGF1R, insulin-TGCAAGTGGC[C/T]AACACCACCASCTAAlike growth factor1 receptorG634u2WIAF-11826X044342279IGF1R, insulin-GTCATGCAAG[T/C]GGCCAACACCMTCVAlike growth factor1 receptorG634u3WIAF-11781X044341731IGF1R, insulin-ACAAGGACGT[G/AIGAGCCCGGCASGAVVlike growth factor1 receptorG634a4WIAF-13106X04434948IGF1R, insulin-TCCACGACGG[C/A]GAGTGCATGCSCAGGlike growth factor1 receptorG634a5WIAF-13107X044341089IGF1R, insulin-CTTCTGCTCA[G/C]ATGCTCCAAGMGCQHlike growth factor1 receptorG634a6WIAF-13108X044342539IGF1R, insulin-AGAAGGAGCA[G/A]ATGACATTCCMGADNlike growth factor1 receptorG634a7WIAF-13109X044342606IGF1R, insulin-AAGTGGCCGG[A/C]ACCTGACAATMACEAlike growth factor1 receptorG634a8WIAF-13111X044341543IGF1R, insulin-CTCCACCACC[A/T]CGTCGAAGAAMATTSlike growth factor1 receptorG634a9WIAF-13112X044341549IGF1R, insulin-CACCACGTCG[A/G]AGAATCGCATMAGKElike growth factor1 receptorG634a10WIAF-13113X044341596IGF1R, insulin-CCCCTGACTA[C/T]AGGGATCTCASCTYYlike growth factor1 receptorG645u1WIAF-12332HT51911127retinoic acid-TCTGCAGACT[C/T]TTCAGGAGAGMCTLFbinding protein IIG645u2WIAF-12333HT51911048retinoic acid-AAGCATTAGA[G/A]GCCTTACAGASGAEEbinding protein IIG646u1WIAF-12303X814791204EMR1, egf-likeCAAATATCCA[T/C]GTGGACTAAAMTCMTmodule containing,mucin-like,hormone receptor-like sequence 1G646u2WIAF-12304X814191919EMR1, egf-likeTTCTGCTGTG[T/G]CGCTCCATCCMTGCWmodule containing,mucin-like,hormone receptor-like sequence 1G646u3WIAF-12316X81479590EMR1, egf-likeCTTGCCCAGA[G/T]CATGCAACTTMGTEDmodule containing,mucin-like,hormone receptor-like sequence 1G646u4WIAF-12317X81479799EMR1, egf-likeGCACCAAGCA[G/A]TGGACAGTTGMGASNmodule containing,mucin-like,hormone receptor-like sequence 1G646u5WIAF-12318X81479558EMR1, egf-likeTGAAGACGTG[A/G]ATGAATGTGCMAGNDmodule containing,mucin-like,hormone receptor-like sequence 1G646u6WIAF-12334X81479207EMR1, egf-likeTTACTATTGC[A/G]CTTGCAAACAMAGTAmodule containing,mucin-like,hormone receptor-like sequence 1G646u7WIAF-12335X81479458EMR1, egf-likeTCACCAGCAG[G/C]GTCTGCCCTGMGCRSmodule containing,mucin-like,hormone receptor-like sequence 1G646u8WIAF-12336X814791308EMR1, egf-likeCTCAGCAAAT[G/A]TCACTCCGGCMGAVImodule containing,mucin-like,hormone receptor-like sequence 1G646u9WIAF-12337X814791285EMR1, egf-likeACACTGGCAT[C/T]TTTTTGGAAAMCTSFmodule containing,mucin-like,hormone receptor-like sequence 1G646u10WIAF-12338X814792026EMR1, egf-likeGACAACAAGA[C/T]GGGCTGCGCCMCTTMmodule containing,mucin-like,hormone receptor-like sequence 1G647u1WIAF-12339HT5190174RARA, retinoic acidTGCCTCCCTA[C/T]GCCTTCTTCTSCTYYreceptor, alphaG648a1WIAF-13332HT0070469retinoic acidAACCTGAGCC[A/G]CGACCAGCGT—AG——receptor, betaG648a2WIAF-13333HT0070532retinoic acidATTGTTTTTA[A/G]GGTGAGAAAT—AG——receptor, betaG6S0u1WIAF-12323X52773862RXRA, retinoid XCTCGCCGAAC[G/A]ACCCTGTCACMGADNreceptor, alphaG650u2WIAF-12341X52773102RXRA, retinoid XTCCTGCCGCT[C/T]GATTTCTCCASCTLLreceptor, alphaG650u3WIAF-12348X52773673RXRA, retinoid XGGCCATCGGC[A/C]TGAAGCGGCAMAGMVreceptor, alphaG650u4WIAF-12349X52773902RXRA, retinoid XGACAAACACC[T/C]TTTCACCCTCMTCLPreceptor, alphaG653a1WIAF-13326HT1458439RARB, retinoicAGGACAAAGC[T/C]CTCAAAGCATSTCAAacid receptor,betaG655a1WIAF-13327J052521158PCSK2, proproteinCCTTCACGAA[C/T]GGGAGGAAAASCTNNconvertasesubtilisin/kexintype 2G655a2WIAF-13334J05252678PCSK2, proproteinCCTATCCTTA[C/A]CCTCCCTACANCAY*convertasesubtilisin/kexintype 2G655a3WIAF-13335J05252744PCSK2, proproteinTTTCTGCTCC[C/T]GCCAACAACASCTAAconvertasesubtilisin/kexintype 2G658u1WIAF-11856J02943971CBG, corticosteroidTCTATGACCT[T/C]CGAGATGTCCSTCLLbinding globulinG658u2WIAF-13407J02943771CBG, corticosteroidCCTTCATGAC[T/C]CACAGCTCCCMTGSAbinding globulinG658u3WIAF-13408J02943773CBG, corticosteroidTTCATCACTC[A/G]GAGCTCCCCTSAGSSbinding globulinG658u4WIAF-13409J029431046CBG, corticosteroidTCACCCAGGA[C/T]GCCCAGCTCASCTDDbinding globulinG663u1WIAF-13400HT31571202TPO, thyroidCGCCACGCGC[G/A]CCTGCGGCCTSGAAAperoxidaseG663u2WIAF-13401HT31571282TPO, thyroidGGCCGCGCCA[G/C]CGAGGTCCCCMGCSTperoxidaseG668a1WIAF-13350U53506350DI02, deiodinase,TCGATGCCTA[C/A]AAACAGGTGANCAY*iodothyronine,type IIG668a2WIAF-13351U53506354DI02, deiodinase,TGCCTACAAA[C/A]AGGTGAAATTMCAQKiodothyronine,type IIG668a3WIAF-13352U53506408DI02, deiodinase,TGTCTCGACT[A/G]CAGAAGGAGGMAGTAiodothyronine,type IIG673a1WIAF-13328M574641723Human ret proto-CGAGCCTGGC[C/A]AGCCCCGGGGMGAEKoncogene mRNA fortyrosine kinase.G673a2WIAF-13338M574641186Human ret proto-GGCTCGCCCA[T/A[TTGCCCAGATMTAFIoncogene mRNA fortyrosine kinase.G673a3WIAF-13337M574641227Hunan ret proto-ACTGCCAGGC[G/A]TTCACTCGGASGAAAoncogene mRNA fortyrosine kinase.G673a4WIAF-13338M574642118Human ret proto-TTGGAAAAAC[T/A]CTAGGAGAAGSTATToncogene mRNA fortyrosine kinase.G673a5WIAF-13339M574642238Human ret proto-CGAGTGAGCT[T/C]CGAGACCTGCSTGLLoncogene mRNA fortyrosine kinase.G678a1WIAF-13353D494921439GDF10, growthTCGGCTGGAA[T/A]GAATGCATAAMTANKdifferentiationfactor 10G55u1WIAF-10434HT11151214ERCC3, excisionCTGTGGAGCA[G/A]TGGAAAGCCCSGAQQrepair cross-complementingrodent repairdeficiency,complementationgroup 3 (xerodermapigmentosum group Bcomplementing)G68u2WIAF-10435HT11151155ERCC3, excisionTGTGACTGCT[G/C]CATGCACTGTMGCAPrepair cross-complementingrodent repairdeficiency,complementationgroup 3 (xerodermapigmentosum group Bcomplementing)G68u3WIAF-10436HT11151327ERCC3, excisionAGCACCTACT[C/T]CATCCTGGGCMCTSFrepair cross-complementingrodent repairdeficiency,complementationgroup 3 (xerodermapigmentosum group Bcomplementing)G68u4WIAF-10461HT1115926ERCC3, excisionAGGAAATCAT[T/C]CACGAACTCCSTCIIrepair cross-complementingrodent repairdeficiency,complementationgroup 3 (xerodermapigmentosum group Bcomplementing)G68u5WIAF-10464HT11151430ERCC3, excisionAAGTGCACAC[C/T]ATACCAGCCASCTTTrepair cross-complementingrodent repairdeficiency,complementationgroup 3 (xerodermapigmentosum group Bcomplementing)G684a1WIAF-13359X51801712BMP7, bone morpho-GTTTATCACG[T/G]GCTCCACCAGMTGVGgenetic protein7 (osteogenicprotein 1)G684a2WIAF-13360X51801719BMP7, bone morpho-AGGTCCTCCA[G/A]GAGCACTTGGSGAQQgenetic protein7 (osteogenicprotein 1)G684a3WIAF-13361X51801796BMP7, bone morpho-GGCTGGCTGG[T/G]GTTTCACATCMTGVGgenetic protein7 (osteogenicprotein 1)G684a4WIAF-13362X51803862BMP7, bone morpho-GGCCTGCAGC[T/G]CTCGGTGGAGMTGLRgenetic protein7 (osteogenicprotein 1)G684a5WIAF-13363X51801658BMP7, bone morpho-ATCTACAAGG[A/G]CTACATCCGCMAGDGgenetic protein7 (osteogenicprotein 1)G684u6WIAF-13834X518011421BMP7, bone morpho-GCCACTAGCT[C/T]CTCCCAGAAT—CT——genetic protein7 (osteogenicprotein 1)G685a1WIAF-13329D89675882BMPR1B, boneGTTCCCTTTA[T/G]GATTATCTGANTGY*morphogeneticprotein receptor,type IBG685a2WIAF-13330D89675920BMPR1B, boneGCTAAATCAA[T/C]GCTGAAGTTAMTCMTmorphogeneticprotein receptor,type IBG685a3WIAF-13331D89675770BMPR1B, boneTATCACACAG[T/C]GTTCATGAGGMTGVGmorphogeneticprotein receptor,type IBG685a4WIAF-13340D896751303BMPR1B, boneTCCTTATCAT[C/A]ACCTACTGCCMGADNmorphogeneticprotein receptor,type IBG685a5WIAF-13341D896751372BMPR1B, boneGTTACCCCCC[T/G]CATTCCCAAAMTGSAmorphogeneticprotein receptor,type IBG685a6WIAF-13342D896751173BMPR1B, boneTGTTGGACGA[C/A]AGCTTGAACASGAEEmorphogeneticprotein receptor,type IBG686u1WIAF-13816Z489232705BMPR2, boneAAATTTGGCA[G/A]CAAGCACAAAMGASNmorphogeneticproteinreceptor, typeII (serine/threonine kinase)G686u2WIAF-13817Z489232749BMPR2, boneTGGAGTTGCC[A/T]AGATGAATACNATK*morphogeneticproteinreceptor, type II(serine/threoninekinase)G687a1WIAF-13343HT1455626CALB1, calbindin 1,ATGATCACGA[C/T]GGCAATCCATSCTDD(28 kD)G696u1WIAF-11839HT277001075calcium-sensingGCCCACAATT[G/C]CACCTGATGAMGCAPreceptorG696u2WIAF-11840HT277001551calcium-sensingTACCTGTGGA[C/T]ACCTTTCTGASCTDDreceptorG696u3WIAF-11841HT277001688calcium-sensingTTACGGATAT[C/T]CTACAATGTGMCTSFreceptorG696u4WIAF-11842HT277001698calcium-sensingCCTACAATGT [G/T]TACTTACCAGSGTVVreceptorG696u5WIAF-11858HT277001767calcium-sensingGGAGAGGGCT[C/T]TTCACCAATGSCTLLreceptorG696u6WIAF-118S9HT277001689calcium-sensingTACGCATATC[C/T]TACAATGTGTSCTSSreceptorG696u7WIAF-11860HT277002541calcium-sensingTCGTCCTCTG[C/T]ATCTCATCCASCTCCreceptorG696u8WIAF-11861HT277002581calcium-sensingTGTCCTCCTG[G/A]TGTTTGAGGCMGAVMreceptorG696u9WIAF-11863HT277003159calcium-sensingTCTCCCGCAA[G/C]CGGTCCAGCAMGCKNreceptorG696u10WIAF-11872HT27700562calcium-sensingTCCTATTCAT[T/AJTTCGAGTACCMTAFIreceptorG696u11WIAF-11878HT277002941calcium-sensingCATTCCAGCC[T/G]ATGCCAGCACMTGYDreceptorG696u12WIAF-13386HT277001145calcium-sensingAGGGATATCT[G/A]CATCGACTTCMGACYreceptorG696u13WIAF-13395HT27700670calcium-sensingCATATTTGCC[A/GJTAGAGGACATMAGIVreceptorG696u14WIAF-13396HT277002243calcium-sensingTTCTGGTCCA[A/G]TGAGAACCACMAGNSreceptorG696u15WIAF-13397HT277002742calcium-sensingAGCTGGAGGA[T/C]GAGATCATCTSTCDDreceptorG698u1WIAF-13547X61598393CBP1, collagen-TCAGCAACTC[G/C]ACGGCGCGCASGCSSbinding protein 1G698u2WIAF-13549X61598628CBP1, collagen-CGGCGCCCTG[C/T]TAGTCAACGCSCTLLbinding protein 1G698u3WIAF-13550X615981230CBP1, collagen-GCGGCTCCCT[G/A]CTATTCATTGSGALLbinding protein 1G701u1WIAF-12382HT27657706CGRP type IAACGATGTTG[C/A]AGCAGGAACTMCAAEreceptorG701u2WIAF-12391HT27657841CGRP type ITGGACAAATT[A/T]TACCCAGTGTMATYFreceptorG704u1WIAF-14046X603821396COL10A1, collagen,AGGCATTCCA[G/A]GATTCCCTGGMGAGRtype X, alpha1 (Schmid meta-physeal chondro-dysplasia)G704u2WIAF-14070X603821648COL10A1, collagen,TGCCAACCAG[G/C]CGGTAACAGCMGCGRtype X, alpha1 (Schmid meta-physeal chondro-dysplasia)G704u3WIAF-14071X603821824COL10A1, collagen,CATACCACGT[G/C]CATCTGAAAGSGCVVtype X, alpha1 (Schmid meta-physeal chondro-dysplasia)G704u4WIAF-14072X603821582COL10A1, collagen,AGTCATCCCT[C/C]ACGGTTTTATMGCEQtype X, alpha1 (Schmid meta-physeal chondro-dysplasia)G705a1WIAF-13228J04177686COL11A1, collagen,ACAACAAAAC[T/A]GTCACAATCASTATTtype XI, alpha 1G705a2WIAF-13229J04177698COL11A1, collagen,TGACAATCAT[T/A]GTTGATTGTASTAIItype XI, alpha 1G705a3WIAF-13230J041778881COL11A1, collagen,TACTCCACAC[T/A]CTGACTCTTCMTACStype XI, alpha 1G705a4WIAF-13231J04177894COL11A1, collagen,AGACTGTGAC[T/A]CTTCAGCACCMTASTtype XI, alpha 1G705a5WIAF-13232J04177651COL11A1, collagen,TGACCGCAAG[T/A]CCCATCCCCTMTAWRtype XI, alpha 1G705a6WIAF-13233J04177661COL11A1, collagen,TGGCATCGGG[T/A]AGCAATCAGCMTAVEtype XI, alpha 1G705a7WIAF-13234J041771597COL11A1, collagen,CGTCCTGGCT[T/C]ACCAGGGGCTMTCLStype XI, alpha 1G705a8WIAF-13235J041772745COL11A1, collagen,TGGGTTTCCA[C/A]GTGCCAATGGMGAGStype XI, alpha 1G705a9WIAF-13236J041774385COL11A1, collagen,GTCCAGAAGG[T/A]CTTCGGGGCASTAGGtype XI, alpha 1G705a10WIAF-13237J041774576COL11A1, collagen,GAAAAAGGTG[A/T]CCGAGGGGTCMATDVtype XI, alpha 1G705a11WIAF-13238J041774306COL11A1, collagen,GCTAAGGGGG[A/C]AGCAGGTCCAMACEAtype XI, alpha 1G705a12WIAF-13239J041774837COL11A1, collagen,AGACATACTG[A/G]AGGCATGCAA MAGEGtype XI, alpha 1G705a13WIAF-13240J041774931COL11A1, collagen,AACAAGACAT[C/T]CACCATATGASCTIItype XI, alpha 1G705a14WIAF-13346J04177299COL11A1, collagen,AAGCACTAGA[T/G]TTTCACAATTMTGDEtype XI, alpha 1G705a15WIAF-13347J041772225COL11A1, collagen,GGGAGCCTGG[G/C]CCTCCAGGTCSGCGGtype XI, alpha 1G705u16WIAF-13679J041775493COL11A1, collagen,AATTCATCAA[G/A]TACCTATTGTMGAVItype XI, alpha 1G705u17WIAF-13700J041773484COL11A1, collagen,GGACTTCAAG[G/A]TCCTGTTGGTMGAGDtype XI, alpha 1G705u18WIAF-13709J041775392COL11A1, collagen,GACATGTCCT[A/T]TGACAATAATMATYFtype XI, alpha 1G707u1WIAF-12363U321694996COL11A2, collagen,TCCCCTGAGA[C/T]TCCGTGGGGCMCTLFtype XI, alpha 2G707u2WIAF-12374U321693580COL11A2, collagen,CAATGGCCCT[C/A]ATGGCCCACAMGADNtype XI, alpha 2G707u3WIAF-12385U321692059COL11A2, collagen,GCCTGGCTCA[C/A]ACGGACCCCCMGADNtype XI, alpha 2G708a1WIAF-13354U737781885COL12A1, collagen,GCCTCTCCTC[C/T]TCCACAGACCMCTPLtype XII,alpha 1G708a2WIAF-13355U737783630COL12A1, collagen,TGTTGGACAA[C/A]AAATGACAACMGAEKtype XII,alpha 1G708a3WIAF-13356U737783905COL12A1, collagen,GCTTCTTGCA[A/T]GCTCTGGCAAMATQHtype XII,alpha 1G708a4WIAF-13357U737787051COL12A1, collagen,ATTCCACCAG[C/A]CCGGGATGTAMCAADtype XII,alpha 1G708a5WIAF-13358U737788036COL12A1, collagen,AAGAAGTAAA[C/A]ACATTATTTTSGAKKtype XII,alpha 1G708a6WIAF-13364U737781461COL12A1, collagen,TGGCTCCTAT[A/T]GCATTGGGATMATSCtype XII,alpha 1G708a7WIAF-13365U737782344COL12A1, collagen,ATTACTTGGA[C/T]TCAAGCTCCAMCTTItype XII,alpha 1G708a8WIAF-13366U737785207COL12A1, collagen,CAGATAAGAT[C/A]GAGACCATCTMGAMItype XII,alpha 1G708a9WIAF-13367U737786592COL12A1, collagen,GAGCCCATGG[A/T]AGCCTTTGTTMATEVtype XII,alpha 1G708a10WIAF-13368U737787434COL12A1, collagen,CCAGGATGAG[G/A]TCAACAAGGCMGAVItype XII,alpha 1G708a11WIAF-13369U737789108COL12A1, collagen,ACCTCGGGGG[C/G]TGCCTGGGCCMCGLVtype XII,alpha 1G708a12WIAF-13370U737789111COL12A1, collagen,TCGGGGGCTG[C/T]CTGGGCCCCCMCTPStype XII,alpha 1G708a13WIAF-13371U737789196COL12A1, collagen,CCCCCTGGCC[G/A]TCCTGGAAACMGARHtype XII,alpha 1G708u14WIAF-13972U737783044COL12A1, collagen,CAGTATTTGC[C/A]ACTTACAGCASCAAAtype XII,alpha 1G708u15WIAF-13977U737785853COL12A1, collagen,TCTGACTCTA[G/C]TTCCCGTTTAMGCVLtype XII,alpha 1G710u1WIAF-12371D381633082COL19A1, collagen,AGGAAACAAG[C/T]GCTCCATGGGMGTGCtype XIX,alpha 1G710u2WIAF-12388D381632089COL19A1, collagen,TCCAGGGACT[C/T]CAGGCAATGAMCTPStype XIX,alpha lC711u1WIAF-12360L252861449COL15A1, collagen,TGTGGGTCCA[A/C]GCACTCAACAMAGSGtype XV, alpha 1C711u2WIAF-12372L252864001COL15A1, collagen,ATATTCCAAT[A/C]TACTCCTTTCMAGIMtype XV, alpha1G711u3WIAF-12373L252863867COL15A1, collagen,CCATTTGCAA[G/T]ATCTGTCCACMGTDYtype XV, alpha1C711a4WIAF-13372L25286395COL15A1, collagen,CCACCAGCAC[C/T]CGTGCTGCCGSCTTTtype XV, alpha1C711a5WIAF-13373L252863101COL15A1, collagen,AAGGCGACCA[G/A]GGACCCCAGGSGAQQtype XV, alpha1G712u1WIAF-13619M926423608COL16A1, collagen,GGCGACCAGG[C/A]ATTTCAAGGCMGAGEtype XVI,alpha 1G712u2WIAF-13620M926424944COL16A1, collagen,CCATGAAAAC[C/T]ATGAAGGGGCSCTTTtype XVI,alpha 1G712u3WIAF-13621M926424707COL16A1, collagen,CCAAACGTCA[A/C]AAAGGGGACAMACEDtype XVI,alpha 1 G712u4WIAF-13654M92642421COL16A1, collagen,GCCCACGCCA[C/A]GAGTATTCCCSCARRtype XVI,alpha 1G712u5WIAF-13655M92642444COL16A1, collagen,GGGGTCTCCC[G/A]GAGGAGTTTGSGAPPtype XVI,alpha 1G712u6WIAF-13656M92642338COL16A1, collagen,CTCATGAAGA[A/C]GTCTGCCATCMACKTtype XVI,alpha 1G712u7WIAF-13862M926423227COL16A1, collagen,CCTGGTCCTC[C/T]GGGATTCCCAMCTPLtype XVI,alpha 1G712u8WIAF-13863M926423199COL16A1, collagen,TCCTGGCTGT[G/T]TTGGGAGCCCMGTVFtype XVI,alpha 1G712u9WIAF-13878M92642318COL16A1, collagen,ACCTCATCCA[C/T]CGACTCAGCCSCTHHtype XVI,alpha 1G712u10WIAF-13882M926421346COL16A1, collagen,ACAGGCGAGA[A/G]GGGCCAGAAAMAGKRtype XVI,alpha 1G712u11WIAF-13883M926421309COL16A1, collagen,GTCACGACCT[C/T]TGGGACCCTCSCTLLtype XVI,alpha 1G715a1WIAF-13344Z746153504COL1A1, collagen,TCCTGGTGAA[C/G]AAGGTCCCTCMCGQEtype I, alpha 1G717u1WIAF-12639Z746163988COL1A2, collagen,ATGAGGAGAC[T/C]GGCAACCTGASTCTTtype I, alpha 2G720u1WIAF-12367X144203494COL3A1, collagen,GGTGCAATCG[G/A]CAGTCCAGGAMGAGDtype III, alpha 1(Ehlers-Danlossyndrome type IV,autosomal dominant)G720u2WIAF-12383X144203035COL3A1, collagen,GGTGTCAAGG[G/A]TGAAAGTGGGMGAGDtype III, alpha 1(Ehlers-Danlossyndrome type IV,autosomal dominant)G720a3WIAF-13374X14420214COL3A1, collagen,TCTTGGTCAG[T/C]CCTATGCGGAMTCSPtype III, alpha 1(Ehlers-Danlossyndrome type IV,autosomal dominant)G720a4WIAF-13375X144201953COL3A1, collagen,CTGGACCTCA[A/G]GGACCCCCAGSAGQQtype III, alpha 1(Ehlers-Danlossyndrome type IV,autosomal dominant)G720a5WIAF-13376X144202194COL3A1, collagen,TAGAGGTGGA[G/A]CTGGTCCCCCMGAATtype III, alpha 1(Ehlers-Danlossyndrome type IV,autosomal dominant)G720a6WIAF-13377X144203731COL3A1, collagen,GGGATTGGAG[G/A]TGAAAAAGCTMGAGDtype III, alpha 1(Ehlers-Danlossyndrome type IV,autosomal dominant)G722u1WIAF-14132HT3162140COL4A2, collagen,GAGATTGGCG[C/T]GACTGGTGATMCTAVtype IV, alpha 2G724a1WIAF-12120X810533892COL4A4, collagen,CTCGTGGAAA[G/A]AAAGGTCCCCSGAKKtype IV, alpha 4G724a2WIAF-12121X810534187COL4A4, collagen,GAAAGGACCA[A/G]TGGGATTCCCMAGHVtype IV, alpha 4G724a3WIAF-12122X810533802COL4A4, collagen,ATGATGTGGG[G/A]CCACCTGGTCSGAGGtype IV, alpha 4G724a4WIAF-12123X810531838COL4A4, collagen,ACCAGGAAAG[C/A]ATGGTGCCTCMCAHNtype IV, alpha 4G724u5WIAF-12364X81053376COL4A4, collagen,CTGTTTGCCA[C/T[TGTCTTCCTGSCTHHtype IV, alpha4G724u6WIAF-12365X810532018COL4A4, collagen,TCCAGGGGAT[C/G]ATGAACATGCMCGHDtype IV, alpha4G724u7WIAF-12366X810534756COL4A4, collagen,GCCTTCCCCT[A/G]TTTACCACGCSAGVVtype IV, alpha4G724u8WIAF-12377X810533595COL4A4, collagen,CTGGACCACC[A/G]GGGTGCCCAGSAGPPtype IV, alpha4G724u9WIAF-12378X810533516COL4A4, collagen,GGAGCATCCG[C/C]ACACCAGGGCMGCGAtype IV, alpha4G724u10WIAF-12379X810534288COL4A4, collagen,CTGGTCTTCC[A/G]GCTCCCAGAGSAGPPtype IV, alpha4G724u11WIAF-12380X810535140COL4A4, collagen,GCCACTTTTT[C/A]GCAAATAAGTMCAFLtype IV, alpha4G724u12WIAF-12387X81053207COL4A4, collagen,GACTTCCCTG[C/T]GATGTGGTCT—CT——type IV, alpha4G727u1WIAF-12362D902795135COL5A1, collagen,TTCAACGTTT[A/T]CTGCAACTTCMATYFtype V, alpha 1G727u2WIAF-12369D902794686COL5A1, collagen,AACAGGGTAT[C/T]ACTGCTCCTTSCTIItype V, alpha 1G727u3WIAF-12370D902794608COL5A1, collagen,TCGGTCCTCC[G/C]GCTGAACAGGSGCPPtype V, alpha 1G727a4WIAF-13300D902792034COL5A1, collagen,ACGGCCTGGC[T/A]GGGTTGCCAGSTAAAtype V, alpha 1G727a5WIAF-13301D902792073COL5A1, collagen,GTGACCCTGG[T/C]CCTTCCGGCCSTCGGtype V, alpha 1G727a6WIAF-13302D902793763COL5A1, collagen,CGGGCACAAA[G/A]GTGATGAAGGMGAGStype V, alpha 1G729u1WIAF-11844L028702345COL7A1, collagen,ATGGACTGGA[G/A]CCAGATACTGSGAEEtype VII, alpha 1(epidermolysisbullosa, dys-trophic, dominantand recessive)G729u2WIAF-11845L028703083COL7A1, collagen,TATCCTGGCG[G/A]CCACTCAGAGSGARRtype VII, alpha 1(epidermolysisbullosa, dys-trophic, dominantand recessive)G729u3WIAF-11846L028103031COL7A1, collagen,GACTCGGTGA[C/T]TTTGGCCTGGMCTTItype VII, alpha 1(epidermolysisbullosa, dys-trophic, dominantand recessive)G729u4WIAF-11851L028701289COL7A1, collagen,CGGACTATGA[G/T]GTGACCGTGAMGTEDtype VII, alpha 1(epidermolysisbullosa, dys-trophic, dominantand recessive)G729u5WIAF-11852L028701032COL7A1, collagen,CCAAGTGACT[G/T]TGATTGCCCTMGTVLtype VII, alpha 1(epidermolysisbullosa, dys-trophic, dominantand recessive)G729u6WIAF-11853L028701897COL7A1, collagen,CGCCGGGAGC[C/T]GGAAACTCCAMCTPLtype VII, alpha 1(epidermolysisbullosa, dys-trophic, dominantand recessive)G729u7WIAF-11854L028701827COL7A1, collagen,GCTTAGCTAC[A/T]CTGTGCGGGTMATTStype VII, alpha 1(epidermolysisbullosa, dys-trophic, dominantand recessive)G729u8WIAF-11855L028701893COL7A1, collagen,TGTCCGCCGG[G/A]AGCCCGAAACMGAEKtype VII, alpha 1(epidermolysisbullosa, dys-trophic, dominantand recessive)G729u9WIAF-11864L028702142COL7A1, collagen,GGGCCCTGCT[G/A]CAGTCATCGTMGAATtype VII, alpha 1(epidermolysisbullosa, dys-trophic, dominantand recessive)G729u10WIAF-11865L028702353COL7A1, collagen,GAGCCAGATA(C/T]TGAGTATACGMCTTItype VII, alpha 1(epidermolysisbullosa, dys-trophic, dominantand recessive)G729u11WIAF-11866L028702221COL7A1, collagen,TCATCTGTCA[C/T]CATTACCTGGMCTTItype VII, alpha(epidermolysisbullosa, dys-trophic, dominantand recessive)G729u12WIAF-11869L028706585COL7A1, collagen,ACCAGGAGAG[C/T]GTGGTATGGCMCTRCtype VII, alpha 1(epidermolysisbullosa, dys-trophic, dominantand recessive)G729u13WIAF-11870L028708169COL7A1, collagen,GGGTGACCGA[G/T]GCTTTGACGGMGTGCtype VII, alpha 1(epidermolysisbullosa, dys-trophic, dominantand recessive)G729u14WIAF-11877L02870438COL7A1, collagen,CGCCATCCGT[G/A]AGCTTAGCTAMGAEKtype VII, alpha 1(epidermolysisbullosa, dys-trophic, dominantand recessive)G729u15WIAF-11882L028703481COL7A1, collagen,AGGATCCGTG[A/T]CATGCCCTACMATDVtype VII, alpha 1(epidermolysisbullosa, dys-trophic, dominantand recessive)G729u16WIAF-11883L028705654COL7A1, collagen,ACGGAGAACC[T/C]GGGGACCCTGSTCPPtype VII, alpha 1(epidermolysisbullosa, dys-trophic, dominantand recessive)G729u17WIAF-11884L028707124COL7A1, collagen,TGCCAGGGCC[G/C]CGAGGCCAGASGCPPtype VII, alpha 1(epidermolysisbullosa, dys-trophic, dominantand recessive)G729u18WIAF-11885L028707757COL7A1, collagen,CCTTGGATGG[T/C]GACAAAGGACSTCGCtype VII, alpha 1(epidermolysisbullosa, dys-trophic, dominantand recessive)G729u19WIAF-13389L028701615COL7A1, collagen,ACCGTGGTTC[C/T]CACTGGACCAMCTPLtype VII, alpha 1(epidermolysisbullosa, dys-trophic, dominantand recessive)G729u20WIAF-13390L028702930COL7A1, collagen,TCCTAGGGCC[G/A]GCTGGAGAAGSGAPPtype VII, alpha 1(epidermolysisbullosa, dys-trophic, dominantand recessive)G729u21WIAF-13399L028705145COL7A1, collagen,CCAGCGACAT[C/T]CTGGACAGGAMCTPStype VII, alpha 1(epidermolysisbullosa, dys-trophic, dominantand recessive)G729u22WIAF-13411L028703472COL7A1, collagen,ATCTTGCAAA[G/A]GATCCCTGACMGARKtype VII, alpha 1(epidermolysisbullosa, dys-trophic, dominantand recessive)G730a1WIAF-13303X57527305COL8A1, collagen,ATGGGCAAGG[A/G]AGCCGTTCCCMAGEGtype VIII,alpha 1G732u1WIAF-l26l6M95610936COL9A2, collagen,CACGGGCCAC[A/G]GCCCGGAACTSAGTTtype IX, alpha 2G732u2WIAF-12617M95610696COL9A2, collagen,AAGGGAGAGA[C/T]GGGCCCTCATSCTDDtype IX, alpha 2G732u3WIAF-12619M956101288COL9A2, collagen,AACTCGGTCA[C/T]CCAGCGCTCGHCTPStype IX, alpha 2G732u4WIAF-12620M95610962COL9A2, collagen,CCACCAGCCC[C/G]TAGCGCCTCTMCGPRtype IX, alpha 2G737u1WIAF-13394M13436?INHBA, inhibin,TGCTCCCTG[G/T]?GTbeta A (activinA, activin AB alphapolypeptide)G738a1WIAF-13383M58549183MGP, matrix GlaATGGAGAGCT[A/G]AAGTCCAAGAMAGKEproteinG738a2WIAF-13384M58549330MGP, matrix GlaGCGCCGAGGG[A/G]CCAAATGAGAMAGTAproteinG739u1WIAF-11867U94332862TNFRSF11B, tumorTGCTGAAGTT[A/G]TGGAAACATCSAGLLnecrosis factorreceptor super-family, member 11b(osteoprotegerin)G739u2WIAF-11874U943321244TNFRSP11B, tumorGTATCACAAG[T/C]TATTTTTAGASTCLLnecrosis factorreceptor-super-family, member 11b(osteoprotegerin)G743u1WIAF-13402HT8471669PTHR1, parathyroidCCCTGGAGAC[C/A]CTCGAGACCASCATThormone receptor 1G747u1WIAF-12414J03040123SPARC, secretedCTCAGCAAGA[A/G]GCCCTGCCTGSAGEEprotein, acidic,cysteine-rich(osteonectin)G748u1WIAF-12628HT0157117VDR, vitamin DCCTTCAGGGA[T/C]GGAGGCAATGMTCMT(1,25-dihydroxy-vitamin D3)receptorG748u2WIAF-12629HT01571171VDR, vitamin DCCGCGCTGAT[T/C]GAGGCCATCCSTCII(1,25-dihydroxy-vitamin D3)receptorG748u3WIAF-12640HT0157172VDR, vitamin DTTGACCGGAA[C/T]GTGCCCCGGASCTNN(1,25-dihydroxy-vitamin D3)receptorG749u1WIAF-11862HT3734679osteopontin, alt.ATCACCTCAC[A/T]CATGGAAAGCMATHLtranscript 1G749u2WIAF-11875HT3734386osteopontin, alt.AAGATGATGA[A/G]GACCATGTGGSAGDDtranscript 1G749u3WIAF-11876HT3734419osteopontin, alt.CCATTGACTC[C/A]AACCACTCTCSGASStranscript 1G749a4WIAF-12084HT3734171osteopontin, alt.TAAACAGGCT[G/A]ATTCTCGAACMGADNtranscript 1G749u5WIAF-13387HT3734738osteopontin, alt.CCAGGACCTG[A/C]ACGCGCCTTCMACNHtranscript 1G749u6WIAF-13388HT3734716osteopontin, alt.CATACAAGGC[C/A]ATCCCCGTTCSCAAAtranscript 1G751u1WIAF-12631HT5036410ADM,GACAGCAGTC[C/G]GGATGCCGCCMCGPRadrenomedullinG752u1WIAF-11843HT17821405CHGA, chromograninCGGCCATTGA[A/G]GCAGAGCTGGSAGEEA (parathyroidsecretory protein1)G752u2WIAF-11873HT17821187CHGA, chromograninGGACAACCCG[C/A]ACAGTTCCATMGADNA (parathyroidsecretory protein1)G754a1WIAF-13382K02043663NPPA, natriureticGTACAATGCC[C/A]TGTCCAACGCMGAVMpeptide precursor AG756u1WIAF-12395HT35082086SCNN1A, sodiumCAGTTCCTCC[A/G]CCTGTCCTCT?AGTAchannel, non-voltage-gated 1alphaG757u1WIAF-12420HT28563797SCNN1B, sodiumCCTGCAGGCC[A/C]CCAACATCTTMACTPchannel, non-voltage-gated 1,beta (Liddlesyndrome)G757u2WIAF-12421HT285631006SCNN1B, sodiumchannel, non-voltage-gated 1,beta (Liddlesyndrome)G757u3WIAF-12430HT285631768SCNN1B, sodiumTCATCGACTT[T/C]GTGTGGATCASTCFFchannel, non-voltage-gated 1,beta (Liddlesyndrome)G757u4WIAF-12494HT28563662SCNN1B, sodiumAAGCAGCTCA[G/C]CATCAGAAAAMGCAPchannel, non-voltage-gated 1,beta (Liddlesyndrome)G757u5WIAF-12506HT285631091SCNN1B, sodiumGATGCTTCAC[G/C]AGCAGAGCTCMGCEQchannel, non-voltage-gated 1,beta (Liddlesyndrome)G757u6WIAF-12507HT285631452SCNN1B, sodiumACCTGCATTC[C/T]CATCTGCAAGMGTGVchannel, non-voltage-gated 1,beta (Liddlesyndrome)G758u1WIAF-12621HT27856415SCNN1D, sodiumCGGGAACCCA[C/T]GTCGGCCGAGMCTRCchannel, non-voltage-gated 1,deltaG758u2WIAF-12632HT27856325SCNN1D, sodiumCCTCTTTGAG[C/T]GTCACTGCCAMCTRCchannel, non-voltage-gated 1,deltaG758u3WIAF-12634HT27856879SCNN1D, sodiumATGGCGTCTG[C/A]ACAGCTCAGCNGAW*channel, non-voltage-gated 1,deltaG758u4WIAF-12635HT278561138SCNN1D, sodiumCGTGGAGGTG[G/C]AGCTCCTACAMGCEQchannel, non-voltage-gated 1,deltaG762u1WIAF-12622HT275311850NPR3, natriureticTAGGACCTGG[C/T]TTGCTAATGGSCTGGpeptide receptorC/guanylate cyclaseC (atrionatriureticpeptide receptor C)G762u2WIAF-12623HT275311926NPR3, natriureticAGAAGAAAGT[A/G]ACCTTGGAAAMAGNDpeptide receptorC/guanylate cyclaseC (atrionatriureticpeptide receptor C)C)G762u3WIAF-12624HT275311791NPR3, natriureticCAAATCATCA[G/T]GTGGCCTAGAMGTGCpeptide receptorC/guanylate cyclaseC (atrionatriureticpeptide receptorG762u4WIAF-12636HT275311963NPR3, natriureticGAAGATTCCA[T/C]CAGATCCCATMTCITpeptide receptorC/guanylate cyclaseC (atrionatriureticpeptide receptorC)G763u1WIAF-12659HT31831633NPR2, natriureticCTGGGCCCTT[C/T]CCTGATGAACMCTSFpeptide receptorB/guanylate cyclaseB (atrionatriureticpeptide receptorB)G763u2WIAF-12678HT3183668NPR2, natriureticTGCCATCACT[T/C]CTGCTGTTGGSTCLLpeptide receptorB/guanylate cyclaseB (atrionatriureticpeptide receptorB)G763u3WIAF-12684HT31832354NPR2, natriureticTGTTTGAACT[C/T]AAACATATGASCTLLpeptide receptorB/guanylate cyclaseB (atrionatriureticpeptide receptorB)G764u1WIAF-12698HT12213021NPR1, natriureticCCCCGTTACT[C/T]TCTCTTTGGGMGTCFpeptide receptorA/guanylate cyclaseA (atrionatriureticpeptide receptorA)G764u2WIAF-12706HT1221588NPR1, natriureticGAGCGCCAAG[C/T]GCTCATGCTCMCTAVpeptide receptorA/guanylate cyclaseA (atrionatriureticpeptide receptorA)G764u3WIAF-12709HT12211897NPR1, natriureticGTCCCCGTGG[G/A]AGCCTGCAGGSGAGGpeptide receptorA/guanylate cyclaseA (atrionatriureticpeptide receptorA)G765u1WIAF-10012HT2456604DCP1, dipeptidylGCTGGCACAA[A/G]GCTGCGGGCASAGNNcarboxypeptidase 1(angiotensin Iconverting enzyme)G765u2WIAF-10014HT24562350DCP1, dipeptidylTGATGGCCAC[A/G]TCCCGCAAATSAGTTcarboxypeptidase 1(angiotensin Iconverting enzyme)G765u3WIAF-10025HT24561688DCP1, dipeptidylCCCACTGCAC[C/A]AGTGTCACATMCAQKcarboxypeptidase 1(angiotensin Iconverting enzyme)G765u4WIAF-10027HT24563220DCP1, dipeptidylTCCCCTTCAG[C/T]TACCTCGTCGSCTSScarboxypeptidase 1(angiotensin Iconverting enzyme)G765u5WIAF-10028HT24563409DCP1, dipeptidylTCAGGTACTT[T/C]GTCAGCTTCASTCFFcarboxypeptidase 1(angiotensin Iconverting enzyme)G765u6WIAF-10040HT2456775DCP1, dipeptidylAGCCCCTCTA[C/T]CTGAACCTCCSCTYYcarboxypeptidase 1(angiotensin Iconverting enzyme)G772u1WIAF-12626HT21211064AVPR2, arginineTCAGCAGCAC[C/T]GTGTCCTCAGSCTSSvasopressinreceptor 2(nephrogenicdiabetesinsipidus)G772u2WIAF-12627HT2121998AVPR2, arginineCCTTTGTGCT[A/G]CTCATGTTGCSAGLLvasopressinreceptor 2(nephrogenicdiabetesinsipidus)G773u1WIAF-12644HT2141163SLC6A6, soluteCTAGCAAGAT[C/T]GACTTTGTGCSCTIIcarrier family 6(neurotransmittertransporter,taurine), member 6G773u2WIAF-12645HT2141445SLC6A6, soluteTCGTCATCCT[G/C]GCCTGGGCCASGCLLcarrier family 6(neurotransmittertransporter,taurine), member 6G773u3WIAF-12665HT2141289SLC6A6, soluteTCTTTGGGAG[C/T]GGCCTGCCTGSCTSScarrier family 6(neurotranemittertransporter,taurine), member 6G773u4WIAF-12666HT2141382SLC6A6, soluteCCTTGTTCTC[T/C]GGTATCGGCTSTCSScarrier family 6(neurotransmittertransporter,taurine), member 6G776u1WIAF-11857U660881457SLC6A6, soluteTAGAACACCT[C/T]ATCAAACCTCSCTLLcarrier family 5(sodium iodidesymporter), member5G776u2WIAF-11871U660882039SLC5A5, soluteGATTGTTGTG[G/C]TGGGACCTCGMGCWCcarrier family 5(sodium iodidesymporter), member5G776u3WIAF-13398U660881379SLC5A5, soluteGGCTTTTCCT[G/A]GCCTGTGCTTSGALLcarrier family 5(sodium iodidesymporter), member5G777u1WIAF-12646HT278434348SMRTATACAATATC[A/G]GCCACCCTGGMAGSGG777u2WIAF-12654HT278432031SMRTCTGAGCTGGG[T/C]AACCCGCGCCSTCGGG777u3WIAF-12655HT276432052SMRTACACCCCCCT[C/A]ACCTATCACCSGALLG777u4WIAF-12675HT278432205SMRTCTCGTGACAT[C/T]GCCAAGTCCCSCTIIG778u1WIAF-14093HT14498212TG, thyroglobulinATCTCCTCTC[T/C]GAACACATCTMTCLPG778u2WIAF-14111HT14496033TG, thyroglobulinATGTCAACGA[C/T]CGTGCGATGCMCTRWG778u3WIAF-14112HT14496894TG, thyroglobulinGTATCTCAAT[G/T]TGTTCATCCCMGTVLG778u4WIAF-14125HT14492375TG, thyroglobulinATGGCCCTCC[T/C]GAGCACCTCTSTCPPG778u5WIAF-14136HT14491931TG, thyroglobulinACCATCTCCA[A/C]TCCTTTTCCCSAGQQG783u1WIAF-12649X976744008H. sapiens mRNA forCTACTGGTAT[G/C]CCAGCAACTAMGCMItranscriptionalintermediaryfactor 2.G783u2WIAF-12658X976742566H. sapiens mRNA forGCCTGCCACT[G/A]AGCTGCACAAMGAEKtranscriptionalintermediaryfactor 2.G783u3WIAF-12671X976743828H. sapiens mRNA forCTCTGAGCCC[T/C]GGACTACCAASTCPPtranscriptionalintermediaryfactor 2.G785u1WIAF-13385HT1291386TTR, transthyretinCCAACCACTC[C/T]GCCCCCCGCCSCTSS(prealbumin,amyloidosis type I)G787u1WIAF-12652HT27477468TRIP15: thyroidGAAAATTATA[T/C]TTAGAACGAGSTCYYreceptorinteractingprotein 15G792u1WIAF-12661HT27476265thyroid receptorCAGCTGGAAC[G/A]TGAACAGGGCMGAVMinteractor 14G793u1WIAF-12643HT5152458thyroid receptorGGAACCTTTT[C/G]AAAGAATGTTNCGS*interactor 8G794u1WIAF-12664HT51361110PSMC5, proteasomeGCGTGTCCAC[G/A]GAACCTGGCASGATT(prosome, macro-pain) 26S subunit,ATPase, 5G797u1WIAF-11847HT3919140glutamate receptorCTCACGGAGG[A/G]TTCCCCAACASAGGG3, flip isoformG797u2WIAF-11848HT3919759glutamate receptorGGTTGTGATC[C/T]TAGGGAAACASCTLL3, flip isoformG797u3WIAF-11849HT39191253glutamate receptorGCTACTCCAA[C/T]GACTATGAAASCTNN3, flip isoformG797u4WIAF-11850HT39191770glutamate receptorTCTTTTCCTA[C/A]TCAGCACGTTMGAVI3, flip isoformG797u5WIAF-13404HT39192711glutamate receptorGCTACAACGT[G/A]TATGGAACAGSGAVV3, flip isoformG797u6WIAF-13405HT39192376glutamate receptorCTCAGCATTA[G/A]GAACGCCTGTMGAGR3, flip isoformG798u1WIAF-11868X777482655GRM3, glutamateTGCAGACGAC[A/G]ACCATGTGCASAGTTreceptor, metabo-tropic 3G798u2WIAF-11879X777482771GRM3, glutamateCACAGACTCC[A/G]CCTCAACAGGMAGHRreceptor,metabotropic 3G798a3WIAF-12085X777482699GRM3, glutamateGTGGTCTTGG[G/C]CTGTTTGTTTMGCGAreceptor,metabotropic 3G798a4WIAF-12086X777482738GRM3, glutamateATCCTGTTTC[A/G]ACCCCAGAAGMAGQRreceptor,metabotropic 3G798a5WIAF-12087X777482072GRM3, glutamateACACCCTTGG[T/C]CAAAGCATCGMTCVAreceptor,metabotropic 3G798a6WIAF-12088X777482235GRM3, glutamateCCCTGCTCAC[C/TI AAGACAAACTSCTTTreceptor,metabotropic 3G798u7WIAF-13391X777481131GRM3, glutamateGCGCCAATGC[C/T]TCCTTCACCTSCTAAreceptor,metabotropic 3G799u1WIAF-11880M818832000GAD1, glutamateCAACAAATGC[C/T]TGGAACTGGCSCTLLdecarboxylase 1(brain, 67 kD)G799u2WIAF-11881M818831822GAD1, glutamateAGGGTATACT[C/T]CAAGGATCCASCTLLdecarboxylase 1(brain, 67 kD)G799u3WIAF-13392M81883661GAD1, glutamateGCGTGGCCCA[T/C]GGATGCACCASTCHHdecarboxylase 1(brain, 67 kD)G799u4WIAF-13393M81883556GAD1, glutamateAGCTGATGGC[G/A]TCTTCGACCCSGAAAdecarboxylase 1(brain, 67 kD)G799u5WIAF-13410M818831229GAD1, glutamateCCTCATGGAA[C/T]AAATAACACTNCTQ*decarboxylase 1(brain, 67 kD)G801u1WIAF-13403D493941596HTR3, 5-hydroxy-TTTACCTGCT[A/G]GCGGTGCTGGSAGLLtryptamine(serotonin)receptor 3G803a1WIAF-13118U664061446EFNB3, ephrin-B3CTGGGCCTGG[G/A]GGGTGGAGGTMGAGEG804u1WIAF-11887Z266537237LAMA2, laminin,TCACTGATGG[G/T]CACATAAAAGSGTGGalpha 2 (merosin,congenital musculardystrophy)G804u2WIAF-11901Z266539351LAMA2, laminin,GCAAGCCACT[G/C]GAGGTTAATTMGCWSalpha 2 (merosin,congenital musculardystrophy)G804u3WIAF-11924Z266538740LAMA2, laminin,ACACTACCCG[A/G]AGAATTGGTCSAGRRalpha 2 (merosin,congenital musculardystrophy)G804u4WIAF-11943Z266538577LAMA2, laminin,ACCAAAATCA[A/G]TGATGGCCAGMAGNSalpha 2 (merosin,congenital musculardystrophy)G804a5WIAF-12089Z266533372LAMA2, laminin,CTCTGTGACT[G/A]CTTCCTCCCTMGACYalpha 2 (merosin,congenital musculardystrophy)G804a6WIAF-13227Z266537047LAMA2, laminin,GTCAGTCCTC[A/G]GGTGGAAGATMAgQRalpha 2 (nerosin,congenital musculardystrophy)G804u7WIAF-13437Z266536791LAMA2, laminin,TGTGAGAGCC[C/T]TGGATGGACCSCTLLalpha 2 (merosin,congenital musculardystrophy)G805u1WIAF-13416U14755799LHX1, LIMAAGTAACAGC[A/G]GTGTTGCCAAMAGSGhomeobox protein 1G805u2WIAF-13417U14755743LHX1, LIMGGCGAGGAAC[T/C]CTACATCATCMTCLPhomeobox protein 1G805u3WIAF-13428U14755639LHX1, LIMGCCGTCAGGG[C/A]ATCTCCCCTASCAGGhomeobox protein 1G806u1WIAF-11886AF0265472656CSPG3, chondroitinTTGGAGTTCC[A/G]GCCATGTCTASAGPPsulfate proteo-glycan 3(neurocan)G606u2WIAF-11895AF026547529CSPG3, chondroitinTGACCTTCGC[T/C]GAGGCCCAGGSTCAAsulfate proteo-glycan 3(neurocan)G806u3WIAF-11896AF026547477CSPG3, chondroitinCAGGTGACAG[G/A]TGTTGTGTTCMGAGDsulfate proteo-glycan 3(neurocan)G806u4WIAF-11917AF02654789CSPG3, chondroitinACAGGATATC[A/G]CCGATGCCAGMAGTAsulfate proteo-glycan 3(neurocan)G806u5WIAF-11918AF026547213CSPG3, chondroitinAGCGCAGCCC[G/C]AGATCCCCCTMGCRPsulfate proteo-glycan 3(neurocan)G806u6WIAF-11929AF026547769CSPG3, chondroitinGCTTTGCCCG[G/A]GAGCTGGGGGSGARRsulfate proteo-glycan 3(neurocan)G806u7WIAF-11931AF0265473148CSPG3, chondroitinACATTGATGA[C/T]TGCCTCTGCASCTDDsulfate proteo-glycan 3(neurocan)G806u8WIAF-11949AF026547209CSPG3, chondroitinGCCAAGCGCA[G/A]CCCGAGATGCMGAATsulfate proteo-glycan 3(neurocan)G806a9WIAF-13114AF0265473430CSPG3, chondroitinATGAAAACAC[G/A]TGGATCGGCCSGATTsulfate proteo-glycan 3(neurocan)G806u10WIAF-13420AF0265472113CSPG3, chondroitinCCAGGGCAGA[C/G]TTCAGAGAAAMCGDSsulfate proteo-glycan 3(neurocan)C806u11WIAF-13431AF02654794CSPG3, chondroitinATATCACCGA[T/C]CCCACCCAAAMTCPEsulfate proteo-glycan 3(neurocan)G806u12WIAF-13432AF026547275CSPG3, chondroitinACAGGACTTC[C/T]CCATCCTGGTMCTPSsulfate proteo-glycan 3(neurocan)G808a1WIAF-13117Y13276177TLX, taillessGCATGAGCAA[G/a]CCAGCCCGATSGaKKhomolog(Drosophila)G810u1WIAF-11890X98248990SORT1, sortilin 1ATAACGATAC[C/A]ACAAGAAGGASCATTG810u2WIAF-11891X982481093SORT1, sortilin 1GGCAGCAAAT[G/T]ATGACATCGTMGTDYG810u3WIAF-11907X982481683SORT1, sortilin 1CAGACGAAGG[T/C]CAATGCTGGCSTGGGG810u4WIAF-11908X982481433SORT1, sortilin 1ATCTCCCAGA[A/C]ACTGAATGTTMACKTG810u5WIAF-11909X982481354SORT1, sortilin 1GAAGCCTGAA[A/G]ACAGTGAATGMAGNDG810u6WIAF-11910X982482180SORT1, sortilin 1TACCGGAAAA[T/A]TCCAGGGGACMTAING810u7WIAF-11911X982482264SORT1, sortilin 1AACTTTTTGA[G/A]TCCGGAAAAAMGASNG810u8WIAF-11925X982481993SORT1, sortilin 1TCGAGACTAT[G/A]TTGTGACCAAMGAVIG810u9WIAF-11939X982481351SORT1, sortilin 1GAGGAAGCCT[G/C]AAAACAGTGAMGCEQG810u10WIAF-11940X982482232SORT1, sortilin 1AACTAAAAGA[C/T]TTCAAAAAGASCTDDG810a11WIAF-13115X982481769SORT1, sortilin 1TCCATCAATA[T/A]CACCATTTGCMTAING810a12WIAF-13116X982481757SORT1, sortilin 1CCTGGAGCTA[G/A]GTCCATGAATMGARKG811u1WIAF-11893HT3676900synapsin I, alt,TGACCAAGAC[G/A]TATGCCACTGSGATTtranscript 1G811u2WIAF-11894HT3676758synapsin I, alt,ACCTTCTACC[C/T]CAATCACAAAMCTPLtranscript 1G811u3WIAF-11927HT3676996synapsin I, alt,CGTCAGTGTC[A/T]GGGAACTGGASATSStranscript 1G811u4WIAF-11928HT36761054synapsin I, alt,CATGTCTCAC[A/G]CATACAAGCTMAGRGtranscript 1G811u5WIAF-13418HT3676249synapsin I, alt,TGTCCAACGC[G/A[GTCAAGCAGASGAAAtranscript 1G811u6WIAF-13419HT3676432synapsin I, alt,TTAAAGTAGA[G/A]CAGGCCGAATSGAEEtranscript 1G812u1WIAF-11898HT4564163STX1A, syntaxinCCAACCCCCA[T/C]GAGAAGACGASTCDD1A (brain)G812u2WIAF-11942HT4564604STX1A, syntaxinTACAGGACAT[C/T]TTCATCGACAMGTMI1A (brain)G813u1WIAF-11934U72508939Human B7 mRNA,TATGACACAG[G/A]ACACAGGATGMGAGEcomplete cds.G813u2WIAF-11946U72508619Human B7 mRNA,GCATCCACAT[G/C]CTCACAGGTCMGCMIcomplete cds.G816u1WIAF-11897HT4230151HTR2B, 5-hydroxy-CTAACTGGTC[T/C]GCATTACAGASTGSStryptamine(serotonin)receptor 2BG816u2WIAF-11930HT4230189HTR2B, 5-hydroxy-GAAATGAAAC[A/G]CATTGTTGACMAGQRtryptamine(serotonin)receptor 2BG818u1WIAF-11902HT2694753TPH, tryptophanGAGTTTTTCA[C/T]TCCACTCAATSCTHHhydroxylase(tryptophan5-monooxygenase)G818u2WIAF-11903HT2694775TPH, tryptophanTGTGAGACAC[A/G]GTTCACATCCMAGSGhydroxylase(tryptophan5-monooxygenase)G818u3WIAF-11904HT26941211TPH, tryptophanTATAATCCAT[A/C]TACACGCAGTMACYShydroxylase(tryptophan5-monooxygenase)G818u4WIAF-11905HT26941081TPH, tryptophanGATTACCTGC[A/C]AACAGGAATGMACKQhydroxylase(tryptophan5-monooxygenase)G818u5WIAF-11933HT2694795TPH, tryptophanCCTTCTATAC[C/T]CCAGAGCCAGSCTTThydroxylase(tryptophan5-monooxygenase)G818u6WIAF-11935HT26941239TPH, tryptophanTCCTGAAAGA[C/T]ACCAAGAGCASCTDDhydroxylase(tryptophan5-monooxygenase)G822u1WIAF-11906HT0207936ASMT, acetyl-CAGACGGAAA[G/T]TGCTCACACCMGTKNserotonin N-methyltransferaseG822u2WIAF-11919HT0207637ASMT, acetyl-TGGTGCGACA[C/T]CGATAAAGCTMCTRWserotonin N-methyltransferaseG822u3WIAF-11936HT0207318ASMT, acetyl-GAAAAGCTTT[C/T]TATCGAAACASCTFFserotonin N-methyltransferaseG822u4WIAF-11937HT0207116ASMT, acetyl-AATGACTACG[C/T]CAACGGCTTCMCTAVserotonin N-methyltransferaseG822u5WIAF-11938HT0207930ASMT, acetyl-ACTGGGCAGA[C/T]GGAAAGTGCTSCTDDserotonin N-methyltransferaseG822u6WIAF-13427HT0207120ASMT, acetyl-ACTACGCCAA[C/A]GGCTTCATGGMCANKserotonin N-methyltransferaseG825u1WIAF-11888HT4974236ADAR, adenosineGCTCAGATAC[C/T]AGCAGCCTGGNCTQ*deaminase, RNA-specificG825u2WIAF-11900HT49743076ADAR, adenosineTCTTTGACAA[A/G]TCCTGCAGCGSAGKKdeaminase, RNAspecificG825u3WIAF-11912HT49742537ADAR, adenosineCTTGATTGGG[G/C]AGAACGAGAAMGCEQdeaminase, RNA-specificG825u4WIAF-11941HT49743558ADAR, adenosineGATGGCTATG[A/G]CCTGGAGATCMAGDGdeaminase, RNA-specificG825a5WIAF-12090HT49741305ADAR, adenosineCCTGAGACCA[A/G]AAGAAACGCAMAGKRdeaminase, RNA-specificG825u6WIAF-13426HT49743683ADAR, adenosineCCGCAGGGAT[C/T]TACTGAGACTSCTLLdeaminase, RNA-specificG826u1WIAF-12554X993832109ADARB1, adenosineAGATTACCAA[A/G]CCCAACGTGTSAGKKdeaminase, RNA-specific, B1(homolog of ratRED1)G826u2WIAF-12566X993831698ADARB1, adenosineTGTCCTCCAG[T/G]GACAAGATTGMTGSRdeaminase, RNA-specific, B1(homolog of ratRED1)G829u1WIAF-13735U492621404DVL3, dishevelled 3GGGTTGGAGG[T/C]CCGTGACTGCMTCVA(homologous toDrosophila dsh)G83u1WIAF-10449HT15761338DNMT1, DNAATGATGACCC[G/A]TCTCTTGAAGSGAPP(cytosine-5-)-methyltransferase 1G83u2WIAF-10450HT15761871DNMT1, DNAAAGCTGGTCT[A/C]CCAGATCTTCMAGYC(cytosine-5-)-methyltransferase 1G83u3WIAF-10468HT1576928DNMT1, DNAAAATCCACAG[A/G]TTTCTGATGAMAGIV(cytosine-5-)-methyltransferase 1G83u4WIAF-10469HT15761562DNMT1, DNAAATTCCGACT[C/T]CACCTATGAGMCTSL(cytosine-5-)-methyltransferase 1G83u5WIAF-10471HT15762424DNMT1, DNAGGGCCACGTC[G/A]GACCCTCTGCSGASS(cytosine-5-)-methyltransferase 1G83u6WIAF-10473HT15763790DNMT1, DNAGTTCTTCCTC[C/T]TGGACAATGTSCTLL(cytosine-5-)-methyltransferase 1G83u7WIAF-10486HT15761581DNMT1, DNAAGGACCTGAT[C/A]AACAAGATCGSCAII(cytosine-5-)-methyltransferase 1G832u1WIAF-12577L133871129PAFAH1B1, platelet-AGACATTCAC[A/T]GGACACAGAGSATTTactivating factoracetylhydrolase,isoform Ib, alphasubunit (45 kD)G835u1WIAF-12555U382761311SEMA3F, semaCCTCTGGCTC[C/A]GTGTTCCGAGSCASSdomain, immuno-globulin domain(Ig), shortbasic domain,secreted, 3FG835u2WIAF-12556U382761229SEMA3F, semaACTCACTTTG[A/T]TGACCTCCAGMATDVdomain, immuno-globulin domain(Ig), shortbasic domain,secreted, 3FG835u3WIAF-12557U382761473SEMA3F, semaGAACCTTCAC[G/A]CCATCTATGASGATTdomain, immuno-globulin domain(Ig), shortbasic domain,secreted, 3FG835a4WIAF-13138U382761726SEMA3F, semaTGACCACCAC[A/T]TCGACCAGCTMATMLdomain, immuno-globulin domain(Ig), shortbasic domain,secreted, 3FG836u1WIAF-12592U283691056SEMA3B, semaAACGACGTGC[G/A]CGGCCAGCGCMGAGDdomain, immuno-globulin domain(Ig), shortbasic domain,secreted, 3BG836u2WIAF-12609U283691479SEMA3B, semaGTCCTCCCCA[C/T]TGGGGGGCGCMCTTIdomain, immuno-globulin domain(Ig), shortbasic domain,secreted, 3BG838u1WIAF-12590U726711107ICAM5, inter-CGCAGCTGGG[A/G]CCCAAGCTCTMAGTAcellular adhesionmolecule 5,telencephalinG838u2WIAF-12591U72671966ICAM5, inter-CAGGCAGCTG[A/G]TCTGCAACGTMAGIVcellular adhesionmolecule 5,telencephalinG840a1WIAF-12109HT9612232SOS1, son of seven-CTCAGGCAAA[T/C]GGACTAAGCCSTCNNless (Drosophila)homolog 1G840a2WIAF-12110HT9612404SOS1, son of seven-ACCGTCTGAA[C/G]TTGTAGGGAGMCGLVless (Drosophila)homolog 1G840u3WIAF-12213HT9613813SOS1, son of seven-CAAGGGTACC[G/A]CGTCGATGCTSGAPPless (Drosophila)homolog 1G841u1WIAF-12153HT974201372SMOH, smoothenedTTTTGGCTTC[C/G]TGGCCTTTGGMCGLV(Drosophila)homologG841u2WIAF-12179HT97420858SMOH, smoothenedCCCAGTTCAT[G/T]GATCCTGCCCMGTMI(Drosophila)homologG841u3WIAF-12185HT974201164SMOH, smoothenedCTCTGAGTGG[G/C]ATTTGTTTTGSCGGG(Drosophila)homologG847u1WIAF-12588L419392019EPHB2, EphB2GGTCTGCAGT[G/T]GCCACCTGAAMGTGCG847u2WIAF-12596L419391806EPHB2, EphB2GTGTAACAGA[A/C]GACCGGCCTTSACRRG847u3WIAF-12613L419392885EPHB2, EphB2AGGCCATCAA[G/C]ATGGGGCAGTMGCKNG848u1WIAF-12685L406362484EPHB1, EphB1GTCAACAGTA[A/C]CCTGGTCTGCMAGNSG848u2WIAF-12690L406362020EPHB1, EphB1CCTTCACTTA[T/C]GAGGATCCCASTCYYG849u1WIAF-11920D834921544EPHB6, EphB6ACCTGTGTGG[C/T]TCATCCACACMCTAVG849u2WIAF-11921D834923301EPHB6, EphB6CTTTGGGATA[C/T]TCATGTGGCAMCTLFG849u3WIAF-13412D834921139EPHB6, EphB6GAGACCTTCA[C/T]CCTTTACTACMCTTIG849u4WIAF-13413D834921895EPHB6, EphH6TTTGAGGTGC[A/C]AGGCTCAGCAMACQPG849u5WIAF-13414D834922338EPHB6, EphB6CTATGACCAG[G/A]CAGAAGACGAMGAATG849u6WIAF-13415D834922567EPHB6, EphB6GGGGCTTTGG[G/C]CTTCCTCCTGMCGAGG849u7WIAF-13422D834922860EPHB6, EphB6GGCCATCCAG[G/A]CCCTCTGGGCMGAATG849u8WIAF-13423D834922782EPHB6, EphB6GGAGGTCATT[G/C]GGACAGGCTCMACGRG849u9WIAF-13424D834923038EPHB6, EphB6TTCCTCAGGC[A/C]GCGGGAGGGCMAGQRG849u10WIAF-13425D834923637EPHB6, EphB6AGCCATTGGA[C/T]TGGAGTGCTASCTLLG856u1WIAF-12625D459061323LIMK2, LIM domainAGCTCAACCT[G/C]CTGACAGAGTSGCLLkinase 2G858u1WIAF-12630U65019864MADH2, MAD (mothersTTTGGTGTTC[G/A]ATAGCATATTSGASSagainst decapenta-plegic, Drosophila)homolog 2G86u1WIAF-10437HT1701263RAD51, RAD51TGAAGCAAAT[G/C]CAGATACTTCMGCAP(S. cerevisiae)homolog (E coliRecA homolog)G86u2WIAF-10465HT1701861RAD51, RAD51GCATCAGCCA[T/C]GATGGTAGAAMTCMT(S. cerevisiae)homolog (E coilRecA homolog)G86u3WIAF-10466HT1701924RAD51, RAD51TACAGAACAC[A/G]CTACTCGGGTMAGDG(S. cerevisiae)homolog (E coliRecA homolog)G864a1WIAF-13139X82324183POU3F4, POU domain,CAGCAATCGG[C/t]ATCCCCTCCGMCtHYclass 3, tran-scription factor 4G866u1WIAF-12637HT01012576glutamate receptorAAATCCCGTA[G/A]TCAATCCAAGMGASN(GB:M64752)G866u2WIAF-12638HT01011131glutamate receptorTAACAGGAAA[C/T]GTGCAGTTTASCTNN(GB:M64752)G869u1WIAF-13406HT336203627GRIN2C, glutamateAGATCAGCAG[G/T]GTACCCCCTCMGTRSreceptor, iono-tropic, N-methylD-aspartate 2CG870u1WZAF-11889HT4468714SLC1A1, soluteCAGAAGAGTC[C/G]TTCACAGCTGSCGSScarrier family 1(neuronal/epithelial highaffinity glutamatetransporter, systemXag), member 1G870u2WIAF-11913HT4468314SLC1A1, soluteCTACAGAAAT[T/A]CTACTTTGCTMTAFYcarrier family 1(neuronal/epithelial highaffinity glutamatetransporter, systemXag), member 1G870u3WIAF-11914HT4468579SLC1A1, soluteAAGTCAGTAC[G/A]CTCGATGCCASGATTcarrier family 1(neuronal/epithelial highaffinity glutamatetransporter, systemXag), member 1G870u4WIAF-11922HT4468706SLC1A1, soluteGAACATGACA[G/A]AAGAGTCCTTMGAEKcarrier family 1(neuronal/epithelial highaffinity glutamatetransporter, systemXag), member 1G870u5WIAF-11923HT4468978SLC1A1, soluteGGAAGATCAT[A/G]GAAGTTGAAGMAGIMcarrier family 1(neuronal/epithelial highaffinity glutamatetransporter, systemXag), member 1G871ulWIAF-11892HT31871004SLC1A3, soluteTTCTCTTAAC[G/C]AAGCCATCATMGCEQcarrier family 1(glial highaffinity glutamatetransporter),member 3G871u2WIAF-11915HT31871154SLC1A3, soluteTGTTGGCTTA[C/T]TCATTCACGCMCTLFcarrier family 1(glial highaffinity glutamatetransporter),member 3G871u3WIAF-11926HT31871412SLC1A3, soluteGGCTGCCATT[T/G]TCATTGCTCAMTGFVcarrier family 1(glial highaffinity glutamatetransporter),member 3G871u4WIAF-11944HT31871217SLC1A3, soluteAAACCCTTGG[G/A]TTTTTATTCCMGAVIcarrier family 1(glial highaffinity glutamatetransporter),member 3G872u1WIAF-13433HT40771271SLC1A2, soluteCTGTTGGAGC[A/C]ACCATTAACASACAAcarrier family 1(glial highaffinity glutamatetransporter),member 2G879u1WIAF-11899HT283171273GRM2, glutamateGACTTTGTGC[T/C]CAACGTCAAGMTCLPreceptor, metabo-tropic 2G879u2WIAF-11932HT283172349GRM2, glutamateCTTCTATGTC[A/C]CCTCCAGTGAMAGTAreceptor, metabo-tropic 2G879u3WIAF-13421HT283172186GRM2, glutamateATGCAAGTAT[G/T]TTGGGCTCGCMGTMIreceptor, metabo-tropic 2G879u4WIAF-13429HT283172567GRM2, glutamateCCCAGTTTGT[C/T]CCCACTGTTTSCTVVreceptor, metabo-tropic 2G879u5WIAF-13436HT283172046CRM2, glutamateACAGGTGGCC[A/G]TCTGCCTGGCMAGIVreceptor, metabo-tropic 2G879u6WIAF-13438HT283172425GRM2, glutamateGTCCTTGGCT[C/T]CCTCTTTGCGMGTCFreceptor, metabo-tropic 2G879u7WIAF-13439HT283172463GRM2, glutamateCCTCTTCCAG[C/T]CGCAGAAGAAMCTPSreceptor, metabo-tropic 2G880u1WIAF-12164HT337192117GRM4, glutamateAGCCCGACCT[T/G]GGCACCTGCTSTGLLreceptor, metabo-tropic 4G880u2WIAF-12176HT337192427GRM4, glutamateGGACCTGTCG[C/T]TCATCTGCCTMCTLFreceptor, metabo-tropic 4G880u3WIAF-12192HT337192372GRM4, glutamateACCAGCGGAC[A/G]CTCGACCCCCSAGTTreceptor, metabo-tropic 4G883a1WIAF-13140HT488631408GRM7, glutamateATCGCAAATC[C/a]ACAGGACAGGNCaC*receptor, metabo-tropic 7G883a2WIAF-13141HT488632027GRM7, glutamateTCCTGTCTTC[C/t]TGGCAATGTTSCtLLreceptor, metabo-tropic 7G883a3WIAF-13147HT488631813GRM7, glutamateTGTGCACACT[A/g]CCATGTAAGCSAgLLreceptor, metabo-tropic 7G883a4WIAF-13148HT488631536GRM7, glutamateTGTGCTGACT[A/t]CCGGGCTCTCMAtYFreceptor, metabo-tropic 7G883a5WIAF-13149HT488632473GRM7, glutamateAAGCCAGAGG[G/a]GTTCTCAAGTSGaGGreceptor, metabo-tropic 7G883a6WIAF-13150HT488632434GRM7, glutamateTCATAGACTA[C/t]GATGAACACASCtYYreceptor, metabo-tropic 7G884u1WIAF-11916U950251052GRM8, glutamateCGAACTCTTG[C/A]CAATAATCGAMCAADreceptor,metabotropic 8G884u2WIAF-11945U950252016GRM8, glutamateAAACAAACCG[T/C]ATCCACCGAASTCRRreceptor, metabo-tropic 8G884u3WIAF-11946U950251852GRM8, glutamateCAGGGCTTCA[G/A]GACGCGAACTMGAGRreceptor, metabo-tropic 8G884u4WIAF-11947U950252078GRM8, glutamateATTAGTCCAG[C/G]ATCTCAGCTGMCGAGreceptor, metabo-tropic 8G884u5WIAF-13430U950251897GRM8, glutamateTTTTCTCTGT[T/G]ATTCAATCACMTGYDreceptor, metabo-tropic 8G884u6WIAF-13435U950252364GRM8, glutamateTTACCATGTA[T/C]ACCACCTGCASTCYYreceptor, metabo-tropic 8G885u1WIAF-13434AF0027001363GFRA2, GDNF familyAACTCAGGCC[C/A]CAGCACAGCCMCAPHreceptor alpha 2G886a1WIAF-13142U95847497GFRA1, GDNF familyGAAGTCCCTC[T/a]ACAACTGCCGMTaYNreceptor alpha 1G886a2WIAF-13143U958471385GFRA1, GDNF familyGTCTGAGAAT[G/a]AAATTCCCACMGaEKreceptor alpha 1G886a3WIAF-13151U95847781GFRA1, GDNF familyGCGTGTCCAA[T/C]GATGTCTGCASTcNNreceptor alpha 1G892u1WIAF-11956U12140798NTRK2, neuro-TGGGCAATCC[A/C]TTTACATGCTSAGPPtrophic tyrosinekinase, receptor,type 2G892u2WIAF-11957U12140834NTRK2, neuro-GGATCAAGAC[T/A]CTCCAACAGCSTATTtrophic tyrosinekinase, receptor,type 2G892u3WIAF-11958U12140956NTRK2, neuro-GCAAATCTGG[C/T]CGCACCTAACMCTAVtrophic tyrosinekinase, receptor,type 2G892u4WIAF-11960U121401738NTRK2, neuro-CTCCAAGTTT[G/A]GCATCAAAGGMGAGStrophic tyrosinekinase, receptor,type 2G892u5WIAF-11962U121402486NTRK2, neuro-GTCGGTGGCC[A/C]CACAATGCTGMAGHRtrophic tyrosinekinase, receptor,type 2G892u6WIAF-11965U121401106NTRK2, neuro-TCCTTAAGGA[T/C]AACTAACATTMTCITtrophic tyrosinekinase, receptor,type 2G892u7WIAF-11966U121402085NTRK2, neuro-AGGATGCCAG[T/C]GACAATGCACSTCSStrophic tyrosinekinase, receptor,type 2G892u8WIAF-11967U121402230NTRK2, neuro-GGACCTCAAC[A/C]AGTTCCTCAGMACKQtrophic tyrosinekinase, receptor,type 2G892u9WIAF-11968U121402223NTRK2, neuro-AGCATGGGGA[C/T]CTCAACAAGTSCTDDtrophic tyrosinekinase, receptor,type 2G892u10WIAF-11992U121401602NTRK2, neuro-GTAATCAAAT[C/T]CCTTCCACAGSCTIItrophic tyrosinekinase, receptor,type 2G892u11WIAF-11998U121401354NTRK2, neuro-TACTAAAATA[C/T]ATGTTACCAAMCTHYtrophic tyrosinekinase, receptor,type 2G892u12WIAF-11999U121401944NTRK2, neuro-CATTTGTTCA[G/C]CACATCAAGCMGCQHtrophic tyrosinekinase, receptor,type 2G892u13WIAF-12000U121402103NTRK2, neuro-CACGCAAGGA[C/T]TTCCACCGTGSCTDDtrophic tyrosinekinase, receptor,type 2G892u14WIAF-12001U121401860NTRK2, neuro-CTGTCATTAT[T/C]GGAATGACCASTCIItrophic tyrosinekinase, receptor,type 2G892a15WIAF-13144U121401868NTRK2, neuro-ATTGGAATGA[C/G]CAAGATCCCTMCGTStrophic tyrosinekinase, receptor,type 2G892a16WIAF-13145U121401903NTRK2, neuro-CCAGTACTTT[C/T]GCATCACCAAMGTGCtrophic tyrosinekinase, receptor,type 2G892a17WIAF-13146U121401965NTRK2, neuro-GACATAACAT[T/G]GTTCTGAAAAMTGIMtrophic tyrosinekinase, receptor,type 2G892u18WIAF-13442U12140958NTRK2, neuro-AAATCTGGCC[G/T]CACCTAACCTMGTAStrophic tyrosinekinase, receptor,type 2G892u19WIAF-13446U121402502NTRK2, neuro-TGCTGCCCAT[T/C]CGCTGGATGCSTCIItrophic tyrosinekinase, receptor,type 2G892u20WIAF-13447U121402317NTRK2, neuro-GATGCTGCAT[A/T]TAGCCCAGCAMATILtrophic tyrosinekinase, receptor,type 2G892u21WIAF-13448U121402364NTRK2, neuro-CGTCCCAGCA[C/A]TTCGTGCACCMCAHQtrophic tyrosinekinase, receptor,type 2G892u22WIAF-13449U121402507NTRK2, neuro-CCCATTCGCT[G/A]GATCCCTCCANGAW*trophic tyrosinekinase, receptor,type 2G892u23WIAF-13471U121402389NTRK2, neuro-TTTGCCCACC[A/C]CGAACTCCCTSACRRtrophic tyrosinekinase, receptor,type 2G892u24WIAF-13472U121402416NTRK2, neuro-GGAGAACTTG[C/T]TCGTGAAAATSCTLLtrophic tyrosinekinase, receptor,type 2G892u25WIAF-13474U12140359NTRK2, neuro-GGGATCTCGT[C/T]CTGGATAAGGMCTSFtrophic tyrosinekinase, receptor,type 2G892u26WIAF-13479U121401044NTRK2, neuro-TGTATTGGGA[T/C]GTTGGTAACCSTCDDtrophic tyrosinekinase, receptor,type 2G9u1WIAF-10222J038261130FDXR, ferredoxinGGTATAAGAG[C/T]CGCCCTGTCGSCTSSreductaseG9u2WIAF-10258J03826388FDXR, ferredoxinCCGGAGCTGC[A/C]GGAGGCCTACMAGQRreductaseG900u1WIAF-11970HT3470497STX4A, syntaxin 4ATGCAATTCAA[T/C]GCACTCCGAAMTCMT(placental)G901u1WIAF-11969HT27792758STX3A, syntaxin 3ATGCACACAGT[G/A]GACCACGTGGSGAVVG901u2WIAF-11971HT27792317STX3A, syntaxin 3AACGTCCGGAA[C/A]AAACTGAAGAMCANKG901u3WIAF-12002HT27792611STX3A, syntaxin 3AAGCAAGCCCT[C/T]AGTGAGATTGSCTLLG901u4WIAF-12003HT27792909STX3A, syntaxin 3ACCTCAATTAA[C/A]ACTCCCCTAA—GA——G901u5WIAF-12004HT27792163STX3A, syntaxin 3AATTGAGGAAA[C/T]TCGGCTTAACMCTTIG901a6WIAF-13152HT2779282STX3A, syntaxin 3ACAGCTGACAC[A/C]GGATGATGATMAGQRG901u7WIAF-13453HT27192828STX3A, syntaxin 3ACCGGAAGAAA[T/C]TGATAATTATSTCLLG901u8WIAF-13455HT27792226STX3A, syntaxin 3ATACAGTATCA[T/C]TCTCTCTGCAMTCITG902u1WIAF-13454HT27744848STX5A, syntaxin 5AACTTCCAGTC[T/A]GTCACCTCCASTASSG902u2WIAF-13456HT27744338STX5A, syntaxin 5AATTTCGTGAG[A/G]GCCAAGGGCASAGRRG905u1WIAF-12202HT27789487CREBL1, cAMPTCCAGATCAA[C/T]GTTATCCCCASCTNNresponsive elementbinding protein-like 1G905u2WIAF-12219HT27789151CREBL1, cAMPATTCTGCCCT[A/T]GATCAAGTGGSATLLresponsive elementbinding protein-like 1G905u3WIAF-12230HT27789649CREBL1, cAMPAGTCCCTGTC[C/G]CCTTCAGGATSCGSSresponsive elementbinding protein-like 1G906u1WIAF-12214HT43722127N-ethylmaleimide-AAGGGAAGAA[G/A]GTCTGGATAGSGAKKsensitive factorG906u2WIAF-12221HT4372514N-ethylmaleimide-GGGAGAGCCT[G/A]CGACAGGGAAMGAATsensitive factorG908u1WIAF-12201HT366598RAB5A, RAB5A,GCCCAAATAC[T/G]GGAAATAAAASTGTTmember RASoncogene familyG91u1WIAF-10438HT1848496ERCC1, excisionTCGTGCGCAA[C/T]GTGCCCTGGGSCTNNrepair cross-complementingrodent repairdeficiency, com-plementation group1 (includes over-lapping antisensesequence)G91u2WIAF-10439HT1848367ERCC1, excisionCTGGCGCCAC[G/A]TGCCCCACAGSCATTrepair cross-complementingrodent repairdeficiency,complementationgroup 1 (includesoverlapping anti-sense sequence)G914a1WIAF-13210HT3672252synaptobrevin 1GCAGTGCTGC[C/A]AAGCTAAAGASGAAAG915a1WIAF-12115D635061390Homo sapiens mRNATTACCTTGGT[G/A]TTCCCATTGTMGAVIfor unc-18homologue,complete cds.G915u2WIAF-12293D63506685Homo sapiens mRNAACAGCTTGTT[G/A]AAAAAAAGCTMGAEKfor unc-18homologue,complete cds.G916a1WIAF-13209HT28523308HuntingtinGAGCACTTTT[C/T]GGAGGCCAGCMCTSLassociated protein1-like proteinG916a2WIAF-13211HT28523762HuntingtinCGGAGGACTT[G/C]GTCCCCCACGMGCLFassociated protein1-like proteinG916a3WIAF-13212HT28523560HuntingtinGAGCTCAGAA[C/T]GTCTCTAAGGMCTTNassociated protein1-like proteinG917u1WIAF-11972U797341075HIP1, huntingtinAGAGCCAGCG[G/A]GTTGTGCTGCSGARRinteractingprotein 1G917u2WIAF-11973U797341005HIP1, huntingtinGACCACTTAA[T/C]TGAGCGACTAMTCITinteractingprotein 1G917u3WIAF-11977U797341539HIP1, huntingtinCTGCAAGGCA[G/A]CCTGGAAACTMGASNinteractingprotein 1G917u4WIAF-12005U79734817HIP1, huntingtinTGGTGGTGAT[C/T]CCTGCAGAGGSCTIIinteractingprotein 1G917u5WIAF-12006U797341906HIP1, huntingtinGCTGGAGCCA[G/C]TATCTGGCCTMGCQHinteractingprotein 1G917a6WIAF-13157U79734993HIP1, huntingtinAAGGATGAGA[A/G]GGACCACTTAMAGKRinteractingprotein 1G919u1WIAF-11974D30742707CAMK4, calcium/ACTGCGCACC[T/C]GAAATTCTTASTCPPcalmodulindependent proteinkinase IVG919u2WIAF-11991D307421139CAMK4, calcium/AGAGCCACAA[G/A]GCTAGCCGAGSGAKKcalmodulindependent proteinkinase IVG919u3WIAF-12007D30742834CAMK4, calcium/CATGTTCAGG[A/T]GAATTCTGAANATR*calmodulindependent proteinkinase IVG919u4WIAF-13443D307421088CAMK4, calcium/TGGCCTCTTC[C/G]CGCCTGGGAASCGSScalmodulin-dependent proteinkinase IVG920u1WIAF-11979X785201952CLCN3, chlorideATGACATTCC[T/C]GATCGTCCAGSTCPPchannel 3G920u2WIAF-11980X785201819CLCN3, chlorideATAGCCTTCC[C/T]TAATCCATACMCTPLchannel 3G920u3WIAF-11981X785202094CLCN3, chlorideCATTGGAGCG[A/C]TCGCAGCGAAGMAGIVchannel 3G920u4WIAF-11983X785202822CLCN3, chlorideATATTTTCCG[A/G]AAGCTGGGACSAGRRchannel 3G920u5WIAF-11984X785202745CLCN3, chlorideGCCATTGAAG[C/T]TTCCAAGCATMCTLFchannel 3G920u6WIAF-11987X785202499CLCN3, chlorideTCCCTTACCT[C/T]TCCTGACACAMGTVFchannel 3G920u7WIAF-12008X785201251CLCN3, chlorideCATCATCACA[G/A]GTTACTTGGCMGAGSchannel 3G920u8WIAF-12011X78520888CLCN3, chlorideAGTACTAACA[C/T]TAACACGATTSCTLLchannel 3G920u9WIAF-13459X785202804CLCN3, chlorideCAATCGACAT[T/C]GTCCTCCATASTCIIchannel 3G921u1WIAF-11954J02908931CLU, clusterinGAGACCTTGA[C/T]CAGGAAATACMCTTI(complement lysisinhibitor, SP-40,40, sulfated glyco-protein 2,testosterone-repressed prostatemessage 2,apolipoprotein J)G921u2WIAF-11955J02908880CLU, clusterinCCCTCCCAGG[C/T]TAAGCTCCGGMCTAV(complement lysisinhibitor, SP-40,40, sulfated glyco-protein 2,testosterone-repressed prostatemessage 2,apolipoprotein J)G921u3WIAF-11990J029081051CLU, clusterinCTCACCCAAG[G/C]CGAACACCAGMGCGA(complement lysisinhibitor, SP-40,40, sulfated glyco-protein 2,testosterone-repressed prostatemessage 2,apolipoprotein J)G921u4WIAF-13469J02908986CLU, clusterinTCAACACCTC[C/T]TCCTTCCTGGSCTSS(complement lysisinhibitor, SP-40,40, sulfated glyco-protein 2,testosterone-repressed prostatemessage 2,apolipoprotein J)G923u1WIAF-11993M196501059Human 2′,3′-cyclicGAGCTAAGCC[G/A]GGGCAAGCTCMGARQnucleotide 3′-phosphodiesterasemRNA, completecds.G923u2WIAF-11994M196501062Human 2′,3′-cyclicCTAAGCCGGG[G/T]CAAGCTCTATMGTGVnucleotide 3′-phosphodiesterasemRNA, completecds.G923u3WIAF-13445M196501141Human 2′,3′-cyclicTCTTCACGGG[C/A]TACTACGGGASGAGGnucleotide 3′-phosphodiesterasemRNA, completecds.G925u1WIAF-11953L11315666CAK, cell adhesionGGGTCATGAG[T/C]GTCTCTCTGCSTCSSkinaseG925u2WIAF-11959L113152562CAK, cell adhesionTGCTGCCCAT[C/T]CGCTGGATCCSCTIIkinaseG925u3WIAF-11996L113152049CAK, cell adhesionAAGATCTCCT[T/C]AGTCTTCATTSTCVVkinaseG925u4WIAF-13440L113151601CAK, cell adhesionTACCAGGAGC[C/T]CCGGCCTCGTMCTPLkinaseG925u5WIAF-13441L113151629CAK, cell adhesionCGCCCCACTC[C/T]GCTCCCTGTGSCTSSkinaseG925u6WIAF-13451L113152262CAK, cell adhesionTGGACAACGG[C/T]GACCTCAACCSCTGGkinaseG926u1WIAF-11961AF018956577NRP1, neuropilin 1TGAAAGCTTT[C/T]ACCTGGACCCMGTDYG926u2WIAF-11963AF0189561683NRP1, neuropilin 1CCACCCGATT[G/C]ATCAGGATCTMCGFLG926u3WIAF-11975AF0189562176NRP1, neuropilin 1GACCTTCTGG[T/C]ATCACATGTCMTCYHG926u4WIAF-11976AF0189562092NRP1, neuropilin 1TTCCCAAGCT[G/T]ACGAAAATCAMGTDYG926a5WIAF-13158AF018956747NRP1, neuropilin 1TTTTTTACAC[C/T]GACAGCGCGASCTTTG926a6WIAF-13159AF018956996NRP1, neuropilin 1ACTTGGGCCT[T/C]CTGCGCTTTCSTCLLG926u7WIAF-13444AF018956644NRP1, neuropilin 1GAAATCTGGG[A/C]TGGATTCCCTMACDAG926u8WIAF-13450AF0189561738NRP1, neuropilin 1CAGAATGGAG[C/G]TGCTCGGCTGMCCLVG926u9WIAF-13452AF018956537NRP1, neuropilin 1TTGTCTTTCC[C/A]CCAAAGATGTSCAAAG926u10WIAF-13457AF0189562197NRP1, neuropilin 1TGGCTCCCAC[G/A]TCGGCACACTMGAVIG927u1WIAF-11978AF022860870NRP2, neuropilin 2GGATTCCTAA[T/C]GAACAGATCASTCNNG927u2WIAF-11982AF0228601674NRP2, neuropilin 2ATCACACCCC[T/G]GACATCCGAASTGPPG927u3WIAF-11985AF0228601250NRP2, neuropilin 2TGGCACTCAG[C/A]TATCGCCCTCMGAGDG927u4WIAF-11986AF0228601071NRP2, neuropilin 2ATGGCTACTA[C/T]GTCAAATCCTSCTYYG927u5WIAF-12009AF022860726NRP2, neuropilin 2GTTCATCCAC[G/A]GCGATCCTCTSGATTG927u6WIAF-12010AF0228602522NRP2, neuropilin 2GCAACCTCAG[G/T]GTCTGGCGCCMGTCVG927u7WIAF-12012AF022860123NRP2, neuropilin 2GCTATATCAC[C/T]TCTCCCCGTTSCTTTG927a8WIAF-13160AF0228602427NRP2, neuropilin 2CTTTTCCAGT[G/T]CACATCCCAGSCTVVG927a9WIAF-13161AF0228602430NRP2, neuropilin 2TTGCAGTGGA[C/G]ATCCCAGAAAMCGDEG927a10WIAF-13162AF0228602463NRP2, neuropilin 2AACCATATCA[A/G]GATCAAATTGSAGEEG927a11WIAF-13163AF0228602473NRP2, neuropilin 2AGATGAAATT[G/T]ATCATCAATAMGTDYG927u12WIAF-13480AF022860724NRP2, neuropilin 2TCGTTCATCG[A/T]CGGGGATCCTMATTSG927u13WIAF-13481AF022860767NRP2, neuropilin 2ATGCCCGTGC[C/T]CAAGGATGCCMCTAVG930a1WIAF-13164HT2608609GABRA2, gamma-ACAATGGGAA[G/a]AAATCAGTAGSGaKKaminobutyric acid(GASA) A receptor,alpha 2G931a1WIAF-13153HT26091111GABRA3, gamma-ACTGGTTCAT[A/g]GCCCTCTGTTMAgIMaminobutyric acid(GABA) A receptor,alpha 3G931a2WIAF-13165HT26091448GABRA3, gamma-TGTCAGCAAG[G/A]TTCACAAAATMGAVIaminobutyric acid(GASA) A receptor,alpha 3G932a1WIAF-13154HT277731077GABRA4, gamma-CAAAAGAAAG[A/G]CATCAAACCCMAGTAaminobutyric acid(GABA) A receptor,alpha 4G932a2WIAF-13155HT277731189GABRA4, gamma-AGAACAAATG[C/A]TTTGGTTCACMCAADaminobutyric acid(GABA) A receptor,alpha 4G936u1WIAF-12308HT34321027GABRB2, gamma-AATTACGATG[C/T]TTCACCTGCAMCTAVaminobutyric acid(GABA) A receptor,beta 2G936u2WIAF-12327HT3432362GABRB2, gamma-AAGGCTATGA[C/T]ATTCGTCTGASCTDDaminobutyric acid(GABA) A receptor,beta 2G936u3WIAF-12328HT3432571GABRB2, gamma-CTCTGGGTG[C/T]TGATACCTATMCTPLaminobutyric acid(GABA) A receptor,beta 2G939u1WIAF-12330HT22361219GABRR2, gamma-CTGGATGGAA[G/C]CTACAGTGAGMGCSTaminobutyric acid(GABA) receptor,rho 2G939u2WIAF-12355HT22361003GABRR2, gamma-ACCACCATCA[T/C]CACGGGCGTGMTCITaminobutyric acid(GABA) receptor,rho 2G939u3WIAF-12356HT22361041CABRR2, gamma-CGTCTCCTAC[G/A]TCAAGGCCGTMGAVIaminobutyric acid(GABA) receptor,rho 2G950u1WIAF-13622U64871725Human putative GGTCCTGCTCC[A/C]GTTCACCACTMACQPprotein-coupledreceptor (GPR19)gene, completecds.G950u2WIAF-13624U64871443Human putative GGATAACAGCA[A/C]GCCACATTTGMACKTprotein-coupledreceptor (GPR19)gene, completecds.G950u3WIAF-13625U64871818Human putative GCTGGGTAGTG[C/T]AACGTGCAAGMCTAVprotein-coupledreceptor (GPR19)gene, completecds.G955a1WIAF-13166HT38605110calcium channel,CTGGCCTCTT[T/c]ACCGTGGAGASTcFFvoltage-gated,alpha 1 subunit,L type, alt.transcript 1G955a2WIAF-13167HT38603842calcium channel,CTACCCCAAC[C/a]CAGAAACTACMCaPTvoltage-gated,alpha 1 subunit,L type, alt.transcript 1G955a3WIAF-13168HT38605624calcium channel,GTGTGCCCCA[G/a]AGTCCGAGCCMGaEKvoltage-gated,alpha 1 subunit,L type, alt.transcript 1G955a4WIAF-13169HT38605703calcium channel,ATCAGCTTCT[A/g]CATGCTCTGTMAgYCvoltage-gated,alpha 1 subunit,L type, alt.transcript 1G955a5WIAF-13170HT38605809calcium channel,ACCACCTGGA[T/c]GAGTTTAAAASTcDDvoltage-gated,alpha 1 subunit,L type, alt.transcript 1G955a6WIAF-13171HT38606616calcium channel,CCGGCTCCAA[C/t]GCCAACATCASCtNNvoltage-gated,alpha 1 subunit,L type, alt.transcript 1G956u1WIAF-14187HT21991334calcium channel,CTTCACATAG[C/T]CCTTTTGGTAMCTAVvoltage-gated,alpha 1D subunit,DHP-sensitiveG956u2WIAF-14188HT21991452calcium channel,AAGAGGACCC[A/T]GCTCCATGTGSATPPvoltage-gated,alpha 1D subunit,DHP-sensitiveG956u3WIAF-14189HT21991614calcium channel,GCTGGACAGA[C/T]GTGCTCTACTSCTDDvoltage-gated,alpha 1D subunit,DHP-sensitiveG956u4WIAF-14190HT21992540calcium channel,GGCAAGTTTA[A/T]TTTTGATGAAMATNIvoltage-gated,alpha 1D subunit,DHP-sensitive.G956u5WIAF-14191HT21993210calcium channel,TGCTGACCAC[T/C]GCTCCCCTGGSTCSSvoltage-gatad,alpha 1D subunit,DHP-sensitiveG956u6WIAF-14192HT21993326calcium channel,TTGAAGATGA[C/T]AACTTTTGGAMCTTIvoltage-gated,alpha 1D subunit,DHP-sensitiveG956u7WIAF-14193HT21993274calcium channel,ACTGGGTTAC[T/C]TTGACTATGCMTCFLvoltage-gated,alpha 1D subunit,DHP-sensitiveG956u8WIAF-14194HT21995127calcium channel,TGCCTCTCAA[C/T)AGTGACGGGASCTNNvoltage-gated,alpha 1D subunit,DHP-sensitiveG956u9WIAF-14195HT21995173calcium channel,TGCTTTGGTT[C/T]GAACCGCTCTNCTR*voltage-gated,alpha 1D subunit,DHP-sensitiveG956u10WIAF-14200HT21991437calcium channel,CAGATATCGT[A/G]GCTGAAGAGGSAGVVvoltage-gated,alpha 1D subunit,DHP-sensitiveG956u11WIAF-14201HT21992567calcium channel,ACCAAGCGCA[G/T]CACCTTTGACMGTSIvoltage-gated,alpha 1D subunit,DHP-sensitiveG956u12WIAF-14202HT21994464calcium channel,TCACCTTTTT[C/T]CGTCTTTTCCSCTFFvoltage-gated,alpha 1D subunit,DHP-sensitiveG956u13WIAF-14215HT21996927calcium channel,GCTACAGCGA[C/T]GAAGAGCCAGSCTFFvoltage-gated,alpha 1D subunit,DHP-sensitiveG956u14WIAF-14216HT21996858calcium channel,CCCGAGCCAA[C/T]GCGGATGTGGSCTNNvoltage-gated,alpha 1D subunit,DHP-sensitiveG957u1WIAF-12306HT4229915calcium channel,TACATCGAGC[G/A]TGCTTCATGAMGA?Rvoltage-gated,alpha 1E subunit,alt. transcript 2G957u2WIAF-12309HT42293555calcium channel,GCCACTACAT[C/T]GTGAACCTGCSCTIIvoltage-gated,alpha 1E subunit,alt. transcript 2G957u3WIAF-12310HT42294116calcium channel,ATGTAGATCA[C/T]GAGAAAAACASCTHHvoltage-gated,alpha 1E subunit,alt. transcript 2G957u4WIAF-12313HT42295181calcium channel,AGAACGACAA[T/C]GAACGCTGCGSTCNNvoltage-gated,alpha 1E subunit,alt. transcriptG957u5WIAF-12314HT42295971calcium channel,TATGGACCCC[C/A]CCCATGACGGSGATTvoltage-gated,alpha 1E subunit,alt. transcript 2G957u6WIAF-12315HT42295985calcium channel,ATGACGGACA[G/T]TTCCAACAACMGTQHvoltage-gated,alpha 1E subunit,alt. transcript 2G957u7WIAF-12329HT42293100calcium channel,GCTGGCAGCA[C/A]GCCTTGATGAMGAGSvoltage-gated,alpha 1E subunit,alt. transcript 2G957u8WIAF-12331HT42296492calcium channel,CCCTCCTTTC[C/T]TACAGCTCCCMCT?Rvoltage-gated,alpha 1E subunit,alt. transcript 2G957u9WIAF-12354HT42293839calcium channel,AACGCTTTGC[G/C]AACCAACAAAMGCGAvoltage-gated,alpha 1E subunit,alt. transcript 2G957u10WIAF-12357HT42294753calcium channel,TGACTTCATC[A/G]CCCTCATTCGMAGTAvoltage-gated,alpha 1E subunit,alt. transcript 2G960u1WIAF-12305HT33361246CACNB3, calciumTTGATCCCCT[C/T]TCATGAGCCCMCTSFchannel, voltagedependent, beta3 subunitG960u2WIAF-12340HT33361288CACNB3, calciumTGGACAGGAT[C/T]TTCACAGCGTMCTSFchannel, voltagedependent, beta3 subunitG960u3WIAF-12345HT3336641CACNB3, calciumAGGCTCTCTT[C/T]CACTTCCTCASCTFFchannel, voltagedependent, beta3 subunitG960u4WIAF-12346HT3336576CACNB3, calciumCATCCCGCCT[G/A]TGGTCCTCCTMGAVMchannel, voltagedependent, beta3 subunitC961u1WIAF-12322U950192037CACNB2, calciumACTCTCCCTA[C/T]GTAGAGCCAASCTYYchannel, voltagedependent, beta2 subunitG961u2WIAF-12347U950192007CACNB2, calciumCATTTGACTC[G/A]GAAACCCAGGSGASSchannel, voltagedependent, beta2 subunitG962u1WIAF-12324U950201423CACNB4, calciumCCAATTGAAA[G/A]ACGAAGTCTAMGARKchannel, voltagedependent, beta4 subunitG962u2WIAF-12342U95020167CACNB4, calciumGGACCAGGTT[G/T]AAAAGATCCGMGTLFchannel, voltagedependent, beta4 subunitG962u3WIAF-12350U950201571CACNB4, calciumACACTTACAA[A/C]CCCCATAGGASAGKKchannel, voltagedependent, beta4 subunitG965u1WIAF-12312U405831276CHRNA7, cholinergicTCCTGCACGC[T/C]GGCCAACCCCSTCGGreceptor,nicotinic, alphapolypeptide 7G968a1WIAF-12119HT275921008CHRNA1, cholinergicACACACACCA[C/T]CGCTCACCCASCTHHreceptor,nicotinic, alphapolypeptide 1(muscle)G968u2WIAF-12368HT275921136CHRNA1, cholinergicAAGATTTTTA[C/T]AGAACACATTMCTTIreceptor,nicotinic, alphapolypeptide 1(muscle)G973a1WIAF-13172HT48774800CHRNA2, cholinergicACACTTCAGA[C/t]GTGGTGATTGSCtDDreceptor,nicotinic, alphapolypeptide 2(neuronal)G973a2WIAF-13173HT48774927CHRNA2, cholinergicCTGGAACCCC[G/a]CTCATTTTGCMGaATreceptor,nicotinic, alphapolypeptide 2(neuronal)G977u1WIAF-13949Y08419366CHRNA5, cholinergicAACTTATACC[T/C]CTTCCTTCACSTCRRreceptor,nicotinic, alphapolypeptide 5G978a1WIAF-13179Y084171331CHRNB3, cholinergicCCATTAGATA[C/a]ATTTCCACACNCaY*receptor,nicotinic, betapolypeptide 3G983a1WIAF-13214HT0374236NPY, neuropeptide YCATACTACTC[C/A]CCCCTCCGACSGASSG983a2WIAF-13215HT0374290NPY, neuropeptide YCAAAACGATC[C/T]AGCCCAGAGASCTSSG983a3WIAF-13216HT0374111NPY, neuropeptide YGCCACTCCCC[C/T]TCTCCGCACTSCTLLG987a1WIAF-13174HT27830159PPYR1, pancreaticTGGTCTTCAT[C/T]GTCACTTCCTSCTIIpolypeptidereceptor 1G987a2WIAF-13175HT27830222PPYR1, pancreaticTGATCTGTGT[G/A]ACTGTGAGGCSGAVVpolypeptidereceptor 1G987a3WIAF-13176HT27830322PPYR1, pancreaticGCCGCTGACC[C/T]CCCTCTACACMGTASpolypeptidereceptor 1G987a4WIAF-13177HT278301074PPYR1, pancreaticTGGACGACTC[G/A]GACCATCTCCSGASSpolypeptide,receptor 1G987a5WIAF-13178HT27830975PPYR1, pancreaticCCTCCACCTG[C/T]GTCAACCCATSCTCCpolypeptidereceptor 1G987a6WIAF-13180HT27830615PPYR1, pancreaticAGTTCCTCCC[A/g]GATAAGCTGCSAgAApolypeptidereceptor 1G987a7WIAF-13181HT27830718PPYR1, pancreaticGGGCTTCATC[C/T]TGGTCTGTTASCTLLpolypeptidereceptor 1G987a8WIAF-13182HT27830745PPYR1, pancreaticCATCTACCGG[C/t]GCCTGCAGAGMCtRCpolypeptidereceptor 1G987a9WIAF-13183HT27830842PPYR1, pancreaticGTGATGCTCC[T/A]GGCCTTTGCCMTAVEpolypeptidereceptor 1G987a10WIAF-13184HT27830852PPYR1, pancreaticTCGCCTTTGC[C/T]GTGCTCTGGCSCTAApolypeptidereceptor 1G987a11WIAF-13185HT27830889PPYR1, pancreaticCAACAGCCTG[G/a]AACACTCGCAMGaEKpolypeptidereceptor 1G987a12WIAF-13186HT27830924PPYR1, pancreaticCCATCTGCCA[C/T]CCGAACCTCASCTHHpolypeptidereceptor 1G989u1WIAF-13573D86519891NPY6R, neuro-TGACTCATGC[C/T]TACTGGGCCASCTAApeptide Y receptorY6G989u2WIAF-13588D86519465NPY6R, neuro-ACCACCCAGC[A/C]TCTAATACAASAGAApeptide Y receptorY6G989u3WIAF-13591D86519980NPY6R, neuro-GAGCCCTTCC[G/A]CAACCTCTCTMGARHpeptide Y receptorY6G991u1WIAF-12390HT97376336Notch2AAGCTACTTG[C/T]GTTCAGAAAASCTCCG993u1WIAF-12359U952991343NOTCH4, NotchTCCACACTCT[G/T]CCTGTGTCAGHGTCF(Drosophila)homolog 4G993u2WIAF-12361U952992020NOTCH4, NotchTAACCACCAC[A/C]AACACAACCCHAGKE(Drosophila)homolog 4G993u3WIAF-12384U952995775NOTCH4, NotchCCGCCTATTC[G/T]CATTGCCGGASCTSS(Drosophila)homolog 4G996a1WIAF-13213HT3329356OPRM1, opioidCTTAGATCCC[A/G]ACCTCTCCCAMAGNDreceptor, mu 1LPLa4WIAF-13314HT1320443LPL, lipoproteinATGTATGACA[C/T]TTGCCTGCCAMCTSIlipaseLPLa5WIAF-13315HT1320579LPL, lipoproteinGACAGCATCT[G/A]GCCCGGTTTASGAVVlipaseLPLa6WIAF-13316HT1320609LPL, lipoproteinTGGACGAGCA[C/A]TTTAACTACCSCAEElipaseLPLa7WIAF-13317HT13201338LPL, lipoproteinCAAATAAGAC[C/A]TACTCCTTCCSCATVlipaseLPLa8WIAF-13318HT13201117LPL, lipoproteinCAATCTGCCC[T/C]ATGAGATCAAMTCYDlipaseLPLa9WIAF-13319HT1320715LPL, lipoproteinCAGAATTACT[G/A]GCCTCCATCCMCACSlipaseLPLa10WIAF-13320HT1320834LPL, lipoproteinCTGGTCGAAC[C/A]ATTGGAATCCMCASRlipaseLPLa11WIAF-13321HT1320951LPL, lipoproteinGACTTGCACA[T/A]CTCCACCAGCMTADElipaseLPLa12WIAF-13322HT13201595LPL, lipoproteinAATAACAACT[C/C]AGCCTCAAACNCGS*lipaseLPLa13WIAF-13323HT13201597LPL, lipoproteinTAAGAAGTCA[G/A]GCTGAAACTGMGAGSlipaseLPLa14WIAF-13324HT13201606LPL, lipoproteinAGGCTGAAAC[T/C]CGGCGAATCTTC——lipaseLPLa15WIAF-13325HT13201611LPL, lipoproteinGAAACTGGGC[G/A]AATcTACAGA—GA——lipase

While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.

Number	Date	Country
60220947	Jul 2000	US
60153357	Sep 1999	US
60225724	Aug 2000	US

	Number	Date	Country
Parent	09657472	Sep 2000	US
Child	10831997	Apr 2004	US

Single nucleotide polymorphisms in genes

Information

Publication Number

Date Filed

Date Published

Inventors

Original Assignees

CPC

US Classifications

International Classifications

Abstract

Description

Claims

RELATED APPLICATIONS

Provisional Applications (3)

Divisions (1)